Cosmetic complications after anterior urethral surgery: a scoping review and photo collection

ACTAS UROL ESP. 2024 [Epub ahead of print].

Genital Art in the 21st Century: Piercings and Tattoos. The EAU YAU Reconstructive Urology Working Party Point of View

ARCH ESP UROL. 2024;77(7):837-838.

Long-term functional success and patient-reported outcomes after female one-stage buccal mucosal graft urethroplasty

ACTAS UROL ESP. 2024 [Epub ahead of print].

Long Term Outcomes From Uncorrected Hypospadias: a Scoping Review

ACTAS UROL ESP. 2024 [Epub ahead of print].

Oral care pathways after oral mucosal graft harvesting: Systematic review

ACTAS UROL ESP. 2024 [Epub ahead of print].

The use of robotic surgery for the management of urethral strictures and bladder neck contractures: A systematic review

ACTAS UROL ESP. 2024 [Epub ahead of print].

Treatment of anastomotic strictures after phalloplasty: An up-to-date review of the literature

ACTAS UROL ESP. 2024 [Epub ahead of print].

Racial differences in knowledge, attitudes, and sources of information about germline cancer genetic testing in the U.S.A.: An analysis of the health information National Trends Survey System
Alkhatib K, Filipas D, Briggs L, Frego N, Koelker M, Lipsitz S, Pierorazio P, Rebbeck T, Kilbridge K, Kibel A, Trinh Q, Rana H, Cole A
PREV MED. 2024;178:.

Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis
Beatrici E, Labban M, Filipas D, Stone B, Reis L, Dagnino F, Lughezzani G, Buffi N, Lipsitz S, Clinton T, Matulewicz R, Trinh Q, Cole A
INT BRAZ J UROL. 2024;50(2):199-208.

Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers
Beatrici E, Paciotti M, Nguyen D, Filipas D, Qian Z, Lughezzani G, Daniels D, Lipsitz S, Kibel A, Cole A, Trinh Q
CANCER-AM CANCER SOC. 2024;130(16):2770-2781.

Socio-Economic Determinants of Cancer Screening Adherence Among Cancer Survivors: Analysis from 2020 Behavioral Risk Factor Surveillance System
Beatrici E, Qian Z, Filipas D, Stone B, Dagnino F, Labban M, Lipsitz S, Lughezzani G, Buffi N, Cole A, Trinh Q
JNCI CANCER SPECT. 2024 [Epub ahead of print].

Enhancing drug therapy in ostomy patients: Best practice recommendations for medication management
Berger V, Reeh M, Scherer M, Härterich S, Möller S, Wansing E, van der Linde A, Langebrake C
PLOS ONE. 2024;19(6):e0305047.

Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model
Chiarelli G, Stephens A, Finati M, Cirulli G, Beatrici E, Filipas D, Arora S, Tinsley S, Bhandari M, Carrieri G, Trinh Q, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F
INT UROL NEPHROL. 2024;56(8):2589-2595.

Urinary bladder transplantation in humans - current status and future perspectives
Czarnogórski M, Koper K, Petrasz P, Vetterlein M, Pokrywczyńska M, Juszczak K, Drewa T, Adamowicz J
NAT REV UROL. 2024 [Epub ahead of print].

Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer
Debatin N, Bady E, Mandelkow T, Huang Z, Lurati M, Raedler J, Müller J, Vettorazzi E, Plage H, Samtleben H, Klatte T, Hofbauer S, Elezkurtaj S, Furlano K, Weinberger S, Giacomo Bruch P, Horst D, Roßner F, Schallenberg S, Marx A, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Lennartz M, Minner S, Simon R, Sauter G, Zecha H, Schlomm T, Blessin N
EUR UROL. 2024;86(1):42-51.

Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysins
Dyshlovoy S, Mansour W, Ramm N, Hauschild J, Zhidkov M, Kriegs M, Zielinski A, Hoffer K, Busenbender T, Glumakova K, Spirin P, Prassolov V, Tilki D, Graefen M, Bokemeyer C, von Amsberg G
SCI REP-UK. 2024;14(1):11788.

MP35-04 SMOKING CHARACTERISTICS AND YEARS SINCE QUITTING SMOKING OF US ADULTS WITH LUNG AND BLADDER CANCER
Edoardo B, Filippo D, Muhieddine L, K. F, J. S, O. R, Giovanni L, M. B, R. L, N. C, S. M, Quoc-Dien T, P. C
J UROLOGY. 2024;211(5S):e581.

Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound
Falkenbach F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, Koehler D, Ambrosini F, Ortner G, Maurer T, Graefen M, Budäus L
PROSTATE. 2024;84(16):1448-1455.

PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
Falkenbach F, Ambrosini F, Kachanov M, Ortner G, Maurer T, Köhler D, Beyersdorff D, Graefen M, Budäus L
WORLD J UROL. 2024;42(1):182.

Size of lymph-node metastases in prostate cancer patients undergoing radical prostatectomy: implication for imaging and oncologic follow-up of 2705 lymph-node positive patients
Falkenbach F, Kachanov M, Leyh-Bannurah S, Maurer T, Knipper S, Köhler D, Graefen M, Sauter G, Budäus L
WORLD J UROL. 2024;42(1):.

Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic
Filipas D, Labban M, Beatrici E, Stone B, Qian Z, D Andrea V, Ludwig T, Reis L, Cole A, Trinh Q
VACCINE. 2024;42(3):441-447.

Impact of COVID-19 on the time to counseling and treatment of prostate cancer
Filipas D, Pose R, Marks P, Tennstedt P, Beyer B, Tilki D, Isbarn H, Maurer T, Ludwig T, Heinzer H, Steuber T
AGING MALE. 2024;27(1):.

Ultrasound imaging of male urethral stricture disease: a narrative review of the available evidence, focusing on selected prospective studies
Frankiewicz M, Vetterlein M, Markiet K, Adamowicz J, Campos-Juanatey F, Cocci A, Rosenbaum C, Verla W, Waterloos M, Mantica G, Matuszewski M
WORLD J UROL. 2024;42(1):32.

Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision-Making
Frego N, Beatrici E, Labban M, Stone B, Filipas D, Koelker M, Lughezzani G, Buffi N, Osman N, Lipsitz S, Sammon J, Kibel A, Trinh Q, Cole A
AM J PREV MED. 2024;66(1):27-36.

Expertise Area 2.1: Complicated and complex pelvic floor disorders
Heesakkers J, Wyndaele M, de Kort L, Sacco E, Bientinesi R, Filipas D, Fruehling I, Ludwig T, Fisch M
2024. Rare and Complex Urology. Feitz W, Tidman J (Hrsg.). 1. Aufl. Oxford: Academic Press, 169-182.

Update Harnleiterrekonstruktion 2024
Hook S, Gross A, Netsch C, Becker B, Filmar S, Vetterlein M, Kluth L, Rosenbaum C
UROLOGE. 2024;63(1):25-33.

Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness
Kardoust Parizi M, Margulis V, Bagrodia A, Bekku K, Klemm J, Matsukawa A, Alimohammadi A, Motlagh R, Mostafaei H, Laukhtina E, Shariat S
UROL ONCOL-SEMIN ORI. 2024;42(4):102-109.

Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Kardoust Parizi M, Matsukawa A, Bekku K, Klemm J, Alimohammadi A, Laukhtina E, Karakiewicz P, Chiujdea S, Abufaraj M, Krauter J, Shariat S
EUR UROL ONCOL. 2024;7(4):663-676.

Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds
Kawada T, Shim S, Quhal F, Rajwa P, Pradere B, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Teoh J, Karakiewicz P, Araki M, Shariat S
EUR UROL ONCOL. 2024;7(4):649-662.

PD61-02 RACIAL DIFFERENCES IN RECOMMENDATION AGAINST PROSTATE CANCER SURGERY IN THE UNITED STATES: A REGISTRY-BASED COMPARATIVE ANALYSIS
K. F, Edoardo B, Yu-Jen C, Charlotte H, V. S, R. S, W. V, R. L, Thomas S, Quoc-Dien T
J UROLOGY. 2024;211(5S):e1279.

Upper Tract Urothelial Carcinoma: A Narrative Review of Current Surveillance Strategies for Non-Metastatic Disease
Klemm J, Bekku K, Abufaraj M, Laukhtina E, Matsukawa A, Parizi M, Karakiewicz P, Shariat S
CANCERS. 2024;16(1):.

Diagnostik und Therapie von Harnröhrenstrikturen – Leitlinienübersicht 2024: Teil 1 – anteriore Harnröhre
Klemm J, Dahlem R, Kluth L, Rosenbaum C, Shariat S, Fisch M, Vetterlein M
UROLOGE. 2024;63(1):3-14.

Diagnostik und Therapie von Harnröhrenstrikturen – Leitlinienübersicht 2024: Teil 2 – posteriore Harnröhre
Klemm J, Dahlem R, Kluth L, Rosenbaum C, Shariat S, Fisch M, Vetterlein M
UROLOGE. 2024;63(1):15-24.

P084 - Delineating functional outcomes and patient-reported treatment satisfaction after perineal urethrostomy as last resort management of complex anterior urethral strictures: Abstracts EAU24 - 39th Annual EAU Congress
Klemm J, Dahlem R, König F, Shariat S, Marks P, Fisch M, Vetterlein M
EUR UROL. 2024;85(S1):S109-S110.

Continent Diversion is Losing its Momentum:: a Nationwide Trend Analysis from Germany 2005-2021
Klemm J, Fisch M, Laukhtina E, Dahlem R, Shariat S, Vetterlein M
BJU INT. 2024;133(2):154-157.

Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
Klemm J, Laukhtina E, Shariat S
NAT REV CLIN ONCOL. 2024;21(2):87–88.

Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy
Klemm J, Shariat S, Laukhtina E, Rajwa P, Vetterlein M, Schuettfort V, von Deimling M, Dahlem R, Fisch M, Rink M
CLIN GENITOURIN CANC. 2024;22(3):.

Female non-obstetric urogenital fistula repair: long-term patient-reported outcomes and a scoping literature review
Klemm J, Stelzl D, Schulz R, Marks P, Shariat S, Fisch M, Dahlem R, Vetterlein M
BJU INT. 2024;134(3):407-415.

Androgendeprivationstherapie und kardiovaskuläre Morbidität beim Prostatakarzinom: ein narratives Review
Klemm J, von Deimling M, Fisch M, Kramer G, Tilki D, Steuber T, von Amsberg G, Hengstenberg C, Shariat S
UROLOGE. 2024;63(3):262-268.

Andrologie
Kliesch S, Diemer T, Soave A, Sperling H
UROLOGE. 2024;63(11):1087-1088.

Prostate-specific membrane antigen radioguided surgery with negative histopathology
Koehler D, Trappe S, Shenas F, Karimzadeh A, Apostolova I, Klutmann S, Ambrosini F, Budäus L, Falkenbach F, Knipper S, Maurer T
EUR J NUCL MED MOL I. 2024;51(2):548-557.

P082 - Short-term morbidity and long-term functional outcomes of the T-plasty for salvage reconstruction of recalcitrant bladder neck stenosis: Abstracts EAU24 - 39th Annual EAU Congress
König F, Dahlem R, Marks P, Kühnke L, Klemm J, Fisch M, Vetterlein M
EUR UROL. 2024;85(1):S107.

Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer
Laukhtina E, Gontero P, Babjuk M, Moschini M, Teoh J, Rouprêt M, Trinh Q, Chlosta P, Nyirády P, Abufaraj M, Soria F, Klemm J, Bekku K, Matsukawa A, Shariat S
BJU INT. 2024;134(4):644-651.

Urinary function in female patients after traditional, organ-sparing and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analysis
Laukhtina E, von Deimling M, Pradere B, Yanagisawa T, Rajwa P, Kawada T, Quhal F, Pallauf M, Bianchi A, Majdoub M, Mostafaei H, Motlagh R, Mori K, Enikeev D, Fisch M, Moschini M, D'Andrea D, Soria F, Albisinni S, Fajkovic H, Rink M, Teoh J, Gontero P, Shariat S
BJU INT. 2024;133(3):246-258.

A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer
Liu K, Zhao H, Chen X, Nicoletti R, Vasdev N, Peter Ka-Fung C, Ng C, Kawada T, Laukthina E, Mori K, Yanagisawa T, D'Andrea D, von Deimling M, Albisinni S, Krajewski W, Pradere B, Soria F, Moschini M, Enikeev D, Shariat S, Kamat A, Giannarini G, Teoh J
EUR UROL ONCOL. 2024;7(3):438-446.

Harnableitungen mit oder ohne simple Zystektomie in der Salvage-Therapie benigner Erkrankungen des unteren Harntraktes
Lutz M, Le Q, Müller M, Müller S, Rosenbaum C, Vetterlein M, Kluth L
UROLOGE. 2024;63(1):34-42.

Advancing Intraoperative Assessment of Urethral Stricture Anatomic Variation: a Prospective Proof-of-concept Study
Marks P, Dahlem R, Daniels P, Klemm J, Kühnke L, Kranzbühler B, König F, Ding L, Engel O, Soave A, Fisch M, Vetterlein M
UROL INT. 2024;108(3):254-258.

Controversies of Mucosa and Spongiosum Preservation in Non-Transecting Augmented Anastomotic Repair
Marks P, Dahlem R, Fisch M, Vetterlein M
BJU INT. 2024;133(3):351-352.

Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis
Matsukawa A, Rajwa P, Kawada T, Bekku K, Laukhtina E, Klemm J, Pradere B, Mori K, Karakiewicz P, Kimura T, Chlosta P, Shariat S, Yanagisawa T
INT J CLIN ONCOL. 2024;29(6):716-725.

Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis
Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, Chiujdea S, Mori K, Kimura S, Fazekas T, Miszczyk M, Miki J, Kimura T, Karakiewicz P, Rajwa P, Shariat S
EUR UROL ONCOL. 2024;7(4):697-704.

Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis
Matsukawa A, Yanagisawa T, Bekku K, Parizi M, Laukhtina E, Klemm J, Chiujdea S, Mori K, Kimura S, Miki J, Pradere B, Rivas J, Gandaglia G, Kimura T, Kasivisvanathan V, Ploussard G, Cornford P, Shariat S, Rajwa P
EUR UROL ONCOL. 2024;7(3):376-400.

Expertise Area 2.2: Rare diseases and conditions affecting the female urethra
Medina-Polo J, Vetterlein M, Klemm J
2024. Rare and Complex Urology. Feitz W, Tidman J (Hrsg.). 1. Aufl. San Diego: Academic Press, 183-193.

Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery
Mehring G, Steinbach C, Pose R, Knipper S, Koehler D, Werner S, Riethdorf S, von Amsberg G, Ambrosini F, Maurer T
WORLD J UROL. 2024;42(1):256.

Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas
Müller J, Plage H, Elezkurtaj S, Mandelkow T, Huang Z, Lurati M, Raedler J, Debatin N, Vettorazzi E, Samtleben H, Hofbauer S, Furlano K, Neymeyer J, Goranova I, Ralla B, Weinberger S, Horst D, Roßner F, Schallenberg S, Marx A, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Lennartz M, Minner S, Simon R, Sauter G, Zecha H, Schlomm T, Bady E
FRONT ONCOL. 2024;13:.

Personalised blood pressure management during major noncardiac surgery and postoperative neurocognitive disorders: a randomised trial
Nicklas J, Bergholz A, Däke F, Pham H, Rabe M, Schlichting H, Skrovanek S, Flick M, Kouz K, Fischer M, Olotu C, Izbicki J, Mann O, Fisch M, Schmalfeldt B, Frosch K, Renné T, Krause L, Zöllner C, Saugel B
BJA Open. 2024;11:100294.

Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management
Pose R, Knipper S, Ekrutt J, Kölker M, Tennstedt P, Heinzer H, Tilki D, Langer F, Graefen M
ASIAN J UROL. 2024;11(1):42-47.

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer
Qian Z, Filipas D, Koelker M, Stone B, Beatrici E, Labban M, Tuncali K, Lipsitz S, Trinh Q, Cole A
CLIN GENITOURIN CANC. 2024;22(6):102184.

P115 - Why underrepresentation costs lives: First results from a high-volume multi-institutional study in Germany about risk factors for mortality in Fournier gangrene: Abstracts EAU24 - 39th Annual EAU Congress
Rieger C, Hübers M, Pfister D, Schleifer S, Hirsch J, Kranz J, Gerdes B, Pantea V, Chachin A, Träger M, Glienke M, Henniges P, Vetterlein M, Klemm J, Roghmann F, Dellino M, Jany U, Tylingr M, Al Assali K, Patroi P, Mayr R, Engelmann S, Schneidewind L, Heidenreich A
EUR UROL. 2024;85(S1):S160-S161.

P175 - What do patients with Peyronie’s disease expect from therapy? A prospective multi-center study: Abstracts EAU24 - 39th Annual EAU Congress
Schaefer L, Cremers J, Witschel B, Schuettfort V, Nieder T, Koenig F, Vetterlein M, Gild P, Dahlem R, Fisch M, Kliesch S, Soave A
EUR UROL. 2024;85(S1):S247.

What do patients with Peyronie's disease expect from therapy?: A prospective multi-center study
Schäfer L, Cremers J, Witschel B, Schüttfort V, Nieder T, König F, Vetterlein M, Gild P, Dahlem R, Fisch M, Kliesch S, Soave A
ANDROLOGY-US. 2024;12(4):821-829.

Patient-reported outcomes after one-stage neourethral reconstruction in transmen with phalloplasty-associated strictures and fistulas
Schuettfort V, Graf R, Vetterlein M, Ludwig T, Gild P, Marks P, Soave A, Dahlem R, Fisch M, Riechardt S
WORLD J UROL. 2024;42(1):.

Kinderwunsch nach Vasektomie: Refertilisierung oder medizinisch assistierte Reproduktionstechniken?
Soave A, Cremers J, Kliesch S
UROLOGE. 2024;63(11):1111-1121.

Evidenzbasierte Medizin in der rekonstruktiven Urologie
Vetterlein M, Rosenbaum C, Kluth L
UROLOGE. 2024;63(1):1-2.

Expertise Area 2.3: Urethral reconstruction in rare diseases and complex conditions
Vetterlein M, Wyndaele M, Campos-Juanatey F, Klemm J, de Kort L, Fisch M, Graaf P, Brits T, De Win G
2024. Rare and Complex Urology. Feitz W, Tidman J (Hrsg.). 1. Aufl. Oxford: Academic Press, 195-203.

Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer
von Deimling M, Furrer M, Mertens L, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein M, Lonati C, Crocetto F, Taylor J, Tully K, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess P, Black P, Kiss B, Pradere B, Shariat S
BJU INT. 2024;133(3):341-350.

Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy
von Deimling M, Rink M, Klemm J, Koelker M, Schuettfort V, König F, Gild P, Ludwig T, Marks P, Dahlem R, Fisch M, Shariat S, Vetterlein M
CLIN GENITOURIN CANC. 2024;22(2):336-346.e9.

Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era
Yanagisawa T, Kawada T, von Deimling M, Bekku K, Laukhtina E, Rajwa P, Chlosta M, Pradere B, D'Andrea D, Moschini M, Karakiewicz P, Teoh J, Miki J, Kimura T, Shariat S
EUR UROL FOCUS. 2024;10(1):41-56.

Germ Cell Maintenance and Sustained Testosterone and Precursor Hormone Production in Human Prepubertal Testis Organ Culture with Tissues from Boys 7 Years+ under Conditions from Adult Testicular Tissue
Aden N, Bleeke M, Kordes U, Brunne B, Holstermann B, Biemann R, Ceglarek U, Soave A, Salzbrunn A, Schneider S, Kopylow K
CELLS-BASEL. 2023;12(3):.

Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer
Ambrosini F, Falkenbach F, Budaeus L, Graefen M, Koehler D, Lischewski F, Gschwend J, Heck M, Eiber M, Knipper S, Maurer T
MINERVA UROL NEPHROL. 2023;75(6):734-742.

PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer
Ambrosini F, Koehler D, Ghadban T, Jacobsen F, Knipper S, von Amsberg G, Steuber T, Maurer T
CENT EUR J UROL. 2023;76(3):182-185.

Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion
Barletta F, Tappero S, Morra S, Incesu R, Cano Garcia C, Piccinelli M, Scheipner L, Baudo A, Tian Z, Gandaglia G, Stabile A, Mazzone E, Terrone C, Longo N, Tilki D, Chun F, de Cobelli O, Ahyai S, Carmignani L, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
CLIN GENITOURIN CANC. 2023;21(6):e461-e466.e1.

Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis
Barletta F, Tappero S, Panunzio A, Incesu R, Cano Garcia C, Piccinelli M, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun F, De Cobelli O, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2023;41(3):147.e1-147.e6.

Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade
Beatrici E, Filipas D, Stone B, Labban M, Qian Z, Lipsitz S, Lughezzani G, Buffi N, Cole A, Trinh Q
UROL ONCOL-SEMIN ORI. 2023;41(12):483.e11-483.e19.

Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base
Beatrici E, Labban M, Stone B, Filipas D, Reis L, Lughezzani G, Buffi N, Kibel A, Cole A, Trinh Q
EUR UROL. 2023;84(6):527-530.

Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T
J NUCL MED. 2023;64(7):1036-1042.

State of the Art in Prostate-specific Membrane Antigen-targeted Surgery-A Systematic Review
Berrens A, Knipper S, Marra G, van Leeuwen P, van der Mierden S, Donswijk M, Maurer T, van Leeuwen F, van der Poel H
EUR UROL OPEN SCI. 2023;54:43-55.

Urethral management after artificial urinary sphincter explantation due to cuff erosion
Białek Ł, Frankiewicz M, Adamowicz J, Campos-Juanatey F, Cocci A, Mantica G, Rosenbaum C, Verla W, Waterloos M, Vetterlein M
CENT EUR J UROL. 2023;76(4):322-324.

A Systematic Review on Postoperative Antibiotic Prophylaxis after Pediatric and Adult Male Urethral Reconstruction
Białek Ł, Rydzińska M, Vetterlein M, Dobruch J, Skrzypczyk M
J CLIN MED. 2023;12(19):.

Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond
Bianchi A, von Deimling M, Pallauf M, Yanagisawa T, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Majdoub M, Sari Motlagh R, Pradère B, Karakiewicz P, Cerruto M, Antonelli A, Shariat S
EXPERT OPIN PHARMACO. 2023;24(2):177-195.

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
Bravi C, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann K, Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat S, Tilki D, Graefen M, Gill I, Mottrie A, Karakiewicz P, Montorsi F, Briganti A, Pfister D
BJUI compass. 2023;4(1):123-129.

Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort
Calleris G, Marra G, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Ghoreifi A, Ribeiro L, Westhofen T, Tourinho-Barbosa R, Raskin Y, Veerman H, Albisinni S, Smith J, Rouprêt M, Oderda M, Massari E, Persad R, Van Der Poel H, Joniau S, Sanchez-Salas R, Kretschmer A, Cathcart P, Gill I, Karnes R, Tilki D, Shariat S, Touijer K, Gontero P
EUR UROL FOCUS. 2023;9(4):645-649.

Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages
Cano Garcia C, Barletta F, Incesu R, Piccinelli M, Tappero S, Panunzio A, Tian Z, Saad F, Shariat S, Antonelli A, Terrone C, De Cobelli O, Graefen M, Tilki D, Briganti A, Wenzel M, Banek S, Kluth L, Chun F, Karakiewicz P
CANCERS. 2023;15(3):.

Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States
Cano Garcia C, Nimer N, Piccinelli M, Tappero S, Panunzio A, Barletta F, Incesu R, Tian Z, Saad F, Kapoor A, Briganti A, Terrone C, Shariat S, Tilki D, Antonelli A, De Cobelli O, Kluth L, Becker A, Chun F, Karakiewicz P
ANN EPIDEMIOL. 2023;79:65-70.

Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages
Cano Garcia C, Panunzio A, Tappero S, Piccinelli M, Barletta F, Incesu R, Law K, Scheipner L, Tian Z, Saad F, Shariat S, Tilki D, Briganti A, De Cobelli O, Terrone C, Antonelli A, Banek S, Kluth L, Chun F, Karakiewicz P
MEDICINA-LITHUANIA. 2023;59(3):.

Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities
Cano Garcia C, Piccinelli M, Tappero S, Panunzio A, Barletta F, Incesu R, Tian Z, Saad F, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, De Cobelli O, Kosiba M, Banek S, Kluth L, Chun F, Karakiewicz P
INT UROL NEPHROL. 2023;55(5):1117-1123.

ASO Visual Abstract: In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urological Cancer Surgery
Cano Garcia C, Tappero S, Piccinelli M, Barletta F, Incesu R, Morra S, Scheipner L, Baudo A, Tian Z, Hoeh B, Chierigo F, Sorce G, Saad F, Shariat S, Carmignani L, Ahyai S, Longo N, Tilki D, Briganti A, De Cobell O, Dell'Oglio P, Mandel P, Terrone C, Chun F, Karakiewicz P
ANN SURG ONCOL. 2023;30(13):8789-8790.

In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery
Cano Garcia C, Tappero S, Piccinelli M, Barletta F, Incesu R, Morra S, Scheipner L, Baudo A, Tian Z, Hoeh B, Chierigo F, Sorce G, Saad F, Shariat S, Carmignani L, Ahyai S, Longo N, Tilki D, Briganti A, De Cobell O, Dell'Oglio P, Mandel P, Terrone C, Chun F, Karakiewicz P
ANN SURG ONCOL. 2023;30(13):8770-8779.

Impact of Age on Long-Term Urinary Continence after Robotic-Assisted Radical Prostatectomy
Cano Garcia C, Wenzel M, Humke C, Wittler C, Dislich J, Incesu R, Köllermann J, Steuber T, Graefen M, Tilki D, Karakiewicz P, Kluth L, Preisser F, Chun F, Mandel P, Hoeh B
MEDICINA-LITHUANIA. 2023;59(6):.

Differences in long-term continence rates between prostate cancer patients with extraprostatic vs. organ-confined disease undergoing robotic-assisted radical prostatectomy: An observational studys
Cano Garcia C, Wenzel M, Koll F, Zatik A, Köllermann J, Graefen M, Tilki D, Karakiewicz P, Kluth L, Chun F, Mandel P, Hoeh B
CLINICS. 2023;78:100284.

External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy
Cano Garcia C, Wenzel M, Piccinelli M, Hoeh B, Landmann L, Tian Z, Humke C, Incesu R, Köllermann J, Wild P, Würnschimmel C, Graefen M, Tilki D, Karakiewicz P, Kluth L, Chun F, Mandel P
DIAGNOSTICS. 2023;13(9):.

The impact of surgical volume on perioperative safety after urethroplasty: the EAU YAU Reconstructive Urology Working Party point of view
Chierigo F, Mantica G, Adamowicz J, Campos-Juanatey F, Cocci A, Frankiewicz M, Rosenbaum C, Verla W, Waterloos M, Vetterlein M
MINERVA UROL NEPHROL. 2023;75(4):537-539.

Can PROMs improve racial equity in outcomes after prostatectomy?
Cole A, Koelker M, Makanjuola J, Moore C
NAT REV UROL. 2023;20(3):125-126.

Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens
Darr C, Costa P, Kahl T, Moraitis A, Engel J, Al-Nader M, Reis H, Köllermann J, Kesch C, Krafft U, Maurer T, Köhler D, Klutmann S, Falkenbach F, Kleesiek J, Fendler W, Hadaschik B, Herrmann K
EUR UROL OPEN SCI. 2023;54:28-32.

Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer: Oncological Outcomes and Toxicity Profile
Demirkol M, Esen B, Seymen H, Şen M, Uçar B, Kurtuldu S, Mandel N, Bavbek S, Falay O, Tilki D, Esen T
CLIN NUCL MED. 2023;48(12):e564-e569.

Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Elsesy M, Oh-Hohenhorst S, Oing C, Eckhardt A, Burdak-Rothkamm S, Alawi M, Müller C, Schüller U, Maurer T, von Amsberg G, Petersen C, Rothkamm K, Mansour W
MOL ONCOL. 2023;17(6):1129-1147.

Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer
Esen B, Herrmann K, Bavbek S, Kordan Y, Tilki D, Esen T
EUR UROL FOCUS. 2023;9(4):596-605.

Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results
Esen B, Seymen H, Tarim K, Koseoglu E, Bolukbasi Y, Falay O, Selçukbiricik F, Molinas Mandel N, Kordan Y, Demirkol M, Tilki D, Esen T
EUR UROL FOCUS. 2023;9(5):832-837.

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
Falkenbach F, Ambrosini F, Tennstedt P, Eiber M, Heck M, Preisser F, Graefen M, Budäus L, Koehler D, Knipper S, Maurer T
CANCERS. 2023;15(20):.

Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support
Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, Budäus L, Eiber M, Lunger L, Lischewski F, Heck M, Maurer T
WORLD J UROL. 2023;41(9):2343-2350.

Metastasengerichtete Therapie des singulär metastasierten Prostatakarzinoms ohne begleitende Androgendeprivationstherapie – ein Kommentar
Falkenbach F, Maurer T
UROLOGE. 2023;62(4):404-406.

PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy
Falkenbach F, Maurer T
NAT REV UROL. 2023;20(12):704-705.

The National Utilization of Non-Operative Management for Small Renal Masses Over 10 Years
Filipas D, Beatrici E, Nolazco J, Qian Z, Marks P, Labban M, Stone B, Pierorazio P, Lipsitz S, Trinh Q, Chang S, Cole A
JNCI CANCER SPECT. 2023;7(6):.

Editorial Comment
Filipas D, Beatrici E, Trinh Q
J UROLOGY. 2023;210(6):863.

Editorial Comment
Filipas D, Cole A
Urol Pract. 2023;10(6):664.

Outcome of patients with epithelialized cavity formation after excessive vesicourethral anastomotic leak post radical prostatectomy
Filipas D, Graefen M, Fisch M, Steuber T, Heinzer H, Schulz R, Kachanov M, Tennstedt P, Hahn L, Ludwig T, Marks P, Hohenhorst L, Pose R
WORLD J UROL. 2023;41(9):2327-2333.

Association of Urinary Incontinence and Depression: Findings from the National Health and Nutrition Examination Survey
Filipas D, Labban M, Beatrici E, Stone B, Qian Z, Zaplatnikova A, Ludwig T, Dahlem R, Fisch M, Cole A, Trinh Q, Dielubanza E
UROLOGY. 2023;181:11-17.

Nephrometry and cumulative morbidity after partial nephrectomy: A standardized assessment of complications in the context of PADUA and R.E.N.A.L. scores
Filipas D, Yu H, Spink C, Rink M, Riechardt S, Gild P, Marks P, Fisch M, Dahlem R, Meyer C, Vetterlein M
UROL ONCOL-SEMIN ORI. 2023;41(1):51.e1-51.e11.

'Case of the Month' from University Medical Center Hamburg-Eppendorf, Germany: Vulvar cancer after female-male gender reassignment
Finger A, Riechardt S, Dahlem R, Soave A, Rink M, Sauter G, Contreras H, Steinhilper L, Fisch M, Vetterlein M, Schuettfort V
BJU INT. 2023;131(6):685-688.

Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Fizazi K, Piulats J, Reaume M, Ostler P, McDermott R, Gingerich J, Pintus E, Sridhar S, Bambury R, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez M, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes C, Watkins S, Chowdhury S, Ryan C, Bryce A
NEW ENGL J MED. 2023;388(8):719-732.

VR, reconstructive urology and the future of surgery education
Frankiewicz M, Vetterlein M, Matuszewski M
NAT REV UROL. 2023;20(6):325-326.

Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries
Garcia C, Tappero S, Piccinelli M, Barletta F, Incesu R, Morra S, Scheipner L, Baudo A, Tian Z, Saad F, Shariat S, Carmignani L, Ahyai S, Longo N, Tilki D, Briganti A, De Cobelli O, Terrone C, Banek S, Kluth L, Chun F, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2023;17(12):E412-419.

Which Men Do or Do Not Achieve Long-Term Symptom Relief After Holmium Laser Enucleation of the Prostate (HoLEP)
Gild P, Vetterlein M, Daoud I, Ludwig T, Soave A, Marks P, Chun F, Ahyai S, Dahlem R, Fisch M, Rink M, Meyer C, Becker A
J ENDOUROL. 2023;37(3):316-322.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A
EUR J CANCER. 2023;185:178-215.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Pablo Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A
EUR UROL. 2023;83(3):267-293.

Hospital rating websites play a minor role for uro-oncologic patients when choosing a hospital for major surgery: results of the German multicenter NAVIGATOR-study
Groeben C, Boehm K, Koch R, Sonntag U, Nestler T, Struck J, Heck M, Baunacke M, Uhlig A, Koelker M, Meyer C, Becker B, Salem J, Huber J, Leitsmann M
WORLD J UROL. 2023;41(2):601-609.

Ultrasound-based "CEUS-Bosniak"classification for cystic renal lesions: an 8-year clinical experience
Herms E, Weirich G, Maurer T, Wagenpfeil S, Preuss S, Sauter A, Heck M, Gärtner A, Hauner K, Autenrieth M, Kübler H, Holzapfel K, Schwarz-Boeger U, Heemann U, Slotta-Huspenina J, Stock K
WORLD J UROL. 2023;41(3):679-685.

Aktuelle Behandlungskonzepte bei der Induratio penis plastica
Hinz J, Soave A, Cremers J
UROLOGE. 2023;62(12):1332-1342.

Regional differences in total hospital costs for radical cystectomy in the United States
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, Kluth L, Becker A, Chun F, Karakiewicz P
SURG ONCOL. 2023;48:101924.

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume
Hoeh B, Garcia C, Wenzel M, Tian Z, Tilki D, Steuber T, Karakiewicz P, Chun F, Mandel P
EUR UROL FOCUS. 2023;9(5):838-842.

Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy
Hoeh B, Hohenhorst J, Wenzel M, Humke C, Preisser F, Wittler C, Brand M, Köllermann J, Steuber T, Graefen M, Tilki D, Karakiewicz P, Becker A, Kluth L, Chun F, Mandel P
J ROBOT SURG. 2023;17(1):177-184.

Conditional survival of stage III non-seminoma testis cancer patients
Incesu R, Barletta F, Tappero S, Morra S, Garcia C, Scheipner L, Piccinelli M, Tian Z, Saad F, Shariat S, de Cobelli O, Ahyai S, Chun F, Longo N, Terrone C, Briganti A, Tilki D, Graefen M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2023;41(10):435.e11-435.e18.

Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection
Kachanov M, Budäus L, Beyersdorff D, Karakiewicz P, Tian Z, Falkenbach F, Tilki D, Maurer T, Sauter G, Graefen M, Leyh-Bannurah S
EUR UROL FOCUS. 2023;9(2):303-308.

Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients
Kamecki H, Mielczarek Ł, Szempliński S, Dębowska M, Rajwa P, Baboudjian M, Klemm J, Rivas J, Modzelewska E, Tayara O, Malewski W, Szostek P, Poletajew S, Kryst P, Sosnowski R, Nyk Ł
CANCERS. 2023;15(22):.

Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis
Kawada T, Laukhtina E, Quhal F, Yanagisawa T, Rajwa P, Pallauf M, von Deimling M, Bianchi A, Pradère B, Fajkovic H, Enikeev D, Gontero P, Roupret M, Seisen T, Araki M, Shariat S
EUR UROL FOCUS. 2023;9(2):236-240.

The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis
Kawada T, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Chlosta M, Pradere B, Teoh J, Babjuk M, Araki M, Shariat S
UROL ONCOL-SEMIN ORI. 2023;41(6):261-273.

Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis
Kawada T, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Majdoub M, Chlosta M, Pradere B, Babjuk M, Gontero P, Moschini M, Araki M, Shariat S
IMMUNOTHERAPY-UK. 2023;15(12):933-943.

Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis
Kawada T, Yanagisawa T, Mostafaei H, Sari Motlagh R, Quhal F, Rajwa P, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pallauf M, Pradere B, Teoh J, Karakiewicz P, Araki M, Shariat S
EUR UROL FOCUS. 2023;9(2):264-274.

MP78-09 SALVAGE DIRECT VISION INTERNAL URETHROTOMY FOR AFTER FAILED SUBSTITUTION URETHROPLASTY: EXTENDED LONG-TERM FOLLOW-UP FROM A RECONSTRUCTIVE REFERRAL CENTER
K. F, Roland D, Phillip M, A. L, Silke R, Margit F, W. V
J UROLOGY. 2023;209(Supplement 4):e1135.

MP64-16 THE EFFECT OF INDETERMINATE PATHOLOGIC MARGINS ON SURVIVAL AFTER SURGERY FOR RENAL CELL CARCINOMA
K. F, V. S, RINK M, Edoardo B, Muhieddine L, S. V, W. V, Mara K, Nicola F, P. C, Quoc-Dien T
J UROLOGY. 2023;209(Supplement 4):e887.

Metastasis-directed therapy: new standard or too early to change paradigm?
Klemm J, Rajwa P, Miszczyk M, Brönimann S, Laukhtina E, Tsuboi I, Matsukawa A, Parizi M, Karakiewicz P, Shariat S
MEMO-MAG EUR MED ONC. 2023;17:45-50.

Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting
Klemm J, Rink M, von Deimling M, Koelker M, Gild P, Shariat S, Dahlem R, Fisch M, Vetterlein M
EUR UROL FOCUS. 2023;9(6):1072-1076.

Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery
Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, van Leeuwen F, van Leeuwen P, de Barros H, van der Poel H, Budäus L, Steuber T, Graefen M, Tennstedt P, Heck M, Horn T, Maurer T
EUR UROL. 2023;83(1):62-69.

(De-)centralized health care delivery, surgical outcome, and psychosocial health of transgender and gender-diverse people undergoing vaginoplasty: results of a retrospective, single-center study
Koehler A, Strauß B, Briken P, Fisch M, Riechardt S, Nieder T
WORLD J UROL. 2023;41(7):1775-1783.

Exploring the Relationship between (De-)Centralized Health Care Delivery, Client-Centeredness, and Health Outcomes: Results of a Retrospective, Single-Center Study of Transgender People Undergoing Vaginoplasty
Koehler A, Strauss B, Briken P, Fisch M, Soave A, Riechardt S, Nieder T
HEALTHCARE-BASEL. 2023;11(12):.

Impact of exercise on physical health status in bladder cancer patients
Koelker M, Alkhatib K, Briggs L, Labban M, Meyer C, Dieli-Conwright C, Kang D, Steele G, Preston M, Clinton T, Chang S, Kibel A, Trinh Q, Mossanen M
CUAJ-CAN UROL ASSOC. 2023;17(1):E8-E14.

Rational peri-operative management of antithrombotic therapy in patients undergoing radical cystectomy: A 30-day morbidity analysis based on the updated European Association of Urology guidelines for standardized complication reporting
Koelker M, Bradtke M, Klemm J, von Deimling M, Gild P, Dahlem R, Fisch M, Rink M, Vetterlein M
EJSO-EUR J SURG ONC. 2023;49(12):107123.

Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients
Köhler D, Sauer M, Klutmann S, Apostolova I, Lehnert W, Budäus L, Knipper S, Maurer T
J NUCL MED. 2023;64(1):59-62.

Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis
Laukhtina E, Kawada T, Quhal F, Yanagisawa T, Rajwa P, von Deimling M, Pallauf M, Bianchi A, Majdoub M, Enikeev D, Fajkovic H, Teoh J, Rouprêt M, Gontero P, Shariat S
EUR UROL FOCUS. 2023;9(2):258-263.

For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy
Laukhtina E, Quhal F, von Deimling M, Kawada T, Yanagisawa T, Rajwa P, Majdoub M, Enikeev D, Shariat S
EUR UROL FOCUS. 2023;9(6):900-902.

Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases
Lunger L, Steinhelfer L, Korn P, Eiber M, Maurer T, Büchler J, Horn T, Gschwend J, Heck M
EUR UROL ONCOL. 2023;6(1):95-98.

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis
Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, Steuber T, Karakiewicz P, Chun F
EUR UROL FOCUS. 2023;9(1):96-105.

Mucomucosal anastomotic non-transecting augmentation (MANTA) urethroplasty: a ventral modification for obliterative strictures
Marks P, Dahlem R, Janisch F, Klemm J, Kühnke L, König F, Ding L, Riechardt S, Fisch M, Vetterlein M
BJU INT. 2023;132(4):444-451.

Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review
Marra G, van Leenders G, Zattoni F, Kesch C, Rajwa P, Cornford P, van der Kwast T, van den Bergh R, Briers E, Van den Broeck T, De Meerleer G, De Santis M, Eberli D, Farolfi A, Gillessen S, Grivas N, Grummet J, Henry A, Lardas M, Lieuw M, Linares Espinós E, Mason M, O'Hanlon S, van Oort I, Oprea-Lager D, Ploussard G, Rouvière O, Schoots I, Stranne J, Tilki D, Wiegel T, Willemse P, Mottet N, Gandaglia G
EUR UROL. 2023;84(1):65-85.

Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
Mehring G, Tilki D, Heinzer H, Steuber T, Pose R, Thederan I, Budäus L, Salomon G, Haese A, Michl U, Maurer T, Huland H, Graefen M, Isbarn H
WORLD J UROL. 2023;41(2):421-425.

Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis
Morra S, Incesu R, Scheipner L, Baudo A, Jannello L, de Angelis M, Siech C, Goyal J, Tian Z, Saad F, Califano G, la Rocca R, Capece M, Shariat S, Ahyai S, Carmignani L, de Cobelli O, Musi G, Tilki D, Briganti A, Chun F, Longo N, Karakiewicz P
CANCERS. 2023;15(18):.

Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls
Morra S, Piccinelli M, Cano Garcia C, Tappero S, Barletta F, Incesu R, Scheipner L, Baudo A, Tian Z, Saad F, Mirone V, Califano G, Colla' Ruvolo C, Shariat S, de Cobelli O, Musi G, Chun F, Terrone C, Briganti A, Tilki D, Ahyai S, Carmignani L, Longo N, Karakiewicz P
INT UROL NEPHROL. 2023;55(12):3119-3128.

Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
Muehlematter U, Schweiger L, Ferraro D, Hermanns T, Maurer T, Heck M, Rupp N, Eiber M, Rauscher I, Burger I
EUR J NUCL MED MOL I. 2023;50(10):3137-3146.

Impact of smoking status on health-related quality of life (HRQoL) in cancer survivors
Nolazco J, Rosner B, Roebuck E, Bergerot C, Rammant E, Iyer G, Tang Y, Al-Faouri R, Filipas D, Leapman M, Mossanen M, Chang S
FRONT ONCOL. 2023;13:1261041.

Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium
Omar M, MacLennan S, Ribal M, Roobol M, Dimitropoulos K, van den Broeck T, MacLennan S, Axelsson S, Gandaglia G, Willemse P, Mastris K, Ransohoff J, Devecseri Z, Abbott T, De Meulder B, Bjartell A, Asiimwe A, N'Dow J
NAT REV UROL. 2023;20(8):494-501.

Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients - A Multicenter, Retrospective, Observational Study
Pallauf M, D'Andrea D, König F, Laukthina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian S, Potretzke A, Mari A, Roumiguié M, Antonelli A, Bianchi A, Khene Z, Sfakianos J, Jamil M, Boormans J, Raman J, Grossmann N, Breda A, Heidenreich A, Del Giudice F, Singla N, Shariat S, Pradere B
J UROLOGY. 2023;209(3):515-524.

Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis
Panunzio A, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu R, Law K, Tian Z, Tafuri A, Tilki D, De Cobelli O, Chun F, Terrone C, Briganti A, Saad F, Shariat S, Bourdeau I, Cerruto M, Antonelli A, Karakiewicz P
J SURG ONCOL. 2023;127(4):560-567.

Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma
Panunzio A, Sorce G, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun F, Tilki D, Terrone C, Briganti A, Kapoor A, Saad F, Shariat S, Cerruto M, Antonelli A, Karakiewicz P
CLIN GENITOURIN CANC. 2023;21(2):295-300.

Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma
Panunzio A, Sorce G, Tappero S, Hohenhorst L, Garcia C, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun F, Tilki D, Terrone C, Briganti A, Kapoor A, Saad F, Shariat S, Cerruto M, Antonelli A, Karakiewicz P
CANCER EPIDEMIOL. 2023;82:102297.

Collecting duct carcinoma: Epidemiology, clinical characteristics and survival
Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun F, Tilki D, Terrone C, Kapoor A, Saad F, Shariat S, Cerruto M, Antonelli A, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2023;41(2):110.e7-110.e14.

African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients
Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun F, Tilki D, Terrone C, Saad F, Shariat S, Bourdeau I, Cerruto M, Antonelli A, Karakiewicz P
ENDOCR-RELAT CANCER. 2023;30(7):.

Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries
Panunzio A, Tappero S, Piccinelli M, Cano Garcia C, Barletta F, Incesu R, Law K, Tian Z, Tafuri A, Saad F, Shariat S, Tilki D, Briganti A, Chun F, DE Cobelli O, Terrone C, Bourdeau I, Cerruto M, Antonelli A, Karakiewicz P
MINERVA UROL NEPHROL. 2023;75(4):443-451.

External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis
Patel S, Ma T, Wong J, Stish B, Dess R, Pilar A, Reddy C, Wedde T, Lilleby W, Fiano R, Merrick G, Stock R, Demanes D, Moran B, Tran P, Krauss D, Abu-Isa E, Pisansky T, Choo C, Song D, Greco S, Deville C, DeWeese T, Tilki D, Ciezki J, Karnes R, Nickols N, Rettig M, Feng F, Berlin A, Tward J, Davis B, Reiter R, Boutros P, Romero T, Horwitz E, Tendulkar R, Steinberg M, Spratt D, Xiang M, Kishan A
INT J RADIAT ONCOL. 2023;115(3):645-653.

European Association of Urology Guidelines on Testicular Cancer: 2023 Update
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D
EUR UROL. 2023;84(3):289-301.

Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients
Piccinelli M, Barletta F, Tappero S, Cano Garcia C, Incesu R, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta F, Ferro M, Saad F, Shariat S, Ahyai S, Longo N, Tilki D, Chun F, Terrone C, Briganti A, de Cobelli O, Musi G, Karakiewicz P
EUR UROL FOCUS. 2023;9(5):799-806.

Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma
Piccinelli M, Morra S, Tappero S, Cano Garcia C, Barletta F, Incesu R, Scheipner L, Baudo A, Tian Z, Luzzago S, Mistretta F, Ferro M, Saad F, Shariat S, Carmignani L, Ahyai S, Tilki D, Briganti A, Chun F, Terrone C, Longo N, de Cobelli O, Musi G, Karakiewicz P
CANCERS. 2023;15(7):.

Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence
Piccinelli M, Panunzio A, Tappero S, Cano Garcia C, Barletta F, Incesu R, Tian Z, Luzzago S, Mistretta F, Ferro M, Saad F, Shariat S, Tilki D, Briganti A, Chun F, Terrone C, Antonelli A, DE Cobelli O, Musi G, Karakiewicz P
MINERVA UROL NEPHROL. 2023;75(3):319-328.

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
Piccinelli M, Tappero S, Cano Garcia C, Barletta F, Incesu R, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta F, Ferro M, Saad F, Shariat S, Ahyai S, Longo N, Tilki D, Briganti A, Chun F, Terrone C, de Cobelli O, Musi G, Karakiewicz P
EUR UROL OPEN SCI. 2023;53:109-115.

Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy
Preisser F, Incesu R, Rajwa P, Chlosta M, Ahmed M, Abreu A, Cacciamani G, Ribeiro L, Kretschmer A, Westhofen T, Smith J, Graefen M, Calleris G, Raskin Y, Gontero P, Joniau S, Sanchez-Salas R, Shariat S, Gill I, Karnes R, Cathcart P, Van Der Poel H, Marra G, Tilki D
CANCERS. 2023;15(12):.

Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S
NAT REV UROL. 2023;20(4):205-216.

Using PSMA imaging for prognostication in localized and advanced prostate cancer
Roberts M, Maurer T, Perera M, Eiber M, Hope T, Ost P, Siva S, Hofman M, Murphy D, Emmett L, Fendler W
NAT REV UROL. 2023;20(1):23-47.

Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer
Sabbagh A, Washington S, Tilki D, Hong J, Feng J, Valdes G, Chen M, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan J, Cooperberg M, Feng F, Roach M, Trock B, Partin A, D'Amico A, Carroll P, Mohamad O
EUR UROL ONCOL. 2023;6(5):501-507.

Rabies post-exposure prophylaxis of international travellers - Results from two major German travel clinics
Saffar F, Heinemann M, Heitkamp C, Stelzl D, Ramharter M, Schunk M, Rothe C, Bühler S
TRAVEL MED INFECT DI. 2023;53:.

Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
Scheipner L, Barletta F, Cano Garcia C, Incesu R, Morra S, Baudo A, Assad A, Tian Z, Saad F, Shariat S, Briganti A, Chun F, Tilki D, Longo N, Carmignani L, Pichler M, Ahyai S, Karakiewicz P
ANN SURG ONCOL. 2023;30(13):8780-8785.

Regional differences in penile cancer patient characteristics and treatment rates across the United States
Scheipner L, Cano Garcia C, Barletta F, Incesu R, Morra S, Baudo A, Assad A, Tian Z, Saad F, Shariat S, Chun F, Briganti A, Tilki D, Longo N, Carmignani L, Leitsmann M, Ahyai S, Karakiewicz P
CANCER EPIDEMIOL. 2023;86:102424.

Regional differences in clear cell metastatic renal cell carcinoma patients across the USA
Scheipner L, Tappero S, Piccinelli M, Barletta F, Garcia C, Incesu R, Morra S, Baudo A, Tian Z, Saad F, Shariat S, Terrone C, De Cobelli O, Briganti A, Chun F, Tilki D, Longo N, Carmignani L, Pichler M, Hutterer G, Ahyai S, Karakiewicz P
WORLD J UROL. 2023;41(11):2991-3000.

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
Seifert R, Emmett L, Rowe S, Herrmann K, Hadaschik B, Calais J, Giesel F, Reiter R, Maurer T, Heck M, Gafita A, Morris M, Fanti S, Weber W, Hope T, Hofman M, Fendler W, Eiber M
EUR UROL. 2023;83(5):405-412.

How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis
Siltari A, Lönnerbro R, Pang K, Shiranov K, Asiimwe A, Evans-Axelsson S, Franks B, Kiran A, Murtola T, Schalken J, Steinbeisser C, Bjartell A, Auvinen A
CLIN GENITOURIN CANC. 2023;21(2):316.e1-316.e11.

Active surveillance in renal transplant patients with prostate cancer: a multicentre analysis
Soeterik T, van den Bergh R, van Melick H, Kelder H, Peretti F, Dariane C, Timsit M, Branchereau J, Mesnard B, Tilki D, Olsburgh J, Kulkarni M, Kasivisvanathan V, Breda A, Biancone L, Gontero P, Gandaglia G, Marra G
WORLD J UROL. 2023;41(3):725-732.

Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma
Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
J UROLOGY. 2023;209(1):81-88.

Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy
Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
EUR UROL FOCUS. 2023;9(1):125-132.

Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
Spohn S, Draulans C, Kishan A, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra A, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer L, Kirste S, Tselis N, Tran P, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann N, Wiegel T, Zilli T, Tree A, Qiu X, Murthy V, Epstein J, Graztke C, Gao X, Grosu A, Kamran S, Zamboglou C
INT J RADIAT ONCOL. 2023;116(3):503-520.

CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
Stanelle-Bertram S, Beck S, Mounogou N, Schaumburg B, Stoll F, Al Jawazneh A, Schmal Z, Bai T, Zickler M, Beythien G, Becker K, de la Roi M, Heinrich F, Schulz C, Sauter M, Krasemann S, Lange P, Heinemann A, van Riel D, Leijten L, Bauer L, van den Bosch T, Lopuhaä B, Busche T, Wibberg D, Schaudien D, Goldmann T, Lüttjohann A, Ruschinski J, Jania H, Müller Z, Pinho Dos Reis V, Krupp-Buzimkic V, Wolff M, Fallerini C, Baldassarri M, Furini S, Norwood K, Käufer C, Schützenmeister N, von Köckritz-Blickwede M, Schroeder M, Jarczak D, Nierhaus A, Welte T, Kluge S, McHardy A, Sommer F, Kalinowski J, Krauss-Etschmann S, Richter F, von der Thüsen J, Baumgärtner W, Klingel K, Ondruschka B, Renieri A, Gabriel G
CELL REP MED. 2023;4(9):101152.

Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy
Tan W, Koelker M, Campain N, Cole A, Labban M, Mossanen M, Barod R, Kibel A, Chang S, Bex A, Trinh Q
EUR UROL FOCUS. 2023;9(2):333-335.

Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program
Thederan I, Pott A, Krueger A, Chandrasekar T, Tennstedt P, Knipper S, Tilki D, Heinzer H, Schulz K, Makarova N, Zyriax B
PROSTATE. 2023;83(10):929-935.

Reply to Z. Mai et al
Tilki D, Chen M, D'Amico A
J CLIN ONCOL. 2023;41(23):3957.

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death
Tilki D, Chen M, Wu J, Huland H, Graefen M, Mohamad O, Cowan J, Feng F, Carroll P, D'Amico A
J CLIN ONCOL. 2023;41(13):2428-2435.

The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis
Tully K, Berg S, Paciotti M, Janisch F, Reese S, Noldus J, Shariat S, Choueiri T, Müller G, McGregor B, Chang S, Trinh Q, Mossanen M
CLIN GENITOURIN CANC. 2023;21(1):63-68.

Treatment Success After Urethroplasty: The Ongoing Quest for a Pragmatic and Universal Definition
Verla W, Mantica G, Waterloos M, Adamowicz J, Frankiewicz M, Cocci A, Rosenbaum C, Campos-Juanatey F, Vetterlein M
EUR UROL FOCUS. 2023;9(4):617-620.

Predefined and Standardized Complication Catalogs: An Essential Tool to Assess Reproducible Estimates of Overall Morbidity After Urological Surgery
Vetterlein M, Leyh-Bannurah S
J ENDOUROL. 2023;37(10):1166-1167.

Re: NIHR Global Research Health Unit on Global Surgery. Routine Sterile Glove and Instrument Change at the Time of Abdominal Wound Closure to Prevent Surgical Site Infection (ChEETAh): A Pragmatic, Cluster-randomised Trial in Seven Low-income and Middle-income Countries. Lancet 2022;400:1767-76
Vetterlein M, Trinh Q, Seisen T
EUR UROL. 2023;83(6):e158.

Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma
von Deimling M, D'Andrea D, Pradere B, Laukhtina E, Yanagisawa T, Kawada T, Majdoub M, Rajwa P, Pallauf M, Singla N, Soria F, Margulis V, Chlosta P, Karakiewicz P, Roupret M, Teoh J, Fisch M, Rink M, Moschini M, Lotan Y, Shariat S
WORLD J UROL. 2023;41(7):1861-1868.

Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer
von Deimling M, Mertens L, van Rhijn B, Lotan Y, Spiess P, Daneshmand S, Black P, Pallauf M, D'Andrea D, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh J, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz P, Babjuk M, Gontero P, Xylinas E, Rink M, Shariat S, Pradere B
EUR UROL OPEN SCI. 2023;51:39-46.

Oncological validation and discriminative ability of pentafecta criteria after open radical cystectomy
von Deimling M, Rink M, Klemm J, Koelker M, König F, Gild P, Khonsari M, Ludwig T, Marks P, Dahlem R, Fisch M, Vetterlein M
BJU INT. 2023;131(1):90-100.

Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy
von Deimling M, Schuettfort V, D'Andrea D, Pradere B, Grossmann N, Kawada T, Yanagisawa T, Majdoub M, Laukhtina E, Rajwa P, Quhal F, Mostafaei H, Fajkovic H, Teoh J, Moschini M, Karakiewicz P, Fisch M, Rink M, Shariat S
CLIN GENITOURIN CANC. 2023;21(4):430-441.

MP12-10 THE EFFECT OF LIMITED ENGLISH PROFICIENCY ON PSA SCREENING RATES IN AMERICAN MEN
V. S, Muhieddine L, K. F, Edoardo B, Nicola F, (Jason) Q, S. V, R. L, S. K, P. C, Quoc-Dien T
J UROLOGY. 2023;209(Supplement 4):e137.

Outcomes and Complication Rates of Cuff Downsizing in the Treatment of Worsening or Persistent Incontinence After Artificial Urinary Sphincter Implantation
Weis S, Ludwig T, Bahassan O, Gild P, Vetterlein M, Fisch M, Dahlem R, Maurer V
INT NEUROUROL J. 2023;27(2):139-145.

Epidemiology of Unconventional Histological Subtypes of Urethral Cancer
Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Hoeh B, Tian Z, Saad F, Briganti A, Tilki D, Banek S, Mandel P, Becker A, Kluth L, Chun F, Karakiewicz P
UROL INT. 2023;107(1):15-22.

Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy
Wenzel M, Garcia C, Hoeh B, Jorias C, Humke C, Koll F, Tselis N, Rödel C, Graefen M, Tilki D, Chun F, Mandel P
PROSTATE. 2023;83(14):1365-1372.

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat S, Saad F, Tilki D, Graefen M, Kluth L, Briganti A, Mandel P, Montorsi F, Chun F, Karakiewicz P
PROSTATE CANCER P D. 2023;26(4):807-808.

MRI as a screening tool for prostate cancer: current evidence and future challenges
Würnschimmel C, Chandrasekar T, Hahn L, Esen T, Shariat S, Tilki D
WORLD J UROL. 2023;41(4):921-928.

Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis
Yanagisawa T, Kawada T, Mori K, Shim S, Mostafaei H, Sari Motlagh R, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pallauf M, Pradere B, Kimura T, Shariat S, Rajwa P
BJU INT. 2023;132(4):365-379.

Role of pelvic drain and timing of urethral catheter removal following RARP: a systematic review and meta-analysis
Yanagisawa T, Kawada T, Mostafaei H, Sari Motlagh R, Quhal F, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Pradere B, Karakiewicz P, Miki J, Kimura T, Shariat S
BJU INT. 2023;132(2):132-145.

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
Yanagisawa T, Kawada T, Quhal F, Bekku K, Laukhtina E, Rajwa P, von Deimling M, Majdoub M, Chlosta M, Pradere B, Mori K, Kimura T, Schmidinger M, Karakiewicz P, Shariat S
WORLD J UROL. 2023;41(7):1763–1774.

Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis
Yanagisawa T, Kawada T, Rajwa P, Mostafaei H, Motlagh R, Quhal F, Laukhtina E, König F, Pallauf M, Pradere B, Karakiewicz P, Nyirady P, Kimura T, Egawa S, Shariat S
UROL ONCOL-SEMIN ORI. 2023;41(4):177-191.

Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023
Yanagisawa T, Kawada T, von Deimling M, Laukhtina E, Kimura T, Shariat S
CURR OPIN UROL. 2023;33(4):258-268.

Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis
Yanagisawa T, Mori K, Quhal F, Kawada T, Mostafaei H, Laukhtina E, Rajwa P, Sari Motlagh R, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat S
BJU INT. 2023;131(5):540-552.

Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis
Yanagisawa T, Quhal F, Kawada T, Bekku K, Laukhtina E, Rajwa P, von Deimling M, Chlosta M, Pradere B, Karakiewicz P, Mori K, Kimura T, Schmidinger M, Shariat S
IMMUNOTHERAPY-UK. 2023;15(15):1309-1322.

Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer
Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradère B, Abufaraj M, Moschini M, Karakiewicz P, Iwatani K, Miki J, Kimura T, Shariat S
BJU INT. 2023;131(6):643-659.

A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer
Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukthina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradere B, Moschini M, Karakiewicz P, Teoh J, Miki J, Kimura T, Shariat S
EUR UROL FOCUS. 2023;9(3):463-479.

An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer
Yanagisawa T, Rajwa P, Kawada T, Bekku K, Laukhtina E, von Deimling M, Majdoub M, Chlosta M, Karakiewicz P, Heidenreich A, Kimura T, Shariat S
CURR ONCOL. 2023;30(2):2194-2216.

Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis
Yanagisawa T, Rajwa P, Kawada T, Mori K, Fukuokaya W, Petrov P, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pradere B, Kramer G, Kimura T, Shariat S
J UROLOGY. 2023;210(3):416-429.

Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review
Yanagisawa T, Rajwa P, Quhal F, Kawada T, Bekku K, Laukhtina E, von Deimling M, Chlosta M, Karakiewicz P, Kimura T, Shariat S
J PERS MED. 2023;13(4):.

Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients
Yu H, Gild P, Pompe R, Vetterlein M, Ludwig T, Soave A, Kölker M, Maurer V, Marks P, Becker A, Punke M, Fisch M, Rink M, Dahlem R, Meyer C
UROL INT. 2023;107(4):336-343.

Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study
Zattoni F, Marra G, Martini A, Kasivisvanathan V, Grummet J, Harkin T, Ploussard G, Olivier J, Chiu P, Valerio M, Marquis A, Gontero P, Guo H, Zhuang J, Frydenberg M, Moon D, Morlacco A, Kretschmer A, Barletta F, Heidegger I, Tilki D, van den Bergh R, Dal Moro F, Briganti A, Montorsi F, Novara G, Gandaglia G
EUR UROL FOCUS. 2023;9(4):621-628.

Auswirkungen der COVID-19 Pandemie auf die urologische Weiterbildung in Deutschland
Aksoy C, Reimold P, Borgmann H, Kölker M, Cebulla A, Struck J, Zehe V, Nestler T, von Landenberg N, Uhlig A, Boehm K, Leitsmann M
AKTUEL UROL. 2022;53(4):317-324.

Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer
Amsberg G, Zilles M, Mansour W, Gild P, Alsdorf W, Kaune M, Böckelmann L, Hauschild J, Krisp C, Rohlfing T, Saygi C, Alawi M, Zielinski A, Langebrake C, Su X, Perner S, Tilki D, Schluter H, Graefen M, Dyshlovoy S, Bokemeyer C
INT J MOL SCI. 2022;23(23):.

Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis
Aydh A, Motlagh R, Abufaraj M, Mori K, Katayama S, Grossmann N, Rajwa P, Mostafai H, Laukhtina E, Pradere B, Quhal F, Schuettfort V, Briganti A, Karakiewicz P, Fajkovic H, Shariat S
ARAB J UROL. 2022;20(2):71-80.

Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype
Barletta F, Tappero S, Panunzio A, Incesu R, Cano Garcia C, Piccinelli M, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun F, de Cobelli O, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
CANCERS. 2022;14(23):.

Early testicular maturation is sensitive to depletion of spermatogonial pool in sickle cell disease
Benninghoven-Frey K, Neuhaus N, Lahtinen A, Krallmann C, Portela J, Jarisch A, Nordhoff V, Soave A, Ba Omar H, Sundin M, Langenskiöld C, Kliesch S, Stukenborg J, Jahnukainen K
HAEMATOLOGICA. 2022;107(4):975-979.

Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen – wann und welcher Tracer?
Berliner C, Kesch C, Fendler W, Eiber M, Maurer T
UROLOGE. 2022;61(4):384-391.

Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy
Bravi C, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann K, Boeri L, Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat S, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill I, Mottrie A, Karakiewicz P, Montorsi F, Briganti A
EUR UROL ONCOL. 2022;5(3):285-295.

Contemporary Management of Male Anterior Urethral Strictures by Reconstructive Urology Experts-Results from an International Survey among ESGURS Members
Campos-Juanatey F, Fes-Ascanio E, Adamowicz J, Castiglione F, Cocci A, Mantica G, Rosenbaum C, Verla W, Vetterlein M, Waterloos M, Kluth L
J CLIN MED. 2022;11(9):.

Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis
Chierigo F, Wenzel M, Würnschimmel C, Flammia R, Horlemann B, Tian Z, Saad F, Chun F, Tilki D, Shariat S, Gallucci M, Borghesi M, Suardi N, Terrone C, Karakiewicz P
CRIT REV ONCOL HEMAT. 2022;169:.

Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study
de Barros H, van Oosterom M, Donswijk M, Hendrikx J, Vis A, Maurer T, van Leeuwen F, van der Poel H, van Leeuwen P
EUR UROL. 2022;82(1):97-105.

New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein
Dyshlovoy S, Shubina L, Makarieva T, Hauschild J, Strewinsky N, Guzii A, Menshov A, Popov R, Grebnev B, Busenbender T, Oh-Hohenhorst S, Maurer T, Tilki D, Graefen M, Bokemeyer C, Stonik V, von Amsberg G
SCI REP-UK. 2022;12(1):.

Increasing the attractiveness of surgical disciplines for students: Implications of a robot-assisted hands-on training course for medical education
Ekrutt J, Leyh-Bannurah S, Knipper S, Schramm F, Beyer B, Maurer T, Graefen M, Budäus L
FRONT SURG. 2022;9:.

[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature
Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, Fanti S, Hofman M
EUR UROL ONCOL. 2022;5(3):273-282.

EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy
Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik B, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy D, Oprea-Lager D, O'Sullivan J, Oyen W, Rouvière O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A
EUR UROL ONCOL. 2022;5(5):530-536.

Gemeinsam Zukunft gestalten
Fisch M, Schüttfort V
UROLOGE. 2022;61(9):923-924.

Zum 74. Kongress der Deutschen Gesellschaft für Urologie
Fisch M, Schüttfort V
UROLOGE. 2022;61(Suppl 3):125-126.

Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma
Flammia R, Chierigo F, Würnschimmel C, Horlemann B, Hoeh B, Sorce G, Tian Z, Leonardo C, Tilki D, Terrone C, Saad F, Shariat S, Montorsi F, Chun F, Gallucci M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2022;40(4):165.e9-165.e15.

Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer
Flammia R, Chierigo F, Würnschimmel C, Wenzel M, Horlemann B, Tian Z, Borghesi M, Leonardo C, Tilki D, Shariat S, Anceschi U, Chun F, Terrone C, Saad F, Gallucci M, Karakiewicz P
CENT EUR J UROL. 2022;75(3):240-247.

Urethroscopic Findings Following Urethroplasty Predict the Need for Secondary Intervention in the Long Term: A Multi-Institutional Study from Trauma and Urologic Reconstructive Network of Surgeons. Letter
Frankiewicz M, Cocci A, Vetterlein M, Verla W, Campos-Juanatey F, Castiglione F, Mantica G, Rosenbaum C, Waterloos M, Adamowicz J, Kluth L
J UROLOGY. 2022;208(5):957-958.

Association Between Alcohol Intake and Prostate Specific Antigen Screening: Results From a National Behavioral Survey
Frego N, Alkhatib K, Labban M, Koelker M, Lughezzani G, Osman N, Solomon S, Lipsitz S, Trinh Q, Cole A
UROLOGY. 2022;167:115-120.

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A
EUR UROL. 2022;82(1):115-141.

Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study
Grossmann N, Pradere B, D'Andrea D, Schuettfort V, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser C, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati C, Nyirady P, Karakiewicz P, Fajkovic H, Shariat S
CLIN GENITOURIN CANC. 2022;20(3):227-236.

Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study
Grossmann N, Rajwa P, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Katayama S, Motlagh R, Fankhauser C, Mattei A, Moschini M, Chlosta P, van Rhijn B, Teoh J, Compérat E, Babjuk M, Abufaraj M, Karakiewicz P, Shariat S, Pradere B
EUR UROL OPEN SCI. 2022;39:14-21.

Risk factors for concomitant positive midstream urine culture in patients presenting with symptomatic ureterolithiasis
Grossmann N, Schuettfort V, Betschart J, Becker A, Hermanns T, Keller E, Fankhauser C, Kranzbühler B
UROLITHIASIS. 2022;50(3):293-302.

Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy
Grossmann N, Schuettfort V, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh R, Aydh A, Katayama S, Moschini M, Fankhauser C, Hermanns T, Abufaraj M, Mun D, Zimmermann K, Fajkovic H, Haydter M, Shariat S
UROL ONCOL-SEMIN ORI. 2022;40(3):106.e11-106.e19.

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
Heidegger I, Kesch C, Kretschmer A, Tsaur I, Ceci F, Valerio M, Tilki D, Marra G, Preisser F, Fankhauser C, Zattoni F, Chiu P, Puche-Sanz I, Olivier J, van den Bergh R, Kasivisvanathan V, Pircher A, Virgolini I, Gandaglia G
THER ADV MED ONCOL. 2022;14:.

Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, Kluth L, Becker A, Chun F, Karakiewicz P
J SURG ONCOL. 2022;126(4):830-837.

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, Kluth L, Mandel P, Chun F, Karakiewicz P
CANCERS. 2022;14(5):.

Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Kluth L, Mandel P, Becker A, Chun F, Karakiewicz P
PROSTATE. 2022;82(6):687-694.

Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Kluth L, Mandel P, Chun F, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2022;40(9):407.e9-407.e19.

Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE INT. 2022;10(1):21-27.

Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Panunzio A, Chierigo F, Nimer N, Tian Z, Saad F, Gallucci M, Briganti A, Shariat S, Graefen M, Tilki D, Antonelli A, Terrone C, Kluth L, Becker A, Chun F, Karakiewicz P
SURG ONCOL. 2022;42:.

IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, Kosiba M, Kluth L, Becker A, Chun F, Karakiewicz P
SEMIN ONCOL. 2022;49(5):394-399.

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat S, Graefen M, Tilki D, Antonelli A, Kosiba M, Mandel P, Kluth L, Becker A, Chun F, Karakiewicz P
EUR UROL OPEN SCI. 2022;44:94-101.

Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration
Hoeh B, Preisser F, Wenzel M, Humke C, Wittler C, Köllermann J, Bodelle B, Bernatz S, Steuber T, Tilki D, Graefen M, Karakiewicz P, Becker A, Kluth L, Chun F, Mandel P
UROL ONCOL-SEMIN ORI. 2022;40(2):59.e7-59.e12.

Anatomical Fundamentals and Current Surgical Knowledge of Prostate Anatomy Related to Functional and Oncological Outcomes for Robotic-Assisted Radical Prostatectomy
Hoeh B, Wenzel M, Hohenhorst L, Köllermann J, Graefen M, Haese A, Tilki D, Walz J, Kosiba M, Becker A, Banek S, Kluth L, Mandel P, Karakiewicz P, Chun F, Preisser F
FRONT SURG. 2022;8:.

Urethral Sphincter Length but Not Prostatic Apex Shape in Preoperative MRI Is Associated with Mid-Term Continence Rates after Radical Prostatectomy
Hoeh B, Wenzel M, Müller M, Wittler C, Schlenke E, Hohenhorst J, Köllermann J, Steuber T, Graefen M, Tilki D, Bernatz S, Karakiewicz P, Preisser F, Becker A, Kluth L, Mandel P, Chun F
DIAGNOSTICS. 2022;12(3):.

Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
Hoeh B, Würnschimmel C, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat S, Tilki D, Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2022;82(6):676-686.

Osteoprotektion als Baustein der Therapie des metastasierten Prostatakarzinoms: Behandlungsrealität in Deutschland und Entscheidungspfade zur Therapieoptimierung
Hupe M, Müller M, Struck J, Wießmeyer J, Ozimek T, Steuber T, Gschwend J, Hammerer P, Kramer M, Merseburger A
AKTUEL UROL. 2022;53(1):43-53.

Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies
Kachanov M, Leyh-Bannurah S, Roberts M, Sauer M, Beyersdorff D, Boiko S, Maurer T, Steuber T, Graefen M, Budäus L
J UROLOGY. 2022;207(2):333-340.

Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis
Kachanov M, Vetterlein M, Soave A, Karakiewicz P, Liakos N, Jankowski T, Pose R, Mandrek M, Fisch M, Witt J, Graefen M, Leyh-Bannurah S
AGING MALE. 2022;25(1):54-61.

Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis
Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort V, Quhal F, Motlagh R, Laukhtina E, Grossmann N, Rajwa P, Aydh A, König F, Mathieu R, Nyirady P, Karakiewicz P, Nasu Y, Shariat S
SCAND J UROL. 2022;56(2):85-93.

Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis
Katayama S, Mori K, Pradere B, Yanagisawa T, Mostafaei H, Quhal F, Motlagh R, Laukhtina E, Grossmann N, Rajwa P, Aydh A, König F, Karakiewicz P, Araki M, Nasu Y, Shariat S
J ROBOT SURG. 2022;16(6):1233-1247.

Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma
Katayama S, Mori K, Schuettfort V, Pradere B, Mostafaei H, Quhal F, Rajwa P, Motlagh R, Laukhtina E, Moschini M, Grossmann N, Araki M, Teoh J, Rouprêt M, Margulis V, Enikeev D, Karakiewicz P, Abufaraj M, Compérat E, Nasu Y, Shariat S
EUR UROL FOCUS. 2022;8(3):761-768.

Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Katayama S, Schuettfort V, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann N, Aydh A, Rajwa P, König F, Karakiewicz P, Haydter M, Moschini M, Abufaraj M, Lotan Y, Lee R, Trinh Q, Compérat E, Teoh J, Nasu Y, Shariat S
J CANCER RES CLIN. 2022;148(11):3091-3102.

Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer:A Systematic Review and Meta-analysis
Kawada T, Yanagisawa T, Rajwa P, Sari Motlagh R, Mostafaei H, Quhal F, Laukhtina E, Aydh A, König F, Pallauf M, Pradere B, Ceci F, Baltzer P, Hacker M, Rasul S, Karakiewicz P, Araki M, Nasu Y, Shariat S
EUR UROL ONCOL. 2022;5(4):390-400.

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts
Kishan A, Steigler A, Denham J, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong J, Stish B, Dess R, Pilar A, Reddy C, Wedde T, Lilleby W, Fiano R, Merrick G, Stock R, Demanes D, Moran B, Tran P, Martin S, Martinez-Monge R, Krauss D, Abu-Isa E, Pisansky T, Choo C, Song D, Greco S, Deville C, McNutt T, DeWeese T, Ross A, Ciezki J, Tilki D, Karnes R, Tosoian J, Nickols N, Bhat P, Shabsovich D, Juarez J, Jiang T, Ma T, Xiang M, Philipson R, Chang A, Kupelian P, Rettig M, Feng F, Berlin A, Tward J, Davis B, Reiter R, Steinberg M, Elashoff D, Boutros P, Horwitz E, Tendulkar R, Spratt D, Romero T
JAMA ONCOL. 2022;8(3):e216871.

Operative Versorgung von Harnröhrenverletzungen nach pelvinen Traumata
Klemm J, Marks P, Dahlem R, Riechardt S, Fisch M, Vetterlein M
UROLOGE. 2022;61(6):602-608.

Case - Salvage nerve-sparing radical cystectomy for pediatric rhabdomyosarcoma of the bladder
Klemm J, Rink M, Riechardt S, Stiel C, Büscheck F, Sauter G, Dahlem R, Fisch M, Vetterlein M
CUAJ-CAN UROL ASSOC. 2022;16(11):E575-E578.

Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria
Koehler D, Sauer M, Karimzadeh A, Apostolova I, Klutmann S, Adam G, Knipper S, Maurer T, Berliner C
EJNMMI RES. 2022;12(1):.

Körperliche Aktivität von Patientinnen und Patienten mit Blasenkrebs
Koelker M
Uroforum. 2022;36-37.

Understanding Hospital-Level Patterns of Nonoperative Management for Low-risk Thyroid and Kidney Cancer
Koelker M, Krimphove M, Alkhatib K, Nabi J, Kuo L, Lipsitz S, Choueiri T, Chang S, Doherty G, Kibel A, Trinh Q, Cole A
JAMA NETW OPEN. 2022;5(11):.

Editorial Commentary: Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Koelker M, Qian Z, Cole A
Urol Pract. 2022;9(2):149-149.

Re: Christopher Soliman, Niranjan J. Sathianathen, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.022
Koelker M, Rink M, Vetterlein M
EUR UROL. 2022;81(6):e150-e151.

Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics
König F, Grossmann N, Soria F, D'Andrea D, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene Z, Fujita K, Raman J, Breda A, Fontana M, Sfakianos J, Pfail J, Laukhtina E, Rajwa P, Pallauf M, Cacciamani G, van Doeveren T, Boormans J, Antonelli A, Jamil M, Abdollah F, Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian S, Rouprêt M, Rink M, Shariat S, Pradere B
CANCERS. 2022;14(7):.

Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review
König F, Pradere B, Grossmann N, Quhal F, Rajwa P, Laukhtina E, Mori K, Katayama S, Yanagisawa T, Mostafai H, Motlagh R, Aydh A, Dahlem R, Shariat S, Rink M
TRANSL CANCER RES. 2022;11(4):908-917.

Preprostatic lymph nodes in prostate cancer hot or not?: Impact on oncological outcome after radical prostatectomy
Korten M, Pose R, Graefen M, Tilki D, Michl U, Knipper S, Beyer B
WORLD J UROL. 2022;40(9):2231-2237.

Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives
Kretschmer A, van den Bergh R, Martini A, Marra G, Valerio M, Tsaur I, Heidegger I, Kasivisvanathan V, Kesch C, Preisser F, Fankhauser C, Zattoni F, Ceci F, Olivier J, Chiu P, Puche-Sanz I, Thibault C, Gandaglia G, Tilki D
CANCERS. 2022;14(1):.

Validation of 18F-rhPSMA-7 and 18F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
Kroenke M, Schweiger L, Horn T, Haller B, Schwamborn K, Wurzer A, Maurer T, Wester H, Eiber M, Rauscher I
J NUCL MED. 2022;63(12):1809-1814.

Urethral Stricture Formation Following Cuff Erosion of AMS Artificial Urinary Sphincter Devices: Implication for a Less Invasive Explantation Approach
Kuhlencord K, Dahlem R, Vetterlein M, Abrams-Pompe R, Maurer V, Meyer C, Riechardt S, Fisch M, Ludwig T, Marks P
FRONT SURG. 2022;9:.

Re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9
Kulkarni S, Joshi P, Bandini M, Morey A, Santucci R, Fisch M, Djinovic R, Montorsi F, Barbagli G, Mundy T
EUR UROL. 2022;81(1):e14-e15.

Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence
Laine C, Gandaglia G, Valerio M, Heidegger I, Tsaur I, Olivier J, Ceci F, van den Bergh R, Kretschmer A, Thibault C, Chiu P, Tilki D, Kasivisvanathan V, Preisser F, Zattoni F, Fankhauser C, Kesch C, Puche-Sanz I, Moschini M, Pradere B, Ploussard G, Marra G
CURR OPIN UROL. 2022;32(1):69-84.

Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
Langbein T, Wang H, Rauscher I, Krönke M, Knorr K, Wurzer A, Schwamborn K, Maurer T, Horn T, Haller B, Wester H, Eiber M
J NUCL MED. 2022;63(9):1334-1342.

Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis
Lardas M, Grivas N, Debray T, Zattoni F, Berridge C, Cumberbatch M, Van den Broeck T, Briers E, De Santis M, Farolfi A, Fossati N, Gandaglia G, Gillessen S, O'Hanlon S, Henry A, Liew M, Mason M, Moris L, Oprea-Lager D, Ploussard G, Rouviere O, Schoots I, van der Kwast T, van der Poel H, Wiegel T, Willemse P, Yuan C, Grummet J, Tilki D, van den Bergh R, Lam T, Cornford P, Mottet N
EUR UROL FOCUS. 2022;8(3):674-689.

Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence
Laukhtina E, Abufaraj M, Al-Ani A, Ali M, Mori K, Moschini M, Quhal F, Sari Motlagh R, Pradere B, Schuettfort V, Mostafaei H, Katayama S, Grossmann N, Fajkovic H, Soria F, Enikeev D, Shariat S
EUR UROL FOCUS. 2022;8(2):447-456.

Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study
Laukhtina E, Boehm A, Peyronnet B, Bravi C, Batista Da Costa J, Soria F, D'Andrea D, Rajwa P, Quhal F, Yanagisawa T, König F, Mostafaei H, Enikeev D, Ingels A, Verhoest G, D'Hondt F, Mottrie A, Joniau S, Van Poppel H, de la Taille A, Bensalah K, Bruyère F, Shariat S, Pradere B
WORLD J UROL. 2022;40(7):1689-1696.

Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma
Laukhtina E, Hassler M, Pradere B, Yanagisawa T, Quhal F, Rajwa P, Sari Motlagh R, König F, Pallauf M, Kawada T, Mostafaei H, D'Andrea D, Enikeev D, Shariat S
EUR UROL FOCUS. 2022;8(6):1683-1686.

Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma
Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz P, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort V, Enikeev D, Shariat S
MINERVA UROL NEPHROL. 2022;74(3):329-336.

Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T, Mostafaei H, König F, Aydh A, Pradere B, Enikeev D, Karakiewicz P, Schmidinger M, Shariat S
EUR UROL ONCOL. 2022;5(1):120-124.

Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder
Laukhtina E, Schuettfort V, D'Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann N, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz P, Fajkovic H, Scherr D, Compérat E, Nyirady P, Rink M, Enikeev D, Shariat S
MOL CARCINOGEN. 2022;61(1):5-18.

Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach
Laukhtina E, Schuettfort V, D'Andrea D, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann N, Rajwa P, Karakiewicz P, Schmidinger M, Fajkovic H, Enikeev D, Shariat S
WORLD J UROL. 2022;40(3):747-754.

Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16
Lennartz M, Csomós H, Bernreuther C, Büscheck F, Fraune C, Simon R, Sauter G, Steurer S, Eichenauer T, Dahlem R, Fisch M, Riechardt S, Rink M, Minner S, Höflmayer D
UROL ONCOL-SEMIN ORI. 2022;40(7):348.e1-348.e8.

Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy
Lonati C, Baumeister P, Ornaghi P, Di Trapani E, De Cobelli O, Rink M, Karnes R, Poyet C, Simone G, Afferi L, Necchi A, Briganti A, Montorsi F, Krajewski W, Antonelli A, Cerruto M, Zamboni S, Simeone C, Mordasini L, Mattei A, Moschini M
EUR UROL FOCUS. 2022;8(2):457-464.

Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies
Luzzago S, Piccinelli M, Marvaso G, Laukhtina E, Miura N, Schuettfort V, Mori K, Aydh A, Ferro M, Mistretta F, Fusco N, Petralia G, Jereczek-Fossa B, Shariat S, Karakiewicz P, de Cobelli O, Musi G
WORLD J UROL. 2022;40(2):443-451.

Urethral fixation to improve urinary continence recovery after radical cystectomy with ileal neobladder: the EAU YAU Reconstructive Working Party point of view
Mantica G, Cocci A, Vetterlein M, Verla W, Campos-Juanatey F, Castiglione F, Rosenbaum C, Waterloos M, Adamowicz J, Frankiewicz M, Kluth L
MINERVA UROL NEPHROL. 2022;74(3):365-367.

Reaching Consensus for Comprehensive Outcome Measurement After Urethral Stricture Surgery: Development of Study Protocol for Stricture-Fecta Criteria
Mantica G, Verla W, Cocci A, Frankiewicz M, Adamowicz J, Campos-Juanatey F, Rosenbaum C, Waterloos M, Kluth L, Vetterlein M
RES REP UROL. 2022;14:423-426.

Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series
Marra G, Agnello M, Giordano A, Soria F, Oderda M, Dariane C, Timsit M, Branchereau J, Hedli O, Mesnard B, Tilki D, Olsburgh J, Kulkarni M, Kasivisvanathan V, Breda A, Biancone L, Gontero P
EUR UROL. 2022;82(6):639-645.

Prostate Cancer in Renal Transplant Recipients: Results from a Large Contemporary Cohort
Marra G, Soria F, Peretti F, Oderda M, Dariane C, Timsit M, Branchereau J, Hedli O, Mesnard B, Tilki D, Olsburgh J, Kulkarni M, Kasivisvanathan V, Lebacle C, Rodriguez-Faba O, Breda A, Soeterik T, Gandaglia G, Todeschini P, Biancone L, Gontero P, On Behalf Of The Collaborators
CANCERS. 2022;15(1):.

Penile Flap Inversion Vaginoplasty in Transgender Women: Contemporary Morbidity and Learning-Curve Analysis From a High-Volume Reconstructive Center
Maurer V, Howaldt M, Feldmann I, Ludwig T, Vetterlein M, Gild P, Weis S, Marks P, Soave A, Meyer C, Fisch M, Dahlem R, Riechardt S
FRONT SURG. 2022;9:.

Reporting and grading of complications for intracorporeal robot-assisted radical cystectomy: An in-depth short-term morbidity assessment using the novel Comprehensive Complication Index®
Mendrek M, Witt J, Sarychev S, Liakos N, Addali M, Wagner C, Karagiotis T, Schuette A, Soave A, Fisch M, Reinisch J, Herrmann T, Vetterlein M, Leyh-Bannurah S
WORLD J UROL. 2022;40(7):1679-1688.

Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma
Mori K, Katayama S, Laukhtina E, Schuettfort V, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann N, Rajwa P, Zimmermann K, Karakiewicz P, Abufaraj M, Fajkovic H, Rouprêt M, Margulis V, Enikeev D, Egawa S, Shariat S
CLIN GENITOURIN CANC. 2022;20(1):95.e1-95.e6.

Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort V, Kramer G, Abufaraj M, Karakiewicz P, Kimura T, Egawa S, Shariat S
BJU INT. 2022;129(4):423-433.

Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis
Mori K, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort V, Sari Motlagh R, Grossmann N, Rajwa P, Ploussard G, Briganti A, Kimura T, Egawa S, Papalia R, Carrion D, Fiori C, Shariat S, Esperto F, Pradere B
MINERVA UROL NEPHROL. 2022;74(3):292-301.

ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Mori K, Schuettfort V, Egawa S, Compérat E, Shariat S
ANN SURG ONCOL. 2022;29(8):5317-5318.

The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy
Mori K, Schuettfort V, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann N, Rajwa P, König F, Aydh A, Soria F, Moschini M, Karakiewicz P, Lotan Y, Scherr D, Haydter M, Nyirady P, Teoh J, Egawa S, Compérat E, Shariat S
EUR UROL FOCUS. 2022;8(4):972-979.

Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy
Mori K, Schuettfort V, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann N, Rajwa P, Teoh J, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz P, Lotan Y, Scherr D, Egawa S, Compérat E, Shariat S
ANN SURG ONCOL. 2022;29(8):5307-5316.

Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis
Mori K, Schuettfort V, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Quhal F, Moschini M, Soria F, Teoh J, D'Andrea D, Abufaraj M, Albisinni S, Krajewski W, Egawa S, Karakiewicz P, Rink M, Shariat S
EUR UROL FOCUS. 2022;8(6):1687-1695.

Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review
Moris L, Gandaglia G, Vilaseca A, Van den Broeck T, Briers E, De Santis M, Gillessen S, Grivas N, O'Hanlon S, Henry A, Lam T, Lardas M, Mason M, Oprea-Lager D, Ploussard G, Rouviere O, Schoots I, van der Poel H, Wiegel T, Willemse P, Yuan C, Grummet J, Tilki D, van den Bergh R, Cornford P, Mottet N
EUR UROL FOCUS. 2022;8(3):690-700.

The placebo and nocebo effects in functional urology
Mostafaei H, Jilch S, Carlin G, Mori K, Quhal F, Pradere B, Laukhtina E, Schuettfort V, Aydh A, Sari Motlagh R, Roehrborn C, Shariat S, Hajebrahimi S
NAT REV UROL. 2022;19(3):171-189.

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis
Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin G, Mori K, Quhal F, Pradere B, Grossmann N, Laukhtina E, Schuettfort V, Aydh A, Sari Motlagh R, König F, Roehrborn C, Katayama S, Rajwa P, Hajebrahimi S, Shariat S
EUR UROL FOCUS. 2022;8(4):1072-1089.

ESSM Position Statement on Surgical Treatment of Peyronie's Disease
Osmonov D, Ragheb A, Ward S, Blecher G, Falcone M, Soave A, Dahlem R, van Renterghem K, Christopher N, Hatzichristodoulou G, Preto M, Garaffa G, Albersen M, Bettocchi C, Corona G, Reisman Y
SEX MED-UK. 2022;10(1):.

A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery
Pallauf M, König F, D'Andrea D, Laukhtina E, Mostafaei H, Motlagh R, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuardi L, Soria F, Karakiewicz P, Rouprêt M, Rink M, Lotan Y, Margulis V, Singla N, Xylinas E, Shariat S, Pradere B
FRONT ONCOL. 2022;12:.

Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients
Panunzio A, Tappero S, Garcia C, Piccinelli M, Barletta F, Incesu R, Tian Z, Tafuri A, Tilki D, Briganti A, DE Cobelli O, Chun F, Terrone C, Saad F, Shariat S, Bourdeau I, Cerruto M, Antonelli A, Karakiewicz P
ANTICANCER RES. 2022;42(11):5579-5585.

Diabetes mellitus lowers the chance of short-term urinary continence recovery in prostate cancer patients undergoing radical prostatectomy
Philippi A, Mandel P, Hohenhorst J, Wenzel M, Humke C, Wittler C, Köllermann J, Steuber T, Graefen M, Tilki D, Karakiewicz P, Preisser F, Becker A, Kluth L, Chun F, Hoeh B
CENT EUR J UROL. 2022;75(2):162-168.

Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer
Piccinelli M, Luzzago S, Marvaso G, Laukhtina E, Miura N, Schuettfort V, Mori K, Colombo A, Ferro M, Mistretta F, Fusco N, Petralia G, Jereczek-Fossa B, Shariat S, Karakiewicz P, de Cobelli O, Musi G
WORLD J UROL. 2022;40(6):1447-1454.

GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder
Plage H, Samtleben H, Hofbauer S, Kornienko K, Weinberger S, Bruch P, Elezkurtaj S, Roßner F, Schallenberg S, Kluth M, Lennartz M, Blessin N, Marx A, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Minner S, Simon R, Sauter G, Klatte T, Schlomm T, Horst D, Zecha H
HUM PATHOL. 2022;130:10-17.

Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer
Preisser F, Heinze A, S Abrams-Pompe R, Budäus L, Chun F, Graefen M, Huland H, Tilki D
PROSTATE. 2022;82(9):949-956.

Multimodale Therapie des Hochrisiko- und lokal fortgeschrittenen Prostatakarzinoms
Preisser F, Tilki D
UROLOGE. 2022;61(12):1341-1344.

Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy
Preisser F, Wang N, Abrams-Pompe R, Chun F, Graefen M, Huland H, Tilki D
UROL ONCOL-SEMIN ORI. 2022;40(4):161.e9-161.e14.

Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer
Preisser F, Würnschimmel C, Pose R, Heinze A, Steuber T, Michl U, Salomon G, Mandel P, Graefen M, Tilki D
PROSTATE. 2022;82(2):254-259.

Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions
Rachubinski P, Witt J, Budäus L, Zinke J, Fangmeyer B, Spieker T, Vetterlein M, Rahbar K, Kachanov M, Leyh-Bannurah S
J UROLOGY. 2022;208(6):1203-1213.

Reply by Authors
Rachubinski P, Witt J, Budäus L, Zinke J, Fangmeyer B, Spieker T, Vetterlein M, Rahbar K, Kachanov M, Leyh-Bannurah S
J UROLOGY. 2022;208(6):1213.

Large-scale analyses of the X chromosome in 2,354 infertile men discover recurrently affected genes associated with spermatogenic failure
Riera-Escamilla A, Vockel M, Nagirnaja L, Xavier M, Carbonell A, Moreno-Mendoza D, Pybus M, Farnetani G, Rosta V, Cioppi F, Friedrich C, Oud M, van der Heijden G, Soave A, Diemer T, Ars E, Sánchez-Curbelo J, Kliesch S, O'Bryan M, Ruiz-Castañe E, Azorín F, Veltman J, Aston K, Conrad D, Tüttelmann F, Krausz C
AM J HUM GENET. 2022;109(8):1458-1471.

Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis and Network Meta-Analysis with Focus on Different Energy Sources
Sari Motlagh R, Rajwa P, Mori K, Laukhtina E, Aydh A, Katayama S, Yanagisawa T, König F, Grossmann N, Pradere B, Mostafai H, Quhal F, Karakiewicz P, Babjuk M, Shariat S
J ENDOUROL. 2022;36(4):535-547.

Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy
Sari Motlagh R, Schuettfort V, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann N, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz P, Lotan Y, Comprate E, Moschini M, Gontero P, Shariat S
INT J UROL. 2022;29(7):676-683.

Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis
Sari Motlagh R, Yanagisawa T, Kawada T, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Huebner N, Baltzer P, Karakiewicz P, Heidenreich A, Shariat S
PROSTATE CANCER P D. 2022;25(2):187-198.

Impact of obesity on perioperative, functional and oncological outcomes after robotic-assisted radical prostatectomy in a high-volume center
Sarychev S, Witt J, Wagner C, Oelke M, Schuette A, Liakos N, Karagiotis T, Mendrek M, Kachanov M, Graefen M, Vetterlein M, Meyer C, Tian Z, Leyh-Bannurah S
WORLD J UROL. 2022;40(6):1419-1425.

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
Schmidinger M, Motzer R, Rolland F, Staehler M, Rink M, Retz M, Csoszi T, McCaffrey J, De Giorgi U, Caserta C, Duran I, Benzaghou F, Clary D, Albiges L, Choueiri T, Tannir N
ACTA ONCOL. 2022;61(1):52-57.

A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma
Schuettfort V, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M, Karakiewicz P, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann N, Katayama S, Pradere B, Shariat S
BJU INT. 2022;129(2):182-193.

Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder
Schuettfort V, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz P, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann N, Katayama S, Pradere B, Shariat S
MINERVA UROL NEPHROL. 2022;74(3):302-312.

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer
Schuettfort V, Pradere B, Trinh Q, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz P, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, Shariat S
CANCER IMMUNOL IMMUN. 2022;71(1):85-95.

Auswahlverfahren wissenschaftlicher Beiträge zum DGU-Kongress 2022
Schüttfort V
UROLOGE. 2022;61(Suppl 3):127-128.

The added value of PSMA PET/MR radiomics for prostate cancer staging
Solari E, Gafita A, Schachoff S, Bogdanović B, Villagrán Asiares A, Amiel T, Hui W, Rauscher I, Visvikis D, Maurer T, Schwamborn K, Mustafa M, Weber W, Navab N, Eiber M, Hatt M, Nekolla S
EUR J NUCL MED MOL I. 2022;49(2):527-538.

Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates
Sorce G, Flammia R, Hoeh B, Chierigo F, Hohenhorst L, Panunzio A, Stabile A, Gandaglia G, Tian Z, Tilki D, Terrone C, Gallucci M, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
PROSTATE. 2022;82(10):1040-1050.

Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level
Sorce G, Hoeh B, Flammia R, Chierigo F, Hohenhorst L, Panunzio A, Nimer N, Tian Z, Gandaglia G, Tilki D, Terrone C, Gallucci M, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
PROSTATE. 2022;82(12):1210-1218.

Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity
Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Nimer N, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
WORLD J UROL. 2022;40(12):2971-2978.

Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity
Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun F, Antonelli A, Saad F, Shariat S, Montorsi F, Briganti A, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2022;40(11):493.e9-493.e16.

Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death
Tilki D, Chen M, Wu J, Huland H, Graefen M, D'Amico A
J CLIN ONCOL. 2022;40(20):2186-2192.

Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis
Tilki D, Preisser F, Thamm R, Pompe R, Chun F, Graefen M, Siegmann A, Böhmer D, Budach V, Wiegel T
CANCERS. 2022;14(3):.

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ekeke Onyeanunam N, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Pablo Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A
EUR UROL. 2022;82(1):6-11.

Distinct loiasis infection states and associated clinical and hematological manifestations in patients from Gabon
Veletzky L, Eberhardt K, Hergeth J, Stelzl D, Zoleko Manego R, Mombo-Ngoma G, Kreuzmair R, Burger G, Adegnika A, Agnandji S, Matsiegui P, Boussinesq M, Mordmüller B, Ramharter M
PLOS NEGLECT TROP D. 2022;16(9):.

Urinary Diversion With or Without Concomitant Cystectomy for Benign Conditions: A Comparative Morbidity Assessment According to the Updated European Association of Urology Guidelines on Reporting and Grading of Complications
Vetterlein M, Buhné M, Yu H, Klemm J, von Deimling M, Gild P, Koelker M, Dahlem R, Fisch M, Soave A, Rink M
EUR UROL FOCUS. 2022;8(6):1831-1839.

Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges—a narrative review
von Deimling M, Laukhtina E, Pradere B, Pallauf M, Klemm J, Fisch M, Shariat S, Rink M
TRANSL ANDROL UROL. 2022;11(11):1598-1610.

Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?
von Deimling M, Pallauf M, Bianchi A, Laukhtina E, Karakiewicz P, Rink M, Shariat S, Pradere B
CURR OPIN UROL. 2022;32(5):567-574.

The current role of precision surgery in oligometastatic prostate cancer
von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, Yanagisawa T, Kawada T, Karakiewicz P, Gontero P, Pradere B, Ploussard G, Rink M, Shariat S
ESMO OPEN. 2022;7(6):100597.

Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Becker A, Roos F, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2022;82(1):78-85.

The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer
Wenzel M, Dariane C, Saad F, Karakiewicz P, Mandel P, Chun F, Tilki D, Graefen M, Delouya G, Taussky D, Würnschimmel C
UROL ONCOL-SEMIN ORI. 2022;40(2):57.e15-57.e23.

PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy
Wenzel M, Hussein R, Maurer T, Karakiewicz P, Tilki D, Graefen M, Würnschimmel C
UROL ONCOL-SEMIN ORI. 2022;40(1):7.e1-7.e8.

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat S, Saad F, Tilki D, Graefen M, Kluth L, Briganti A, Mandel P, Montorsi F, Chun F, Karakiewicz P
PROSTATE CANCER P D. 2022;25(2):139-148.

Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma
Wenzel M, Siron N, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, Shariat S, Saad F, Briganti A, Tilki D, Banek S, Kluth L, Roos F, Chun F, Karakiewicz P
CANCER CAUSE CONTROL. 2022;33(1):25-35.

Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy
Wenzel M, Würnschimmel C, Chierigo F, Flammia R, Tian Z, Shariat S, Gallucci M, Terrone C, Saad F, Tilki D, Graefen M, Becker A, Kluth L, Mandel P, Chun F, Karakiewicz P
EUR UROL FOCUS. 2022;8(5):1133-1140.

Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy
Wenzel M, Würnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, Shariat S, Saad F, Tilki D, Graefen M, Mandel P, Roos F, Chun F, Karakiewicz P
EUR UROL FOCUS. 2022;8(3):710-717.

Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis
Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat S, Saad F, Briganti A, Tilki D, Graefen M, Kluth L, Roos F, Mandel P, Chun F, Karakiewicz P
EUR UROL FOCUS. 2022;8(2):399-408.

Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy
Willemse P, Davis N, Grivas N, Zattoni F, Lardas M, Briers E, Cumberbatch M, De Santis M, Dell'Oglio P, Donaldson J, Fossati N, Gandaglia G, Gillessen S, Grummet J, Henry A, Liew M, MacLennan S, Mason M, Moris L, Plass K, O'Hanlon S, Omar M, Oprea-Lager D, Pang K, Paterson C, Ploussard G, Rouvière O, Schoots I, Tilki D, van den Bergh R, Van den Broeck T, van der Kwast T, van der Poel H, Wiegel T, Yuan C, Cornford P, Mottet N, Lam T
EUR UROL. 2022;81(4):337-346.

Radiation therapy after radical prostatectomy is associated with higher other-cause mortality
Würnschimmel C, Wenzel M, Chierigo F, Flammia R, Horlemann B, Tian Z, Saad F, Briganti A, Shariat S, Gallucci M, Suardi N, Chun F, Tilki D, Graefen M, Karakiewicz P
CANCER CAUSE CONTROL. 2022;33(5):769-777.

External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients
Würnschimmel C, Wenzel M, Chierigo F, Flammia R, Tian Z, Saad F, Briganti A, Shariat S, Suardi N, Terrone C, Gallucci M, Chun F, Tilki D, Graefen M, Karakiewicz P
INT J UROL. 2022;29(1):17-24.

Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients
Würnschimmel C, Wenzel M, Chierigo F, Simone Flammia R, Tian Z, Saad F, Briganti A, Shariat S, Suardi N, Terrone C, Gallucci M, Chun F, Tilki D, Graefen M, Karakiewicz P
INT J UROL. 2022;29(1):96.

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis
Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh R, Aydh A, König F, Grossmann N, Pradere B, Miki J, Kimura T, Egawa S, Shariat S
INT J CLIN ONCOL. 2022;27(1):59-71.

Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis
Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh R, Aydh A, König F, Grossmann N, Pradere B, Miki J, Schmidinger M, Egawa S, Shariat S
IMMUNOTHERAPY-UK. 2022;14(9):709-725.

Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis
Yanagisawa T, Mori K, Kawada T, Motlagh R, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat S
UROL ONCOL-SEMIN ORI. 2022;40(7):315-330.

En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology
Yanagisawa T, Mori K, Motlagh R, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, D'Andrea D, Compérat E, Miki J, Kimura T, Egawa S, Shariat S
J UROLOGY. 2022;207(4):754-768.

The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature
Abrams-Pompe R, Fanti S, Schoots I, Moore C, Turkbey B, Vickers A, Walz J, Steuber T, Eastham J
EUR UROL ONCOL. 2021;4(3):370-395.

Ex vivo testis explant culture of human testicular tissue
Aden N, Soave A, Kordes U, Bleeke M, Salzbrunn A, von Kopylow K
J Reprodmed Endokrinol. 2021;2020(17 (Supplementum 1), 39-40):.

The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration
Afferi L, Zamboni S, Karnes R, Roghmann F, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz G, Hendricksen K, Voskuilen C, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez-Maestro M, Martínez-Piñeiro L, Aziz A, Shariat S, Abufaraj M, Xylinas E, Moschini M
WORLD J UROL. 2021;39(2):443-451.

Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study
Amiel T, Würnschimmel C, Heck M, Horn T, Nguyen N, Budäus L, Knipper S, Wenzel M, Rauscher I, Eiber M, Wang H, Maurer T
J UROLOGY. 2021;205(6):1663-1670.

Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy
Aydh A, Mori K, D'Andrea D, Motlagh R, Abufaraj M, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz P, Luzzago S, Briganti A, Trinh Q, Parizi M, Tilki D, Enikeev D, Shariat S
INT J CLIN ONCOL. 2021;26(9):1729-1735.

Squamous cell carcinoma of the renal pelvis in a patient with long-term spinal cord injury-a case report
Balzer O, Böthig R, Schöps W, Thietje R, Soave A, Kadhum T, Golka K
SPINAL CORD SER CASE. 2021;7(1):.

A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research
Bates A, Ayers J, Kostakopoulos N, Lumsden T, Schoots I, Willemse P, Yuan Y, van den Bergh R, Grummet J, van der Poel H, Rouvière O, Moris L, Cumberbatch M, Lardas M, Liew M, Van den Broeck T, Gandaglia G, Fossati N, Briers E, De Santis M, Fanti S, Gillessen S, Oprea-Lager D, Ploussard G, Henry A, Tilki D, van der Kwast T, Wiegel T, N'Dow J, Mason M, Cornford P, Mottet N, Lam T
EUR UROL ONCOL. 2021;4(3):405-423.

Implementation of radioguided surgery in prostate cancer
Berrens A, van Leeuwen P, Maurer T, Hadaschik B, Krafft U
Q J NUCL MED MOL IM. 2021;65(3):202-214.

Physiotherapy and combined cognitive-behavioural therapy for patients with chronic pelvic pain syndrome: results of a non-randomised controlled feasibility trial
Brünahl C, Klotz S, Dybowski C, Albrecht R, Höink J, Fisch M, Ketels G, Löwe B
BMJ OPEN. 2021;11(12):.

Image-guided surgery: from classical techniques to novel aspects and approaches
Buckle T, Schilling C, Maurer T, Vidal-Sicart S
Q J NUCL MED MOL IM. 2021;65(3):187-189.

Y-chromosome loss is frequent in male renal tumors
Büscheck F, Fraune C, Garmestani S, Simon R, Kluth M, Hube-Magg C, Ketterer K, Eichelberg C, Höflmayer D, Jacobsen F, Wittmer C, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M
ANN TRANSL MED. 2021;9(3):209.

A non-diploid DNA status is linked to poor prognosis in renal cell cancer
Büscheck F, Fraune C, Kluth M, Lennartz M, Simon R, Hube-Magg C, Morlock C, Barbieri S, Wahl C, Eichelberg C, Möller-Koop C, Höflmayer D, Wittmer C, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M
WORLD J UROL. 2021;39(3):829-837.

Fighting the 'tobacco epidemic' - A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer
Cacciamani G, Matulewicz R, Kumar R, Teoh J, Mari A, Pradere B, Gomez Rivas J, Necchi A, Kumar Pal S, Ribal M, Shariat S, Rink M
UROL ONCOL-SEMIN ORI. 2021;39(12):793-796.

Positive predictive value and correct detection rate of 18F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard
Chantadisai M, Buschner G, Krönke M, Rauscher I, Langbein T, Nekolla S, Schiller K, Heck M, Maurer T, Wurzer A, Wester H, D'Alessandria C, Weber W, Eiber M
J NUCL MED. 2021;62(7):968-974.

Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates
Collà Ruvolo C, Stolzenbach L, Nocera L, Deuker M, Mistretta F, Luzzago S, Tian Z, Longo N, Graefen M, Chun F, Saad F, Briganti A, De Cobelli O, Mirone V, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2021;39(1):74.e1-74.e7.

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Cornford P, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry A, der Kwast T, Lam T, Lardas M, Liew M, Mason M, Moris L, Oprea-Lager D, der Poel H, Rouvière O, Schoots I, Tilki D, Wiegel T, Willemse P, Mottet N
EUR UROL. 2021;79(2):263-282.

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
Deek M, Van der Eecken K, Phillips R, Parikh N, Isaacsson Velho P, Lotan T, Kishan A, Maurer T, Boutros P, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng F, Eisenberger M, Carducci M, Pienta K, Markowski M, Paller C, Antonarakis E, Berlin A, Ost P, Tran P
EUR UROL. 2021;80(5):632-640.

Editorial: Advances in reconstructive urology
Dropkin B, Morey A, Fisch M
CURR OPIN UROL. 2021;31(5):479.

Mismatch repair deficiency occurs very rarely in seminomas
Dum D, Steurer S, Simon R, Zimmermann P, Burandt E, Clauditz T, Fisch M, Rink M, Dahlem R, Höppner W, Zecha H, Doh O, Matthies C, Wilczak W, Sauter G, Fraune C
TRANSL ANDROL UROL. 2021;10(3):1048-1055.

High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma
Eichenauer T, Simmendinger L, Fraune C, Mandelkow T, Blessin N, Kluth M, Hube-Magg C, Möller K, Clauditz T, Weidemann S, Dahlem R, Fisch M, Riechardt S, Simon R, Sauter G, Büscheck F, Rink M
WORLD J UROL. 2021;39(2):481-490.

68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy
Esen T, Falay O, Tarim K, Armutlu A, Koseoglu E, Kilic M, Seymen H, Sarikaya A, Kiremit M, Balbay M, Canda A, Baydar D, Kordan Y, Demirkol M, Tilki D
EUR UROL FOCUS. 2021;7(2):288-293.

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser C, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans J, Fischer S, Fizazi K, Gremmels H, Mayor de Castro J, Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna M
EUR UROL. 2021;80(1):4-6.

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Fanti S, Goffin K, Hadaschik B, Herrmann K, Maurer T, MacLennan S, Oprea-Lager D, Oyen W, Rouvière O, Mottet N, Bjartell A
EUR J NUCL MED MOL I. 2021;48(2):469-476.

Nociception level-guided opioid administration in radical retropubic prostatectomy
Funcke S, Pinnschmidt H, Brinkmann C, Wesseler S, Beyer B, Fischer M, Nitzschke R
BRIT J ANAESTH. 2021;126(2):516-524.

Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases
Gild P, Lenke L, Pompe R, Vetterlein M, Ludwig T, Soave A, Chun F, Ahyai S, Dahlem R, Fisch M, Rink M, Meyer C, Becker A
J ENDOUROL. 2021;35(5):639-646.

Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets
Grossmann N, Schuettfort V, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz P, Shariat S, D'Andrea D
ONCOTARGETS THER. 2021;14:315-324.

Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response
Grubmüller B, Jahrreiss V, Brönimann S, Quhal F, Mori K, Heidenreich A, Briganti A, Tilki D, Shariat S
CURR ONCOL. 2021;28(4):2881-2892.

A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I, Necchi A, Pircher A, Tsaur I, Marra G, Kasivisvanathan V, Kretschmer A, Mathieu R, Ceci F, van den Bergh R, Thibault C, Tilki D, Valerio M, Surcel C, Gandaglia G
EUR UROL ONCOL. 2021;4(5):745-754.

Outcome groups and a practical tool to predict success of shock wave lithotripsy in daily clinical routine
Hirsch B, Abt D, Güsewell S, Langenauer J, Betschart P, Pratsinis M, Vetterlein M, Schmid H, Wildermuth S, Zumstein V
WORLD J UROL. 2021;39(3):943-951.

Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy
Hoeh B, Preisser F, Wenzel M, Humke C, Wittler C, Hohenhorst J, Volckmann-Wilde M, Köllermann J, Steuber T, Graefen M, Tilki D, Karakiewicz P, Becker A, Kluth L, Chun F, Mandel P
CURR ONCOL. 2021;28(6):4738-4747.

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
Hoeh B, Würnschimmel C, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat S, Tilki D, Kluth L, Mandel P, Chun F, Karakiewicz P
FRONT ONCOL. 2021;11:.

Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
Hoeh B, Würnschimmel C, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat S, Tilki D, Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2021;81(16):1374-1381.

Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer C, Iwata T, Parizi M, Sauter G, Fisch M, Shariat S, Dahlem R, Rink M
FRONT SURG. 2021;8:.

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
Janisch F, Klotzbücher T, Marks P, Kienapfel C, Meyer C, Yu H, Fühner C, Hillemacher T, Mori K, Mostafei H, Shariat S, Fisch M, Dahlem R, Rink M
WORLD J UROL. 2021;39(8):2977-2985.

Health-related quality of life and self-reported cognitive function in patients with delayed neurocognitive recovery after radical prostatectomy: a prospective follow-up study
Kahl U, Callsen S, Beck S, Pinnschmidt H, von Breunig F, Haese A, Graefen M, Zöllner C, Fischer M
HEALTH QUAL LIFE OUT. 2021;19(1):64.

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort V, Quhal F, Motlagh R, Mostafaei H, Grossmann N, Rajwa P, Moschini M, Mathieu R, Abufaraj M, D'Andrea D, Compérat E, Haydter M, Egawa S, Nasu Y, Shariat S
WORLD J UROL. 2021;39(12):4355-4361.

Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis
Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort V, Quhal F, Motlagh R, Laukhtina E, Moschini M, Grossmann N, Nasu Y, Shariat S, Fajkovic H
INT J CLIN ONCOL. 2021;26(9):1587-1599.

Radical Prostatectomy: Sequelae in the Course of Time
Kesch C, Heidegger I, Kasivisvanathan V, Kretschmer A, Marra G, Preisser F, Tilki D, Tsaur I, Valerio M, van den Bergh R, Fankhauser C, Zattoni F, Gandaglia G
FRONT SURG. 2021;8:.

Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer
Kim D, Chen M, Wu J, Huland H, Graefen M, Tilki D, D'Amico A
CANCER-AM CANCER SOC. 2021;127(13):2222-2228.

Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10
Kim D, Tilki D, D'Amico A
CANCER-AM CANCER SOC. 2021;127(22):4312.

Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features
Kishan A, Karnes R, Romero T, Wong J, Motterle G, Tosoian J, Trock B, Klein E, Stish B, Dess R, Spratt D, Pilar A, Reddy C, Levin-Epstein R, Wedde T, Lilleby W, Fiano R, Merrick G, Stock R, Demanes D, Moran B, Braccioforte M, Huland H, Tran P, Martin S, Martínez-Monge R, Krauss D, Abu-Isa E, Alam R, Schwen Z, Chang A, Pisansky T, Choo R, Song D, Greco S, Deville C, McNutt T, DeWeese T, Ross A, Ciezki J, Boutros P, Nickols N, Bhat P, Shabsovich D, Juarez J, Chong N, Kupelian P, D'Amico A, Rettig M, Berlin A, Tward J, Davis B, Reiter R, Steinberg M, Elashoff D, Horwitz E, Tendulkar R, Tilki D
JAMA NETW OPEN. 2021;4(7):.

Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy
Knipper S, Ascalone L, Ziegler B, Hohenhorst J, Simon R, Berliner C, van Leeuwen F, van der Poel H, Giesel F, Graefen M, Eiber M, Heck M, Horn T, Maurer T
EUR UROL. 2021;79(4):537-544.

Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer
Knipper S, Budäus L, Graefen M, Maurer T
EUR UROL FOCUS. 2021;7(2):294-296.

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
Knipper S, Riethdorf S, Werner S, Tilki D, Graefen M, Pantel K, Maurer T
EUR UROL OPEN SCI. 2021;34:55-58.

Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579)
Knipper S, Tilki D, Graefen M, Maurer T
BJU INT. 2021;128(3):301-303.

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?
Knipper S, von Amsberg G, Stolzenbach F, Steuber T, Heck M, Eiber M, Berliner C, Maurer T
ASIAN J UROL. 2021;8(2):248-250.

The Impact of COVID-19 on Cancer Screening and Treatment.
Koelker M, Labban M, Trinh Q
American Urological Association News. 2021;12-13.

Interdisziplinär integriert oder dezentral verteilt? Versorgungssettings im Kontext feminisierender Genitaloperationen – Studienprotokoll zur Hamburger TransCare-Studie
Köhler A, Strauß B, Briken P, Riechardt S, Fisch M, Nieder T
PSYCHOTHER PSYCH MED. 2021;71(3-04):132-140.

Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy
König F, Shariat S, Karakiewicz P, Mun D, Rink M, Pradere B
CURR OPIN UROL. 2021;31(4):291-296.

"Dos und Don'ts" bei Hypogonadismus
König F, Soave A
Uro-News. 2021;25:20–25.

Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate
Kretschmer A, Mazzone E, Barletta F, Leni R, Heidegger I, Tsaur I, van den Bergh R, Valerio M, Marra G, Kasivisvanathan V, Buchner A, Stief C, Briganti A, Montorsi F, Tilki D, Gandaglia G
EUR UROL FOCUS. 2021;7(6):1247-1253.

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review
Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, Mathieu R, de Visschere P, Valerio M, van den Bergh R, Marra G, Thibault C, Ost P, Gandaglia G, Tilki D
EUR UROL FOCUS. 2021;7(4):742-751.

Harnröhrenstrikturen der Frau: Aktuelles zu Diagnostik und Therapie
Kühnke L, Fisch M, Vetterlein M
AKTUEL UROL. 2021;52(3):260-267.

Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
Laukhtina E, Mori K, Mostafaei H, Merseburger A, Nyirady P, Moschini M, Quhal F, Schuettfort V, Pradere B, Motlagh R, Enikeev D, Shariat S
IMMUNOTHERAPY-UK. 2021;13(11):917-929.

Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)
Laukhtina E, Mostafaei H, D'Andrea D, Pradere B, Quhal F, Mori K, Miura N, Schuettfort V, Sari Motlagh R, Aydh A, Abufaraj M, Karakiewicz P, Enikeev D, Kimura S, Shariat S
WORLD J UROL. 2021;39(6):1961-1968.

Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma
Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz P, Margulis V, Quhal F, Motlagh R, Mostafaei H, Mori K, Schuettfort V, Enikeev D, Shariat S
TRANSL ANDROL UROL. 2021;10(2):609-619.

Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review
Laukhtina E, Pradere B, Mori K, Schuettfort V, Quhal F, Mostafaei H, Sari Motlagh R, Aydh A, Moschini M, Enikeev D, Karakiewicz P, Abufaraj M, Shariat S
UROL ONCOL-SEMIN ORI. 2021;39(8):471-479.

Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review
Laukhtina E, Pradere B, Mori K, Schuettfort V, Quhal F, Mostafaei H, Sari Motlangh R, Katayama S, Grossmann N, Moschini M, Enikeev D, Shariat S
UROL ONCOL-SEMIN ORI. 2021;39(3):180-190.

Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis
Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Pradere B, Schuettfort V, Mostafaei H, Katayama S, Grossmann N, Rajwa P, Resch I, Enikeev D, Karakiewicz P, Shariat S, Schmidinger M
UROL ONCOL-SEMIN ORI. 2021;39(11):764-773.

Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes
Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann N, König F, Aydh A, Pradere B, Resch I, Merseburger A, Enikeev D, Shariat S
CRIT REV ONCOL HEMAT. 2021;169:.

Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review
Laukhtina E, Sari Motlagh R, Mori K, Quhal F, Schuettfort V, Mostafaei H, Katayama S, Grossmann N, Ploussard G, Karakiewicz P, Briganti A, Abufaraj M, Enikeev D, Pradere B, Shariat S
WORLD J UROL. 2021;39(11):4085-4099.

Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS)
Lebentrau S, Wakileh G, Schostak M, Schmid H, Suarez-Ibarrola R, Merseburger A, Hutterer G, Necknig U, Rink M, Bögemann M, Kluth L, Pycha A, Burger M, Brookman-May S, Bründl J, May M
FRONT ONCOL. 2021;11:.

Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer
Leyh-Bannurah S, Kachanov M, Karakiewicz P, Beyersdorff D, Pompe R, Oh-Hohenhorst S, Fisch M, Maurer T, Graefen M, Budäus L
WORLD J UROL. 2021;39(1):81-88.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial
Mandel P, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T
EUR UROL FOCUS. 2021;7(1):55-62.

Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making
Mandel P, Wenzel M, Hoeh B, Welte M, Preisser F, Inam T, Wittler C, Humke C, Köllermann J, Wild P, Würnschimmel C, Tilki D, Graefen M, Kluth L, Karakiewicz P, Chun F, Becker A
CURR ONCOL. 2021;28(3):2123-2133.

Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?
Marra G, Calleris G, Alessio P, Oderda M, Palou J, Joniau S, Piechaud T, Smelzo S, Morlacco A, Sharma V, Tilki D, Van der Poel H, Veerman H, Karnes R, Gontero P
EUR UROL FOCUS. 2021;7(4):807-811.

Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer
Marx A, Koopmann L, Höflmayer D, Büscheck F, Hube-Magg C, Steurer S, Eichenauer T, Clauditz T, Wilczak W, Simon R, Sauter G, Izbicki J, Huland H, Heinzer H, Graefen M, Haese A, Schlomm T, Bernreuther C, Lebok P, Bonk S
CANCER BIOL MED. 2021;18(1):245-255.

68Ga-PSMA-11 PET/mpMRT zur Lokaldetektion des primären Prostatakarzinom bei Männern mit negativer Vorbiopsie
Maurer T, Gesterkamp H, Nguyen N, Westenfelder K, Gschwend J, Budäus L, Rauscher I, Vag T, Weber W, Eiber M
AKTUEL UROL. 2021;52(2):143-148.

Continence and Complication Rates of Artificial Urinary Sphincter Devices (AMS 800) for Parkinson and Stroke Patients with Incontinence after Prostate Surgery: Retrospective Analysis of a Prospective Database
Maurer V, Stahlberg J, Schiffmann I, Marks P, Rosenbaum C, Soave A, Vetterlein M, Meyer C, Riechardt S, Fisch M, Ludwig T, Dahlem R
UROL INT. 2021;105(3-4):225-231.

Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration
Miura N, Mori K, Laukhtina E, Schuettfort V, Abufaraj M, Teoh J, Luzzago S, Stolzenbach F, Deuker M, Karakiewicz P, Briganti A, Enikeev D, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Saika T, Shariat S
JPN J CLIN ONCOL. 2021;51(7):1149-1157.

Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer
Möller K, Fraune C, Blessin N, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, Büscheck F, Höppner W, Matthies C, Doh O, Krech T, Marx A, Zecha H, Rink M, Steurer S, Clauditz T
INT UROL NEPHROL. 2021;53(12):2493-2503.

First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis
Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort V, Sari Motlagh R, Soria F, Teoh J, Egawa S, Powles T, Shariat S
EUR J CANCER. 2021;151:35-48.

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort V, D'Andrea D, Egawa S, Bensalah K, Schmidinger M, Powles T, Shariat S
CANCER TREAT REV. 2021;99:.

Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration
Mori K, Resch I, Miura N, Laukhtina E, Schuettfort V, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi M, Abufaraj M, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz P, Briganti A, Enikeev D, Rouprêt M, Margulis V, Egawa S, Shariat S
CANCER IMMUNOL IMMUN. 2021;70(9):2641-2650.

Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens
Mori K, Sharma V, Comperat E, Sato S, Laukhtina E, Schuettfort V, Pradere B, Parizi M, Karakiewicz P, Egawa S, Tilki D, Boorjian S, Shariat S
EJSO-EUR J SURG ONC. 2021;47(5):1172-1178.

Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer
Mori K, Sharma V, Comperat E, Sato S, Laukhtina E, Schuettfort V, Pradere B, Sari Motlagh R, Mostafaei H, Quhal F, Kardoust Parizi M, Abufaraj M, Karakiewicz P, Egawa S, Tilki D, Boorjian S, Shariat S
ANN SURG ONCOL. 2021;28(13):9179-9187.

ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Mori K, Sharma V, Egawa S, Tilki D, Boorjian S, Shariat S
ANN SURG ONCOL. 2021;28(13):9188-9189.

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch M, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry A, van der Kwast T, Lam T, Lardas M, Liew M, Mason M, Moris L, Oprea-Lager D, van der Poel H, Rouvière O, Schoots I, Tilki D, Wiegel T, Willemse P, Cornford P
EUR UROL. 2021;79(2):243-262.

Editorial comment: Clinical Recommendations From the European Society for Sexual Medicine Exploring Partner Expectations, Satisfaction in Male and Phalloplasty Cohorts, the Impact of Penile Length, Girth and Implant Type, Reservoir Placement, and the Influence of Comorbidities and Social Circumstances
Osmonov D, Christopher A, Blecher G, Falcone M, Soave A, Dahlem R, Javaroni V
INT BRAZ J UROL. 2021;47(3):663-665.

Vesico-urethral anastomotic stenosis following radical prostatectomy: a multi-institutional outcome analysis with a focus on endoscopic approach, surgical sequence, and the impact of radiation therapy
Pfalzgraf D, Worst T, Kranz J, Steffens J, Salomon G, Fisch M, Reiß C, Vetterlein M, Rosenbaum C
WORLD J UROL. 2021;39(1):89-95.

Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
Philipson R, Romero T, Wong J, Stish B, Dess R, Spratt D, Pilar A, Reddy C, Wedde T, Lilleby W, Fiano R, Merrick G, Stock R, Demanes D, Moran B, Braccioforte M, Tran P, Martin S, Martinez-Monge R, Krauss D, Abu-Isa E, Valle L, Chong N, Pisansky T, Choo C, Song D, Greco S, Deville C, McNutt T, DeWeese T, Ross A, Ciezki J, Tilki D, Karnes R, Klein E, Tosoian J, Boutros P, Nickols N, Bhat P, Shabsovich D, Juarez J, Kupelian P, Rettig M, Berlin A, Tward J, Davis B, Reiter R, Steinberg M, Elashoff D, Horwitz E, Tendulkar R, Kishan A
EUR UROL. 2021;80(2):142-146.

Significant reduction of lymphoceles after radical prostatectomy and pelvic lymph node dissection
Pose R, Knipper S, Würnschimmel C, Tennstedt P, Michl U, Maurer T, Graefen M, Steuber T
BJU INT. 2021;128(6):728-733.

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Preisser F, Chun F, Banek S, Wenzel M, Graefen M, Steuber T, Tilki D, Mandel P
PROSTATE INT. 2021;9(3):113-118.

Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer
Preisser F, Gandaglia G, Arad F, Karakiewicz P, Bandini M, Pompe R, Montorsi F, Graefen M, Huland H, Briganti A, Tilki D
PROSTATE CANCER P D. 2021;24(1):193-201.

Primary Ta high grade bladder tumors: Determination of the risk of progression
Quhal F, D'Andrea D, Soria F, Moschini M, Abufaraj M, Rouprêt M, Karakiewicz P, Yang L, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Shariat S
UROL ONCOL-SEMIN ORI. 2021;39(2):132.e7-132.e11.

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort V, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat S, Schmidinger M
EUR UROL ONCOL. 2021;4(5):755-765.

Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort V, Karakiewicz P, Rouprêt M, Enikeev D, Rink M, Abufaraj M, Shariat S
WORLD J UROL. 2021;39(9):3345-3352.

Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer
Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort V, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz P, Chlosta P, Shariat S
MINERVA UROL NEFROL. 2021;73(5):610-615.

The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer
Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann N, Schuettfort V, König F, Aydh A, Motlagh R, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz P, Briganti A, Shariat S, Heidenreich A
PROSTATE. 2021;81(11):765-771.

Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy
Rajwa P, Huebner N, Hostermann D, Grossmann N, Schuettfort V, Korn S, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Motlagh R, Yanagisawa T, Aydh A, Bryniarski P, Pradere B, Paradysz A, Baltzer P, Grubmüller B, Shariat S
J PERS MED. 2021;11(11):.

Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer
Rajwa P, Schuettfort V, D'Andrea D, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh R, Mostafaei H, Grossmann N, Huebner N, Aulitzky A, Mun D, Briganti A, Karakiewicz P, Fajkovic H, Shariat S
UROL ONCOL-SEMIN ORI. 2021;39(11):785.e19-785.e27.

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy
Rajwa P, Schuettfort V, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh R, Mostafaei H, Grossmann N, Aulitzky A, Paradysz A, Karakiewicz P, Fajkovic H, Zimmermann K, Heidenreich A, Gontero P, Shariat S
WORLD J UROL. 2021;39(10):3771-3779.

Focal Therapy for Prostate Cancer: Complications and Their Treatment
Rakauskas A, Marra G, Heidegger I, Kasivisvanathan V, Kretschmer A, Zattoni F, Preisser F, Tilki D, Tsaur I, van den Bergh R, Kesch C, Ceci F, Fankhauser C, Gandaglia G, Valerio M
FRONT SURG. 2021;8:.

Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy
Rakic N, Jamil M, Keeley J, Sood A, Vetterlein M, Dalela D, Arora S, Modonutti D, Bronkema C, Novara G, Peabody J, Rogers C, Menon M, Abdollah F
UROL ONCOL-SEMIN ORI. 2021;39(8):495.e1-495.e6.

Contemporary Outcomes after Transurethral Procedures for Bladder Neck Contracture Following Endoscopic Treatment of Benign Prostatic Hyperplasia
Rosenbaum C, Vetterlein M, Fisch M, Reiss P, Worst T, Kranz J, Steffens J, Kluth L, Pfalzgraf D
J CLIN MED. 2021;10(13):.

Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials
Sari Motlagh R, Abufaraj M, Yang L, Mori K, Pradere B, Laukhtina E, Mostafaei H, Schuettfort V, Quhal F, Montorsi F, Amjadi M, Gratzke C, Shariat S
J UROLOGY. 2021;205(4):1018-1030.

Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials
Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Katayama S, Grossmann N, Mostafai H, Pradere B, Quhal F, Schuettfort V, Roshandel M, Karakiewicz P, Teoh J, Shariat S, Fajkovic H
BJU INT. 2021;128(3):280-289.

Final results of the PräVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure
Schmid S, Seitz A, Haller B, Fritsche H, Huber T, Burger M, Gschwend J, Maurer T
WORLD J UROL. 2021;39(2):613-620.

Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder
Schuettfort V, D Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Abufaraj M, Karakiewicz P, Luzzago S, Rouprêt M, Chlosta P, Babjuk M, Deuker M, Moschini M, Shariat S, Pradere B
UROL ONCOL-SEMIN ORI. 2021;39(4):235.e5-235.e14.

Learning benefits of live surgery and semi-live surgery in urology-informing the debate with results from the International Meeting of Reconstructive Urology (IMORU) VIII
Schuettfort V, Ludwig T, Marks P, Vetterlein M, Maurer V, Fuehner C, Janisch F, Soave A, Rink M, Riechardt S, Engel O, Fisch M, Dahlem R, Meyer C
WORLD J UROL. 2021;39(7):2801-2807.

Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review
Schuettfort V, Pradere B, Compérat E, Abufaraj M, Shariat S
CURR OPIN UROL. 2021;31(4):324-331.

Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy
Schuettfort V, Pradere B, D'Andrea D, Grossmann N, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz P, Motlagh R, Katayama S, Lotan Y, Scherr D, Abufaraj M, Fajkovica H, Compérat E, Enikeev D, Shariat S
J UROLOGY. 2021;206(5):1122-1131.

Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma
Schuettfort V, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh R, Rink M, D'Andrea D, Abufaraj M, Karakiewicz P, Shariat S
TURK J UROL. 2021;47(Supp. 1):S33-S44.

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
Schuettfort V, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Fisch M, D'Andrea D, Rink M, Gontero P, Soria F, Shariat S
WORLD J UROL. 2021;39(6):1757-1768.

Blasenaugmentation und Blasenersatz mit kontinentem Appendixstoma
Schüttfort V, Dahlem R, Fisch M, Meyer C
AKTUEL UROL. 2021;52(4):386-395.

Induratio penis plastica: Herausforderungen der somatischen Therapie und Unterstützungsmöglichkeiten durch Psychotherapie
Soave A, König F, Dahlem R, Rink M, Riechardt S, Fisch M, Briken P, Nieder T
Z SEXUALFORSCH. 2021;34(4):208-218.

Metachron oligometastasiertes Prostatakarzinom – viel hilft viel oder alleinige lokale Therapie?
Steuber T, Maurer T, Miller K
UROLOGE. 2021;60(12):1534-1545.

p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors
Steurer S, Riemann C, Büscheck F, Luebke A, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Weidemann S, Fraune C, Möller K, Menz A, Fisch M, Rink M, Bernreuther C, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Dum D, Simon R, Minner S, Burandt E, Krech R, Krech T, Marx A
BIOMARK RES. 2021;9(1):.

Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study
Stolzenbach L, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Steuber T, Tilki D, Briganti A, Saad F, Chun F, Graefen M, Karakiewicz P
INT J UROL. 2021;28(8):834-839.

Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy
Stolzenbach L, Knipper S, Mandel P, Ascalone L, Deuker M, Tian Z, Heinzer H, Tilki D, Maurer T, Graefen M, Karakiewicz P, Steuber T
UROL ONCOL-SEMIN ORI. 2021;39(4):234.e1-234.e7.

Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities
Stolzenbach L, Löcherbach F, Wargenau K, Pose R, Steuber T, Tian Z, Budäus L, Tilki D, Graefen M, Köhler D, Karakiewicz P, Sauer M, Apostolova I, Maurer T, Berliner C
NUKLEARMED-NUCL MED. 2021;60(6):417-424.

Improving the Stratification of Patients With Intermediate-risk Prostate Cancer
Stolzenbach L, Nocera L, Collà-Ruvolo C, Tian Z, Knipper S, Maurer T, Tilki D, Graefen M, Karakiewicz P
CLIN GENITOURIN CANC. 2021;19(2):e120-e128.

Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry
Strauss A, Schmid M, Rink M, Moran M, Bernhardt S, Hubbe M, Bergmann L, Schlack K, Boegemann M
FUTURE ONCOL. 2021;17(18):2325-2338.

Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis
Tellini R, Mari A, Muto G, Cacciamani G, Ferro M, Stangl-Kremser J, Campi R, Soria F, Rink M, Xylinas E, Minervini A, Briganti A, Montorsi F, Roupret M, Shariat S, Moschini M
EUR UROL ONCOL. 2021;4(4):580-593.

Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort
Thederan I, Chandrasekar T, Tennstedt P, Knipper S, Kuehl L, Tilki D, Augustin M, Heinzer H, Zyriax B
EUR UROL FOCUS. 2021;7(5):973-979.

Editorial Comment: Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer
Tilki D
J UROLOGY. 2021;205(2):460.

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death
Tilki D, Chen M, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan J, Feng F, Carroll P, Trock B, Partin A, D'Amico A
J CLIN ONCOL. 2021;39(20):2284-2293.

Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Tilki D, Evans C
EUR UROL. 2021;80(4):519-520.

Evaluation of Risk Factors for Adverse Functional Outcomes after Radical Prostatectomy in Patients with Previous Transurethral Surgery of the Prostate
Tolle J, Knipper S, Pose R, Tennstedt P, Tilki D, Graefen M, Isbarn H
UROL INT. 2021;105(5-6):408-413.

A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Tsaur I, Heidegger I, Bektic J, Kafka M, van den Bergh R, Hunting J, Thomas A, Brandt M, Höfner T, Debedde E, Thibault C, Ermacora P, Zattoni F, Foti S, Kretschmer A, Ploussard G, Rodler S, von Amsberg G, Tilki D, Surcel C, Rosenzweig B, Gadot M, Gandaglia G, Dotzauer R
CANCER MED-US. 2021;10(18):6354-6364.

Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment
Tsaur I, Heidegger I, van den Bergh R, Bektic J, Borgmann H, Foti S, Hunting J, Kretschmer A, Ploussard G, Tilki D, Gandaglia G, Dotzauer R
EUR UROL FOCUS. 2021;7(6):1308-1315.

Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review
Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy D, Nickols N, Vapiwala N, Calais J, Kishan A
EUR UROL ONCOL. 2021;4(3):339-355.

A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer
Van den Broeck T, Oprea-Lager D, Moris L, Kailavasan M, Briers E, Cornford P, De Santis M, Gandaglia G, Gillessen Sommer S, Grummet J, Grivas N, Lam T, Lardas M, Liew M, Mason M, O'Hanlon S, Pecanka J, Ploussard G, Rouviere O, Schoots I, Tilki D, van den Bergh R, van der Poel H, Wiegel T, Willemse P, Yuan C, Mottet N
EUR UROL. 2021;80(5):531-545.

Perceived Positive and Negative Life Changes in Testicular Cancer Survivors
Vehling S, Oechsle K, Hartmann M, Bokemeyer C, Mehnert-Theuerkauf A
MEDICINA-LITHUANIA. 2021;57(9):993.

Update on the management of penile and meatal strictures
Vetterlein M, Fisch M, Zumstein V
CURR OPIN UROL. 2021;31(5):493-497.

Exploring the intersection of functional recurrence, patient-reported sexual function, and treatment satisfaction after anterior buccal mucosal graft urethroplasty
Vetterlein M, Gödde A, Zumstein V, Gild P, Marks P, Soave A, Meyer C, Riechardt S, Dahlem R, Fisch M, Kluth L
WORLD J UROL. 2021;39(9):3533-3539.

Nomenclature and treatment of secondary urethral strictures following primary hypospadias repair: weighing up academic principles and clinical pragmatism
Vetterlein M, Zumstein V, Kluth L, Riechardt S, Dahlem R, Fisch M
WORLD J UROL. 2021;39(12):4513–4515.

Diagnose und Therapie seltener Hodentumoren am Beispiel des malignen Mesothelioms der Tunica vaginalis testis und Sertoli-Zell-Tumoren
von Amsberg G, Sehovic M, Hartmann M, Bokemeyer C
UROLOGE. 2021;60(7):872-879.

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
Wang H, Amiel T, Würnschimmel C, Langbein T, Steiger K, Rauscher I, Horn T, Maurer T, Weber W, Wester H, Knorr K, Eiber M
EJNMMI RES. 2021;11(1):76.

PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study
Weber M, Kurek C, Barbato F, Eiber M, Maurer T, Nader M, Hadaschik B, Grünwald V, Herrmann K, Wetter A, Fendler W
J NUCL MED. 2021;62(1):88-91.

Napsin A Expression in Human Tumors and Normal Tissues
Weidemann S, Böhle J, Contreras H, Luebke A, Kluth M, Büscheck F, Hube-Magg C, Höflmayer D, Möller K, Fraune C, Bernreuther C, Rink M, Simon R, Menz A, Hinsch A, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Steurer S, Burandt E, Krech R, Dum D, Krech T, Marx A, Minner S
PATHOL ONCOL RES. 2021;27:613099.

Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis
Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat S, Saad F, Briganti A, Tilki D, Graefen M, Kluth L, Becker A, Roos F, Chun F, Karakiewicz P
EUR J CANCER. 2021;155:245-255.

Impact of comorbidities on acute kidney injury and renal function impairment after partial and radical tumor nephrectomy
Wenzel M, Kleimaker A, Uhlig A, Würnschimmel C, Becker A, Yu H, Meyer C, Fisch M, Chun F, Leitsmann M
SCAND J UROL. 2021;55(5):377-382.

The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer
Wenzel M, Nocera L, Würnschimmel C, Collà Ruvolo C, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Becker A, Roos F, Chun F, Karakiewicz P
FRONT ONCOL. 2021;11:.

Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy
Wenzel M, Preisser F, Mueller M, Theissen L, Welte M, Hoeh B, Humke C, Bernatz S, Bodelle B, Würnschimmel C, Tilki D, Huland H, Graefen M, Roos F, Becker A, Karakiewicz P, Chun F, Kluth L, Mandel P
INT UROL NEPHROL. 2021;53(7):1297-1303.

Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy
Wenzel M, Preisser F, Wittler C, Hoeh B, Wild P, Tschäbunin A, Bodelle B, Würnschimmel C, Tilki D, Graefen M, Becker A, Karakiewicz P, Chun F, Kluth L, Köllermann J, Mandel P
DIAGNOSTICS. 2021;11(5):.

Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy
Wenzel M, Welte M, Theissen L, Wittler C, Hoeh B, Humke C, Preisser F, Würnschimmel C, Tilki D, Graefen M, Roos F, Becker A, Karakiewicz P, Chun F, Kluth L, Mandel P
EUR UROL FOCUS. 2021;7(5):980-986.

Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant
Wenzel M, Würnschimmel C, Chierigo F, Tian Z, Shariat S, Terrone C, Saad F, Tilki D, Graefen M, Banek S, Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2021;81(16):1294-1302.

Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy
Wenzel M, Würnschimmel C, Chierigo F, Tian Z, Shariat S, Terrone C, Saad F, Tilki D, Graefen M, Mandel P, Kluth L, Chun F, Karakiewicz P
PROSTATE. 2021;81(11):728-735.

Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Wenzel M, Würnschimmel C, Chierigo F, Tian Z, Shariat S, Terrone C, Saad F, Tilki D, Graefen M, Roos F, A Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2021;81(14):1055-1063.

The effect of primary urological cancers on survival in men with secondary prostate cancer
Wenzel M, Würnschimmel C, Nocera L, Ruvolo C, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Roos F, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2021;81(15):1149-1158.

Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores
Wenzel M, Würnschimmel C, Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Kluth L, Mandel P, Chun F, Karakiewicz P
PROSTATE. 2021;81(12):874-881.

Cystatin C predicts renal function impairment after partial or radical tumor nephrectomy
Wenzel M, Yu H, Uhlig A, Würnschimmel C, Wallbach M, Becker A, Fisch M, Chun F, Meyer C, Leitsmann M
INT UROL NEPHROL. 2021;53(10):2041-2049.

Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort
Würnschimmel C, Kachanov M, Wenzel M, Mandel P, Karakiewicz P, Maurer T, Steuber T, Tilki D, Graefen M, Budäus L
PROSTATE. 2021;81(12):849-856.

Tumorbiologie des metastasierten Prostatakarzinoms: klinische Implikationen
Würnschimmel C, Maurer T
UROLOGE. 2021;60(4):509-510.

Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort
Würnschimmel C, Pose R, Wenzel M, Tian Z, Incesu R, Karakiewicz P, Graefen M, Tilki D
EUR UROL. 2021;80(4):400-404.

Update zur adjuvanten vs. Early-Salvage-Radiotherapie nach radikaler Prostatektomie
Würnschimmel C, Tilki D
UROLOGE. 2021;60(6):790-791.

Qualitätskriterien in der Urologie: Wie kann eine Vergleichbarkeit der Ergebnisse geschaffen werden?
Würnschimmel C, Tilki D, Huland H, Graefen M, Beyer B
UROLOGE. 2021;60(2):193-198.

Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns
Würnschimmel C, Wenzel M, Chierigo F, Flammia R, Mori K, Tian Z, Shariat S, Saad F, Briganti A, Suardi N, Terrone C, Gallucci M, Chun F, Tilki D, Graefen M, Karakiewicz P
PROSTATE. 2021;81(11):778-784.

Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Shariat S, Mandel P, Chun F, Tilki D, Graefen M, Karakiewicz P
WORLD J UROL. 2021;39(10):3781-3787.

Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups
Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Shariat S, Mirone V, Chun F, Tilki D, Graefen M, Karakiewicz P
INT J UROL. 2021;28(8):862-869.

Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology
Würnschimmel C, Wenzel M, Maurer T, Valdés Olmos R, Vidal-Sicart S
Q J NUCL MED MOL IM. 2021;65(3):215-228.

Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data
Würnschimmel C, Wenzel M, Wang N, Tian Z, Karakiewicz P, Graefen M, Huland H, Tilki D
PROSTATE. 2021;81(11):785-793.

Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center
Würnschimmel C, Wenzel M, Wang N, Tian Z, Karakiewicz P, Graefen M, Huland H, Tilki D
UROL ONCOL-SEMIN ORI. 2021;39(12):830.e17-830.e26.

Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Xiang M, Ma T, Savjani R, Pollom E, Karnes R, Grogan T, Wong J, Motterle G, Tosoian J, Trock B, Klein E, Stish B, Dess R, Spratt D, Pilar A, Reddy C, Levin-Epstein R, Wedde T, Lilleby W, Fiano R, Merrick G, Stock R, Demanes D, Moran B, Huland H, Tran P, Martin S, Martinez-Monge R, Krauss D, Abu-Isa E, Alam R, Schwen Z, Pisansky T, Choo C, Song D, Greco S, Deville C, McNutt T, DeWeese T, Ross A, Ciezki J, Boutros P, Nickols N, Bhat P, Shabsovich D, Juarez J, Chong N, Kupelian P, Rettig M, Zaorsky N, Berlin A, Tward J, Davis B, Reiter R, Steinberg M, Elashoff D, Horwitz E, Tendulkar R, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan A
JAMA NETW OPEN. 2021;4(12):.

Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent
Zamboni S, Afferi L, Soria F, Aziz A, Abufaraj M, Poyet C, Necchi A, D'Andrea D, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, Briganti A, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen C, Rink M, Shariat S, Xylinas E, Moschini M
WORLD J UROL. 2021;39(6):1947-1953.

Salvage therapy for prostate cancer after radical prostatectomy
Zaorsky N, Calais J, Fanti S, Tilki D, Dorff T, Spratt D, Kishan A
NAT REV UROL. 2021;18(11):643-668.

Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?
Zattoni F, Heidegger I, Kasivisvanathan V, Kretschmer A, Marra G, Magli A, Preisser F, Tilki D, Tsaur I, Valerio M, van den Bergh R, Kesch C, Ceci F, Fankhauser C, Gandaglia G
FRONT SURG. 2021;8:.

Has the COVID-19 outbreak changed the way we are treating prostate cancer? - An EAU - YAU Prostate Cancer Working Group multi-institutional study
Zattoni F, Marra G, Kretschmer A, Preisser F, Tilki D, Kesch C, Radtke J, Hoffmann N, Morlacco A, Dal Moro F, Soeterik T, van den Bergh R, Barletta F, Briganti A, Montorsi F, Gandaglia G
CENT EUR J UROL. 2021;74(3):362-365.

A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis
Zhao C, Bjurlin M, Roberts T, Rink M, Shariat S, Matulewicz R
J UROLOGY. 2021;205(5):1275-1285.

PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor
Zippel C, Giesel F, Kratochwil C, Eiber M, Rahbar K, Albers P, Maurer T, Krause B, Bohnet-Joschko S
NUKLEARMED-NUCL MED. 2021;60(3):216-223.

The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy
Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz P, Shariat S
UROL ONCOL-SEMIN ORI. 2020;38(8):685.e17-685.e25.

Super early detailed assessment of lower urinary tract symptoms after holmium laser enucleation of the prostate (HoLEP): a prospective study
Ahyai S, Marik I, Ludwig T, Becker A, Asdjodi S, Kluth L, Chun F, Fisch M, Schmid M
WORLD J UROL. 2020;38(12):3207-3217.

Impact of Sarcopenia on Functional and Oncological Outcomes After Radical Prostatectomy
Angerer M, Salomon G, Beyersdorff D, Fisch M, Graefen M, Rosenbaum C
FRONT SURG. 2020;7:.

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, Riethdorf S
ONCOIMMUNOLOGY. 2020;9(1):.

Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions
Bernreuther C, Daghigh F, Möller K, Hube-Magg C, Lennartz M, Lutz F, Rico S, Fraune C, Dum D, Luebke A, Eichenauer T, Möller-Koop C, Schlomm T, Wittmer C, Huland H, Heinzer H, Graefen M, Haese A, Burandt E, Tsourlakis M, Clauditz T, Höflmayer D, Izbicki J, Simon R, Sauter G, Minner S, Steurer S, Meiners J
PATHOL ONCOL RES. 2020;26(4):2709-2722.

Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry
Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, Bergmann L, Schmid M, Strauss A
FUTURE ONCOL. 2020;16(35):2939-2948.

Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series
Bravi C, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann K, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat S, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill I, Mottrie A, Karakiewicz P, Montorsi F, Briganti A
EUR UROL. 2020;78(6):779-782.

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
Bravi C, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann K, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat S, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill I, Mottrie A, Karakiewicz P, Montorsi F, Briganti A
EUR UROL. 2020;78(5):661-669.

Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Sarper I, Ketterer K, Henke T, Eichelberg C, Dahlem R, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M
ONCOTARGET. 2020;11(3):237-249.

Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
Chys B, Devos G, Everaerts W, Albersen M, Moris L, Claessens F, De Meerleer G, Haustermans K, Briganti A, Chlosta P, Gontero P, Graefen M, Gratzke C, Karnes R, Kneitz B, Marchioro G, Salas R, Spahn M, Tombal B, Van Der Poel H, Walz J, Van Poppel H, Joniau S
FRONT ONCOL. 2020;10:246.

Adherence to the EAU guideline recommendations for systemic chemotherapy in penile cancer: results of the E-PROPS study group survey
Distler F, Pahernik S, Gakis G, Hutterer G, Lebentrau S, Rink M, Nuhn P, Brookman-May S, Burger M, Gratzke C, Wolff I, May M
WORLD J UROL. 2020;38(10):2523-2530.

Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group
Dobé T, Califano G, von Rundstedt F, Ouzaid I, Albisinni S, Aziz A, Di Trapani E, Hendricksen K, Krajewski W, Mari A, Moschini M, Necchi A, Noon A, Poyet C, Pradère B, Rink M, Roghmann F, Sargos P, Seiler R, Soria F, Vetterlein M, Xylinas E
EUR UROL OPEN SCI. 2020;22:45-50.

Défaut d’adoption de l’instillation intravésicale postopératoire précoce de chimiothérapie après néphro-urétérectomie totale
Dobé T, Ouzaid I, Califano G, Von Rundstedt F, Albisinni S, Aziz A, Di Trapani E, Hendricksen K, Krajewski W, Mari A, Moschini M, Necchi A, Moon A, Poyet C, Pradère B, Rink M, Roghmann F, Sargos P, Seiler R, Xylinas E
PROG UROL. 2020;30(13):822.

Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells
Dyshlovoy S, Kaune M, Hauschild J, Kriegs M, Hoffer K, Busenbender T, Smirnova P, Zhidkov M, Poverennaya E, Oh-Hohenhorst S, Spirin P, Prassolov V, Tilki D, Bokemeyer C, Graefen M, von Amsberg G
MAR DRUGS. 2020;18(12):.

Treatment Strategies and Outcome of the Exstrophy-Epispadias Complex in Germany: Data From the German CURE-Net
Ebert A, Zwink N, Reutter H, Jenetzky E, Stein R, Hölscher A, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Promm M, Hirsch K, Schäfer F, Rösch W
FRONT PEDIATR. 2020;8:174.

18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
Eiber M, Kroenke M, Wurzer A, Ulbrich L, Jooß L, Maurer T, Horn T, Schiller K, Langbein T, Buschner G, Wester H, Weber W
J NUCL MED. 2020;61(5):696-701.

8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival
Eichenauer T, Bannenberg D, Kluth M, Wittmer C, Büscheck F, Möller K, Dum D, Fraune C, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Tsourlakis M, Bernreuther C, Minner S, Simon R, Sauter G, Wilczak W, Clauditz T
UROL ONCOL-SEMIN ORI. 2020;38(2):43.e13-43.e20.

High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer
Eichenauer T, Federlein F, Möller K, Chirico V, Kind S, Lennartz M, Lutz F, Hube-Magg C, Höflmayer D, Fisch M, Huland H, Heinzer H, Graefen M, Haese A, Schroeder C, Lebok P, Minner S, Simon R, Sauter G, Schlomm T, Wilczak W, Steurer S, Luebke A
PATHOLOGY. 2020;52(4):421-430.

Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma
Eichenauer T, Shadanpour N, Kluth M, Göbel C, Weidemann S, Fraune C, Büscheck F, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Burandt E, Bernreuther C, Minner S, Simon R, Sauter G, Wilczak W, Clauditz T
WORLD J SURG ONCOL. 2020;18(1):128.

Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer
Eichenauer T, Simmendinger L, Kluth M, Chirico V, Luebke A, Höflmayer D, Hinsch A, Jacobsen F, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Tsourlakis M, Büscheck F, Bernreuther C, Clauditz T, Lebok P, Simon R, Sauter G, Wilczak W, Fraune C
UROL ONCOL-SEMIN ORI. 2020;38(6):605.e1-605.e8.

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
Elsesy M, Oh-Hohenhorst S, Löser A, Oing C, Mutiara S, Köcher S, Meien S, Zielinski A, Burdak-Rothkamm S, Tilki D, Huland H, Schwarz R, Petersen C, Bokemeyer C, Rothkamm K, Mansour W
CANCERS. 2020;12(9):.

Contemporary national trends in prostate cancer risk profile at diagnosis
Fletcher S, von Landenberg N, Cole A, Gild P, Choueiri T, Lipsitz S, Trinh Q, Kibel A
PROSTATE CANCER P D. 2020;23(1):81-87.

Reply by Authors
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes R, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann K, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill I, Mottrie A, Galosi A, Montorsi F, Briganti A
J UROLOGY. 2020;204(2):302.

Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes R, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann K, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill I, Mottrie A, Galosi A, Montorsi F, Briganti A
J UROLOGY. 2020;204(2):296-302.

Longitudinal Evaluation of Perineogenital Pain and Postoperative Complications After One-stage Buccal Mucosal Graft Urethroplasty: A Secondary Analysis of a Randomized Controlled Trial
Fuehner C, Vetterlein M, Lesske J, Rink M, Riechardt S, König F, Gild P, Pinnschmidt H, Meyer C, Ludwig T, Engel O, Fisch M, Dahlem R, Soave A
EUR UROL FOCUS. 2020;7(5):1157-1165.

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection
Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, Borgmann H, Heidegger I, Steinkohl F, Kretschmer A, Marra G, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, Van den Bergh R, Ost P, Gontero P, Montorsi F, Briganti A
EUR UROL. 2020;78(2):138-142.

Retrograde Ejaculation After Holmium Laser Enucleation Of The Prostate (HoLEP) - Impact On Sexual Function and Evaluation Of Patient Bother Using Validated Questionnaires
Gild P, Dahlem R, Pompe R, Soave A, Vetterlein M, Ludwig T, Maurer V, Marks P, Ahyai S, Chun F, Lenke L, Ernst T, Fisch M, Rink M, Meyer C, Becker A
ANDROLOGY-US. 2020;8(6):1779-1786.

The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group
Gild P, Vetterlein M, Seiler R, Necchi A, Hendricksen K, Mertens L, Roghmann F, Landenberg N, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, D'Andrea D, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn B, Noon A, Roupret M, Shariat S, Fisch M, Xylinas E, Rink M
SURG ONCOL. 2020;34:312-317.

Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases
Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba O, van Rhijn B, van de Putte E, Babjuk M, Fritsche H, Mayr R, Albers P, Niegisch G, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes A, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes J, Scherr D, O'Malley P, Taylor B, Shariat S, Black P, Abdi H, Matveev V, Samuseva O, Parekh D, Gonzalgo M, Vetterlein M, Aziz A, Fisch M, Catto J, Pang K, Xylinas E, Rink M
WORLD J UROL. 2020;38(8):1959-1968.

Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?
Hensbergen A, van Willigen D, van Beurden F, van Leeuwen P, Buckle T, Schottelius M, Maurer T, Wester H, van Leeuwen F
BIOCONJUGATE CHEM. 2020;31(2):375-395.

The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)
Janisch F, D'Andrea D, Iwata T, Kimura S, Abufaraj M, Enikeev D, Glybochko P, Karakiewicz P, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, Shariat S
UROL ONCOL-SEMIN ORI. 2020;38(5):423-432.

The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort
Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer C, Klotzbücher T, Kienapfel C, Vetterlein M, Kimura S, Abufaraj M, Dahlem R, Shariat S, Fisch M, Rink M
UROL ONCOL-SEMIN ORI. 2020;38(9):739.e9-739.e15.

The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer
Janisch F, Rink M, Shariat S
BJU INT. 2020;125(6):753-755.

Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis
Janisch F, Shariat S, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko P, Rink M, Abufaraj M
WORLD J UROL. 2020;38(5):1165-1175.

Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer
Joosse S, Beyer B, Gasch C, Nastały P, Kuske A, Isbarn H, Horst L, Hille C, Gorges T, Cayrefourcq L, Alix-Panabières C, Tennstedt P, Riethdorf S, Schlomm T, Pantel K
CLIN CHEM. 2020;66(1):161-168.

Rekonstruktive Urologie
Kälble T, Fisch M, Manseck A
UROLOGE. 2020;59(4):397.

Long-Term Effects of Mental Training on Manual and Cognitive Skills in Surgical Education - A Prospective Study
Kaulfuss J, Kluth L, Marks P, Grange P, Fisch M, Chun F, Meyer C
J SURG EDUC. 2020;78(4):1216-1226.

Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer
Kim D, Chen M, Huland H, Graefen M, Tilki D, D'Amico A
JAMA NETW OPEN. 2020;3(4):e202041.

Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
Kind S, Büscheck F, Höflmayer D, Hube-Magg C, Kluth M, Tsourlakis M, Steurer S, Clauditz T, Luebke A, Burandt E, Wilczak W, Hinsch A, Dum D, Weidemann S, Fraune C, Beyer B, Steuber T, Huland H, Graefen M, Fisch M, Simon R, Sauter G, Schlomm T, Minner S, Eichenauer T
WORLD J UROL. 2020;38(9):2185-2196.

Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H
Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, Graefen M
WORLD J UROL. 2020;38(6):1459-1464.

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients
Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz P
INT UROL NEPHROL. 2020;52(1):59-66.

Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy
Knipper S, Hagedorn M, Sadat-Khonsari M, Tian Z, Karakiewicz P, Tilki D, Heinzer H, Michl U, Steuber T, von Breunig F, Zöllner C, Graefen M
WORLD J UROL. 2020;38(6):1451-1457.

Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy
Knipper S, Karakiewicz P, Heinze A, Preisser F, Steuber T, Huland H, Graefen M, Tilki D
UROL ONCOL-SEMIN ORI. 2020;38(4):184-190.

Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis
Knipper S, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Zorn K, Saad F, Tilki D, Graefen M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2020;38(3):79.e9-79.e14.

The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages
Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Deuker M, Tian Z, Shariat S, Saad F, Tilki D, Graefen M, Karakiewicz P
CANCER CAUSE CONTROL. 2020;31(3):283-290.

Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence
Knipper S, Sadat-Khonsari M, Boehm K, Mandel P, Budäus L, Steuber T, Maurer T, Heinzer H, Schwarz R, Sauter G, Tilki D, Huland H, Graefen M
CLIN GENITOURIN CANC. 2020;18(2):e112-e121.

Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model
Kraft P, Maurer T, Gafita A, Krönke M, Haller B, Weber W, Eiber M, Rauscher I
EJNMMI RES. 2020;10(1):6.

Pathogen-induced tissue-resident memory TH17 (TRM17) cells amplify autoimmune kidney disease
Krebs C, Reimers D, Zhao Y, Paust H, Bartsch P, Nuñez S, Rosemblatt M, Hellmig M, Kilian C, Borchers A, Enk L, Zinke M, Becker M, Schmid J, Klinge S, Wong M, Puelles V, Schmidt C, Bertram T, Stumpf N, Hoxha E, Meyer-Schwesinger C, Lindenmeyer M, Cohen C, Rink M, Kurts C, Franzenburg S, Koch-Nolte F, Turner J, Riedel J, Huber S, Gagliani N, Huber T, Wiech T, Rohde H, Bono M, Bonn S, Panzer U, Mittrücker H
SCI IMMUNOL. 2020;5(50):.

Symposium Genderdysphorie (28./29. Juni 2019 in Essen)
Krege S, Hess J, Güldenring A, Richter E, Lederbogen S, Mengel M, Seppel T, Hetkamp M, Küntscher M, Sollenböhmer K, Henkel U, Möller B, Romer G, Löwenberg H, Riechardt S
UROLOGE. 2020;59(11):1320-1330.

Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer
Kroenke M, Wurzer A, Schwamborn K, Ulbrich L, Jooß L, Maurer T, Horn T, Rauscher I, Haller B, Herz M, Wester H, Weber W, Eiber M
J NUCL MED. 2020;61(5):710-715.

Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis
Leong J, Herrera-Caceres J, Goldberg H, Tham E, Teplitsky S, Gomella L, Trabulsi E, Lallas C, Fleshner N, Tilki D, Chandrasekar T
UROLOGY. 2020;137:102-107.

Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy
Leyh-Bannurah S, Kachanov M, Beyersdorff D, Tian Z, Karakiewicz P, Tilki D, Fisch M, Maurer T, Graefen M, Budäus L
J UROLOGY. 2020;203(2):299-303.

Accuracy of Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage Lymphadenectomy
Mandel P, Tilki D, Chun F, Pristupa E, Graefen M, Klutmann S, Budäus L, Steuber T
EUR UROL FOCUS. 2020;6(1):71-73.

Vesikovaginale Fisteln - Diagnostik und operatives Management
Marks P, Kluth L, Lang I, Fisch M
UROLOGE. 2020;59(4):432-441.

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review
Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh R, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes R, Montorsi F, Gandaglia G
EUR UROL ONCOL. 2020;3(5):565-581.

Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers
Marx A, Schumann A, Höflmayer D, Bady E, Hube-Magg C, Möller K, Tsourlakis M, Steurer S, Büscheck F, Eichenauer T, Clauditz T, Graefen M, Simon R, Sauter G, Izbicki J, Huland H, Heinzer H, Haese A, Schlomm T, Bernreuther C, Lebok P, Polonski A
SCI REP-UK. 2020;10(1):8916.

Prostate-Specific Membrane Antigen-Guided Surgery
Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, Wester H, van Leeuwen F
J NUCL MED. 2020;61(1):6-12.

[99mTc]Tc-PSMA-I&S: Anwendung zur Radioguided Surgery beim rezidivierten Prostatakarzinom
Maurer T, Knipper S, Heck M, Horn T, Berliner C, Köhler D, Krönke M, Rauscher I, Eiber M
Der Nuklearmediziner. 2020;2020(43):309-315.

Why is the principle of "as much radicality as needed, as much organ preservation as possible" only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?
May M, Rink M, Merseburger A, Brookman-May S
TRANSL ANDROL UROL. 2020;9(5):1901-1903.

Trends of Metastasis-Directed Treatments in Patients with Renal Cell Carcinoma: A Total Population-Based Analysis in Germany in the Era of Targeted Therapies
Meyer C, Groeben C, Marks P, Koch R, Huber J
ONCOL RES TREAT. 2020;43(12):679-685.

Re: Karl H. Pang, Diego M. Carrion, Juan Gomez Rivas, et al. The Impact of COVID-19 on European Health Care and Urology Trainees.Eur Urol 2020:78;6-8
Meyer C, Kaulfuss J, Grange P
EUR UROL. 2020;78(6):e236.

Impact of Cardiovascular and Metabolic Risk Factors on Stricture Recurrence After Anterior One-stage Buccal Mucosal Graft Urethroplasty
Meyer C, Lamp J, Vetterlein M, Soave A, Engel O, Dahlem R, Fisch M, Kluth L
UROLOGY. 2020;146:253-259.

Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes
Mistretta F, Cyr S, Luzzago S, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, Shariat S, de Cobelli O, Karakiewicz P
CLIN GENITOURIN CANC. 2020;18(2):129-137.e3.

Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes
Mistretta F, Cyr S, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, Briganti A, Shariat S, Perrotte P, Saad F, de Cobelli O, Karakiewicz P
CLIN ONCOL-UK. 2020;32(4):e93-e101.

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Mori K, Mostafaei H, Pradere B, Motlagh R, Quhal F, Laukhtina E, Schuettfort V, Abufaraj M, Karakiewicz P, Kimura T, Egawa S, Shariat S
INT J CLIN ONCOL. 2020;25(11):1892-1900.

Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
Moris L, Cumberbatch M, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet J, Henry A, Lam T, Lardas M, Liew M, Mason M, Omar M, Rouvière O, Schoots I, Tilki D, van den Bergh R, van Der Kwast T, van Der Poel H, Willemse P, Yuan C, Konety B, Dorff T, Jain S, Mottet N, Wiegel T
EUR UROL. 2020;77(5):614-627.

Prevalence of APC and PTEN Alterations in Urachal Cancer
Nagy N, Reis H, Hadaschik B, Niedworok C, Módos O, Szendrői A, Bíró K, Hager T, Herold T, Ablat J, Black P, Okon K, Tolkach Y, Csizmarik A, Oláh C, Keresztes D, Bremmer F, Gaisa N, Kriegsmann J, Kovalszky I, Kiss A, Tímár J, Szász M, Rink M, Fisch M, Nyirády P, Szarvas T
PATHOL ONCOL RES. 2020;26(4):2773-2781.

Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial
Nicklas J, Diener O, Leistenschneider M, Sellhorn C, Schön G, Winkler M, Daum G, Schwedhelm E, Schröder J, Fisch M, Schmalfeldt B, Izbicki J, Bauer M, Coldewey S, Reuter D, Saugel B
BRIT J ANAESTH. 2020;125(2):122-132.

Clinical Recommendations From the European Society for Sexual Medicine Exploring Partner Expectations, Satisfaction in Male and Phalloplasty Cohorts, the Impact of Penile Length, Girth and Implant Type, Reservoir Placement, and the Influence of Comorbidities and Social Circumstances
Osmonov D, Christopher A, Blecher G, Falcone M, Soave A, Dahlem R, Czeloth K, Bannowsky A, Matanes E, Ward S, Martínez-Salamanca J, Bettocchi C, Garaffa G, Reisman Y, Corona G
J SEX MED. 2020;17(2):210-237.

Amnion-scaffolds in tissue engineered constructs for reconstructive urology
Pagerols Raluy L, Schmitz L, Hellwinkel O, Rink M, Soave A, Fisch M, Engel O
Journal of Translational Science. 2020;7:.

A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients
Peeken J, Shouman M, Kroenke M, Rauscher I, Maurer T, Gschwend J, Eiber M, Combs S
EUR J NUCL MED MOL I. 2020;47(13):2968-2977.

The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy
Pompe R, Krüger A, Preisser F, Karakiewicz P, Michl U, Graefen M, Huland H, Tilki D
EUR UROL FOCUS. 2020;6(6):1199-1204.

Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages - Does extent of tumor involvement matter?
Pompe R, Neumann T, Kühnke L, Preisser F, Gild P, Tennstedt P, Salomon G, Huland H, Tilki D
UROL ONCOL-SEMIN ORI. 2020;38(7):637.e1-637.e7.

Management of de-novo urothelial carcinoma in transplanted patients
Pradere B, Schuettfort V, Mori K, Quhal F, Aydh A, Sari Motlagh R
CURR OPIN UROL. 2020;30(3):467-474.

Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups
Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun F, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz P
EUR UROL ONCOL. 2020;3(5):631-639.

Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence
Preisser F, Busto Martin L, Pompe R, Heinze A, Haese A, Graefen M, Tilki D
UROL ONCOL-SEMIN ORI. 2020;38(1):1.e11-1.e16.

Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy
Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat S, Marchioni M, Tian Z, Saad F, Taussky D, Briganti A, Huland H, Graefen M, Tilki D, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2020;14(5):E173-E179.

Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study
Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, Shariat S, Huland H, Graefen M, Tilki D, Karakiewicz P
EUR UROL FOCUS. 2020;6(6):1213-1219.

Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study
Preisser F, van den Bergh R, Gandaglia G, Ost P, Surcel C, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D
J UROLOGY. 2020;203(2):338-343.

Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy
Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, Schiller K, Weber W, Eiber M
J NUCL MED. 2020;61(1):51-57.

Operative Zugangswege beim Gleithoden und tiefen Leistenhoden – inguinaler Zugang
Riechardt S, Fisch M
AKTUEL UROL. 2020;51(2):191-194.

Novel Wide-Band Dielectric Imaging System and Occlusion Tool to Guide Cryoballoon-Based Pulmonary Vein Isolation: Feasibility and First Insights
Rillig A, Rottner L, Nodorp M, Lin T, Weimann J, Münkler P, Dinshaw L, Schleberger R, Lemoine M, Nies M, Risius T, Blankenberg S, Kirchhof P, Meyer C, Reissmann B, Metzner A
CIRC-ARRHYTHMIA ELEC. 2020;13(12):.

Electronic cigarettes and bladder cancer - a game-changer?
Rink M
NAT REV UROL. 2020;17(8):435-436.

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
Rink M, Riethdorf S, Yu H, Kölker M, Vetterlein M, Dahlem R, Fisch M, Pantel K, Soave A
J CLIN MED. 2020;9(11):.

Contemporary Management of Vesico-Urethral Anastomotic Stenosis After Radical Prostatectomy
Rosenbaum C, Fisch M, Vetterlein M
FRONT SURG. 2020;7:587271.

Fistelchirurgie
Rosenbaum C, Vetterlein M, Fisch M
UROLOGE. 2020;59(4):489-498.

The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery
Schmitz L, Berdien B, Huland E, Dase P, Beutel K, Fisch M, Engel O
LIFE-BASEL. 2020;10(10):.

Pathomics in urology
Schuettfort V, Pradere B, Rink M, Comperat E, Shariat S
CURR OPIN UROL. 2020;30(6):823-831.

Nur die Chirurgie? Multimodalkonzepte mit kurativer Intention für das Urothelkarzinom der Harnblase
Schuettfort V, Shariat S, Rink M
AKTUEL UROL. 2020;51(4):353-362.

Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
Soave A, Kluwe L, Yu H, Rink M, Gild P, Vetterlein M, Marks P, Sauter G, Fisch M, Meyer C, Ludwig T, Dahlem R, Minner S, Pantel K, Steinbach B, Schwarzenbach H
SCI REP-UK. 2020;10(1):21562.

Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients
Stolzenbach L, Rosiello G, Pecoraro A, Palumbo C, Luzzago S, Deuker M, Tian Z, Knipper A, Pompe R, Zorn K, Shariat S, Chun F, Graefen M, Saad F, Karakiewicz P
J NATL COMPR CANC NE. 2020;18(11):1492-1499.

Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort
Thederan I, Chandrasekar T, Tennstedt P, Kuehl L, Sorbe C, Tilki D, Augustin M, Heinzer H, Zyriax B
EUR UROL FOCUS. 2020;6(5):935-940.

Localized Prostate Cancer: Exploring the Boundaries of Current Treatment Paradigms
Tilki D, Chandrasekar T
EUR UROL FOCUS. 2020;6(2):199-200.

Timing of radiotherapy after radical prostatectomy
Tilki D, D'Amico A
LANCET. 2020;396(10260):1374-1375.

The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer
Tilki D, Mandel P, Karakiewicz P, Heinze A, Huland H, Graefen M, Knipper S
UROL ONCOL-SEMIN ORI. 2020;38(5):379-385.

Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men ≤ 45 years of age
Tilki D, Maurer V, Pompe R, Chun F, Preisser F, Haese A, Graefen M, Huland H, Mandel P
WORLD J UROL. 2020;38(1):95-101.

The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer
Tilki D, Würnschimmel C, Preisser F, Graefen M, Huland H, Mandel P, Tennstedt P
EUR UROL FOCUS. 2020;6(2):255-258.

Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size
Tully K, Moschini M, von Rundstedt F, Aziz A, Kluth L, Necchi A, Rink M, Hendricksen K, Sargos P, Vetterlein M, Seiler R, Poyet C, Krajewski W, Fajkovic H, Shariat S, Xylinas E, Roghmann F
UROL ONCOL-SEMIN ORI. 2020;38(11):851.e19-851.e25.

Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol 2020;77:713-24
van den Bergh R, Valerio M, Tilki D, Gandaglia G
EUR UROL. 2020;78(2):e67-e68.

Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
Van den Broeck T, van den Bergh R, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet J, Henry A, Lardas M, Liew M, Mason M, Moris L, Schoots I, van der Kwast T, van der Poel H, Wiegel T, Willemse P, Rouvière O, Lam T, Mottet N
EUR UROL FOCUS. 2020;6(2):231-234.

Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer
Vetterlein M, Gild P, Fisch M, Rink M
EUR UROL. 2020;78(2):e77-e78.

Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index
Vetterlein M, Klemm J, Gild P, Bradtke M, Soave A, Dahlem R, Fisch M, Rink M
EUR UROL. 2020;77(1):55-65.

Buccal mucosal graft urethroplasty for radiation-induced urethral strictures: an evaluation using the extended Urethral Stricture Surgery Patient-Reported Outcome Measure (USS PROM)
Vetterlein M, Kluth L, Zumstein V, Meyer C, Ludwig T, Soave A, Riechardt S, Engel O, Dahlem R, Fisch M, Rosenbaum C
WORLD J UROL. 2020;38(11):2863-2872.

Reply to Liang Sun and Yi Feng's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.08.011: Importance of Surgical and Anesthesiological Standard Operating Procedures for Radical Cystectomy in a Bundled Care Setting
Vetterlein M, Rink M
EUR UROL. 2020;77(1):e12-e13.

Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future
Vetterlein M, Witjes J, Loriot Y, Giannarini G, Albersen M, Ribal M, Rouprêt M
EUR UROL ONCOL. 2020;3(6):789-801.

Is Standardization Transferable? Initial Experience of Urethral Surgery at the University Hospital Frankfurt
Wenzel M, Krimphove M, Lauer B, Hoeh B, Müller M, Mandel P, Becker A, Vetterlein M, Mueller S, Dahlem R, Fisch M, Chun F, Kluth L
FRONT SURG. 2020;7:600090.

Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics
Wildeboer R, Mannaerts C, van Sloun R, Budäus L, Tilki D, Wijkstra H, Salomon G, Mischi M
EUR RADIOL. 2020;30(2):806-815.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees
Witjes J, Babjuk M, Bellmunt J, Bruins H, De Reijke T, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Jones R, Kamat A, Khoo V, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M, Moschini M, Mostafid H, Müller A, Müller C, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Thalmann G, Tombal B, Turkbey B, Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A
EUR UROL. 2020;77(2):223-250.

Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]
Witjes J, Babjuk M, Bellmunt J, Bruins H, De Reijke T, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Jones R, Kamat A, Khoo V, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M, Moschini M, Mostafid H, Müller A, Müller C, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Thalmann G, Tombal B, Turkbey B, Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Rivera F, Wiegel T, Wiklund P, Willemse P, Williams A, Zigeuner R, Horwich A
EUR UROL. 2020;78(1):e48-e50.

Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings
Würnschimmel C, Busto Martin L, Leyh-Bannurah S, Oh-Hohenhorst S, Kachanov M, Maurer T, Knipper S, Graefen M, Budäus L
UROLOGY. 2020;136:127-132.

Salvage-Lymphadenektomie beim Prostatakarzinomrezidiv: Ernüchternde Langzeitergebnisse?
Würnschimmel C, Maurer T
UROLOGE. 2020;59(11):1392-1393.

Martini-Klinik experience of prostate cancer surgery during the early phase of the COVID-19 pandemic
Würnschimmel C, Maurer T, Knipper S, von Breunig F, Zoellner C, Thederan I, Huland H, Graefen M, Michl U
BJU INT. 2020;126(2):252-255.

A critical outcome analysis of Asopa single-stage dorsal inlay substitution urethroplasty for penile urethral stricture
Zumstein V, Dahlem R, Kluth L, Rosenbaum C, Maurer V, Bahassan O, Engel O, Fisch M, Vetterlein M
WORLD J UROL. 2020;38(5):1283-1294.

Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration

BJU INT. 2019 [Epub ahead of print].

Hereditary prostate cancer - Primetime for genetic testing?

CANCER TREAT REV. 2019;81:101927.

Increased urinary bladder volume improves the detectability of urinary stones at the ureterovesical junction in non-enhanced computed tomography (NECT)
Avanesov M, Togmat J, Solmaz M, Kaul M, Laqmani A, Guerreiro H, Keller S, Weisbach L, Adam G, Yamamura J
EUR RADIOL. 2019;29(12):6953-6964.

Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment
Beckmann A, Spalteholz J, Langer F, Heinzer H, Budäus L, Tilki D, Michl U, Soave A, Steuber T, Veleva V, Salomon G, Haese A, Huland H, Graefen M, Isbarn H
WORLD J UROL. 2019;37(12):2657-2662.

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S, D'Andrea D, Vetterlein M, Cole A, Fletcher S, Krimphove M, Marchese M, Lipsitz S, Sonpavde G, Noldus J, Shariat S, Kibel A, Trinh Q, Mossanen M
CANCER-AM CANCER SOC. 2019;125(9):1449-1458.

Detection rate of Tc-99 m-PSMA I&S SPECT/CT in comparison to Ga-68-PSMA PET/CT in patients with biochemically recurrent prostate cancer planned for radioguided surgery
Berliner C, Sauer M, Kobayashi Y, Buchert R, Mester J, Maurer T, Stolzenbach F, Wester H, Apostolova I, Bannas P
NUKLEARMED-NUCL MED. 2019;58(02):P9.

Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges
Bradtke M, Rink M, Büscheck F, Sauter G, Dahlem R, Fisch M, Vetterlein M
CLIN GENITOURIN CANC. 2019;17(3):e522-e525.

Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?
Cole A, Ramaswamy A, Harmouch S, Fletcher S, Gild P, Sun M, Lipsitz S, Chiang H, Haider A, Preston M, Kibel A, Trinh Q
EUR UROL ONCOL. 2019;2(4):349-354.

Ernährung und Baucharortenaneurysma
Daniels P, Debus S, Grundmann R
GEFASSCHIRURGIE. 2019;2019(24):329-337.

Association Between Exstrophy-epispadias Complex And Congenital Anomalies: A German Multicenter Study
Ebert A, Zwink N, Jenetzky E, Stein R, Boemers T, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Eisenschmidt V, Schäfer M, Hirsch K, Rösch W, Reutter H
UROLOGY. 2019;123:210-219.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer
Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis M, Steurer S, Clauditz T, Luebke A, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S
ONCOTARGET. 2019;10(18):1729-1744.

Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique
Fosså S, Beyer B, Dahl A, Aas K, Eri L, Kvan E, Falk R, Graefen M, Huland H, Berge V
SCAND J UROL. 2019;53(6):385-391.

Update on managing anterior urethral strictures
Fühner C, Dahlem R, Fisch M, Vetterlein M
INDIAN J UROL. 2019;35(2):94-100.

Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy
Gild P, Nguyen D, Fletcher S, Cole A, Lipsitz S, Kibel A, Fisch M, Preston M, Trinh Q
CLIN GENITOURIN CANC. 2019;17(3):e488-e493.

Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer
Gild P, Pompe R, Seisen T, Keeley J, Tang H, Bossi A, Tilki D, Menon M, Abdollah F
EUR UROL ONCOL. 2019.

Bedeutung der VI-RADS-Klassifikation für die Bildgebung beim Harnblasenkarzinom – Stand der Dinge
Hechler V, Rink M, Beyersdorff D, Beer M, Beer A, Panebianco V, Pecoraro M, Bolenz C, Salomon G
UROLOGE. 2019;58(12):1443-1450.

Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey
Hendricksen K, Aziz A, Bes P, Chun F, Dobruch J, Kluth L, Gontero P, Necchi A, Noon A, van Rhijn B, Rink M, Roghmann F, Rouprêt M, Seiler R, Shariat S, Qvick B, Babjuk M, Xylinas E
EUR UROL FOCUS. 2019;5(4):681-688.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
Horwich A, Babjuk M, Bellmunt J, Bruins H, De Reijke T, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Jones R, Kamat A, Khoo V, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Thalmann G, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Vives Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes J
ANN ONCOL. 2019;30(11):1697-1727.

Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer
Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi M, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz P, Enikeev D, Rapoport L, Nasu Y, Shariat S
UROL ONCOL-SEMIN ORI. 2019;37(10):774-783.

Current Disease Management of Primary Urethral Carcinoma
Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, Shariat S
EUR UROL FOCUS. 2019;5(5):722-734.

The interaction of gender and smoking on bladder cancer risks
Janisch F, Shariat S, Schernhammer E, Rink M, Fajkovic H
CURR OPIN UROL. 2019;29(3):249-255.

Do Younger Patients With Muscle-invasive Bladder Cancer Have Better Outcomes?
Janisch F, Yu H, Vetterlein M, Dahlem R, Engel O, Fisch M, Shariat S, Soave A, Rink M
J CLIN MED. 2019;8(9):.

Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer
Kimura S, D' Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei M, Iwata T, Karakiewicz P, Rink M, Gust K, Egawa S, Shariat S
UROL ONCOL-SEMIN ORI. 2019;37(3):179.e19-179.e28.

Messung von Mobilität und Funktion der unteren Extremität in einem ambulanten neurorehabilitativen Setting: Retrospektive Fallserie
Klotz S, Ketels G, Pichler J, Scherer M, Barzel A
PHYSOSCIENCE. 2019;15(2):73-80.

Verbessert Tacrolimus die erektile Funktion nach nervschonender radikaler Prostatektomie?
Kneip J, Soave A
UROLOGE. 2019;58(5):559-561.

A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer
Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz P
CLIN GENITOURIN CANC. 2019;17(5):395-401.

Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery
Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M
EUR UROL FOCUS. 2019;5(1):50-53.

Interdisziplinär integriert oder dezentral verteilt? Die Hamburger TransCare-Studie zu Versorgungssettings im Kontext feminisierender Genitaloperationen
Köhler A, Briken P, Riechardt S, Fisch M, Strauß B, Nieder T
2019. Innovative Forschung für eine personenzentrierte Psychiatrie und Psychotherapie, DGPPN Kongress Berlin. .

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Lam T, MacLennan S, Willemse P, Mason M, Plass K, Shepherd R, Baanders R, Bangma C, Bjartell A, Bossi A, Briers E, Briganti A, Buddingh K, Catto J, Colecchia M, Cox B, Cumberbatch M, Davies J, Davis N, De Santis M, Dell'Oglio P, Deschamps A, Donaldson J, Egawa S, Fankhauser C, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet J, Henry A, Ingels A, Irani J, Lardas M, Liew M, Lin D, Moris L, Omar M, Pang K, Paterson C, Renard-Penna R, Ribal M, Roobol M, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots I, Sedelaar J, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh R, Van den Broeck T, van der Kwast T, van der Poel H, van Leenders G, Varma M, Violette P, Wallis C, Wiegel T, Wilkinson K, Zattoni F, N'Dow J, Van Poppel H, Cornford P, Mottet N
EUR UROL. 2019;76(6):790-813.

Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer
Leeman J, Chen M, Huland H, Graefen M, D'Amico A, Tilki D
CLIN GENITOURIN CANC. 2019;17(6):e1116-e1121.

Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations
Leyh-Bannurah S, Karakiewicz P, Pompe R, Preisser F, Zaffuto E, Dell'Oglio P, Briganti A, Nafez O, Fisch M, Steuber T, Graefen M, Budäus L
WORLD J UROL. 2019;37(3):469-479.

Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes
Leyh-Bannurah S, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, Capitanio U, Briganti A, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland H, Karakiewicz P
UROL INT. 2019;102(1):51-59.

Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer
Löser A, Beyer B, Carl C, Löser B, Nagaraj Y, Frenzel T, Petersen C, Krüll A, Graefen M, Schwarz R
STRAHLENTHER ONKOL. 2019;195(5):374-382.

The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy
Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein M, Shariat S, Sauter G, Dahlem R, Fisch M, Rink M
SURG ONCOL. 2019;28:208-213.

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review
Matta R, Chapple C, Fisch M, Heidenreich A, Herschorn S, Kodama R, Koontz B, Murphy D, Nguyen P, Nam R
EUR UROL. 2019;75(3):464-476.

PSA-Anstieg nach definitiver Therapie
Maurer T, Hadaschik B, Budäus L, Steuber T, Salomon G, Horn T, Herrmann K, Weber M, Giesel F, Berliner C, Eiber M
UROLOGE. 2019;58(5):569-582.

Entering the era of molecular-targeted precision surgery in recurrent prostate cancer: J Nucl Med
Maurer T, van Leeuwen F, Schottelius M, Wester H, Eiber M
J NUCL MED. 2019;60(2):156-157.

Distal Double Cuff Vs. Transcorporal Cuff as Salvage Options - a Prospective Analysis of Different Artificial Urinary Sphincter (AMS 800) Implantation Sites
Maurer V, Dahlem R, Rosenbaum C, Gild P, Vetterlein M, Schüttfort V, Meyer C, Riechardt S, Fisch M, Marks P, Ludwig T
UROLOGY. 2019;133:234-239.

Prospective analysis of artificial urinary sphincter AMS 800 implantation after buccal mucosa graft urethroplasty.
Maurer V, Marks P, Dahlem R, Rosenbaum C, Meyer C, Riechardt S, Fisch M, Ludwig T
WORLD J UROL. 2019.

Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies
Mazzone E, Knipper S, Mistretta F, Palumbo C, Tian Z, Gallina A, Tilki D, Shariat S, Montorsi F, Saad F, Briganti A, Karakiewicz P
J NATL COMPR CANC NE. 2019;17(11):1344-1352.

Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy
Mazzone E, Mistretta F, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz P
CLIN GENITOURIN CANC. 2019;17(6):e1153-e1162.

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status
McClintock T, von Landenberg N, Cole A, Lipsitz S, Gild P, Sun M, Fletcher S, Roghmann F, Menon M, Nguyen P, Noldus J, Choueiri T, Kibel A, Trinh Q
ANN SURG ONCOL. 2019;26(1):297-305.

Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy
Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan W, Kelly J, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, Briganti A, Montorsi F, Galucci M, Rink M, Karakiewicz P, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Sooriakumaran P, Shariat S
UROL ONCOL-SEMIN ORI. 2019;37(3):179.e1-179.e7.

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan W, Kelly J, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz P, Rouprêt M, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Lotan Y, Sooriakumaran P, Shariat S
J CLIN MED. 2019;8(8):.

Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer
Preisser F, Coxilha G, Heinze A, Oh S, Chun F, Sauter G, Pompe R, Huland H, Graefen M, Tilki D
PROSTATE. 2019;79(16):1832-1836.

The Impact of Lymph Node Metastases Burden at Radical Prostatectomy
Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz P
EUR UROL FOCUS. 2019;5(3):399-406.

Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer
Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat S, Graefen M, Tilki D, Karakiewicz P
CLIN GENITOURIN CANC. 2019;17(5):e939-e945.

The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder
Rink M, Schwarzenbach H, Riethdorf S, Soave A
WORLD J UROL. 2019;37(9):1785-1799.

The current role of circulating biomarkers in non-muscle invasive bladder cancer
Rink M, Schwarzenbach H, Vetterlein M, Riethdorf S, Soave A
TRANSL ANDROL UROL. 2019;8(1):61-75.

The impact of surgical sequence on outcome rates of artificial urinary sphincter implantation: comparative effectiveness of primary, secondary and repeat implantation
Rosenbaum C, Pham T, Dahlem R, Maurer V, Marks P, Vetterlein M, Fisch M, Ludwig T
WORLD J UROL. 2019 [Epub ahead of print].

Feedback eines Patienten
Rosenbaum C, Vetterlein M
Uro-News. 2019;23(10):14-17.

Reply: Letter-to-the-editor: Direct Vision Internal Urethrotomy for short anterior urethral strictures and Beyond: Success Rates, Predictors of Treatment Failure and Recurrence Management
Rosenbaum C, Vetterlein M, Kluth L
UROLOGY. 2019;124(313):313.

Positronenemissionstomographie bei Keimzelltumoren des Mannes: Einsatzmöglichkeiten und Grenzen
Schriefer P, Hartmann M, Oechsle K, Meyer C, Klutmann S, Fisch M, Bokemeyer C, Oing C
UROLOGE. 2019;58(4):418-423.

Live surgery in reconstructive urology: evaluation of the surgical outcome and educational benefit of the international meeting on reconstructive urology (IMORU)
Schuettfort V, Schoof J, Rosenbaum C, Ludwig T, Vetterlein M, Leyh-Bannurah S, Maurer V, Meyer C, Dahlem R, Fisch M, Reiss C
WORLD J UROL. 2019;37(11):2533-2539.

Outcome of buccal mucosa graft urethroplasty: a detailed analysis of success, morbidity and quality of life in a contemporary patient cohort at a referral center
Soave A, Kluth L, Dahlem R, Rohwer A, Rink M, Reiss P, Fisch M, Engel O
BMC UROL. 2019;19:.

Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronie's Disease
Soave A, Laurich S, Dahlem R, Vetterlein M, Engel O, Nieder T, Briken P, Rink M, Fisch M, Reiss C
J CLIN MED. 2019;8(8):.

Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey
Spachmann P, May M, Vetterlein M, Fritsche H, Steffen S, Schostak M, Wagenlehner F, Burger M, Weylandt K, Salzberger B, Brookman-May S, Gilfrich C
CASP J INTERN MED. 2019;10(2):132-141.

Clinical impact of “true whole-body” Ga-68-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities
Stolzenbach F, Maurer T, Budäus L, Steuber T, Graefen M, Sauer M, Kobayashi Y, Apostolova I, Berliner C
NUKLEARMED-NUCL MED. 2019;58(02):P16.

Vergleich von Tc-99 m-PSMA I&S SPECT/CT und Ga-68-PSMA PET/CT vor Gammasonden-gesteuerter Operation bei Prostatakarzinomrezidiv
Stolzenbach F, Sauer M, Kobayashi Y, Buchert R, Mester J, Maurer T, Wester H, Apostolova I, Bannas P, Berliner C
ROFO-FORTSCHR RONTG. 2019;191(S 01):WISS 401.5.

Characterization of a Standardized Postoperative Radiographic and Functional Voiding Trial after 1-Stage Bulbar Ventral Onlay Buccal Mucosal Graft Urethroplasty and the Impact on Stricture Recurrence-Free Survival
Vetterlein M, Loewe C, Zumstein V, Rosenbaum C, Engel O, Dahlem R, Fisch M, Kluth L
J UROLOGY. 2019;201(3):563-572.

Surgical Reconstruction of Posterior Urethral Complications Following Prostate Cancer Treatments
Vetterlein M, Rosenbaum C, Fisch M
2019 [Epub ahead of print]. Textbook of Male Genitourethral Reconstruction. Martins F, Kulkarni S, Köhler T (Hrsg.). Cham: Springer International Publishing, 303-317.

Anterior Urethral Strictures in Children: Disease Etiology and Comparative Effectiveness of Endoscopic Treatment vs. Open Surgical Reconstruction
Vetterlein M, Weisbach L, Riechardt S, Fisch M
FRONT PEDIATR. 2019;7:5.

Comparison of testis cancer-specific survival: an analysis of national cancer registry data from the USA, UK and Germany
Withington J, Cole A, Meyer C, Seisen T, Schmid M, Lipsitz S, Sweeney C, Dasgupta P, Trinh Q
BJU INT. 2019;123(3):385-387.

Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis
Zumstein V, Betschart P, Vetterlein M, Kluth L, Hechelhammer L, Mordasini L, Engeler D, Kessler T, Schmid H, Abt D
EUR UROL FOCUS. 2019;5(6):1091-1100.

Single-stage buccal mucosal graft urethroplasty for meatal stenoses and fossa navicularis strictures: a monocentric outcome analysis and literature review on alternative treatment options
Zumstein V, Dahlem R, Maurer V, Marks P, Kluth L, Rosenbaum C, Ludwig T, Meyer C, Riechardt S, Engel O, Fisch M, Vetterlein M
WORLD J UROL. 2019 [Epub ahead of print].

Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer

BJU INT. 2018;121(1):101-110.

Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer
Abdollah F, Arora S, von Landenberg N, Gild P, Sood A, Dalela D, Trinh Q, Menon M, Rogers C
BJU INT. 2018;121(3):345-347.

Training, Research, and Working Conditions for Urology Residents in Germany: A Contemporary Survey
Borgmann H, Arnold H, Meyer C, Bründl J, König J, Nestler T, Ruf C, Struck J, Salem J
EUR UROL FOCUS. 2018;4(3):455-460.

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Shadanpour N, Bannenberg C, Eichelberg C, Höflmayer D, Clauditz T, Wittmer C, Wilczak W, Sauter G, Fisch M, Rink M, Eichenauer T
UROL ONCOL-SEMIN ORI. 2018;36(12):531.e19-531.e25.

Ernährung und periphere arterielle Verschlusskrankheit - Teil 2
Daniels P, Debus S, Grundmann R
GEFASSCHIRURGIE. 2018;2019(24):62-64.

The effect of treatment at minority-serving hospitals on outcomes for bladder cancer
Fletcher S, Gild P, Cole A, Vetterlein M, Kibel A, Choueiri T, Sonpavde G, Preston M, Pucheril D, Menon M, Sun M, Lipsitz S, Trinh Q
UROL ONCOL-SEMIN ORI. 2018;36(5):238.e7-238.e17.

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era
Fletcher S, Harmouch S, Krimphove M, Cole A, Berg S, Gild P, Preston M, Sonpavde G, Kibel A, Sun M, Choueiri T, Trinh Q
WORLD J UROL. 2018;36(11):1767-1774.

The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma
Gakis G, Schubert T, Morgan T, Daneshmand S, Keegan K, Mischinger J, Clayman R, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K, Rink M, Fritsche H, Burger M, Babjuk M, Stenzl A, Thalmann G, Kübler H, Efstathiou J
UROL ONCOL-SEMIN ORI. 2018;36(1):10.e7-10.e14.

Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions
Gandaglia G, Tilki D, Zaffuto E, Fossati N, Pompe R, Dell'Oglio P, Graefen M, Montorsi F, Briganti A
EUR UROL FOCUS. 2018.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study
Gierth M, Zeman F, Denzinger S, Vetterlein M, Fisch M, Bastian P, Syring I, Ellinger J, Müller S, Herrmann E, Gilfrich C, May M, Pycha A, Wagenlehner F, Vallo S, Bartsch G, Haferkamp A, Grimm M, Roigas J, Protzel C, Hakenberg O, Fritsche H, Burger M, Aziz A, Mayr R
UROL INT. 2018;101(1):16-24.

Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer
Gild P, Cole A, Krasnova A, Dickerman B, von Landenberg N, Sun M, Mucci L, Lipsitz S, Chun F, Nguyen P, Kibel A, Choueiri T, Basaria S, Trinh Q
J UROLOGY. 2018;200(3):573-581.

Adult iatrogenic ureteral injury and stricture – incidence and treatment strategies
Gild P, Kluth L, Vetterlein M, Engel O, Chun F, Fisch M
ASIAN J UROL. 2018;5(2):101-106.

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis
Gild P, Wankowicz S, Sood A, von Landenberg N, Friedlander D, Alanee S, Chun F, Fisch M, Menon M, Trinh Q, Bellmunt J, Abdollah F
UROL ONCOL-SEMIN ORI. 2018;36(10):469.e1-469.e11.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer
Heinrich M, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A
BMC CANCER. 2018;18(1):612.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer
Heumann A, Heinemann N, Hube-Magg C, Lang D, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis M, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A
BMC CANCER. 2018;18(1):37.

Author Correction: Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang D, Simon R, Beyer B, Thederan I, Sauter G, Izbicki J, Luebke A, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis M, Schlomm T, Wilczak W
SCI REP-UK. 2018;8(1):12821.

Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer
Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz T, Krech T, Tsourlakis M, Schroeder C
WORLD J UROL. 2018;36(6):877-882.

Soziale Ungleichheit bei der Inanspruchnahme onkologischer Versorgungsangebote
Hofreuter-Gätgens K, Klein J, Fisch M, Graefen M, Schlotfeldt T, Witzel I, von dem Knesebeck O
GESUNDHEITSWESEN. 2018;80(2):94-100.

Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer
Kimura S, Soria F, D'Andrea D, Foerster B, Abufaraj M, Vartolomei M, Karakiewicz P, Mathieu R, Moschini M, Rink M, Egawa S, Shariat S, Gust K
CLIN GENITOURIN CANC. 2018;16(6):e1123-e1132.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer
Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis M, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke A, Burandt E, Steurer S, Schlomm T, Simon R
GENE CHROMOSOME CANC. 2018;57(10):504-512.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer
Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis M, Lübke A, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R
CANCER MANAG RES. 2018;10:5909-5917.

Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy
Landenberg N, Speed J, Cole A, Seisen T, Lipsitz S, Gild P, Menon M, Kibel A, Roghmann F, Noldus J, Sun M, Trinh Q
UROL ONCOL-SEMIN ORI. 2018;36(2):78.e13-78.e19.

Diagnostik und Therapie vesikovaginaler und ureterovaginaler Fisteln
Lang I, Fisch M, Kluth L
AKTUEL UROL. 2018;49(1):83-91.

Re: Letter to the editor
Lebentrau S, Gilfrich C, Vetterlein M, Schumacher H, Spachmann P, Brookman-May S, Fritsche H, Schostak M, Wagenlehner F, Burger M, May M
INT UROL NEPHROL. 2018;50(5):875.

Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification
Leyh-Bannurah S, Budäus L, Zaffuto E, Pompe R, Bandini M, Briganti A, Montorsi F, Schiffmann J, Shariat S, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2018;36(2):81.e17-81.e24.

Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience
Leyh-Bannurah S, Dell'Oglio P, Zaffuto E, Briganti A, Schiffmann J, Pompe R, Tilki D, Heinzer H, Graefen M, Karakiewicz P, Budäus L
EUR UROL FOCUS. 2018.

Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies
Leyh-Bannurah S, Kachanov M, Beyersdorff D, Preisser F, Tilki D, Fisch M, Graefen M, Budäus L
J UROLOGY. 2018;200(5):1035-1040.

Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records
Leyh-Bannurah S, Tian Z, Karakiewicz P, Wolffgang U, Sauter G, Fisch M, Pehrke D, Huland H, Graefen M, Budäus L
JCO CLIN CANCER INFO. 2018;2:1-9.

Sphinkter- und Schwellkörperprothesen als Teile der Endoprothetik in der Urologie
Ludwig T, Dahlem R
UROLOGE. 2018;57(2):211-222.

Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy
Mandel P, Linnemannstöns A, Chun F, Schlomm T, Pompe R, Budäus L, Rosenbaum C, Ludwig T, Dahlem R, Fisch M, Graefen M, Huland H, Tilki D, Steuber T
EUR UROL FOCUS. 2018;4(4):554-557.

Practice changing for prostate cancer: a vision of the future: Nat Rev Urol
Maurer T, Eiber M
NAT REV UROL. 2018.

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration
Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman J, Wood C, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat S
BJU INT. 2018;121(2):252-259.

Immunotherapy for metastatic urothelial carcinoma: status quo and the future
Necchi A, Rink M, Giannatempo P, Raggi D, Xylinas E
CURR OPIN UROL. 2018;28(1):1-7.

Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer
Neubauer E, Latif M, Krause J, Heumann A, Armbrust M, Luehr C, Fraune C, Hube-Magg C, Kluth M, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, Büscheck F
EXP MOL PATHOL. 2018;105(1):50-56.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence
Pompe R, Gild P, Karakiewicz P, Bock L, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D
PROSTATE. 2018;78(9):676-681.

Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI
Pompe R, Kühn-Thomä B, Nagaraj Y, Veleva V, Preisser F, Leyh-Bannurah S, Graefen M, Huland H, Tilki D, Salomon G
WORLD J UROL. 2018;36(5):705-712.

Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes
Pompe R, Leyh-Bannurah S, Preisser F, Salomon G, Graefen M, Huland H, Karakiewicz P, Tilki D
UROL ONCOL-SEMIN ORI. 2018;36(12):527.e21-527.e28.

Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study
Pompe R, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, Leyh-Bannurah S, Schiffmann J, Saad F, Huland H, Graefen M, Shariat S, Tilki D, Karakiewicz P
PROSTATE CANCER P D. 2018;21(1):71-77.

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages
Pompe R, Tilki D, Preisser F, Leyh-Bannurah S, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat S, Huland H, Graefen M, Briganti A, Karakiewicz P
PROSTATE. 2018;78(10):753-757.

Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion
Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe R, Fossati N, Briganti A, Saad F, Shariat S, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz P
PROSTATE. 2018;78(6):469-475.

Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer
Rieken M, Shariat S, Kluth L, Crivelli J, Abufaraj M, Foerster B, Mari A, Ilijazi D, Karakiewicz P, Babjuk M, Gönen M, Xylinas E
UROL ONCOL-SEMIN ORI. 2018;36(1):8.e17-8.e24.

Effect of repeat prostate biopsies on functional outcomes after radical prostatectomy
Rosenbaum C, Mandel P, Tennstedt P, Preisser F, Marks P, Chun F, Graefen M, Tilki D, Salomon G
UROL ONCOL-SEMIN ORI. 2018;36(3):91.e17-91.e22.

Worth a second look: outcomes of patients with initial finding of regular renal tissue in CT-guided renal tumor biopsies
Sadat-Khonsari M, Papayannis M, Schriefer P, Kluth L, Meyer C, Schüttfort V, Regier M, Rink M, Chun F, Fisch M, Becker A
WORLD J UROL. 2018;36(5):789-792.

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy:results from a prospective randomized trial
Salomon G, Saul J, Prues S, Schneider M, Budäus L, Tilki D, Rohde H, Haferkamp A, Graefen M, Boehm K
WORLD J UROL. 2018;36(6):871-876.

Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens
Sauter G, Clauditz T, Steurer S, Wittmer C, Büscheck F, Krech T, Lutz F, Lennartz M, Harms L, Lawrenz L, Möller-Koop C, Simon R, Jacobsen F, Wilczak W, Minner S, Tsourlakis M, Chirico V, Weidemann S, Haese A, Steuber T, Salomon G, Matiu M, Vettorazzi E, Michl U, Budäus L, Tilki D, Thederan I, Pehrke D, Beyer B, Fraune C, Göbel C, Heinrich M, Juhnke M, Möller K, Bawahab A, Uhlig R, Huland H, Heinzer H, Graefen M, Schlomm T
EUR UROL. 2018;73(5):674-683.

Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients
Schiffmann J, Karakiewicz P, Rink M, Manka L, Salomon G, Tilki D, Budäus L, Pompe R, Leyh-Bannurah S, Haese A, Hammerer P, Huland H, Graefen M, Tennstedt P
WORLD J UROL. 2018;36(7):1067-1072.

Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis
Seisen T, Vetterlein M, Karabon P, Jindal T, Sood A, Nocera L, Nguyen P, Choueiri T, Trinh Q, Menon M, Abdollah F
EUR UROL. 2018;73(3):452–461.

Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity
Soave A, Dahlem R, Pinnschmidt H, Rink M, Langetepe J, Engel O, Kluth L, Loechelt B, Reiss P, Ahyai S, Fisch M
EUR UROL. 2018;73(6):910-922.

Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."
Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
UROL ONCOL-SEMIN ORI. 2018;36(7):347-348.

[CEUS-diagnosis of solid renal tumors]: Radiologe
Stock K, Kubler H, Maurer T, Slotta-Huspenina J, Holzapfel K
RADIOLOGE. 2018.

The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis
Tosco L, Laenen A, Briganti A, Gontero P, Karnes R, Bastian P, Chlosta P, Claessens F, Chun F, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas R, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S
EUR UROL FOCUS. 2018;4(3):369-375.

Screening utilization among cancer survivors: a meta-analysis
Uhlig A, Mei J, Baik I, Meyer C, Uhlig J
J PUBLIC HEALTH-UK. 2018;40(1):129-137.

Re: Vetterlein et al.: State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update (Urology 2018;112:56-65) Reply
Vetterlein M, Abdollah F
UROLOGY. 2018;116:232-233.

State-by-State Variation in Prostate-Specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update
Vetterlein M, Dalela D, Sammon J, Karabon P, Sood A, Jindal T, Meyer C, Löppenberg B, Sun M, Trinh Q, Menon M, Abdollah F
UROLOGY. 2018;112:56-65.

Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation
Vetterlein M, Gild P, Marks P, Roschinski J, Doh O, Höppner W, Wagner W, Isbarn H, Büscheck F, Sauter G, Dahlem R, Soave A, Fisch M, Rink M
UROL INT. 2018;101(3):285-292.

Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder
Vetterlein M, Karabon P, Dalela D, Jindal T, Sood A, Seisen T, Trinh Q, Menon M, Abdollah F
EUR UROL FOCUS. 2018;4(4):568-571.

Robot-Assisted Laparoscopic Radical Prostatectomy in Patients with Clinically High-Risk Prostate Cancer
Vetterlein M, Menon M, Abdollah F
2018. Robotics in Genitourinary Surgery. Hemal A, Menon M (Hrsg.). Cham: Springer International Publishing, 363-373.

EDITORIAL COMMENT REPLY
Vetterlein M, Sammon J, Abdollah F
UROLOGY. 2018;112:64-65.

Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer
Vetterlein M, Seisen T, Leow J, Preston M, Sun M, Friedlander D, Meyer C, Chun F, Lipsitz S, Menon M, Kibel A, Bellmunt J, Choueiri T, Trinh Q
CLIN GENITOURIN CANC. 2018;16(1):e129-e139.

The Impact of Surgical Sequence on Stricture Recurrence after Anterior 1-Stage Buccal Mucosal Graft Urethroplasty: Comparative Effectiveness of Initial, Repeat and Secondary Procedures
Vetterlein M, Stahlberg J, Zumstein V, Engel O, Dahlem R, Fisch M, Rosenbaum C, Kluth L
J UROLOGY. 2018;200(6):1308-1314.

Antigen-Specific IgG Subclasses in Primary and Malignancy-Associated Membranous Nephropathy
von Haxthausen F, Reinhard L, Pinnschmidt H, Rink M, Soave A, Hoxha E, Stahl R
FRONT IMMUNOL. 2018;9:3035.

Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer
von Landenberg N, Aziz A, von Rundstedt F, Dobruch J, Kluth L, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker K, Seiler R, Poyet C, Fajkovic H, Shariat S, Xylinas E, Roghmann F
UROL ONCOL-SEMIN ORI. 2018;36(5):238.e19-238.e27.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes
Voskuilen C, Seiler R, Rink M, Poyet C, Noon A, Roghmann F, Necchi A, Aziz A, Lavollé A, Young M, Marks P, Saba K, van Rhijn B, Fransen van de Putte E, Ablat J, Black P, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto J, Xylinas E, Hendricksen K
EUR UROL FOCUS. 2018.

Low-Dose CT for Evaluation of Suspected Urolithiasis: Diagnostic Yield for Assessment of Alternative Diagnoses
Weinrich J, Bannas P, Regier M, Keller S, Kluth L, Adam G, Henes F
AM J ROENTGENOL. 2018;210(3):557-563.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer
Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther C, Koop C, Simon R, Jacobsen F, Tsourlakis M, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich M, Juhnke M, Möller K, Bawahab A, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T
EUR UROL. 2018;74(3):376-386.

Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C
Xylinas E, Kent M, Dabi Y, Rieken M, Kluth L, Al Awamlh B, Ouzaid I, Pycha A, Comploj E, Svatek R, Lotan Y, Karakiewicz P, Holmang S, Shariat S
UROL ONCOL-SEMIN ORI. 2018;36(3):89.e1-89.e5.

Meatusenge und glanduläre Harnröhrenstriktur
Zeller S, Vetterlein M, Fisch M, Kluth L
UROLOGE. 2018;57(1):11-16.

Utilization of pelvic lymph node dissection in patients undergoing robot-assisted radical prostatectomy in India versus the United States - A Vattikuti Collective Quality Initiative database analysis
Abdollah F, Arora S, Jindal T, Gild P, Sood A, Yuvaraja T, Ahlawat R, Gupta N, Bhandari M, Menon M
INDIAN J CANCER. 2017;54(2):421-425.

Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy
Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe R, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T
EUR UROL. 2017;71(3):330-336.

Weiterbildungs- und Arbeitsbedingungen urologischer Assistenzärzte in Deutschland: Ergebnisse einer GeSRU-Umfrage von 2015
Arnold H, Meyer C, Salem N, Raspe M, Struck J, Borgmann H
UROLOGE. 2017;56(10):1311-1319.

Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review
Aziz A, Dobruch J, Hendricksen K, Kluth L, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat S, Xylinas E
WORLD J UROL. 2017;35(9):1401-1407.

Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III
Bach T, Bastian P, Blana A, Kaminsky A, Keller S, Knoll T, Lang C, Promnitz S, Ubrig B, Keller T, Qvick B, Burger M
WORLD J UROL. 2017;35(5):737-744.

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
Bernhardt M, Novak D, Assenov Y, Orouji E, Knappe N, Weina K, Reith M, Larribere L, Gebhardt C, Plass C, Umansky V, Utikal J
STEM CELL REP. 2017;8(5):1379-1391.

Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using Ga-PSMA PET/CT
Bieth M, Krönke M, Tauber R, Dahlbender M, Retz M, Nekolla S, Menze B, Maurer T, Eiber M, Schwaiger M
J NUCL MED. 2017;58(10):1632-1637.

Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer
Boehm K, Dell'Oglio P, Tian Z, Capitanio U, Chun F, Tilki D, Haferkamp A, Saad F, Montorsi F, Graefen M, Karakiewicz P
WORLD J UROL. 2017;35(7):1031-1036.

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy
Boehm K, Leyh-Bannurah S, Rosenbaum C, Brandi L, Budäus L, Graefen M, Huland H, Haferkamp A, Tilki D
BJU INT. 2017;120(5):666-672.

Mental disorders in patients with chronic pelvic pain syndrome (CPPS)
Brünahl C, Dybowski C, Albrecht R, Riegel B, Höink J, Fisch M, Löwe B
J PSYCHOSOM RES. 2017;98:19-26.

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer
Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl H, Tsourlakis M, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki J, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W
ONCOTARGET. 2017;8(19):31494-31508.

Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers
Burdelski C, Fitzner M, Hube-Magg C, Kluth M, Heumann A, Simon R, Krech T, Clauditz T, Büscheck F, Steurer S, Wittmer C, Hinsch A, Luebke A, Jacobsen F, Minner S, Tsourlakis M, Beyer B, Steuber T, Thederan I, Sauter G, Izbicki J, Schlomm T, Wilczak W
NEOPLASIA. 2017;19(4):279-287.

High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer
Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis M, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F
PROSTATE. 2017;77(15):1528-1538.

Immunohistochemical and serological characterization of membranous nephropathy in children and adolescents
Dettmar A, Wiech T, Kemper M, Soave A, Rink M, Oh J, Stahl R, Hoxha E
PEDIATR NEPHROL. 2017;33(3):463-472.

Corrigendum re: "Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours" [Eur Urol 2017;71:213-20]
Dieckmann K, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G
EUR UROL. 2017;71(5):e161.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

The contemporary role and impact of urine-based biomarkers in bladder cancer
Duquesne I, Weisbach L, Aziz A, Kluth L, Xylinas E
TRANSL ANDROL UROL. 2017;6(6):1031-1042.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study
Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann G, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi B, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen A, Jensen J, Keck B, Grimm M, Horstmann M, Maurer T, Steyerberg E, Zwarthoff E, Real F, Malats N, Malmström P, Ørntoft T
EUR UROL. 2017;72(3):461-469.

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy: J Nucl Med
Eiber M, Fendler W, Rowe S, Calais J, Hofman M, Maurer T, Schwarzenboeck S, Kratowchil C, Herrmann K, Giesel F
J NUCL MED. 2017;58(Suppl 2):67s-76s.

Prospective head-to-head comparison of C-choline-PET/MR and C-choline-PET/CT for restaging of biochemical recurrent prostate cancer
Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, Beer A
EUR J NUCL MED MOL I. 2017;44(13):2179-2188.

Detection Efficacy of Hybrid Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria
Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester H, Schwaiger M, Maurer T, Eiber M
J NUCL MED. 2017;58(7):1081-1087.

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study
Favaretto R, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam J, Rouprêt M, Seitz C, Karakiewicz P, Cunha I, Zequi S, Wood C, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, Shariat S
WORLD J UROL. 2017;35(1):113-120.

Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Fendler W, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope T, Okamoto S, Pfob C, Pöppel T, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho H, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M
J NUCL MED. 2017;58(10):1617-1623.

Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma
Foerster B, Moschini M, Abufaraj M, Soria F, Gust K, Rouprêt M, Karakiewicz P, Briganti A, Rink M, Kluth L, Mathieu R, Margulis V, Lotan Y, Aziz A, John H, Shariat S
CLIN GENITOURIN CANC. 2017;15(6):e1039-e1045.

[Significance of PSMA imaging in prostate cancer]: Urologe A
Gasch C, Duwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T, Haberkorn U, Hadaschik B, Giesel F
UROLOGE. 2017;56(1):3-12.

Editorial Comment
Gild P, Abdollah F
J UROLOGY. 2017;198(2):361.

Editorial Comment
Gild P, Chun F, Becker A
J UROLOGY. 2017;197(4):996-997.

Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival
Gild P, Ehdaie B, Kluth L
CURR OPIN UROL. 2017;27(5):409-414.

Online tools for patient counseling in bladder and kidney cancer-ready for prime time?
Gild P, Rink M, Meyer C
TRANSL ANDROL UROL. 2017;6(6):1123-1131.

Racial disparities in prostate cancer treatment—does facility level make a difference?
Gild P, Vetterlein M, Meyer C, Schmid M, Chun F
J XiangYa Med. 2017;2(16):1-2.

Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol 2017;71:729-37
Gild P, von Landenberg N, Cole A
EUR UROL. 2017;71(6):e181-e182.

Upregulated Heat Shock Proteins After Hyperthermic Chemotherapy Point to Induced Cell Survival Mechanisms in Affected Tumor Cells From Peritoneal Carcinomatosis
Grimmig T, Moll E, Kloos K, Thumm R, Moench R, Callies S, Kreckel J, Vetterlein M, Pelz J, Polat B, Tripathi S, Rehder R, Ribas C, Chandraker A, Germer C, Waaga-Gasser A, Gasser M
Cancer Growth and Metastasis. 2017;(10):1179064417730559.

(68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment: Prostate
Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs S
PROSTATE. 2017;77(8):920-927.

Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy
Heck M, Thaler M, Schmid S, Seitz A, Tauber R, Kübler H, Maurer T, Thalgott M, Hatzichristodoulou G, Höppner M, Nawroth R, Luppa P, Gschwend J, Retz M
BJU INT. 2017;119(1):30-37.

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer
Heumann A, Kaya Ö, Burdelski C, Hube-Magg C, Kluth M, Lang D, Simon R, Beyer B, Thederan I, Sauter G, Izbicki J, Luebke A, Hinsch A, Jacobsen F, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis M, Schlomm T, Wilczak W
SCI REP-UK. 2017;7(1):2056.

βIII-tubulin overexpression is linked to agressive tumor features and genetic instability in urinary bladder cancer
Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis M, Steurer S, Rink M, Eichenauer T, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F
HUM PATHOL. 2017;61:210-220.

[PSMA-radioguided surgery in localised recurrent prostate cancer]: Urologe A
Horn T, Rauscher I, Eiber M, Gschwend J, Maurer T
UROLOGE. 2017;56(11):1417-1423.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Sauter G, Izbicki J, Clauditz T, Luebke A, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis M, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N
NEOPLASIA. 2017;19(9):707-715.

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann S, Burdak-Rothkamm S
BMC CANCER. 2017;17(1):504.

Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists
James N, Graham J, Maurer T, Eiber M, Gschwend J
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017;37:344-357.

Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses
Jindal T, Kachroo N, Sammon J, Dalela D, Sood A, Vetterlein M, Karabon P, Jeong W, Menon M, Trinh Q, Abdollah F
UROL ONCOL-SEMIN ORI. 2017;35(7):460.e9-460.e20.

Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion
Juhnke M, Heumann A, Chirico V, Höflmayer D, Menz A, Hinsch A, Hube-Magg C, Kluth M, Lang D, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, Luebke A
MOL CARCINOGEN. 2017;56(9):2135-2145.

EDF lichen sclerosus guideline Response
Kirtschig G, Becker K, Günthert A, Jasaitiene D, Cooper S, Chi C, Kreuter A, Rall K, Aberer W, Riechardt S, Casabona F, Powell J, Brackenbury F, Erdmann R, Lazzeri M, Barbagli G, Wojnarowska F
J EUR ACAD DERMATOL. 2017;31(2):e104-e105.

Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus
Kirtschig G, Cooper S, Aberer W, Günthert A, Becker K, Jasaitiene D, Chi C, Kreuter A, Rall K, Riechardt S, Casabona F, Powell J, Brackenbury F, Erdmann R, Lazzeri M, Barbagli G, Wojnarowska F
J EUR ACAD DERMATOL. 2017;31(2):e81-e83.

Akutes Nierenversagen bei Urachuszyste?
Klaassen I, Wolf M, Kemper M, Riechardt S, Boettcher M, Herrmann J, Singer D
Z GEBURTSH NEONATOL. 2017;221(2):88-91.

Income and health-related quality of life among prostate cancer patients over a one-year period after radical prostatectomy: a linear mixed model Analysis: a linear mixed model analysis
Klein J, Lüdecke D, Hofreuter-Gätgens K, Fisch M, Graefen M, von dem Knesebeck O
QUAL LIFE RES. 2017;26(9):2363-2373.

Direct Vision Internal Urethrotomy for Short Anterior Urethral Strictures and Beyond: Success Rates, Predictors of Treatment Failure and Recurrence Management
Kluth L, Ernst L, Vetterlein M, Meyer C, Reiss C, Fisch M, Rosenbaum C
UROLOGY. 2017;106:210-215.

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer
Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T
ONCOTARGET. 2017;8(2):3761.

Deletion of 8p is an independent prognostic parameter in prostate cancer
Kluth M, Amschler N, Galal R, Möller-Koop C, Barrow P, Tsourlakis M, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz T, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R
ONCOTARGET. 2017;8(1):379-392.

[PET-CT and PET-MRI of the prostate : From (18)F-FDG to (68)Ga-PSMA]: Radiologe
Knorr K, Eiber M, Maurer T, Wester H, Scheidhauer K
RADIOLOGE. 2017;57(8):631-636.

Differences in Recurrence Rate andIncontinence after Endoscopic Treatment of Vesicourethral Stenosis and Bladder Neck Stenosis
Kranz J, Reiss P, Salomon G, Steffens J, Fisch M, Rosenbaum C
FRONT SURG. 2017;4:44.

Digital Mapping of the Urinary Bladder: Potential for Standardized Cystoscopy Reports
Kriegmair M, Bergen T, Ritter M, Mandel P, Michel M, Wittenberg T, Bolenz C
UROLOGY. 2017;104:235-241.

Tumor size and invasiveness matters for partial nephrectomy: External validation and modification of the arterial based complexity score
Kriegmair M, Hetjens S, Mandel P, Wadle J, Budjan J, Michel M, Pfalzgraf D, Wagener N
J SURG ONCOL. 2017;115(6):768-774.

Defining Renal Masses: Comprehensive Comparison of RENAL, PADUA, NePhRO, and C-Index Score
Kriegmair M, Mandel P, Moses A, Lenk J, Rothamel M, Budjan J, Michel M, Wagener N, Pfalzgraf D
CLIN GENITOURIN CANC. 2017;15(2):248-255.e1.

Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma
Kriegmair M, Mandel P, Porubsky S, Dürr J, Huck N, Nuhn P, Pfalzgraf D, Michel M, Wagener N
DISCOV ONCOL. 2017;8(2):127-134.

Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship
Lebentrau S, Gilfrich C, Vetterlein M, Schumacher H, Spachmann P, Brookman-May S, Fritsche H, Schostak M, Wagenlehner F, Burger M, May M
INT UROL NEPHROL. 2017;49(8):1311-1318.

The Urologist's Role in Antibiotic Stewardship: Results from the MR2 Study
Lebentrau S, Vetterlein M, May M
EUR UROL. 2017;71(6):995-996.

North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer
Leyh-Bannurah S, Budäus L, Pompe R, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat S, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz P
PROSTATE. 2017;77(5):542-548.

Local Therapy Improves Survival in Metastatic Prostate Cancer
Leyh-Bannurah S, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat S, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz P
EUR UROL. 2017;72(1):118-124.

Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients
Leyh-Bannurah S, Gazdovich S, Budäus L, Zaffuto E, Dell'Oglio P, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat S, Fisch M, Chun F, Graefen M, Karakiewicz P
PROSTATE. 2017;77(1):105-113.

Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy
Leyh-Bannurah S, Karakiewicz P, Dell'Oglio P, Briganti A, Schiffmann J, Pompe R, Sauter G, Schlomm T, Heinzer H, Huland H, Graefen M, Budäus L
CLIN GENITOURIN CANC. 2017 [Epub ahead of print].

The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis
Löppenberg B, Dalela D, Karabon P, Sood A, Sammon J, Meyer C, Sun M, Noldus J, Peabody J, Trinh Q, Menon M, Abdollah F
EUR UROL. 2017;72(1):14-19.

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort
Lotan T, Heumann A, Rico S, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T, Simon R
ONCOTARGET. 2017;8(39):65566-65576.

Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study
Malte R, Kluth L, Kaushik D, Boorjian S, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz P, Rouprêt M, Briganti A, Scherr D, Shariat S, Seebacher V
EJSO-EUR J SURG ONC. 2017;43(11):2193-2199.

Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?
Mandel P, Graefen M, Huland H, Tilki D
EUR UROL. 2017;72(6):e179.

Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer
Mandel P, Kriegmair M, Bogdan K, Böhm K, Budäus L, Graefen M, Huland H, Tilki D
EUR UROL FOCUS. 2017;3(2-3):248-255.

High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy
Mandel P, Preisser F, Graefen M, Steuber T, Salomon G, Haese A, Michl U, Huland H, Tilki D
EUR UROL. 2017;71(6):848-850.

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment
Mandel P, Rosenbaum C, Pompe R, Steuber T, Salomon G, Chun F, Graefen M, Huland H, Tilki D
WORLD J UROL. 2017;35(12):1833-1839.

Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848-50
Mandel P, Tilki D
EUR UROL. 2017;72(6):e176.

The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians
Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief C, Müller S, Wagenlehner F, Roigas J, Hakenberg O, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm M, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C
CLIN GENITOURIN CANC. 2017;15(3):356-362.

Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study
Mathieu R, Lucca I, Vartolomei M, MBeutcha A, Klatte T, Seitz C, Karakiewicz P, Fajkovic H, Sun M, Lotan Y, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolgang L, Shariat S
BJU INT. 2017;119(2):234-238.

Diagnostische Innovationen
Maurer T
AKTUEL UROL. 2017;48(2):89.

PSMA-targeted imaging of prostate cancer: evolution of a success story: Asian J Androl
Maurer T, Eiber M
ASIAN J ANDROL. 2017;19(3):388.

[Innovative radionuclide use in urology]: Urologe A
Maurer T, Gschwend J, Schwaiger M, Eiber M
UROLOGE. 2017;56(1):1-2.

PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?
Maurer T, Murphy D, Hofman M, Eiber M
THERANOSTICS. 2017;7(7):2046-2047.

Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: Results from PROMETRICS 2011
May M, Fritsche H, Vetterlein M, Bastian P, Gierth M, Nuhn P, Aziz A, Fisch M, Stief C, Hohenfellner M, Wirth M, Novotny V, Hakenberg O, Noldus J, Gilfrich C, Bolenz C, Burger M, Brookman-May S
WORLD J UROL. 2017;35(2):245-250.

Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database
May M, Protzel C, Vetterlein M, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm M, Nuhn P, Bastian P, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg O
INT UROL NEPHROL. 2017;49(2):247-254.

Fühlen sich Chirurgen gerüstet für die komplexen Fragestellungen im Umgang mit multiresistenten Erregern? – Ergebnisse der Fragebogenstudie MR2
May M, Spachmann P, Lebentrau S, Schumacher H, Gilfrich C, Fritsche H, Vetterlein M, Brookman-May S, Schostak M, Wagenlehner F, Burger M, Novotny A, Obermaier R
ZBL CHIR. 2017;142(3):297-305.

Wie werden der 10-Punkte-Plan des Deutschen Bundesministeriums für Gesundheit zur Bekämpfung resistenter Erreger und Maßnahmen des Antibiotic Stewardship wahrgenommen?: Eine fachübergreifende Analyse der Kenntnis deutscher Klinikärzte und Entwicklung einer urologischen Handlungsanweisung
May M, Vetterlein M, Wagenlehner F, Brookman-May S, Gilfrich C, Fritsche H, Spachmann P, Burger M, Schostak M, Lebentrau S
UROLOGE. 2017;56(10):1302-1310.

High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis M, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W
INT J MOL SCI. 2017;18(2):286.

Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins
Meyer C, Hansen J, Boehm K, Tilki D, Abdollah F, Trinh Q, Fisch M, Sauter G, Graefen M, Huland H, Chun F, Ahyai S
WORLD J UROL. 2017;35(2):199-206.

The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures
Meyer C, Rios-Diaz A, Dalela D, Ravi P, Sood A, Hanske J, Chun F, Kibel A, Lipsitz S, Sun M, Trinh Q
AM J SURG. 2017;214(5):871-883.

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment
Meyer C, Sun M, Karam J, Leow J, de Velasco G, Pal S, Chang S, Trinh Q, Choueiri T
EUR UROL. 2017;72(2):171-174.

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy
Moschini M, Soria F, Susani M, Korn S, Briganti A, Roupret M, Seitz C, Gust K, Haitel A, Montorsi F, Wirth G, Robinson B, Karakiewicz P, Özsoy M, Rink M, Shariat S
Bladder Cancer. 2017;3(3):161-169.

Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer: BJU Int
Murphy D, Hofman M, Lawrentschuk N, Maurer T
BJU INT. 2017;119(2):194-195.

AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy
Oh S, Mandel P, Chun F, Tennstedt P, Peine S, Hohenhorst J, Hiller J, Graefen M, Tilki D, Steuber T
FRONT SURG. 2017;4:75.

Radiation Dosimetry for Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck M, Wester H, Tamaki N, Fendler W, Herrmann K, Pfob C, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M
J NUCL MED. 2017;58(3):445-450.

Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment
Pompe R, Davis-Bondarenko H, Zaffuto E, Tian Z, Shariat S, Leyh-Bannurah S, Schiffmann J, Saad F, Huland H, Graefen M, Tilki D, Karakiewicz P
PROSTATE. 2017;77(6):686-693.

Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline
Pompe R, Karakiewicz P, Tian Z, Mandel P, Steuber T, Schlomm T, Salomon G, Graefen M, Huland H, Tilki D
J UROLOGY. 2017;198(2):354-361.

External Beam Radiotherapy Affects Serum Testosterone in Patients With Localized Prostate Cancer
Pompe R, Karakiewicz P, Zaffuto E, Smith A, Bandini M, Marchioni M, Tian Z, Leyh-Bannurah S, Schiffmann J, Delouya G, Lambert C, Bahary J, Beauchemin M, Barkati M, Ménard C, Graefen M, Saad F, Tilki D, Taussky D
J SEX MED. 2017;14(7):876-882.

Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention
Pompe R, Tilki D
TRANSL ANDROL UROL. 2017;6(5):994-996.

Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017
Pradère B, Thibault C, Vetterlein M, Leow J, Peyronnet B, Rouprêt M, Seisen T
TRANSL ANDROL UROL. 2017;6(6):1049-1059.

Value of In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up
Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester H, Schwamborn K, Haller B, Schwaiger M, Gschwend J, Eiber M, Maurer T
BJU INT. 2017;120(1):40-47.

[PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects]: Urologe A
Rauscher I, Eiber M, Jilg C, Gschwend J, Maurer T
UROLOGE. 2017;56(1):18-23.

[PSMA-Radioguided Surgery for Salvage Lymphadenectomy in Recurrent Prostate Cancer]: Aktuelle Urol
Rauscher I, Eiber M, Maurer T
AKTUEL UROL. 2017;48(2):148-152.

Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma: Clin Nucl Med
Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M
CLIN NUCL MED. 2017;42(7):547-548.

Entscheidung zur Nephrektomie bei klinisch instabilen Patienten mit pränataler ARPKD zur Verbesserung der Prognose
Riechardt S
UROLOGE. 2017;56(11):1467.

Frühe beidseitige Nephrektomie bei Säuglingen mit pränataler ARPKD: Prognoseverbesserung oder unnötiger Aufwand?
Riechardt S, Koch M, Oh J, Fisch M
UROLOGE. 2017;56(7):882-886.

IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis
Riedel J, Becker M, Kopp K, Düster M, Brix S, Meyer-Schwesinger C, Kluth L, Gnirck A, Attar M, Krohn S, Fehse B, Stahl R, Panzer U, Turner J
J AM SOC NEPHROL. 2017;28(7):2068-2080.

External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study
Rieken M, Kluth L, Seitz C, Abufaraj M, Foerster B, Mathieu R, Karakiewicz P, Bachmann A, Briganti A, Rouprê M, Gönen M, Shariat S, Seebacher V
CLIN GENITOURIN CANC. 2017 [Epub ahead of print].

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer
Riethdorf S, Soave A, Rink M
TRANSL ANDROL UROL. 2017;6(6):1090-1110.

Editorial Comment
Rink M
J UROLOGY. 2017;197(3 Pt 1):558.

Genetics and biomarker in bladder cancer for optimized clinical decision-making and improved outcomes
Rink M
TRANSL ANDROL UROL. 2017;6(6):1014-1017.

The landscape of genetics and biomarkers in bladder cancer
Rink M
TRANSL ANDROL UROL. 2017;6(6):1027-1030.

The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma
Rink M, Engel O, Gakis G, Fritsche H, Vetterlein M, Soave A, Peine S, Aziz A, Dahlem R, Stenzl A, Burger M, Shariat S, Fisch M, Gild P
UROL ONCOL-SEMIN ORI. 2017;35(12):671.e17-671.e23.

An Undissolved Urological Myth – Health-Related Quality of Life after Radical Cystectomy
Rink M, Vetterlein M
SIU Academy. 2017.

Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester H
J NUCL MED. 2017;58(2):235-242.

The T-plasty as therapy for recurrent bladder neck stenosis: success rate, functional outcome, and patient satisfaction
Rosenbaum C, Dahlem R, Maurer V, Kluth L, Vetterlein M, Fisch M, Schuettfort V, Reiss C
WORLD J UROL. 2017;35(12):1907-1911.

Harnröhrenstrikturen nach Strahlentherapie
Rosenbaum C, Engel O, Fisch M, Kluth L
UROLOGE. 2017;56(3):306-312.

Redo-Harnröhrenplastik mit Mundschleimhaut
Rosenbaum C, Ernst L, Engel O, Dahlem R, Fisch M, Kluth L
UROLOGE. 2017;56(10):1274-1281.

The Impact of Repeat Prostate Biopsies on Oncologic, Pathological and Perioperative Outcomes after Radical Prostatectomy
Rosenbaum C, Mandel P, Tennstedt P, Boehm K, Chun F, Graefen M, Heinzer H, Tilki D, Salomon G
J UROLOGY. 2017;197(1):103-108.

Management of Anterior Urethral Strictures in Adults: A Survey of Contemporary Practice in Germany
Rosenbaum C, Reiss C, Borgmann H, Salem J, Fisch M, Huber J, Schmid M, Ahyai S
UROL INT. 2017;99(1):43-50.

Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression
Schiffmann J, Salomon G, Tilki D, Budäus L, Karakiewicz P, Leyh-Bannurah S, Pompe R, Haese A, Heinzer H, Huland H, Graefen M, Tennstedt P
UROL ONCOL-SEMIN ORI. 2017;35(5):243-249.

Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after (68)Ga-PSMA-PET imaging: Eur J Nucl Med Mol Imaging
Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs S, Habl G
EUR J NUCL MED MOL I. 2017;44(10):1656-1662.

Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin: Urol Oncol
Schmid S, Sathe A, Guerth F, Seitz A, Heck M, Maurer T, Schwarzenbock S, Krause B, Schulz W, Stoehr R, Gschwend J, Retz M, Nawroth R
UROL ONCOL-SEMIN ORI. 2017;35(9):544.e1-544.e10.

Transperineal reanastomosis for treatment of highly recurrent anastomotic strictures after radical retropubic prostatectomy: extended follow-up
Schüttfort V, Dahlem R, Kluth L, Pfalzgraf D, Rosenbaum C, Ludwig T, Fisch M, Reiß C
WORLD J UROL. 2017;35(12):1885-1890.

Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer: Sci Rep
Seitz A, Christensen L, Christensen E, Faarkrog K, Ostenfeld M, Hedegaard J, Nordentoft I, Nielsen M, Palmfeldt J, Thomson M, Jensen M, Nawroth R, Maurer T, Orntoft T, Jensen J, Damgaard C, Dyrskjot L
SCI REP-UK. 2017;7(1):395.

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study
Soave A, Chun F, Hillebrand T, Rink M, Weisbach L, Steinbach B, Fisch M, Pantel K, Schwarzenbach H
ONCOTARGET. 2017;8(34):56398-56407.

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy
Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
BJU INT. 2017;119(6):854-861.

A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy
Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
INT J CANCER. 2017;140(2):381-389.

Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer
Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz P, Briganti A, Rink M, Gust K, Hassler M, Foerster B, Abufarraj M, Haitel A, Klatte T, Shariat S
UROL ONCOL-SEMIN ORI. 2017;35(6):356-362.

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
Soria F, Shariat S, Lerner S, Fritsche H, Rink M, Kassouf W, Spiess P, Lotan Y, Ye D, Fernández M, Kikuchi E, Chade D, Babjuk M, Grollman A, Thalmann G
WORLD J UROL. 2017;35(3):379-387.

Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis?: Results from a Prospective Case-Control Study
Steuber T, Berg K, Røder M, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G, Budäus L, Tilki D, Heinzer H, Graefen M, Mandel P
EUR UROL FOCUS. 2017;3(6):646-649.

High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens
Steurer S, Rico S, Simon R, Minner S, Tsourlakis M, Krech T, Koop C, Graefen M, Heinzer H, Adam M, Huland H, Schlomm T, Sauter G, Lumiani A
BJU INT. 2017;120(3):365-376.

[Correction: Innovative Ultrasound: Contrast-Enhanced Ultrasound of the Kidneys]: Aktuelle Urol
Stock K, Kubler H, Maurer T, Weiss D, Weskott H, Heemann U
AKTUEL UROL. 2017;48(2):e2.

[Innovative Ultrasound: Contrast-Enhanced Ultrasound of the Kidneys]: Aktuelle Urol
Stock K, Kubler H, Maurer T, Weiss D, Weskott H, Heemann U
AKTUEL UROL. 2017;48(2):120-126.

Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center
Tian Z, Preisser F, Tennstedt P, Beyer B, Michl U, Graefen M, Huland H, Karakiewicz P, Tilki D
EUR UROL FOCUS. 2017;3(6):615-620.

Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy
Tilki D, Preisser F, Tennstedt P, Tober P, Mandel P, Schlomm T, Steuber T, Huland H, Schwarz R, Petersen C, Graefen M, Ahyai S
BJU INT. 2017;119(5):717-723.

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer
Tosco L, Laenen A, Briganti A, Gontero P, Karnes R, Albersen M, Bastian P, Chlosta P, Claessens F, Chun F, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas R, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S
PROSTATE CANCER P D. 2017;20(4):407-412.

FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy
Tsourlakis M, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F
CARCINOGENESIS. 2017;38(12):1180-1187.

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Urbanucci A, Barfeld S, Kytölä V, Itkonen H, Coleman I, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi K, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes R, Ross A, Schaeffer E, Vander Griend D, Knapp S, Corey E, Feng F, Nelson P, Saatcioglu F, Knudsen K, Tammela T, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills I
CELL REP. 2017;19(10):2045-2059.

Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy
Vartolomei M, Mathieu R, Margulis V, Karam J, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P, Fajkovic H, Wood C, Weizer A, Raman J, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, Shariat S
WORLD J UROL. 2017;35(1):121-130.

Zwischenergebnisse der PROMETRICS 2011 nach fünf Jahren
Vetterlein M, Aziz A, May M, Bastian P
Uro-News. 2017 [Epub ahead of print];21(4):37-41.

Facing the Fate of the Remnant Urothelium After Radical Cystectomy: There Is Room for Improvement
Vetterlein M, Chun F, Kluth L
EUR UROL. 2017;71(4):558-559.

Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer
Vetterlein M, Löppenberg B, Karabon P, Dalela D, Jindal T, Sood A, Chun F, Trinh Q, Menon M, Abdollah F
CANCER-AM CANCER SOC. 2017;123(17):3241-3252.

Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort
Vetterlein M, Meyer C, Leyh-Bannurah S, Mayr R, Gierth M, Fritsche H, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian P, Gilfrich C, May M, Rink M, Chun F, Dahlem R, Fisch M, Aziz A
CLIN GENITOURIN CANC. 2017;15(5):e809-e817.

Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder
Vetterlein M, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat S, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M
TRANSL ANDROL UROL. 2017;6(6):1018-1026.

Resident Involvement in Radical Inguinal Orchiectomy for Testicular Cancer Does Not Adversely Impact Perioperative Outcomes - A Retrospective Study
Vetterlein M, Seisen T, Löppenberg B, Hanna N, Cheng P, Fisch M, Chun F, Kibel A, Preston M, Meyer C
UROL INT. 2017;98(4):472-477.

30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions
Vetterlein M, Seisen T, Speed J, Friedlander D, Meyer C, Kibel A, Menon M, Fisch M, Chun F, Sun M, Eswara J, Trinh Q
Urol Pract. 2017;4(5):388-394.

Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology
Vetterlein M, Wankowicz S, Seisen T, Lander R, Löppenberg B, Chun F, Menon M, Sun M, Barletta J, Choueiri T, Bellmunt J, Trinh Q, Preston M
CANCER-AM CANCER SOC. 2017;123(22):4346-4355.

Challenging Residual Contamination of Instruments for Robotic Surgery in Japan
von Landenberg N, Cole A, Gild P, Trinh Q
INFECT CONT HOSP EP. 2017;38(4):501-502.

Factors Influencing Prostate Specific Antigen Testing in the United States
von Landenberg N, Mossanen M, Wang Y, Sammon J, Hanna N, Gild P, Noldus J, Roghmann F, Menon M, Kibel A, Sun M, Chang S, Trinh Q
Urol Pract. 2017;5(6):438-443.

Nierenzellkarzinome im Kindesalter
Weisbach L, Aziz A, Fisch M, Riechardt S
UROLOGE. 2017;56(7):900-904.

11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer
Wieder H, Beer A, Holzapfel K, Henninger M, Maurer T, Schwarzenboeck S, Rummeny E, Eiber M, Stollfuss J
ONCOTARGET. 2017;8(39):66516-66527.

Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability, and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer
Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz T, Grupp K, Minner S, Tsourlakis M, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki J, Huland H, Schlomm T, Steurer S, Krech T, Lebok P
CARCINOGENESIS. 2017;38(1):19-27.

External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study
Xylinas E, Kluth L, Rieken M, Rouprêt M, Al Awamlh B, Clozel T, Sun M, Karakiewicz P, Gonen M, Shariat S
UROL ONCOL-SEMIN ORI. 2017;35(1):33.e21-33.e26.

Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence.
Ahyai S, Ludwig T, Dahlem R, Soave A, Rosenbaum C, Chun F, Fisch M, Schmid M, Kluth L
BJU INT. 2016;118(4):625-32.

L’impact de l’intoxication tabagique sur l’agressivité tumorale au moment de la cystectomie totale
Anract J, Barry Delongchamps N, Gontero P, Dobruch J, Necchi A, Seisen T, Rouprêt M, Shariat S, Aziz A, Rink M, Xylinas E
PROG UROL. 2016;26(13):764-765.

Some like it safe
Aziz A, Schmid M
BJU INT. 2016;117(4):546-7.

Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making
Aziz A, Shariat S, Roghmann F, Brookman-May S, Stief C, Rink M, Chun F, Fisch M, Novotny V, Froehner M, Wirth M, Schnabel M, Fritsche H, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian P, Xylinas E, May M
BJU INT. 2016;117(2):272-9.

Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma - Impact on prognosis
Becker A, Hickmann D, Hansen J, Meyer C, Rink M, Schmid M, Eichelberg C, Strini K, Chromecki T, Jesche J, Regier M, Randazzo M, Tilki D, Ahyai S, Dahlem R, Fisch M, Zigeuner R, Chun F
EJSO-EUR J SURG ONC. 2016;42(3):419-425.

Editorial Comment
Becker A, Kluth L
J UROLOGY. 2016;195(5):1360-1.

Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy
Beyer B, Mandel P, Michl U, Pompe R, Veleva V, Steuber T, Huland H, Graefen M, Tilki D
WORLD J UROL. 2016;34(8):1101-5.

Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy
Boehm K, Larcher A, Tian Z, Mandel P, Schiffmann J, Karakiewicz P, Graefen M, Huland H, Tilki D
J UROLOGY. 2016;196(1):82-8.

Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer
Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz P, Graefen M, Schwarz R, Krüll A, Tilki D
UROL ONCOL-SEMIN ORI. 2016;34(3):e11-8.

Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models
Böhm K, Larcher A, Beyer B, Tian Z, Tilki D, Steuber T, Karakiewicz P, Heinzer H, Graefen M, Budäus L
EUR UROL. 2016;69(6):1038-43.

Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma
Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C, Otto W
WORLD J UROL. 2016;34(5):709-16.

Magnetic resonance imaging-fusion biopsy: behind the scenes
Budäus L, Leyh-Bannurah S
BJU INT. 2016;118(1):8-9.

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy
Budäus L, Leyh-Bannurah S, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C
EUR UROL. 2016;69(3):393-6.

Reply to Thorsten Derlin, Matthias Eiber, Markus Schwaiger, and Frank M. Bengel's Letter to the Editor re: Lars Budäus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393-6
Budäus L, Leyh-Bannurah S, Steuber T
EUR UROL. 2016;70(2):e39-40.

p16 upregulation is linked to poor prognosis in ERG negative prostate cancer
Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, Minner S, Tsourlakis M, Koop C, Izbicki J, Sauter G, Krech T, Schlomm T, Wilczak W, Lebok P
TUMOR BIOL. 2016;37(9):12655-12663.

Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers
Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis M, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S
INT J CANCER. 2016;138(5):1199-206.

Surgical management of pituitary metastases
Burkhardt T, Henze M, Kluth L, Westphal M, Schmidt N, Flitsch J
PITUITARY. 2016;19(1):11-18.

Traumatische Harnröhrenverletzung--Primär endoskopische versus konservative Therapie
Dahlem R
AKTUEL UROL. 2016;47(2):118-9.

Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study
Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah S, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat S, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz P
EUR UROL. 2016;70(3):429-35.

Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer
Dell'Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah S, Moschini M, Capitanio U, Shariat S, Briganti A, Montorsi F, Saad F, Karakiewicz P
INT J RADIAT ONCOL. 2016;96(5):1037-1045.

The diagnosis of benign prostatic obstruction: Development of a clinical nomogram
De Nunzio C, Autorino R, Bachmann A, Briganti A, Carter S, Chun F, Novara G, Sosnowski R, Thiruchelvam N, Tubaro A, Ahyai S
NEUROUROL URODYNAM. 2016;35(2):235-40.

Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study: Radiat Oncol
Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend J, Combs S, Habl G
RADIAT ONCOL. 2016;11:73.

Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon A, Resnick M, Shariat S, Zlotta A, Boorjian S
EUR UROL. 2016;69(2):300-10.

[Rectal mucosa metastasis in recurrent prostate cancer : (68)Ga-PSMA-PET/CT allows targeted salvage radiotherapy]: Urologe A
Duwel C, Blumel C, Westenfelder K, Wagner-Thiessen E, Becker A, Gschwend J, Eiber M, Maurer T
UROLOGE. 2016;55(8):1086-1088.

[Will 68Ga-PSMA PET become the New Imaging Standard for Prostate Cancer?]: Aktuelle Urol
Duwel C, Eiber M, Maurer T
AKTUEL UROL. 2016;47(5):378-382.

(68)Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?: Eur Urol
Eiber M, Herrmann K, Fendler W, Maurer T
EUR UROL. 2016;70(6):938-940.

Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer A, Wester H, Gschwend J, Schwaiger M, Maurer T
EUR UROL. 2016;70(5):829-836.

68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases: Clin Nucl Med
Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M
CLIN NUCL MED. 2016;41(5):e261-2.

Infra- und supradiaphragmale Urethraverletzungen. Akute Therapie
Engel O, Boehm K, Rink M, Soave A, Fisch M
UROLOGE. 2016;55(4):475-8.

Spätfolgen von Urethraverletzungen. Rekonstruktive Möglichkeiten
Engel O, Reiß C, Ludwig T, Riechardt S, Dahlem R, Fisch M
UROLOGE. 2016;55(4):479-483.

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy
Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Hussein Al Awamlh B, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, Shariat S
UROL ONCOL-SEMIN ORI. 2016;34(5):233.e1-6.

Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
Fajkovic H, Shariat S, Klatte T, Vartolomei M, Lucca I, Mbeutcha A, Rouprêt M, Briganti A, Karakiewicz P, Margulis V, Rink M, Remzi M, Seitz C, Bensalah K, Mathieu R
WORLD J UROL. 2016;34(10):1411-9.

Vesikovaginale Fisteln: transperitoneale operative Versorgung mit Netz- oder Peritonealinterponat, vaginale operative Versorgung mittels Martiuslappen
Fisch M
AKTUEL UROL. 2016;47(4):321-36.

Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma
Gakis G, Efstathiou J, Daneshmand S, Keegan K, Clayman R, Hrbacek J, Ali-El-Dein B, Zaid H, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K, Rink M, Fritsche H, Burger M, Chang S, Babjuk M, Thalmann G, Stenzl A, Morgan T
UROL INT. 2016;97(2):134-41.

Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma
Gakis G, Morgan T, Efstathiou J, Keegan K, Mischinger J, Todenhoefer T, Schubert T, Zaid H, Hrbacek J, Ali-El-Dein B, Clayman R, Galland S, Olugbade K, Rink M, Fritsche H, Burger M, Chang S, Babjuk M, Thalmann G, Stenzl A, Daneshmand S
WORLD J UROL. 2016;34(1):97-103.

Prognostic Significance of Incidental Prostate Cancer at Radical Cystoprostatectomy for Bladder Cancer
Gakis G, Rink M, Fritsche H, Graefen M, Schubert T, Hassan F, Chun F, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M
UROL INT. 2016;97(1):42-8.

Harnstauungsnieren beidseits infolge opiatinduzierter Darmspastik bei einer Patientin mit Ileumconduit
Girtler F, Rödder K, Fisch M
UROLOGE. 2016;55(10):1347-1349.

The influence of marital status on the use of breast, cervical, and colorectal cancer screening
Hanske J, Meyer C, Sammon J, Choueiri T, Menon M, Lipsitz S, Noldus J, Nguyen P, Sun M, Trinh Q
PREV MED. 2016;89:140-5.

Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome: World J Urol
Hatzichristodoulou G, Wagenpfeil S, Weirich G, Autenrieth M, Maurer T, Thalgott M, Horn T, Heck M, Herkommer K, Gschwend J, Kubler H
WORLD J UROL. 2016;34(2):229-236.

Socioeconomic status and health-related quality of life among patients with prostate cancer 6 months after radical prostatectomy: a longitudinal analysis
Klein J, Hofreuter-Gätgens K, Lüdecke D, Fisch M, Graefen M, von dem Knesebeck O
BMJ OPEN. 2016;6(6):e010968.

Prostatakarzinom--pN1: Sind wirklich alle Patienten gleich?
Kluth L, Chun F
AKTUEL UROL. 2016;47(02):113-115.

Psychometric validation of a German language version of a PROM for urethral stricture surgery and preliminary testing of supplementary ED and UI constructs
Kluth L, Dahlem R, Becker A, Schmid M, Soave A, Rosenbaum C, Ludwig T, Christ N, Rink M, Reiss P, Engel O, Riechardt S, Chun F, Fisch M, Ahyai S
WORLD J UROL. 2016;34(3):369-375.

Deletion of 18q is a strong and independent prognostic feature in prostate cancer
Kluth M, Graunke M, Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, Simon R
ONCOTARGET. 2016;7(52):86339-86349.

Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer
Kluth M, Meyer D, Krohn A, Freudenthaler F, Bauer M, Salomon G, Heinzer H, Michl U, Steurer S, Simon R, Sauter G, Schlomm T, Minner S
ONCOTARGET. 2016;7(4):3897-904.

Drain placement can safely be omitted for open partial nephrectomy: Results from a prospective randomized trial
Kriegmair M, Mandel P, Krombach P, Dönmez H, John A, Häcker A, Michel M
INT J UROL. 2016;23(5):390-4.

Zonal NephRo Score: external validation for predicting complications after open partial nephrectomy
Kriegmair M, Mandel P, Moses A, Bolenz C, Michel M, Pfalzgraf D
WORLD J UROL. 2016;34(4):545-51.

Diagnostic and Prognostic Markers in Bladder Cancer
Ku J, Kim W, Lerner S, Chun F, Kluth L
DIS MARKERS. 2016;2016:2425091.

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M, Koop C, Wilczak W, Krech T, Lebok P, Wittmer C, Heinzer H, Steuber T, Adam M, Huland H, Graefen M, Haese A, Simon R, Sauter G, Schlomm T
CLIN CANCER RES. 2016;22(11):2802-11.

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen
Lieb V, Rink M, Sikic D, Keck B
UROLOGE. 2016;55(6):805-12.

The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair
Löppenberg B, Cheng P, Speed J, Cole A, Vetterlein M, Kibel A, Noldus J, Trinh Q, Meyer C
UROLOGY. 2016;94:70-6.

The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis
Lucca I, Jichlinski P, Shariat S, Rouprêt M, Rieken M, Kluth L, Rink M, Mathieu R, Mbeutcha A, Maj-Hes A, Fajkovic H, Briganti A, Seitz C, Karakiewicz P, de Martino M, Lotan Y, Babjuk M, Klatte T
EUR UROL FOCUS. 2016;2(1):79-85.

Tumor Characteristics and Oncologic Outcome after Radical Prostatectomy in Men 75 Years Old or Older
Mandel P, Kriegmair M, Kamphake J, Chun F, Graefen M, Huland H, Tilki D
J UROLOGY. 2016;196(1):89-94.

The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer
Mandel P, Kriegmair M, Veleva V, Salomon G, Graefen M, Huland H, Tilki D
UROLOGY. 2016;93:141-6.

Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates
Mandel P, Oh S, Hagner C, Tennstedt P, Kriegmair M, Huland H, Graefen M, Tilki D
WORLD J UROL. 2016;34(11):1547-1553.

Female with bladder cancer: what and why is there a difference?
Marks P, Soave A, Shariat S, Fajkovic H, Fisch M, Rink M
TRANSL ANDROL UROL. 2016;5(5):668-682.

Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study
Mathieu R, Klatte T, Lucca I, Beutcha A, Seitz C, Karakiewicz P, Fajkovic H, Sun M, Lotan Y, Scherr D, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth L, Rieken M, Kenner L, Susani M, Robinson B, Xylinas E, Loidl W, Shariat S
BJU INT. 2016;118(2):243-9.

Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent
Mbeutcha A, Lucca I, Margulis V, Karam J, Wood C, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz P, Briganti A, Rink M, Rieken M, Weizer A, Raman J, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat S, Klatte T
WORLD J UROL. 2016;34(8):1155-61.

Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer
Mbeutcha A, Shariat S, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Rouprêt M, Briganti A, Karakiewicz P, Klatte T
UROL ONCOL-SEMIN ORI. 2016;34(11):483.e17-483.e24.

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer
Melling N, Taskin B, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Heinzer H, Tsourlakis M, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Schlomm T, Krech T
PROSTATE. 2016;76(3):259-72.

The Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two Referral Centers from Austria and Germany
Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, Chromecki T, Jesche-Chromecki J, Fisch M, Zigeuner R, Chun F
UROL INT. 2016;96(3):330-6.

Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010
Meyer C, Hollis M, Cole A, Hanske J, O'Leary J, Gupta S, Löppenberg B, Zavaski M, Sun M, Sammon J, Kibel A, Fisch M, Chun F, Trinh Q
EUR UROL FOCUS. 2016;2(1):3-9.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer
Meyer C, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T
UROL ONCOL-SEMIN ORI. 2016;34(5):235.e11-6.

Wound dehiscence in a sample of 1 776 cystectomies: identification of predictors and implications for outcomes
Meyer C, Rios Diaz A, Dalela D, Hanske J, Pucheril D, Schmid M, Trinh V, Sammon J, Menon M, Chun F, Noldus J, Fisch M, Trinh Q
BJU INT. 2016;117(6B):E95-E101.

Das GeSRU Endo-Training - Strategien zur Optimierung der endourologischen Ausbildung
Meyer C, Salem J, Kluth L, Sanatgar N, Borgmann H, Grange P, Chun F
UROLOGE. 2016;55(2):253-6.

Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy
Michl U, Tennstedt P, Feldmeier L, Mandel P, Oh S, Ahyai S, Budäus L, Chun F, Haese A, Heinzer H, Salomon G, Schlomm T, Steuber T, Huland H, Graefen M, Tilki D
EUR UROL. 2016;69(4):584-9.

Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection
Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes R, Everaerts W, Albersen M, Bastian P, Chlosta P, Claessens F, Chun F, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas R, Tombal B, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S
FRONT SURG. 2016;3:65.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature
Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C
J UROLOGY. 2016;195(2):254-63.

Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence
Pust A, Kylies D, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Salomon G, Tsourlakis M, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Krech T, Schlomm T, Melling N
HUM PATHOL. 2016;48:102-10.

Comparison of bone scintigraphy and Ga-PSMA PET for skeletal staging in prostate cancer
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M
EUR J NUCL MED MOL I. 2016;43(12):2114-2121.

The T-plasty: a modified YV-plasty for highly recurrent bladder neck contracture after transurethral surgery for benign hyperplasia of the prostate: clinical outcome and patient satisfaction
Reiss C, Rosenbaum C, Becker A, Schriefer P, Ludwig T, Engel O, Riechardt S, Fisch M, Dahlem R
WORLD J UROL. 2016;34(10):1437-42.

Inkontinente Harnableitungen
Rink M
2016. Die Urologie. Michel M, Thüroff J, Janetschek G, Wirth M (Hrsg.). 1. Aufl. Springer, 797-809.

Kommentar zu: "Sunitinib und Sorafenib: Ist die Reihenfolge entscheidend?"
Rink M
Urologie Scan. 2016;(2):88-89.

Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?
Rink M, Shariat S, Soave A
TRANSL ANDROL UROL. 2016;5(6):980-983.

Redo buccal mucosa graft urethroplasty: success rate, oral morbidity and functional outcomes
Rosenbaum C, Schmid M, Ludwig T, Kluth L, Dahlem R, Fisch M, Ahyai S
BJU INT. 2016;118(5):797-803.

Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens
Sauter G, Steurer S, Clauditz T, Krech T, Wittmer C, Lutz F, Lennartz M, Janssen T, Hakimi N, Simon R, von Petersdorff-Campen M, Jacobsen F, Loga K, Wilczak W, Minner S, Tsourlakis M, Chirico V, Haese A, Heinzer H, Beyer B, Graefen M, Michl U, Salomon G, Steuber T, Budäus L, Hekeler E, Malsy-Mink J, Kutzera S, Fraune C, Göbel C, Huland H, Schlomm T
EUR UROL. 2016;69(4):592-8.

Limitations of Elastography Based Prostate Biopsy
Schiffmann J, Grindei M, Tian Z, Yassin D, Steinwender T, Leyh-Bannurah S, Randazzo M, Kwiatkowski M, Karakiewicz P, Hammerer P, Manka L
J UROLOGY. 2016;195(6):1731-6.

True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts
Schiffmann J, Mehring G, Tennstedt P, Manka L, Boehm K, Leyh-Bannurah S, Karakiewicz P, Hammerer P, Graefen M, Salomon G
WORLD J UROL. 2016;34(4):495-500.

Causes of hospital readmissions after urologic cancer surgery
Schmid M, Chiang H, Sood A, Campbell L, Chun F, Dalela D, Okwara J, Sammon J, Kibel A, Menon M, Fisch M, Trinh Q
UROL ONCOL-SEMIN ORI. 2016;34(5):236.e1-11.

Targeted Cancer Screening After Solid-Organ Transplantation
Schmid M, Chun F, Trinh Q
JAMA ONCOL. 2016;2(4):470.

Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer
Schmid M, Hanske J, Ravi P, Krishna N, Reznor G, Meyer C, Fisch M, Noldus J, Nguyen P, Trinh Q
INT J UROL. 2016;23(4):305-11.

Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma
Schmid M, Krishna N, Ravi P, Meyer C, Becker A, Dalela D, Sood A, Chun F, Kibel A, Menon M, Fisch M, Trinh Q, Sun M
UROL ONCOL-SEMIN ORI. 2016;34(7):293.e1-293.e10.

Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer
Schmid M, Meyer C, Reznor G, Choueiri T, Hanske J, Sammon J, Abdollah F, Chun F, Kibel A, Tucker-Seeley R, Kantoff P, Lipsitz S, Menon M, Nguyen P, Trinh Q
JAMA ONCOL. 2016;2(1):85-93.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events
Schmid M, Sammon J, Reznor G, Kapoor V, Speed J, Abdollah F, Sood A, Chun F, Kibel A, Menon M, Fisch M, Sun M, Trinh Q
BJU INT. 2016;118(2):221-9.

Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base
Seisen T, Sun M, Leow J, Preston M, Cole A, Gelpi-Hammerschmidt F, Hanna N, Meyer C, Kibel A, Lipsitz S, Nguyen P, Bellmunt J, Choueiri T, Trinh Q
J CLIN ONCOL. 2016;34(29):3529-3536.

The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy
Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz P, Rouprêt M, Rink M, Kluth L, Trinh Q, Loidl W, Briganti A, Scherr D, Shariat S
PROSTATE CANCER P D. 2016;19(2):163-7.

Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinoma-Data from a Prospective, Multicenter Experience
Soave A, Rink M
EUR UROL. 2016;69(2):373-4.

Redox Imaging Using Cardiac Myocyte-Specific Transgenic Biosensor Mice
Swain L, Kesemeyer A, Meyer-Roxlau S, Vettel C, Zieseniss A, Güntsch A, Jatho A, Becker A, Nanadikar M, Morgan B, Dennerlein S, Shah A, El-Armouche A, Nikolaev V, Katschinski D
CIRC RES. 2016;119(9):1004-1016.

Pneumonia after Major Cancer Surgery: Temporal Trends and Patterns of Care
Trinh V, Ravi P, Abd-El-Barr A, Jhaveri J, Gervais M, Meyer C, Hanske J, Sammon J, Trinh Q
CAN RESPIR J. 2016;2016:6019416.

Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients
Tsourlakis M, Stender A, Quaas A, Kluth M, Wittmer C, Haese A, Graefen M, Steurer S, Simon R, Korbel J, Weischenfeldt J, Huland H, Sauter G, Schlomm T, Minner S
BMC CANCER. 2016;16:641.

Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder
Vallo S, Gilfrich C, Burger M, Volkmer B, Boehm K, Rink M, Chun F, Roghmann F, Novotny V, Mani J, Brisuda A, Mayr R, Stredele R, Noldus J, Schnabel M, May M, Fritsche H, Pycha A, Martini T, Wirth M, Roigas J, Bastian P, Nuhn P, Dahlem R, Haferkamp A, Fisch M, Aziz A
UROL ONCOL-SEMIN ORI. 2016;34(10):432.e1-8.

Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies
Vetterlein M, Jindal T, Becker A, Regier M, Kluth L, Tilki D, Chun F
Investig Clin Urol. 2016;57(4):231-9.

Androgenentzugstherapie und Risiko für venöse Thrombembolien
Vetterlein M, Schmid M, Trinh Q, Chun F
Urologie Scan. 2016;03(04):266-267.

Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis
Vetterlein M, Seisen T, May M, Nuhn P, Gierth M, Mayr R, Fritsche H, Burger M, Novotny V, Froehner M, Wirth M, Protzel C, Hakenberg O, Roghmann F, Palisaar R, Noldus J, Pycha A, Bastian P, Trinh Q, Xylinas E, Shariat S, Rink M, Chun F, Dahlem R, Fisch M, Aziz A
EUR UROL FOCUS. 2016.

Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years
Abdollah F, Sammon J, Reznor G, Sood A, Schmid M, Klett D, Sun M, Aizer A, Choueiri T, Hu J, Kim S, Kibel A, Nguyen P, Menon M, Trinh Q
EJSO-EUR J SURG ONC. 2015;41(11):1529-1539.

Outcomes of Ventral Onlay Buccal Mucosa Graft Urethroplasty in Patients after Radiotherapy
Ahyai S, Schmid M, Kuhl M, Kluth L, Soave A, Riechardt S, Chun F, Engel O, Fisch M, Dahlem R
J UROLOGY. 2015;194(2):441-6.

The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries
Allard C, Meyer C, Gandaglia G, Chang S, Chun F, Gelpi-Hammerschmidt F, Hanske J, Kibel A, Preston M, Trinh Q
J SURG EDUC. 2015;72(5):1018-25.

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta
Aziz A, Gierth M, Rink M, Schmid M, Chun F, Dahlem R, Roghmann F, Palisaar R, Noldus J, Ellinger J, Müller S, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche H, Burger M, Bastian P, Seitz C, Brookman-May S, Xylinas E, Shariat S, Fisch M, May M
WORLD J UROL. 2015;33(12):1945-1950.

Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer
Aziz A, Kempkensteffen C, May M, Lebentrau S, Burger M, Chun F, Brookman-May S
EXPERT REV ANTICANC. 2015;15(6):649-66.

Laparoscopic versus open partial nephrectomy for clinical T1 renal masses: no impact of surgical approach on perioperative complications and long-term postoperative quality of life
Becker A, Pradel L, Kluth L, Schmid M, Eichelberg C, Ahyai S, Trinh Q, Seiler D, Dahlem R, Hansen J, Rink M, Zacharias M, Mehnert A, Bergelt C, Fisch M, Chun F
WORLD J UROL. 2015;33:421-426.

No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer
Boehm K, Beyer B, Tennstedt P, Schiffmann J, Budaeus L, Haese A, Graefen M, Schlomm T, Heinzer H, Salomon G
WORLD J UROL. 2015;33(6):801-6.

Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography
Boehm K, Budäus L, Tennstedt P, Beyer B, Schiffmann J, Larcher A, Simonis K, Graefen M, Beyersdorff D, Salomon G
UROL INT. 2015;95(2):189-96.

Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: implications for targeted biopsies and active surveillance protocols
Boehm K, Salomon G, Beyer B, Schiffmann J, Simonis K, Graefen M, Budäus L
J UROLOGY. 2015;193(3):794-800.

Natural history of surgically treated high-risk prostate cancer
Briganti A, Karnes R, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun F, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz P, Van Poppel H, Montorsi F, Joniau S
UROL ONCOL-SEMIN ORI. 2015;33(4):163.e7-13.

Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers
Burdelski C, Barreau Y, Simon R, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Sauter G, Wittmer C, Steurer S, Adam M, Huland H, Schlomm T, Tsourlakis M, Quaas A
HUM PATHOL. 2015;46(4):514-23.

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
Burdelski C, Bujupi E, Tsourlakis M, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T
PLOS ONE. 2015;10(6):e0128525.

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion
Burdelski C, Menan D, Tsourlakis M, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T
BMC CANCER. 2015;15:538.

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer
Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis M, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, Steurer S
CLIN CANCER RES. 2015;21(15):3471-9.

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer
Burdelski C, Ruge O, Melling N, Koop C, Simon R, Steurer S, Sauter G, Kluth M, Hube-Magg C, Minner S, Wittmer C, Wilczak W, Hinsch A, Lebok P, Izbicki J, Heinzer H, Graefen M, Huland H, Schlomm T, Krech T
EXP MOL PATHOL. 2015;98(3):419-426.

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer
Burdelski C, Strauss C, Tsourlakis M, Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Krech T, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S
ONCOTARGET. 2015.

Die Versorgung von Patienten mit lokal begrenztem Prostatakarzinom in Deutschland: Active-Surveillance-Ergebnisse einer nicht-interventionellen Versorgungsstudie
Chun F, Becker A, Kluth L, Seiler D, Schnell D, Fisch M, Graefen M, Weissbach L
UROLOGE. 2015;54(1):6-13.

Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Eiber M, Maurer T, Souvatzoglou M, Beer A, Ruffani A, Haller B, Graner F, Kübler H, Haberkorn U, Eisenhut M, Wester H, Gschwend J, Schwaiger M
J NUCL MED. 2015;56(5):668-74.

(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer: Abdom Imaging
Eiber M, Nekolla S, Maurer T, Weirich G, Wester H, Schwaiger M
ABDOM IMAGING. 2015;40(6):1769-1771.

Unsuccessful outcomes after posterior urethroplasty
Engel O, Fisch M
ARAB J UROL. 2015;13(1):57-59.

Management of iatrogenic ureteral injury and techniques for ureteral reconstruction
Engel O, Rink M, Fisch M
CURR OPIN UROL. 2015;25(4):331-5.

The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy
Engel O, Soave A, Peine S, Kluth L, Schmid M, Shariat S, Dahlem R, Fisch M, Rink M
WORLD J UROL. 2015;33(11):1769-1776.

"Tissue engineering" in der rekonstruktiven Urologie
Engel O, Soave A, Rink M, Dahlem R, Hellwinkel O, Chun F, Fisch M
UROLOGE. 2015;54(5):690-695.

Reconstructive management with urethroplasty.
Engel O, Soave A, Rink M, Fisch M
EUR UROL SUPPL. 2015;15(1):13-16.

Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma
Gakis G, Morgan T, Daneshmand S, Keegan K, Todenhöfer T, Mischinger J, Schubert T, Zaid H, Hrbacek J, Ali-El-Dein B, Clayman R, Galland S, Olugbade K, Rink M, Fritsche H, Burger M, Chang S, Babjuk M, Thalmann G, Stenzl A, Efstathiou J
ANN ONCOL. 2015;26(8):1754-9.

Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection
Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun F, Montorsi F, Graefen M, Briganti A
PROSTATE. 2015;75(13):1484-91.

Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy
Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A, Lodde M, Salvadori U, Bründl J, Fritsche H, Hofstädter F, Pawlik M, Otto W, May M, Burger M, Denzinger S
J CANCER RES CLIN. 2015;141(10):1819-26.

Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion
Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis M, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T
ONCOL REP. 2015;34(3):1211-20.

BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence
Gu L, Frommel S, Oakes C, Simon R, Grupp K, Gerig C, Bär D, Robinson M, Baer C, Weiss M, Gu Z, Schapira M, Kuner R, Sültmann H, Provenzano M, Yaspo M, Brors B, Korbel J, Schlomm T, Sauter G, Eils R, Plass C, Santoro R
NAT GENET. 2015;47(1):22-30.

Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation
Hansen J, Becker A, Kluth L, Rink M, Steuber T, Zacharias M, Briganti A, Fisch M, Graefen M, Chun F
UROL ONCOL-SEMIN ORI. 2015;33(9):384.e1-8.

How can we improve surgical outcomes?
Hanske J, Meyer C, Trinh Q
BJU INT. 2015;116(6):835-6.

A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database
Hanske J, Sanchez A, Schmid M, Meyer C, Abdollah F, Feldman A, Kibel A, Sammon J, Menon M, Eswara J, Noldus J, Trinh Q
J ENDOUROL. 2015;29(9):1052-8.

Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database
Hanske J, Sanchez A, Schmid M, Meyer C, Abdollah F, Roghmann F, Feldman A, Kibel A, Sammon J, Noldus J, Trinh Q, Eswara J
WORLD J UROL. 2015;33(12):2107-2113.

Age-related variation and predictors of long-term quality of life in germ cell tumor survivors
Hartung T, Mehnert A, Friedrich M, Hartmann M, Vehling S, Bokemeyer C, Oechsle K
UROL ONCOL-SEMIN ORI. 2015.

UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Itkonen H, Engedal N, Babaie E, Luhr M, Guldvik I, Minner S, Hohloch J, Tsourlakis M, Schlomm T, Mills I
ONCOGENE. 2015;34(28):3744-50.

Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study
Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes R, Montorsi F, Van Poppel H, Spahn M
EUR UROL. 2015;67(1):157-64.

Pretreatment tables predicting pathologic stage of locally advanced prostate cancer
Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu C, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes R, Montorsi F, van Poppel H, Gontero P
EUR UROL. 2015;67(2):319-25.

Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus
Kirtschig G, Becker K, Günthert A, Jasaitiene D, Cooper S, Chi C, Kreuter A, Rall K, Aberer W, Riechardt S, Casabona F, Powell J, Brackenbury F, Erdmann R, Lazzeri M, Barbagli G, Wojnarowska F
J EUR ACAD DERMATOL. 2015;29(10):e1-43.

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy
Klatte T, Seitz C, Rink M, Rouprêt M, Xylinas E, Karakiewicz P, Susani M, Shariat S
J UROLOGY. 2015;194(5):1456-1462.

Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature
Kluth L, Black P, Bochner B, Catto J, Lerner S, Stenzl A, Sylvester R, Vickers A, Xylinas E, Shariat S
EUR UROL. 2015;68(2):238-53.

Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy
Kluth L, Xylinas E, Rieken M, Kent M, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Bing M, Gupta A, Sewell J, Konety B, Todenhöfer T, Schwentner C, Masson-Lecomte A, Vordos D, Roghmann F, Noldus J, Razmaria A, Smith N, Comploj E, Pycha A, Rink M, Baniel J, Mano R, Novara G, Aziz A, Fritsche H, Brisuda A, Bivalacqua T, Gontero P, Boorjian S, Vickers A, Shariat S
EUR UROL FOCUS. 2015;1(1):75-81.

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer
Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T
ONCOTARGET. 2015;6(29):27966-79.

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer
Kluth M, Galal R, Krohn A, Weischenfeldt J, Tsourlakis M, Paustian L, Ahrary R, Ahmed M, Scherzai S, Meyer A, Sirma H, Korbel J, Sauter G, Schlomm T, Simon R, Minner S
INT J ONCOL. 2015;46(4):1637-42.

Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer
Kluth M, Runte F, Barow P, Omari J, Abdelaziz Z, Paustian L, Steurer S, Christina Tsourlakis M, Fisch M, Graefen M, Tennstedt P, Huland H, Michl U, Minner S, Sauter G, Simon R, Adam M, Schlomm T
INT J CANCER. 2015;137(10):2354-63.

Surgical learning curve for open radical prostatectomy: Is there an end to the learning curve?
Kretschmer A, Mandel P, Buchner A, Stief C, Tilki D
WORLD J UROL. 2015;33(11):1721-7.

Open Partial Nephrectomy for High-Risk Renal Masses Is Associated with Renal Pseudoaneurysms: Assessment of a Severe Procedure-Related Complication
Kriegmair M, Mandel P, Rathmann N, Diehl S, Pfalzgraf D, Ritter M
BIOMED RES INT . 2015;2015:981251.

SUPRAPUR(®): Safe and convenient percutaneous suprapubic catheterisation in high-risk patients
Kriegmair M, Mandel P, Ritter M
CENT EUR J UROL. 2015;68(4):478-83.

Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma
Kumar P, Nandi S, Tan T, Ler S, Chia K, Lim W, Bütow Z, Vordos D, De la Taille A, Al-Haddawi M, Raida M, Beyer B, Ricci E, Colombel M, Chong T, Chiong E, Soo R, Park M, Ha H, Gunaratne J, Thiery J
ONCOTARGET. 2015;6(15):13539-49.

Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients
Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer S, de Martino M, Karakiewicz P, Briganti A, Trinh Q, Seitz C, Fritsche H, Burger M, Lotan Y, Kramer G, Shariat S, Klatte T
BJU INT. 2015;115(5):722-727.

The ARTUS device: the first feasibility study in human cadavers
Ludwig T, Reiß C, Wieland M, Becker A, Fisch M, Chun F, Dahlem R
CAN J UROL. 2015;22(6):8100-4.

The effect of age on functional outcomes after radical prostatectomy.
Mandel P, Graefen M, Michl U, Huland H, Tilki D
UROL ONCOL-SEMIN ORI. 2015;33(5):203.e11-203.e18.

Salvage Radical Prostatectomy for recurrent Prostate Cancer: Verification of EAU guideline criteria
Mandel P, Steuber T, Ahyai S, Kriegmair M, Schiffmann J, Boehm K, Heinzer H, Michl U, Schlomm T, Haese A, Huland H, Graefen M, Tilki D
BJU INT. 2015;117(1):55-61.

Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy
Mandel P, Weinhold P, Michl U, Huland H, Graefen M, Tilki D
PROSTATE. 2015;75(13):1436-46.

Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study
Martini T, Aziz A, Roghmann F, Rink M, Chun F, Fisch M, Trojan L, Hakenberg O, Zastrow S, Wirth M, Moersdorf J, Brookman-May S, Stief C, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm M, Müller S, Roigas J, Bastian P, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C
UROL INT. 2015;96(1):57-64.

Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study
Mathieu R, Klatte T, Margulis V, Karam J, Rouprêt M, Seitz C, Karakiewicz P, Fajkovic H, Wood C, Weizer A, Raman J, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth L, Scherr D, Robinson B, Shariat S
UROL ONCOL-SEMIN ORI. 2015;33(11):495.e15-22.

Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy
Mathieu R, Shariat S, Seitz C, Karakiewicz P, Fajkovic H, Sun M, Lotan Y, Scherr D, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth L, Rieken M, Bachman A, Xylinas E, Robinson B, Bensalah K, Margreiter M
WORLD J UROL. 2015;33(8):1165-1171.

Le rapport neutrophiles/lymphocytes est un facteur prédictif indépendant de récidive et de progression dans les tumeurs de vessie non infiltrantes
Mbeutcha A, Lucca I, De Martino M, Mathieu R, Rieken M, Xylinas E, Kluth L, Crivelli J, Lotan Y, Shariat S, Klatte T, Karakiewicz P
PROG UROL. 2015;25(13):759-60.

High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer
Melling N, Harutyunyan L, Hube-Magg C, Kluth M, Simon R, Lebok P, Minner S, Tsourlakis M, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Steurer S, Izbicki J, Sauter G, Wilczak W, Schlomm T, Krech T
PLOS ONE. 2015;10(7):e0134614.

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters
Melling N, Thomsen E, Tsourlakis M, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S, Krech T
CARCINOGENESIS. 2015;36(11):1333-40.

The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties
Meyer C, Hanske J, Friedlander D, Schmid M, Dahlem R, Trinh V, Chang S, Kibel A, Chun F, Fisch M, Trinh Q, Eswara J
UROLOGY. 2015;85(4):937-41.

Prediction and predicament: complications after inguinal lymph node dissection for penile cancer
Meyer C, Hanske J, Sammon J
BJU INT. 2015;116(2):165.

Corrigendum: Inpatient hypospadias care: Trends and outcomes from the American nationwide inpatient sample
Meyer C, Sukumar S, Sood A, Hanske J, Vetterlein M, Elder J, Fisch M, Trinh Q, Friedman A
Korean J Urol. 2015;56(9):670.

Inpatients hypospadias care: trends and outcomes from the American nationwide inpatient sample
Meyer C, Sukumar S, Sood A, Hanske J, Vetterlein M, Elder J, Fisch M, Trinh Q, Friedman A
Korean J Urol. 2015;56(8):594-600.

Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy
Michl U, Molfenter F, Graefen M, Tennstedt P, Ahyai S, Beyer B, Budäus L, Haese A, Heinzer H, Oh S, Salomon G, Schlomm T, Steuber T, Thederan I, Huland H, Tilki D
J UROLOGY. 2015;193(2):479-83.

Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis
Nguyen H, Tilki D, Dall'Era M, Durbin-Johnson B, Carballido J, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Espinós E, Mandel P, Martinez-Salamanca J, Master V, McKiernan J, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi R, Rodriguez-Faba O, Russo P, Scherr D, Shariat S, Spahn M, Terrone C, Vergho D, Wallen E, Xylinas E, Zigeuner R, Libertino J, Evans C
J UROLOGY. 2015;194(2):304-308.

Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder
Novotny V, Froehner M, May M, Protzel C, Hergenröther K, Rink M, Chun F, Fisch M, Roghmann F, Palisaar R, Noldus J, Gierth M, Fritsche H, Burger M, Sikic D, Keck B, Wullich B, Nuhn P, Buchner A, Stief C, Vallo S, Bartsch G, Haferkamp A, Bastian P, Hakenberg O, Propping S, Aziz A
WORLD J UROL. 2015;33(11):1753-1761.

Symptom burden in long-term germ cell tumor survivors
Oechsle K, Hartmann M, Mehnert A, Oing C, Bokemeyer C, Vehling S
SUPPORT CARE CANCER. 2015.

Staged urethroplasty: comparison of early functional results and quality of life in mesh graft and buccal mucosa technique
Pfalzgraf D, Kluth L, Reiss P, Fisch M, Dahlem R
CAN J UROL. 2015;22(2):7720-6.

βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma
Quaas A, Rahvar A, Burdelski C, Koop C, Eichelberg C, Rink M, Dahlem R, Schlomm T, Tsourlakis M, Simon R, Minner S, Sauter G, Steurer S
WORLD J UROL. 2015;33(10):1561-1569.

Is further screening of men with baseline PSA : The discussion continues-Results of the Swiss ERSPC (Aarau)
Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun F, Kluth L, Wyler S, Recker F, Kwiatkowski M
INT J CANCER. 2015;137(3):553-9.

A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening
Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun F, Recker F, Kwiatkowski M
EUR UROL. 2015;68(4):591-7.

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)
Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler S, Chun F, Recker F, Kwiatkowski M
WORLD J UROL. 2015;33(8):1189-96.

Patient Characteristics and Perioperative Outcomes of Female Urethral Diverticulectomy: Analysis of a Multi-Institutional Prospective Database
Raup V, Hess D, Hanske J, Schmid M, Varda B, Das A, Trinh Q, Eswara J
UROLOGY. 2015;86(4):712-715.

Thermal Ablation of Renal Tumors: Indications, Techniques and Results
Regier M, Chun F
DTSCH ARZTEBL INT. 2015;112(24):412-8.

Optimisation de la transcription des résultats de la cystectomie totale: vers la définition d'un Trifecta et d'un Pentafecta
Riccio R, Aziz A, Rink M, Peyromaure M, Shariat S, May M, Xylinas E
PROG UROL. 2015;25(13):770.

Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy
Rieken M, Shariat S, Kluth L, Fajkovic H, Rink M, Karakiewicz P, Seitz C, Briganti A, Rouprêt M, Loidl W, Trinh Q, Bachmann A, Pourmand G
EUR UROL. 2015;68(6):949-956.

Editorial Commentary
Rink M
Urol Pract. 2015;2(6):341–342.

Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes
Rink M, Crivelli J, Shariat S, Chun F, Messing E, Soloway M
EUR UROL FOCUS. 2015;1(1):17-27.

Smoking and Bladder Cancer: A Systematic Review of Risk and Outcome
Rink M, Crivelli J, Shariat S, Chun F, Messing E, Soloway M
EUR UROL FOCUS. 2015;1(1):17-27.

Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S, Engel O, Kluth L, Stenzl A, Burger M, Shariat S, Fisch M, Fritsche H, Gakis G
CLIN GENITOURIN CANC. 2015;14(1):96-104.

Internal urethrotomy in patients with recurrent urethral stricture after buccal mucosa graft urethroplasty
Rosenbaum C, Schmid M, Ludwig T, Kluth L, Reiß C, Dahlem R, Engel O, Chun F, Riechardt S, Fisch M, Ahyai S
WORLD J UROL. 2015;33(9):1337-1344.

Oncological outcome after radical prostatectomy: Marital status does not make a difference
Schiffmann J, Beyer B, Tennstedt P, Boehm K, Mehring G, Schlomm T, Salomon G, Karakiewicz P, Graefen M
INT J UROL. 2015;22(5):484-489.

Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk
Schiffmann J, Connan J, Salomon G, Boehm K, Beyer B, Schlomm T, Tennstedt P, Sauter G, Karakiewicz P, Graefen M, Huland H
PROSTATE. 2015;75(1):45-9.

Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume Center: Differences between open and robot-assisted radical prostatectomy
Schiffmann J, Haese A, Leyh-Bannurah S, Salomon G, Steuber T, Schlomm T, Boehm K, Beyer B, Larcher A, Michl U, Heinzer H, Huland H, Graefen M, Karakiewicz P
EJSO-EUR J SURG ONC. 2015;41(11):1547-53.

Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy
Schiffmann J, Lesmana H, Tennstedt P, Beyer B, Boehm K, Platz V, Tilki D, Salomon G, Petersen C, Krüll A, Graefen M, Schwarz R
STRAHLENTHER ONKOL. 2015;191(4):330-337.

Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer
Schiffmann J, Manka L, Boehm K, Leyh-Bannurah S, Karakiewicz P, Graefen M, Hammerer P, Salomon G
WORLD J UROL. 2015;33(12):1993-1999.

Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility
Schiffmann J, Wenzel P, Salomon G, Budäus L, Schlomm T, Minner S, Wittmer C, Kraft S, Krech T, Steurer S, Sauter G, Beyer B, Boehm K, Tilki D, Michl U, Huland H, Graefen M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2015;33(7):329.e13-9.

The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun
Schlomm T
EUR UROL. 2015;68(2):214-215.

The aging prostate is never "normal": implications from the genomic characterization of multifocal prostate cancers
Schlomm T, Weischenfeldt J, Korbel J, Sauter G
EUR UROL. 2015;68(3):348-50.

Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery
Schmid M, Dalela D, Tahbaz R, Langetepe J, Randazzo M, Dahlem R, Fisch M, Trinh Q, Chun F
World J Nephrol. 2015;4(2):160-8.

The controversy that will not go away
Schmid M, Gandaglia G, Trinh Q
EUR UROL. 2015;67(3):439-40.

An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer
Schmid M, Ghani K, Choueiri T, Sood A, Kapoor V, Abdollah F, Chun F, Leow J, Olugbade K, Sammon J, Menon M, Kibel A, Fisch M, Nguyen P, Trinh Q
BJU INT. 2015;116(6):911-9.

Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects
Schmid M, Hansen J, Chun F
ADV EXP MED BIOL. 2015;867:277-89.

The need for standardised reporting of complications: Comment on: Minimum 5-years follow-up of 1138 consecutive laparoscopic radical prostatectomies (BJU Int 2015 Apr;115(4):546-53)
Schmid M, Meyer C, Trinh Q
BJU INT. 2015;115(4):501-2.

Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?
Schmid M, Rink M, Traumann M, Bastian P, Bartsch G, Ellinger J, Grimm M, Hadaschik B, Haferkamp A, Hakenberg O, Aziz A, Hartmann F, Herrmann E, Hohenfellner M, Janetschek G, Gierth M, Pahernik S, Protzel C, Roigas J, Gördük M, Lusuardi L, May M, Trinh Q, Fisch M, Chun F
ANN SURG ONCOL. 2015;22(3):1032-42.

Impact of smoking on perioperative outcomes after major surgery
Schmid M, Sood A, Campbell L, Kapoor V, Dalela D, Klett D, Chun F, Kibel A, Sammon J, Menon M, Fisch M, Trinh Q
AM J SURG. 2015;210(2):221-229.e6.

Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy
Simone G, Bianchi M, Giannarelli D, Daneshmand S, Papalia R, Ferriero M, Guaglianone S, Sentinelli S, Colombo R, Montorsi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Miranda G, Desai M, Gill I, Gallucci M
WORLD J UROL. 2015;33(10):1419-1428.

Management of advanced bladder cancer in the era of targeted therapies
Soave A, Engel O, von Amsberg G, Becker A, Dahlem R, Shariat S, Fisch M, Rink M
MINERVA UROL NEFROL. 2015;67(2):103-15.

The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy
Soave A, John L, Dahlem R, Minner S, Engel O, Schmidt S, Kluth L, Fisch M, Rink M
UROLOGY. 2015;86(1):92-8.

Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?
Soave A, Riethdorf S, Pantel K, Fisch M, Rink M
CURR UROL REP. 2015;16(7):Art. 46.

Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?
Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth L, John L, Hansen J, Schmid M, Sauter G, Shariat S, Fisch M, Rink M
UROL ONCOL-SEMIN ORI. 2015;33(1):21.e1-9.

Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy
Tilki D, Hu B, Nguyen H, Dall'Era M, Bertini R, Carballido J, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Linares E, Lorentz C, Mandel P, Martinez-Salamanca J, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi R, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat S, Spahn M, Terrone C, Thieu W, Vergho D, Wallen E, Xylinas E, Zigeuner R, Libertino J, Evans C
J UROLOGY. 2015;193(2):436-42.

Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy.
Tilki D, Mandel P, Flora S, Kretschmer A, Karl A, Ergün S, Seitz M, Stief C
J UROLOGY. 2015;193(2):484-490.

External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort
Tilki D, Mandel P, Schlomm T, Chun F, Tennstedt P, Pehrke D, Haese A, Huland H, Graefen M, Salomon G
J UROLOGY. 2015;193(6):1970-1975.

Roboterassistierte laparoskopische Pyeloplastik bei Erwachsenen: Exzellente Langzeitergebnisse der primären Pyeloplastik
Traumann M, Kluth L, Schmid M, Meyer C, Schwaiger B, Rosenbaum C, Schriefer P, Fisch M, Dahlem R, Seiler D, Ahyai S, Haese A, Chun F
UROLOGE. 2015;54(5):703-708.

VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy
Tsourlakis M, Khosrawi P, Weigand P, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Krech T, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S
INT J MOL SCI. 2015;16(4):8591-606.

PSMA expression is highly homogenous in primary prostate cancer
Tsourlakis M, Klein F, Kluth M, Quaas A, Graefen M, Haese A, Simon R, Sauter G, Schlomm T, Minner S
APPL IMMUNOHISTO M M. 2015;23(6):449-55.

Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers
Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf T, Murthy P, Balabanov S
J PROTEOMICS. 2015;119:218-29.

Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009
Varda B, McNabb-Baltar J, Sood A, Ghani K, Kibel A, Letendre J, Menon M, Sammon J, Schmid M, Sun M, Trinh Q, Bhojani N
UROLOGY. 2015;85(4):764-70.

Anxiety and depression in long-term testicular germ cell tumor survivors
Vehling S, Mehnert A, Hartmann M, Oing C, Bokemeyer C, Oechsle K
GEN HOSP PSYCHIAT. 2015.

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy
Zabalza C, Adam M, Burdelski C, Wilczak W, Wittmer C, Kraft S, Krech T, Steurer S, Koop C, Hube-Magg C, Graefen M, Heinzer H, Minner S, Simon R, Sauter G, Schlomm T, Tsourlakis M
ONCOTARGET. 2015;6(14):12822-12834.

Molecular Characterization of the NLRC4 Expression in Relation to Interleukin-18 Levels
Zeller T, Haase T, Müller C, Riess H, Lau D, Zeller S, Krause J, Baumert J, Pless O, Dupuis J, Wild P, Eleftheriadis M, Waldenberger M, Zeilinger S, Ziegler A, Peters A, Tiret L, Proust C, Marzi C, Munzel T, Strauch K, Prokisch H, Lackner K, Herder C, Thorand B, Benjamin E, Blankenberg S, Koenig W, Schnabel R
CIRC-CARDIOVASC GENE. 2015;8(5):717-726.

Multimodal image-guided prostate fusion biopsy based on automatic deformable registration: Int J Comput Assist Radiol Surg
Zettinig O, Shah A, Hennersperger C, Eiber M, Kroll C, Kubler H, Maurer T, Milletari F, Rackerseder J, Schulte Zu Berge C, Storz E, Frisch B, Navab N
INT J COMPUT ASS RAD. 2015;10(12):1997-2007.

A Tertiary Gleason Pattern in the Prostatectomy Specimen and its Association with Adverse Outcome after Radical Prostatectomy
Adam M, Hannah A, Budäus L, Steuber T, Salomon G, Michl U, Haese A, Fisch M, Wittmer C, Steurer S, Minner S, Heinzer H, Huland H, Graefen M, Sauter G, Schlomm T, Isbarn H
J UROLOGY. 2014;192(1):97-101.

Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy
Aziz A, Fritsche H, Gakis G, Kluth L, Al-Sayed Hassan F, Engel O, Dahlem R, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, Shariat S, Fisch M, Burger M, Rink M
UROL ONCOL-SEMIN ORI. 2014;32(8):1141-1150.

Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort
Aziz A, May M, Burger M, Palisaar R, Trinh Q, Fritsche H, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, Shariat S, Brookman-May S, Bastian P, Denzinger S, Gierth M, Roghmann F
EUR UROL. 2014;66(1):156-163.

Preoperative C-reactive protein in the Serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy
Aziz A, Rink M, Gakis G, Kluth L, Dechet C, Miller F, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, Fisch M, Burger M, Fritsche H
UROL INT. 2014;93(3):352-360.

Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer
Becker A, Coelius C, Adam M, Tennstedt P, Kluth L, Steuber T, Heinzer H, Graefen M, Schlomm T, Michl U
WORLD J UROL. 2014;33(1):77-83.

Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
Becker A, Eichelberg C, Sun M
CANCER J. 2014;120(1):7-10.

Holmium laser enucleation of the prostate is safe in patients with prostate cancer and lower urinary tract symptoms--a retrospective feasibility study
Becker A, Placke A, Kluth L, Schwarz R, Isbarn H, Chun F, Heuer R, Schlomm T, Seiler D, Engel O, Fisch M, Graefen M, Ahyai S
J ENDOUROL. 2014;28(3):335-41.

Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption
Becker A, Ravi P, Roghmann F, Trinh Q, Tian Z, Larouche A, Kim S, Shariat S, Kluth L, Dahlem R, Fisch M, Graefen M, Eichelberg C, Karakiewicz P, Sun M
UROLOGY. 2014;83(6):1285-1291.

Delay in nephrectomy and cancer control outcomes in elderly patients with small renal masses
Becker A, Roghmann F, Ravi P, Tian Z, Kluth L, Gandaglia G, Noldus J, Dahlem R, Schlomm T, Graefen M, Karakiewicz P, Trinh Q, Sun M
UROL INT. 2014;92(4):455-461.

A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center
Becker A, Seiler D, Kwiatkowski M, Kluth L, Schnell D, Graefen M, Schlomm T, Fisch M, Recker F, Weissbach L, Chun F
WORLD J UROL. 2014;32(4):891-897.

Functional and oncological outcomes of patients aged < 50 years treated with radical prostatectomy for localised prostate cancer in a European population
Becker A, Tennstedt P, Hansen J, Trinh Q, Kluth L, Atassi N, Schlomm T, Salomon G, Haese A, Budaeus L, Michl U, Heinzer H, Huland H, Graefen M, Steuber T
BJU INT. 2014;114(1):38-45.

A Feasible and Time-efficient Adaptation of NeuroSAFE for da Vinci Robot-assisted Radical Prostatectomy
Beyer B, Schlomm T, Tennstedt P, Boehm K, Adam M, Schiffmann J, Sauter G, Wittmer C, Steuber T, Graefen M, Huland H, Haese A
EUR UROL. 2014;66(1):138-44.

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy
Bishoff J, Freedland S, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury J, Sauter G, Brawer M, Stone S, Schlomm T
J UROLOGY. 2014;192(2):409-14.

Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors
Brand S, Amann K, Mandel P, Zimnol A, Schupp N
PLOS ONE. 2014;9(12):e115715.

Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer
Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka D, Weischenfeldt J, Feuerbach L, Cowper-Sal Lari R, Lupien M, Brors B, Korbel J, Schlomm T, Tanay A, Sauter G, Gerhäuser C, Plass C
CELL REP. 2014;8(3):798-806.

Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface
Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, Kohler I, Bausch D, Hoeppner J, Hopt U, Keck T, Stickeler E, Passlick B, Schilling O, Reiss C, Vashist Y, Brabletz T, Lotz J, Olesch J, Werner M, Wellner U
J PATHOL. 2014;234(3):410-22.

Psychosomatische Aspekte des chronischen Unterbauchschmerzsyndroms: Psychometrische Ergebnisse der Pilotphase einer interdisziplinären Sprechstunde
Brünahl C, Riegel B, Höink J, Kutup A, Eichelberg E, Löwe B
SCHMERZ. 2014;28(3):311-318.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
Burandt E, Schreiber M, Stein A, Minner S, Clauditz T, Bokemeyer C, Jänicke F, Fisch M, Izbicki J, Knecht R, Sauter G, Stahl P
GENE CHROMOSOME CANC. 2014;53(3):228-39.

Prostatakarzinom - Langzeitwirksamkeit und - sicherheit von Degarelix
Chun F
AKTUEL UROL. 2014;45(5):348-349.

Prostate imaging-the future is now: current concepts and future potentials
Chun F, Herrmann T
WORLD J UROL. 2014;32(4):843-845.

Effect of smoking on outcomes of urothelial carcinoma - a systematic review of the literature
Crivelli J, Xylinas E, Kluth L, Rieken M, Rink M, Shariat S
EUR UROL. 2014;65(4):742-754.

Kapitel Urologie und Nephrologie
Engel O
2014. Checkliste Tauchtauglichkeit. 2. Aufl. Gentner, .

The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results.
Engel O, de Petriconi R, Volkmer B, Gust K, Mani J, Haferkamp A, Hautmann R, Bartsch G
J Negat Results Biomed. 2014;13:17.

Harnröhrenstriktur
Engel O, Fisch M
2014;Therapie-Handbuch:.

Postprostatectomy Strictures
Fisch M, Pfalzgraf D, Reiß C
2014. Advanced Male Urethral and Genital Reconstructive Surgery. Brandes S, Morey A (Hrsg.). 1. Aufl. Humana Press, 321-336.

Does increasing life expectancy affect competing mortality after radical prostatectomy?
Froehner M, Koch R, Wirth M, Adam M, Schlomm T, Huland H, Graefen M
UROL ONCOL-SEMIN ORI. 2014;32(4):413-418.

External validation of a model to predict locoregional failure after radical cystectomy
Froehner M, Novotny V, Wirth M, Brookman-May S, Aziz A, May M
CANCER-AM CANCER SOC. 2014;120(22):3584.

Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy
Gakis G, Fritsche H, Hassan F, Kluth L, Miller F, Soave A, Otto W, Schwentner C, Todenhöfer T, Dahlem R, Burger M, Fisch M, Stenzl A, Aziz A, Rink M
EUR J CANCER. 2014;50(15):2583-2591.

The effect of intra- and postoperative allogenic blood transfusion on patients' survival undergoing radical cystectomy for urothelial carcinoma of the bladder
Gierth M, Aziz A, Fritsche H, Burger M, Otto W, Zeman F, Pawlik M, Hansen E, May M, Denzinger S
WORLD J UROL. 2014;32(6):1447-53.

Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation
Gierth M, Fritsche H, Buchner H, May M, Aziz A, Otto W, Bolenz C, Trojan L, Hermann E, Tiemann A, Müller S, Ellinger J, Brookman-May S, Stief C, Tilki D, Nuhn P, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland W, Riedmiller H, Denzinger S, Bastian P, Burger M
WORLD J UROL. 2014;32(2):365-71.

Outcome of radical prostatectomy: is it the approach or the surgical expertise?
Graefen M, Beyer B, Schlomm T
EUR UROL. 2014;66(3):457-458.

Current resultson PSA-based prostate cancer detection
Graefen M, Schlomm T, Steuber T, Sauter G
BUNDESGESUNDHEITSBLA. 2014;57(3):312-7.

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression
Grupp K, Boumesli R, Tsourlakis M, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki J, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A
INT J CANCER. 2014;135(6):1399-1407.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy
Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis M
MODERN PATHOL. 2014;27(1):96-106.

NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer
Grupp K, Ospina-Klinck D, Tsourlakis M, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki J, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A
PROSTATE. 2014;74(10):1012-22.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions
Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis M
EUR J CANCER. 2014;50(4):852-61.

Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score
Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai S, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat S, Fisch M, Graefen M, Karakiewicz P, Briganti A, Chun F
BJU INT. 2014;113(3):399-407.

Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy
Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh Q, Shariat S, Perrotte P, Chun F, Graefen M, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2014;8(1-2):E75-80.

Prognostische und prädiktive molekulare Marker urologischer Tumoren
Hartmann K, Schlomm T, Bertz S, Heinzelmann J, Hölters S, Simon R, Stoehr R, Junker K
UROLOGE. 2014;53(4):491-500.

Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse
Hennigs J, Müller J, Adam M, Spin J, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S
PLOS ONE. 2014;9(7):e100469.

Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer
Klatte T, Xylinas E, Rieken M, Kluth L, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz P, Lotan Y, Babjuk M, de Martino M, Scherr D, Shariat S
J UROLOGY. 2014;191(5):1238-1243.

Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment
Kluth L, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz P, Schramek P, Herman M, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee R, Lotan Y, Scherr D, Seiler D, Ahyai S, Chun F, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, Shariat S
BRIT J CANCER. 2014;111(2):213-219.

Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool
Kluth L, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz P, Seitz C, Schramek P, Herman M, Becker A, Loidl W, Pummer K, Nonis A, Lee R, Lotan Y, Scherr D, Seiler D, Chun F, Graefen M, Tewari A, Gönen M, Montorsi F, Shariat S, Briganti A
EUR UROL. 2014;66(3):439-446.

Panurethral and complex urethral strictures. Reconstruction in several steps: current techniques and indications
Kluth L, Riechardt S, Reiss C, Dahlem R, Fisch M
ARCH ESP UROL. 2014;67(1):104-110.

Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients
Kluth L, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian S, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr D, Vickers A, Shariat S
EUR UROL. 2014;66(5):913-919.

Predictors of survival in patients with disease recurrence after radical nephroureterectomy
Kluth L, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Dalpiaz O, Zigeuner R, Aziz A, Fritsche H, Deliere A, Raman J, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa S, Chun F, Scherr D, Vickers A, Shariat S
BJU INT. 2014;113(6):911-917.

Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
Kluth L, Xylinas E, Rieken M, Chun F, Fajkovic H, Becker A, Karakiewicz P, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr D, Graefen M, Tewari A, Shariat S
UROL ONCOL-SEMIN ORI. 2014;32(1):47.e1-8.

Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Kluth L, Xylinas E, Rieken M, El Ghouayel M, Sun M, Karakiewicz P, Lotan Y, Chun F, Boorjian S, Lee R, Briganti A, Rouprêt M, Fisch M, Scherr D, Shariat S
BJU INT. 2014;113(3):393-398.

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer
Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, Gjoni J, Hass T, Galal R, Graefen M, Haese A, Simon R, Hühne-Simon J, Koop C, Korbel J, Weischenfeld J, Huland H, Sauter G, Quaas A, Wilczak W, Tsourlakis M, Minner S, Schlomm T
INT J CANCER. 2014;135(6):1369-1380.

Reduced membranous MET expression is linked to bladder cancer progression
Kluth M, Reynolds K, Rink M, Chun F, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Sauter G, Minner S
CANCER GENET-NY. 2014;207(4):147-52.

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer. SUSE (AUO-AB 31/05)
Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M
BJU INT. 2014;113(3):429-436.

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer
Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L, Stahl P, C Tsourlakis M, Bauer M, Tennstedt P, Graefen M, Steurer S, Sirma H, Sauter G, Schlomm T, Simon R, Minner S
MODERN PATHOL. 2014;27(12):1612-1620.

Chronische Pollakisurie - Zystektomie oder Psychotherapie
Kuffel A, Kapitza K, Löwe B, Eichelberg E, Gumz A
UROLOGE. 2014;53(10):1495-1499.

Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer
Lange T, Kupfernagel M, Wicklein D, Gebauer F, Maar H, Brügge K, Müller I, Simon R, Schlomm T, Sauter G, Schumacher U
CLIN CANCER RES. 2014;20(7):1791-802.

Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study
Larouche A, Becker A, Schiffmann J, Roghmann F, Gandaglia G, Hanna N, Tian Z, Perrotte P, Schlomm T, Graefen M, Ahyai S, Trinh Q, Karakiewicz P, Sun M
CUAJ-CAN UROL ASSOC. 2014;8(5-6):E419-24.

Readmissions after major urologic cancer surgery
Leow J, Gandaglia G, Sood A, Ruhotina N, Klett D, Sammon J, Schmid M, Sun M, Chang S, Kibel A, Trinh Q
CAN J UROL. 2014;21(6):7537-7546.

Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia
Leyh-Bannurah S, Prugger C, de Koning M, Goette H, Lellé R
INFECT AGENTS CANCER. 2014;9(1):33.

Body mass index has no impact on sperm quality but on reproductive hormones levels
M Al-Ali B, Gutschi T, Pummer K, Zigeuner R, Brookman-May S, Wieland W, Fritsche H, Aziz A
ANDROLOGIA. 2014;46(2):106-11.

The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy
Mandel P, Kretschmer A, Chandrasekar T, Nguyen H, Buchner A, Stief C, Tilki D
UROL ONCOL-SEMIN ORI. 2014;32(3):297-302.

Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis
Mandel P, Tilki D, Eslick G
UROL ONCOL-SEMIN ORI. 2014;32(8):1184-90.

Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series
May M, Aziz A, Brookman-May S, Roghmann F, Noldus J, Rink M, Chun F, Fisch M, Novotny V, Wirth M, Mayr R, Pycha A, Brisuda A, Volkmer B, Stredele R, Dechet C, Vallo S, Haferkamp A, Schnabel M, Denzinger S, Roigas J, Stief C, Gilfrich C, Bastian P, Engel J, Burger M, Fritsche H
WORLD J UROL. 2014;33(3):343-350.

Concomitant Seminal Vesicle Invasion in pT4a Urothelial Carcinoma of the Bladder with Contiguous Prostatic Infiltration is an Adverse Prognosticator for Cancer-Specific Survival after Radical Cystectomy
May M, Brookman-May S, Burger M, Gilfrich C, Fritsche H, Rink M, Chun F, Fisch M, Roghmann F, Noldus J, Mayr R, Pycha A, Novotny V, Wirth M, Vallo S, Haferkamp A, Roigas J, Brisuda A, Stredele R, Volkmer B, Dechet C, Schnabel M, Denzinger S, Stief C, Bastian P, Aziz A
ANN SURG ONCOL. 2014;21(12):4034-4040.

EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer
May M, Burger M, Brookman-May S, Stief C, Fritsche H, Roigas J, Zacharias M, Bader M, Mandel P, Gilfrich C, Seitz M, Tilki D
CLIN GENITOURIN CANC. 2014;12(4):278-86.

Die postoperative Prognose des chromophoben Nierenzellkarzinoms: Eine vergleichende Analyse anhand der multinationalen CORONA-Datenbank
May M, Zigeuner R, Aziz A, Cindolo L, Gilfrich C, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Hoschke B, Dalpiaz O, Stoltze A, Fenske F, Fritsche H, Chromecki T, Lebentrau S, Figenshau R, Madison K, Sánchez-Chapado M, Del Carmen Santiago Martin M, Salzano L, Lotrecchiano G, Joniau S, Waidelich R, Stief C, Brookman-May S
UROLOGE. 2014;53(2):228-35.

Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma
Meskawi M, Becker A, Bianchi M, Trinh Q, Roghmann F, Tian Z, Graefen M, Perrotte P, Karakiewicz P, Sun M
INT J UROL. 2014;21(2):122-128.

GeSRU-Jahresüberblick 2015: Weiterbilden, Netzwerken und Karriereplanen
Meyer C, Beyer B, Arnold H, Borgmann H, Salem J
UROLOGE. 2014;53(12):1817-9.

Circulating tumor cells in patients with testicular germ cell tumors
Nastały P, Ruf C, Becker P, Bednarz-Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Höppner D, Fisch M, Bokemeyer C, Ahyai S, Honecker F, Riethdorf S, Pantel K
CLIN CANCER RES. 2014;20(14):3830-41.

Outcomes after recto-anastomosis fistula repair in patients who underwent radical prostatectomy for prostate cancer
Pfalzgraf D, Isbarn H, Reiss P, Meyer-Moldenhauer W, Fisch M, Dahlem R
BJU INT. 2014;113(4):568-573.

Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time
Ploussard G, Shariat S, Dragomir A, Kluth L, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian S, Lotan Y, Roghmann F, Fairey A, Fradet Y, Black P, Rendon R, Izawa J, Kassouf W
EUR UROL. 2014;66(2):361-370.

Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men - a systematic review
Riegel B, Brünahl C, Ahyai S, Bingel U, Fisch M, Löwe B
J PSYCHOSOM RES. 2014;77(5):333-350.

Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis
Rieken M, Djajadiningrat R, Kluth L, Favaretto R, Xylinas E, Guimaraes G, Soares F, Kent M, Sjoberg D, Horenblas S, Shariat S
EUR UROL. 2014;66(5):811-814.

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer
Rieken M, Kluth L, Xylinas E, Fajkovic H, Becker A, Karakiewicz P, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee R, Faison T, Scherr D, Kautzky-Willer A, Bachmann A, Tewari A, Shariat S
WORLD J UROL. 2014;32(4):999-1005.

Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh Q, Lee R, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca J, Matsumoto K, Seitz C, Remzi M, Karakiewicz P, Scherr D, Briganti A, Bachmann A, Shariat S
EJSO-EUR J SURG ONC. 2014;40(12):1693-1699.

Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder
Rieken M, Xylinas E, Kluth L, Crivelli J, Chrystal J, Faison T, Lotan Y, Karakiewicz P, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha A, Bachmann A, Scherr D, Shariat S
EUR UROL. 2014;65(1):201-209.

Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma
Rieken M, Xylinas E, Kluth L, Crivelli J, Chrystal J, Faison T, Lotan Y, Karakiewicz P, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr D, Shariat S
UROL ONCOL-SEMIN ORI. 2014;32(1):49.e7-14.

Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
Rieken M, Xylinas E, Kluth L, Trinh Q, Lee R, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca J, Matsumoto K, Seitz C, Remzi M, Karakiewicz P, Scherr D, Briganti A, Kautzky-Willer A, Bachmann A, Shariat S
EJSO-EUR J SURG ONC. 2014;40(1):113-120.

Re: Global effects of smoking, of quitting, and of taxing tobacco
Rink M, Shariat S
EUR UROL. 2014;66(1):176-178.

Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy
Rink M, Sharifi N, Fritsche H, Aziz A, Miller F, Kluth L, Ngamsri T, Dahlem R, Chun F, Shariat S, Stenzl A, Fisch M, Gakis G
J UROLOGY. 2014;191(2):316-322.

Erratum zu: Detektion und Stellenwert von zirkulierenden Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase
Rink M, Soave A, Engel O, Fisch M, Riethdorf S, Pantel K
UROLOGE. 2014;53(5):740.

Zirkulierende Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase: Detektion und Stellenwert
Rink M, Soave A, Engel O, Fisch M, Riethdorf S, Pantel K
UROLOGE. 2014;53(4):501-508.

Oncological long-term outcome of 4772 patients with prostate cancer undergoing radical prostatectomy: Does the anaesthetic technique matter?
Roiss M, Schiffmann J, Tennstedt P, Kessler T, Blanc-Groebe I, Goetz A, Schlomm T, Graefen M, Reuter D
EJSO-EUR J SURG ONC. 2014;40(12):1686-1692.

Incremental detection rate of prostate cancer by real-time elastography targeted biopsies in combination with a conventional 10-core biopsy in 1024 consecutive patients
Salomon G, Drews N, Autier P, Beckmann A, Heinzer H, Hansen J, Michl U, Schlomm T, Haese A, Steuber T, Graefen M, Becker A
BJU INT. 2014;113(4):548-553.

Trends in surgical management of T1 renal cell carcinoma
Schiffmann J, Bianchi M, Sun M, Becker A
CURR UROL REP. 2014;15(2):383.

Editorial comment to Preservation of the smooth muscular internal (vesical) sphincter and of the proximal urethra for the early recovery of urinary continence after retropubic radical prostatectomy: a prospective case-control study
Schlomm T
INT J UROL. 2014;21(2):162-163.

Quality of life after radical prostatectomy: can we give a "lifetime guarantee" to our patients?
Schlomm T, Adam M
EUR UROL. 2014;65(1):66-67.

Improving outcome of surgical procedures is not possible without adequate quality measurement
Schlomm T, Huland H, Graefen M
EUR UROL. 2014;65(6):1017-1019.

Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma
Schmid M, Abd-El-Barr A, Gandaglia G, Sood A, Olugbade K, Ruhotina N, Sammon J, Varda B, Chang S, Kibel A, Chun F, Menon M, Fisch M, Trinh Q
UROL ONCOL-SEMIN ORI. 2014;32(8):1259-1266.

Chronic kidney disease and perioperative outcomes in urological oncological surgery
Schmid M, Ravi P, Abd-El-Barr A, Klap J, Sammon J, Chang S, Menon M, Kibel A, Fisch M, Trinh Q
INT J UROL. 2014;21(12):1245-1252.

Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer
Schmid M, Shariat S, Soave A, Engel O, Fisch M, Rink M
CURR UROL REP. 2014;15(6):409.

The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M, Trinh Q, Graefen M, Fisch M, Chun F, Hansen J
WORLD J UROL. 2014;32(4):871-880.

Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer
Simonis K, Shariat S, Rink M
CURR OPIN UROL. 2014;24(5):492-499.

Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort
Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth L, Chun F, Shariat S, Fisch M, Rink M
EJSO-EUR J SURG ONC. 2014;41(3):368-377.

Therapieoptionen der rezidivierenden oder persistierenden Belastungsharninkontinenz
Soave A, Engel O, Rink M, Fisch M, Dahlem R
UROLOGE. 2014;53(3):346-353.

Komplikationen bei Hypospadiekorrekturen
Soave A, Riechardt S, Engel O, Rink M, Fisch M
UROLOGE. 2014;53(7):1001-1005.

Epispadie-Ekstrophie-Komplex
Soave A, Rink M, Fisch M
2014. Facharztwissen Urologie: Differenzierte Diagnostik und Therapie. Schmelz H, Sparwasser C, Weidner W (Hrsg.). 3. Aufl. Springer, 359-362.

Hyospadie
Soave A, Rink M, Fisch M
2014. Facharztwissen Urologie: Differenzierte Diagnostik und Therapie. Schmelz H, Sparwasser C, Weidner W (Hrsg.). 3. Aufl. Springer, 353-358.

Harnröhrenklappen
Soave A, Rink M, Fisch M, Beetz R
2014. Facharztwissen Urologie: Differenzierte Diagnostik und Therapie. Schmelz H, Sparwasser C, Weidner W (Hrsg.). 3. Aufl. Springer, 363-366.

Histopathological Characteristics of Buccal Mucosa Transplants in Humans after Engraftment to the Urethra: A Prospective Study
Soave A, Steurer S, Dahlem R, Rink M, Reiss P, Fisch M, Engel O
J UROLOGY. 2014;192(6):1725-9.

TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer
Steurer S, Mayer P, Adam M, Krohn A, Koop C, Ospina-Klinck D, Tehrani A, Simon R, Tennstedt P, Graefen M, Wittmer C, Brors B, Plass C, Korbel J, Weischenfeldt J, Sauter G, Huland H, Tsourlakis M, Minner S, Schlomm T
EUR UROL. 2014;66(6):978-981.

MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype
Steurer S, Seddiqi A, Singer J, Bahar A, Eichelberg C, Rink M, Dahlem R, Huland H, Sauter G, Simon R, Minner S, Burandt E, Stahl P, Schlomm T, Wurlitzer M, Schlüter H
ANTICANCER RES. 2014;34(5):2255-61.

MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays
Steurer S, Singer J, Rink M, Chun F, Dahlem R, Simon R, Burandt E, Stahl P, Terracciano L, Schlomm T, Wagner W, Höppner W, Omidi M, Kraus O, Kwiatkowski M, Doh O, Fisch M, Soave A, Sauter G, Wurlitzer M, Schlüter H, Minner S
UROL ONCOL-SEMIN ORI. 2014;32(8):1225-33.

Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR
Tennstedt P, Bölch C, Strobel G, Minner S, Burkhardt L, Grob T, Masser S, Sauter G, Schlomm T, Simon R
INT J ONCOL. 2014;44(2):609-15.

Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review.
Tilki D, Kim S, Hu B, Dall'Era M, Evans C
J UROLOGY. 2014;193(5):1525-1531.

Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus
Tilki D, Nguyen H, Dall'Era M, Bertini R, Carballido J, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Lorentz C, Mandel P, Martinez-Salamanca J, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi R, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat S, Spahn M, Terrone C, Vergho D, Wallen E, Xylinas E, Zigeuner R, Libertino J, Evans C
EUR UROL. 2014;66(3):577-83.

Local tumor destruction in renal cell carcinoma-an inpatient population-based study
Trudeau V, Becker A, Roghmann F, Shariat S, Kluth L, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh Q, Karakiewicz P, Sun M
UROL ONCOL-SEMIN ORI. 2014;32(1):54.e1-7.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion
Tsourlakis M, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A
AM J PATHOL. 2014;184(3):609-17.

256-MDCT for evaluation of urolithiasis: Iterative reconstruction allows for a significant reduction of the applied radiation dose while maintaining high subjective and objective image quality
Veldhoen S, Laqmani A, Derlin T, Karul M, Hammerle D, Buhk J, Sehner S, Nagel H, Chun F, Adam G, Regier M
J MED IMAG RADIAT ON. 2014;58(3):283-90.

Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder
von Hardenberg J, Martini T, Knauer A, Ströbel P, Becker A, Herrmann E, Schubert C, Steidler A, Bolenz C
UROL ONCOL-SEMIN ORI. 2014;32(1):54.e9-17.

CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate
Wangerin H, Kristiansen G, Schlomm T, Stephan C, Gunia S, Zimpfer A, Weichert W, Sauter G, Erbersdobler A
BIOMED RES INT . 2014;2014:356427.

Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder
Wang L, Xylinas E, Kent M, Kluth L, Rink M, Jamzadeh A, Rieken M, Al Awamlh B, Trinh Q, Sun M, Karakiewicz P, Novara G, Chrystal J, Zerbib M, Scherr D, Lotan Y, Vickers A, Shariat S
UROL ONCOL-SEMIN ORI. 2014;32(4):433-440.

Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder
Xylinas E, Cha E, Khani F, Kluth L, Rieken M, Volkmer B, Hautmann R, Küfer R, Chen Y, Zerbib M, Rubin M, Scherr D, Shariat S, Robinson B
J UROLOGY. 2014;191(3):830-841.

Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool
Xylinas E, Kluth L, Passoni N, Trinh Q, Rieken M, Lee R, Fajkovic H, Novara G, Margulis V, Raman J, Lotan Y, Rouprêt M, Aziz A, Fritsche H, Weizer A, Martinez-Salamanca J, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz P, Montorsi F, Zerbib M, Scherr D, Shariat S
EUR UROL. 2014;65(3):650-658.

Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma
Xylinas E, Rink M, Cha E, Clozel T, Lee R, Fajkovic H, Comploj E, Novara G, Margulis V, Raman J, Lotan Y, Kassouf W, Fritsche H, Weizer A, Martinez-Salamanca J, Matsumoto K, Zigeuner R, Pycha A, Scherr D, Seitz C, Walton T, Trinh Q, Karakiewicz P, Matin S, Montorsi F, Zerbib M, Shariat S
EUR UROL. 2014;65(1):210-217.

Impact de la consommation tabagique sur la récidive vésicale après néphro-urétérectomie totale pour tumeur de la voie excrétrice supérieure
Xylinas E, Rink M, Rouprêt M, Shariat S
PROG UROL. 2014;24(13):845.

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder
Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson R, Boorjian S, Shariat S
EJSO-EUR J SURG ONC. 2014;40(1):121-127.

Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy
Aziz A, Gierth M, Fritsche H, May M, Otto W, Denzinger S, Wieland W, Merseburger A, Riedmiller H, Kocot A, Burger M
UROL INT. 2013;91(1):97-102.

Sociodemographic disparities in the treatment of small renal masses.
Becker A, Roghmann F, Trinh Q, Hansen J, Tian Z, Shariat S, Noldus J, Perrotte P, Graefen M, Karakiewicz P, Sun M
BJU INT. 2013;111(8):274-282.

Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.
Bianchi M, Becker A, Hansen J, Trinh Q, Tian Z, Abdollah F, Briganti A, Shariat S, Perrotte P, Montorsi F, Karakiewicz P, Sun M
BJU INT. 2013;111(8):283-289.

An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.
Bianchi M, Becker A, Trinh Q, Abdollah F, Tian Z, Shariat S, Montorsi F, Perrotte P, Graefen M, Karakiewicz P, Sun M
BJU INT. 2013;111(8):1184-1190.

Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis
Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun F, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz P, Montorsi F, Van Poppel H, Jeffrey Karnes R
EUR UROL. 2013;63(4):693-701.

Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens: Eur J Nucl Med Mol Imaging
Bundschuh R, Wendl C, Weirich G, Eiber M, Souvatzoglou M, Treiber U, Kubler H, Maurer T, Gschwend J, Geinitz H, Grosu A, Ziegler S, Krause B
EUR J NUCL MED MOL I. 2013;40(6):824-831.

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer
Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R
CANCER RES. 2013;73(9):2795-805.

Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy
Chromecki T, Cha E, Fajkovic H, Rink M, Ehdaie B, Svatek R, Karakiewicz P, Lotan Y, Tilki D, Bastian P, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche H, Burger M, Izawa J, Brisuda A, Babjuk M, Pummer K, Shariat S
BJU INT. 2013;111(2):249-55.

Radikale Zystektomie - Roboterassistiertes Ileumkonduit: 100 Fälle
Chun F
AKTUEL UROL. 2013;44(4):260-1.

PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer
Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, Dahlem R, Fisch M, Höppner W, Wagner W, Doh O, Terracciano L, Simon R, Wilczak W, Sauter G, Minner S
HISTOPATHOLOGY. 2013;63(5):670-7.

Effect of statin use on outcomes of non-muscle-invasive bladder cancer
Crivelli J, Xylinas E, Kluth L, da Silva R, Chrystal J, Novara G, Karakiewicz P, David S, Scherr D, Lotan Y, Shariat S
BJU INT. 2013;112(2):E4-12.

Einführung in die evidenzbasierte Urologie
Dahm P, Rink M
UROLOGE. 2013;52(3):327-8.

Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy
da Silva R, Xylinas E, Kluth L, Crivelli J, Chrystal J, Chade D, Guglielmetti G, Pycha A, Lotan Y, Karakiewicz P, Sun M, Fajkovic H, Zerbib M, Scherr D, Shariat S
J UROLOGY. 2013;190(2):487-92.

Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma.
Eichelberg C, Chun F, Bedke J, Heuer R, Adam M, Moch H, Terracciano L, Hinrichs K, Dahlem R, Fisch M, Schlomm T, Sauter G, Minner S
INT J CANCER. 2013;132(12):2948-2955.

Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Eichelberg C, Minner S, Isbarn H, Burandt E, Terracciano L, Moch H, Kell A, Heuer R, Chun F, Sauter G, Fisch M, Tennstedt P
WORLD J UROL. 2013;31(4):847-53.

Hemodynamic effects of orally administered delta-ALA during radical prostatectomy
Eichhorn V, März A, Salomon G, Blanc-Groebe I, Reuter D, Goetz A
WORLD J UROL. 2013;31(2):371-6.

Harnröhrenrekonstruktion unter Verwendung von Mundschleimhauttransplantaten
Engel O, Ahyai S, Rink M, Eichelberg C, Dahlem R, Fisch M
UROLOGE. 2013;52(5):650-6.

Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis
Fajkovic H, Cha E, Jeldres C, Robinson B, Rink M, Xylinas E, Chromecki T, Breinl E, Svatek R, Donner G, Tagawa S, Tilki D, Bastian P, Karakiewicz P, Volkmer B, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr D, Shariat S
EUR UROL. 2013;64(5):837-45.

Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma
Fajkovic H, Cha E, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh Q, Karakiewicz P, Margulis V, Raman J, Walton T, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche H, Bensalah K, Zigeuner R, Scherr D, Sonpavde G, Roupret M, Shariat S
WORLD J UROL. 2013;31(1):5-11.

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun F, Terracciano D
PLOS ONE. 2013;8(7):e67687.

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
EUR J CANCER. 2013;49(6):1273-9.

Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma
Fritsche H, May M, Denzinger S, Otto W, Siegert S, Giedl C, Giedl J, Eder F, Agaimy A, Novotny V, Wirth M, Stief C, Brookman-May S, Hofstädter F, Gierth M, Aziz A, Kocot A, Riedmiller H, Bastian P, Toma M, Wieland W, Hartmann A, Burger M
EUR UROL. 2013;63(4):739-44.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer
Gannon P, Lessard L, Stevens L, Forest V, Bégin L, Minner S, Tennstedt P, Schlomm T, Mes-Masson A, Saad F
EUR J CANCER. 2013;49(10):2441-8.

The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial
Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth L, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat S, Chun F
J UROLOGY. 2013;190(3):857-62.

Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain.
Graefen M, Schlomm T
EUR UROL. 2013;63(4):604-605.

From diagnostic tool to disease monitoring: the growing role of prostate biopsies.
Graefen M, Schlomm T
EUR UROL. 2013;63(2):231-233.

Cost-effective treatment of low-risk carcinoma not invading bladder muscle
Green D, Rink M, Cha E, Xylinas E, Chughtai B, Scherr D, Shariat S, Lee R
BJU INT. 2013;111(3 Pt B):E78-84.

Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy
Green D, Rink M, Hansen J, Cha E, Robinson B, Tian Z, Chun F, Tagawa S, Karakiewicz P, Fisch M, Scherr D, Shariat S
BJU INT. 2013;111(3):404-11.

Urothelial carcinoma of the bladder and the upper tract: disparate twins.
Green D, Rink M, Xylinas E, Matin S, Stenzl A, Roupret M, Karakiewicz P, Scherr D, Shariat S
J UROLOGY. 2013;189(4):1214-1221.

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence
Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis M, Izbicki J, Sauter G, Schlomm T, Wilczak W
PROSTATE. 2013;73(15):1690-8.

Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
Grupp K, Höhne T, Prien K, Hube-Magg C, Tsourlakis M, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S
EXP MOL PATHOL. 2013;95(2):227-34.

High mitochondria content is associated with prostate cancer disease progression
Grupp K, Jedrzejewska K, Tsourlakis M, Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki J, Graefen M, Huland H, Schlomm T, Minner S, Steurer S
MOL CANCER. 2013;12(1):145.

Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.
Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis M
MODERN PATHOL. 2013;26(5):733-742.

High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers
Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, Hube-Magg C, Salomon G, Graefen M, Heinzer H, Minner S, Izbicki J, Sauter G, Schlomm T, Tsourlakis M
MOL ONCOL. 2013;7(6):1001-11.

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J, Auprich M, Ahyai S, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Fisch M, Abbou C, Schalken J, Fradet Y, Marks L, Ellis W, Partin A, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat S, Chun F
EUR UROL. 2013;63(2):201-209.

External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.
Hansen J, Rink M, Bianchi M, Kluth L, Tian Z, Ahyai S, Shariat S, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz P, Chun F
PROSTATE. 2013;73(2):211-218.

Assays for prostate cancer: changing the screening paradigm?
Hansen J, Rink M, Graefen M, Shariat S, Chun F
MOL DIAGN THER. 2013;17(1):1-8.

A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.
Hellwinkel O, Sellier C, Sylvester Y, Brase J, Isbarn H, Erbersdobler A, Steuber T, Sültmann H, Schlomm T, Wagner C
INT J MOL SCI. 2013;14(3):5239-5249.

Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers
Isbarn H, Huland H, Graefen M
DTSCH ARZTEBL INT. 2013;110(29-30):497-503.

O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Itkonen H, Minner S, Guldvik I, Sandmann M, Tsourlakis M, Berge V, Svindland A, Schlomm T, Mills I
CANCER RES. 2013;73(16):5277-87.

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer.
Jacobsen F, Ashtiani S, Tennstedt P, Heinzer H, Simon R, Sauter G, Sirma H, Tsourlakis M, Minner S, Schlomm T, Michl U
EXP THER MED. 2013;5(1):102-106.

Multidetektor-Computertomografie der Urolithiasis: Technik und Ergebnisse: Multidetector Computed Tomography of Urolithiasis: Technique and Results
Karul M, Heuer R, Regier M
ROFO-FORTSCHR RONTG. 2013;185(2):121-127.

Short-term outcome and morbidity of different contemporary urethroplasty techniques--a preliminary comparison
Kluth L, Dahlem R, Reiß C, Pfalzgraf D, Becker A, Engel O, Chun F, Fisch M, Ahyai S
J ENDOUROL. 2013;27(7):925-9.

Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder.
Kluth L, Fajkovic H, Xylinas E, Crivelli J, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz P, Gontero P, Chun F, Fisch M, Scherr D, Shariat S
WORLD J UROL. 2013;31(5):1029-36.

Vorzeitiger Abbruch randomisierter kontrollierter Studien: Vorteilsbedingter Therapieeffekt
Kluth L, Rink M, Ahyai S, Fisch M, Shariat S, Dahm P
UROLOGE. 2013;52(8):1080-3.

Die "likelihood ratio": Beeinflussung der Therapieentscheidung durch einen diagnostischen Test
Kluth L, Rink M, Chun F, Fisch M, Shariat S, Dahm P
UROLOGE. 2013;52(7):982-5.

Verwendung und Bedeutung der "number needed to treat" in der urologischen Praxis
Kluth L, Rink M, Shariat S, Chun F, Fisch M, Dahm P
UROLOGE. 2013;52(5):682-5.

Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder
Kluth L, Xylinas E, Crivelli J, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz P, Gontero P, Lotan Y, Chun F, Fisch M, Scherr D, Shariat S
J UROLOGY. 2013;190(2):480-6.

re: a prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma
Kluth L, Xylinas E, Shariat S
EUR UROL. 2013;63(2):399-400.

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer P, Schumacher U, Grupp K, Izbicki J, Pantel K, Dikomey E, Korbel J, Plass C, Sauter G, Schlomm T, Minner S
MODERN PATHOL. 2013;26(7):975-83.

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis M, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H
AM J PATHOL. 2013;231(1):130-41.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project
Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta J, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G
BJU INT. 2013;112(3):313-21.

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study
Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernández S, Graefen M, Guazzoni G
EUR UROL. 2013;63(6):986-94.

Open and robot-assisted radical retropubic prostatectomy in men receiving ongoing low-dose aspirin medication: revisiting an old paradigm?
Leyh-Bannurah S, Hansen J, Isbarn H, Steuber T, Tennstedt P, Michl U, Schlomm T, Haese A, Heinzer H, Huland H, Graefen M, Budäus L
BJU INT. 2013.

Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database
May M, Aziz A, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Truss M, Dalpiaz O, Hoschke B, Gilfrich C, Feciche B, Stoltze A, Fenske F, Fritsche H, Figenshau R, Madison K, Sánchez-Chapado M, Martin M, Salzano L, Lotrecchiano G, Joniau S, Waidelich R, Stief C, Brookman-May S
WORLD J UROL. 2013;31(5):1073-80.

Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model
May M, Ficarra V, Shariat S, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S
J UROLOGY. 2013;190(2):458-63.

Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients
Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh Q, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
MODERN PATHOL. 2013;26(8):1144-9.

Gebrauch der partiellen Nephrektomie in zwei Maximalversorgungszentren
Meyer C
Urologische Nachrichten. 2013.

Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S, Gärtner M, Freudenthaler F, Bauer M, Kluth M, Salomon G, Heinzer H, Graefen M, Bokemeyer C, Simon R, Sauter G, Schlomm T, Wilczak W
MODERN PATHOL. 2013;26(1):106-116.

DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer
Moritz R, Ellinger J, Nuhn P, Haese A, Müller S, Graefen M, Schlomm T, Bastian P
ANTICANCER RES. 2013;33(12):5249-54.

Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
Müller J, Ehlers A, Burkhardt L, Sirma H, Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, Michl U
INT J CANCER. 2013;132(6):1333-1340.

Sex disparities in cancer mortality: the risks of being a man in the United States.
Najari B, Rink M, Li P, Karakiewicz P, Scherr D, Shabsigh R, Meryn S, Schlegel P, Shariat S
J UROLOGY. 2013;189(4):1470-1474.

Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol
Nicolaiew N, Ploussard G, Chun F, Xylinas E, Allory Y, Salomon L, de la Taille A
UROL INT. 2013;90(3):306-11.

Etiology and outcome of the perineal repair of posterior and bulbar urethral strictures in children: A single surgeon experience.
Pfalzgraf D, Isbarn H, Meyer-Moldenhauer W, Fisch M, Riechardt S
J PEDIATR UROL. 2013;9(6 Pt A):769-74.

The Barbagli technique: 3-year experience with a modified approach.
Pfalzgraf D, Kluth L, Isbarn H, Reiß C, Riechardt S, Fisch M, Dahlem R
BJU INT. 2013;111(3 Pt B):132-136.

Redo-urethroplasty: comparison of early functional results and quality of life in penile and bulbar strictures
Pfalzgraf D, Kluth L, Reiß C, Fisch M, Dahlem R
WORLD J UROL. 2013.

Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature
Punnen S, Cooperberg M, D'Amico A, Karakiewicz P, Moul J, Scher H, Schlomm T, Freedland S
EUR UROL. 2013;64(6):905-15.

Versorgungsstandard bei neu diagnostiziertem Blasenkarzinom: Eine prospektive Erhebung in Norddeutschland
Reek C, Rink M, Bloch M, Hansen J, Chun F, Schneider A, Busche J, Fisch M
UROLOGE. 2013;52(7):986-90.

Transperineal reanastomosis for the treatment for highly recurrent anastomotic strictures as a last option before urinary diversion
Reiß C, Pfalzgraf D, Kluth L, Soave A, Fisch M, Dahlem R
WORLD J UROL. 2013.

Modified Y/V-plasty for the treatment of recurrent bladder neck contracture: Outcome and patient satisfaction.
Reiß C, Schriefer P, Struss W, Schwaiger B, Isbarn H, Engel O, Riechardt S, Fisch M, Ahyai S, Dahlem R
2013. Eur Urol. e866.

Modified Y/V-Plasty For The Treatment Of Recurrent Bladder Neck Contracture: Outcome And Patient Satisfaction.
Reiß C, Schriefer P, Struss W, Schwaiger B, Isbarn H, Engel O, Riechardt S, Fisch M, Ahyai S, Dahlem R
J UROLOGY. 2013;(189(4)):e39-e39.

Virale Transmission--Orale Mucosa beherbergt häufig Papillomaviren
Riechardt S
AKTUEL UROL. 2013;44(3):175-6.

Der vergrabene Penis: Indikationen, Vorstellung einer neuen Technik und Ergebnisse
Riechardt S, Fisch M
UROLOGE. 2013;52(10):1430-3.

Zweizeitige Harnröhrenrekonstruktion mit Mundschleimhaut bei Hypospadiekrüppeln: Langzeitergebnisse
Riechardt S, Isbarn H, Dahlem R, Fisch M
UROLOGE. 2013;52(10):1434-7.

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy
Rieken M, Kluth L, Xylinas E, Seitz C, Fajkovic H, Karakiewicz P, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli J, Scherr D, Bachmann A, Tewari A, Kautzky-Willer A, Pummer K, Shariat S
PROSTATE CANCER P D. 2013;16(4):367-71.

Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer
Rieken M, Xylinas E, Kluth L, Crivelli J, Chrystal J, Faison T, Lotan Y, Karakiewicz P, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr D, Shariat S
BJU INT. 2013;112(8):1105-12.

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer - a critical review of the current literature
Rink M, Babjuk M, Catto J, Jichlinski P, Shariat S, Stenzl A, Stepp H, Zaak D, Witjes J
EUR UROL. 2013;64(4):624-38.

Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer.
Rink M, Furberg H, Zabor E, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz P, Novara G, Robinson B, Montorsi F, Chun F, Scherr D, Shariat S
EUR UROL. 2013;63(4):724-732.

Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.
Rink M, Hansen J, Cha E, Green D, Babjuk M, Svatek R, Xylinas E, Tagawa S, Faison T, Novara G, Karakiewicz P, Daneshmand S, Lotan Y, Kassouf W, Fritsche H, Pycha A, Comploj E, Tilki D, Bastian P, Chun F, Dahlem R, Scherr D, Shariat S
BJU INT. 2013;111(1):74-84.

Die Verwendung von PubMed zur Verbesserung evidenzbasierter Medizin in der Urologie
Rink M, Kluth L, Shariat S, Chun F, Fisch M, Dahm P
UROLOGE. 2013;52(3):367-72.

Konfidenzintervalle und p-Werte in der Urologie: Interpretation und Fehlinterpretation
Rink M, Kluth L, Shariat S, Dahlem R, Fisch M, Dahm P
UROLOGE. 2013;52(4):546-8.

Kaplan-Meier-Analysen in der urologischen Praxis
Rink M, Kluth L, Shariat S, Fisch M, Dahlem R, Dahm P
UROLOGE. 2013;52(6):838-41.

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
Rink M, Lee D, Kent M, Xylinas E, Fritsche H, Babjuk M, Brisuda A, Hansen J, Green D, Aziz A, Cha E, Novara G, Chun F, Lotan Y, Bastian P, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh Q, Tagawa S, Karakiewicz P, Scherr D, Sjoberg D, Shariat S
BJU INT. 2013;111(3 Pt B):30-36.

Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy
Rink M, Park K, Volkmer B, Xylinas E, Hansen J, Cha E, Robinson B, Hautmann R, Küfer R, Engel O, Chun F, Dahlem R, Rubin M, Shariat S, Mosquera J
UROL ONCOL-SEMIN ORI. 2013;31(8):1716-24.

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.
Rink M, Xylinas E, Margulis V, Cha E, Ehdaie B, Raman J, Chun F, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood C, Karakiewicz P, Fisch M, Scherr D, Shariat S
EUR UROL. 2013;63(6):1082-1090.

Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes
Rink M, Xylinas E, Trinh Q, Lotan Y, Margulis V, Raman J, Fisch M, Lee R, Chun F, Abdennabi J, Seitz C, Pycha A, Zlotta A, Karakiewicz P, Babjuk M, Scherr D, Shariat S
BJU INT. 2013;112(5):623-37.

Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
Rink M, Zabor E, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh Q, Chun F, Lee R, Karakiewicz P, Fisch M, Robinson B, Scherr D, Shariat S
EUR UROL. 2013;64(3):456-464.

Oncologic outcomes and survival in pT0 tumors after radical nephroureterectomy for upper tract urothelial carcinoma: results from of a large multicenter international collaborative study
Rouprêt M, Xylinas E, Colin P, Kluth L, Karakiewicz P, Shariat S
EUR UROL. 2013;63(2):404-5.

The search for biomarkers of metastatic seminoma
Ruf C, Khalili-Harbi N, Sachs S, Isbarn H, Wagner W, Matthies C, Meineke V, Fisch M, Chun F, Abend M
J UROLOGY. 2013;190(3):1046-51.

Prediction of metastatic status in non-seminomatous testicular cancer
Ruf C, Sachs S, Khalili-Harbi N, Isbarn H, Wagner W, Matthies C, Meineke V, Fisch M, Chun F, Abend M
WORLD J UROL. 2013.

Accuracy of HistoScanning™ for the prediction of a negative surgical margin in patients undergoing radical prostatectomy.
Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T
BJU INT. 2013;111(1):60-66.

Editorial comment
Schlomm T
J UROLOGY. 2013;190(2):520.

The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy
Schmid M, Hansen J, Rink M, Fisch M, Chun F
BIOMARK MED. 2013;7(6):843-50.

Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy.
Shariat S, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger A, Svatek R, Cha E, Tagawa S, Fajkovic H, Novara G, Karakiewicz P, Trinh Q, Daneshmand S, Lotan Y, Kassouf W, Fritsche H, Chun F, Sonpavde G, Joual A, Scherr D, Gonen M
EUR UROL. 2013;63(2):371-378.

Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis
Sirma H, Broemel M, Stumm L, Tsourlakis M, Steurer S, Tennstedt P, Salomon G, Michl U, Haese A, Simon R, Sauter G, Schlomm T, Minner S
ONCOL LETT. 2013;6(5):1245-1252.

MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.
Steurer S, Borkowski C, Odinga S, Buchholz M, Koop C, Huland H, Becker M, Witt M, Trede D, Omidi M, Kraus O, Bahar A, Seddiqi A, Singer J, Kwiatkowski M, Trusch M, Simon R, Wurlitzer M, Minner S, Schlomm T, Sauter G, Schlüter H
INT J CANCER. 2013;133(4):920-928.

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L, Burkhardt L, Steurer S, Simon R, Adam M, Becker A, Sauter G, Minner S, Schlomm T, Sirma H, Michl U
J CLIN PATHOL. 2013;66(7):563-568.

Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis.
Thuret R, Sun M, Abdollah F, Budäus L, Shariat S, Iborra F, Guiter J, Patard J, Karakiewicz P
BJU INT. 2013;111(4 Pt B):174-179.

A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis.
Thuret R, Sun M, Budäus L, Abdollah F, Liberman D, Shariat S, Iborra F, Guiter J, Patard J, Perrotte P, Karakiewicz P
CANCER CAUSE CONTROL. 2013;24(1):71-79.

Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.
Tilki D, Shariat S, Lotan Y, Rink M, Karakiewicz P, Schoenberg M, Lerner S, Sonpavde G, Sagalowsky A, Gupta A
BJU INT. 2013;111(8):1215-1221.

Xerostomia after radiotherapy. What matters--mean total dose or dose to each parotid gland?
Tribius S, Sommer J, Prosch C, Bajrovic A, Münscher A, Blessmann M, Krüll A, Petersen C, Todorovic M, Tennstedt P
STRAHLENTHER ONKOL. 2013;189(3):216-222.

Discharge patterns after radical prostatectomy in the United States of America.
Trinh Q, Bianchi M, Sun M, Sammon J, Schmitges J, Shariat S, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers C, Peabody J, Montorsi F, Menon M, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2013.

Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy.
Trinh Q, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat S, Sammon J, Jeldres C, Zorn K, Perrotte P, Graefen M, Rogers C, Peabody J, Menon M, Karakiewicz P
ANN SURG ONCOL. 2013;20(6):2096-2102.

High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy
Tsourlakis M, Delmo Walter E, Quaas A, Graefen M, Huland H, Simon R, Sauter G, Steurer S, Schlomm T, Minner S
PROSTATE CANCER P D. 2013;16(2):159-64.

Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence
Tsourlakis M, Schoop M, Plaß C, Huland H, Graefen M, Steuber T, Schlomm T, Simon R, Sauter G, Sirma H, Minner S
HUM PATHOL. 2013;44(9):1789-96.

Timing of curative treatment for prostate cancer: a systematic review
van den Bergh R, Albertsen P, Bangma C, Freedland S, Graefen M, Vickers A, van der Poel H
EUR UROL. 2013;64(2):204-15.

Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent
Weisbach L, Dahlem R, Simone G, Hansen J, Soave A, Engel O, Chun F, Shariat S, Fisch M, Rink M
INT UROL NEPHROL. 2013;45(6):1561-7.

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz H, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz A, Claus R, Eils J, Eils R, Gerhäuser C, Huang P, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae C, Fälth M, Gade S, Schmidt M, Amschler N, Hass T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo M, Korbel J, Schlomm T
CANCER CELL. 2013;23(2):159-170.

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek R, Lotan Y, Trinh Q, Karakiewicz P, Holmang S, Scherr D, Zerbib M, Vickers A, Shariat S
BRIT J CANCER. 2013;109(6):1460-6.

Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy
Xylinas E, Kluth L, Crivelli J, Rieken M, Margulis V, Seitz C, Shariat S
EUR UROL. 2013;63(6):1134-5.

Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma
Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz P, Shariat S
WORLD J UROL. 2013;31(1):31-6.

Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy
Xylinas E, Kluth L, Rieken M, Lee R, Elghouayel M, Ficarra V, Margulis V, Lotan Y, Rouprêt M, Martinez-Salamanca J, Matsumoto K, Seitz C, Karakiewicz P, Zerbib M, Scherr D, Shariat S
BJU INT. 2013.

re: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Xylinas E, Kluth L, Shariat S
EUR UROL. 2013;63(6):1132-3.

Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy
Xylinas E, Rink M, Margulis V, Clozel T, Lee R, Comploj E, Novara G, Raman J, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr D, Seitz C, Ficarra V, Trinh Q, Karakiewicz P, Montorsi F, Zerbib M, Shariat S
BJU INT. 2013;112(4):453-61.

Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy.
Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman J, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr D, Seitz C, Sun M, Trinh Q, Karakiewicz P, Montorsi F, Zerbib M, Gönen M, Shariat S
J UROLOGY. 2013;189(2):468-473.

Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.
Xylinas E, Rink M, Novara G, Green D, Clozel T, Fritsche H, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz P, Montorsi F, Abdennabi J, Trinh Q, Svatek R, Scherr D, Zerbib M, Shariat S
ANN SURG ONCOL. 2013;20(3):1027-1034.

Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy
Xylinas E, Rink M, Robinson B, Lotan Y, Babjuk M, Brisuda A, Green D, Kluth L, Pycha A, Fradet Y, Faison T, Lee R, Karakiewicz P, Zerbib M, Scherr D, Shariat S
EUR J CANCER. 2013;49(8):1889-97.

The effect of insurance status on outcomes after partial nephrectomy.
Abdo A, Trinh Q, Sun M, Schmitges J, Bianchi M, Sammon J, Shariat S, Sukumar S, Zorn K, Jeldres C, Perrotte P, Rogers C, Peabody J, Menon M, Karakiewicz P
INT UROL NEPHROL. 2012;44(2):343-351.

A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy.
Abdollah F, Schmitges J, Sun M, Shariat S, Briganti A, Abdo A, Tian Z, Perrotte P, Montorsi F, Karakiewicz P
BJU INT. 2012;109(8):1177-1182.

Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis.
Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O, Tian Z, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
BJU INT. 2012;109(4):564-569.

Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy.
Abdollah F, Sun M, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Shariat S, Montorsi F, Karakiewicz P
BJU INT. 2012;109(8):1147-1154.

Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study.
Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
ANN SURG ONCOL. 2012;19(1):309-317.

Transurethral holmium laser enucleation versus transurethral resection of the prostate and simple open prostatectomy--which procedure is faster?
Ahyai S, Chun F, Lehrich K, Dahlem R, Zacharias M, Fisch M, Kuntz R
J UROLOGY. 2012;187(5):1608-1613.

Harnableitung und Dickdarm: Das Transversumconduit und der Transversumpouch
Ahyai S, Sayedahmed K, Engel O, Chun F, Dahlem R, Fisch M
UROLOGE. 2012;51(7):937-46.

[Urinary diversion and colon: transverse conduit and transverse pouch].
Ahyai S, Sayedahmed K, Engel O, Chun F, Dahlem R, Fisch M
UROLOGE. 2012;51(7):937-946.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat S, Fisch M, Graefen M, Pummer K, Chun F
BJU INT. 2012;109(11):1627-1635.

Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy
Bedke J, Chun F, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert K, Stenzl A, Kruck S
BJU INT. 2012;110(11 Pt B):771-777.

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.
Bianchi M, Sun M, Jeldres C, Shariat S, Trinh Q, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz P
ANN ONCOL. 2012;23(4):973-980.

Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study.
Bianchi M, Trinh Q, Sun M, Meskawi M, Schmitges J, Shariat S, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2012;6(4):245-250.

A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.
Boorjian S, Eastham J, Graefen M, Guillonneau B, Karnes R, Moul J, Schaeffer E, Stief C, Zorn K
EUR UROL. 2012;61(4):664-675.

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
Börno S, Fischer A, Kerick M, Fälth M, Laible M, Brase J, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin M, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger M
CANCER DISCOV. 2012;2(11):1024-1035.

Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A, Joniau S, Gontero P, Abdollah F, Passoni N, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma C, Graefen M, Tizzani A, Frea B, Karnes R, Montorsi F, Hein V, Spahn M
EUR UROL. 2012;61(3):584-592.

Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T
EUR UROL. 2012;61(1):112-127.

LANGZEITERGEBNISSE - Stete Verbesserung der Behandlungsqualität
Budäus L, Huland H, Graefen M
Deutsches Ärzteblatt. 2012;109(37):1814-1814.

Controversies in the management of localized prostate cancer: Radical prostatectomy still the standard of care.
Budäus L, Huland H, Graefen M, Radiotherapy O, ArEa O
CRIT REV ONCOL HEMAT. 2012;84(Suppl. 1):24-29.

Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L, Isbarn H, Tennstedt P, Salomon G, Schlomm T, Steuber T, Haese A, Chun F, Fisch M, Michl U, Heinzer H, Huland H, Graefen M
BJU INT. 2012;110(11):1714-1720.

Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
Chade D, Eastham J, Graefen M, Hu J, Karnes R, Klotz L, Montorsi F, van Poppel H, Scardino P, Shariat S
EUR UROL. 2012;61(5):961-971.

Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.
Ficarra V, Novara G, Ahlering T, Costello A, Eastham J, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel V, Henk V, Rosen R, Tewari A, Wilson T, Zattoni F, Montorsi F
EUR UROL. 2012;62(3):418-430.

[Comments on pyeloplasty - laparoscopic versus robotic].
Fisch M
UROLOGE. 2012;51(5):645.

Editorial comment on urethral reconstruction.
Fisch M
CURR OPIN UROL. 2012;22(6):445-446.

[Sigmoid-rectum pouch: a modification of the ureterosigmoidostomy].
Fisch M
AKTUEL UROL. 2012;43(2):123-133.

A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting.
Fitzpatrick J, Graefen M, Payne H, Scotté F, Aapro M
ONCOLOGIST. 2012;17 Suppl 1:31-35.

Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M
APMIS. 2012;120(11):901-8.

Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene.
Fleischmann A, Huland H, Mirlacher M, Wilczak W, Simon R, Erbersdobler A, Sauter G, Schlomm T
PROSTATE. 2012;72(9):991-997.

Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens
Fritsche H, Aziz A, Eder F, Otto W, Denzinger S, Wieland W, May M, Hofstädter F, Hartmann A, Burger M
VIRCHOWS ARCH. 2012;461(6):655-61.

Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy
Gandaglia G, Suardi N, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, Bianchi M, Chun F, Hansen J, Rigatti P, Montorsi F, Briganti A
J SEX MED. 2012;9(8):2187-2194.

Is radical prostatectomy a useful therapeutic option for high-risk prostate cancer in older men?
Graefen M, Schlomm T
ONCOLOGIST. 2012;17 Suppl 1:4-8.

Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques.
Green D, Durand M, Gumpeni N, Rink M, Cha E, Karakiewicz P, Scherr D, Shariat S
BJU INT. 2012;110(10):1463-1470.

Predictive tools for prostate cancer staging, treatment response and outcomes
Green D, Osterberg E, Xylinas E, Rink M, Karakiewicz P, Scherr D, Shariat S
ARCH ESP UROL. 2012;65(9):787-807.

[Personal factors of the ICF].
Grotkamp S, Cibis W, Nüchtern E, Baldus A, Behrens J, Bucher P, Dommen Nyffeler I, Gmünder H, Gutenbrunner C, Hagen T, Keller K, Pöthig D, Queri S, Rentsch H, Rink M, Schian H, Schian M, Schwarze M, von Mittelstaedt G, Seger W
GESUNDHEITSWESEN. 2012;74(7):449-458.

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
Hadji P, Ziller M, Maurer T, Autenrieth M, Muth M, Ruebel A, May C, Birkholz K, Diebel E, Gleissner J, Rothe P, Gschwend J
J BONE ONCOL. 2012;1(3):88-94.

Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.
Hanna N, Sun M, Trinh Q, Hansen J, Bianchi M, Montorsi F, Shariat S, Graefen M, Perrotte P, Karakiewicz P
EUR UROL. 2012;61(4):715-721.

Assessment of rates of lymph nodes and lymph node metastases in periprostatic fat pads in a consecutive cohort treated with retropubic radical prostatectomy
Hansen J, Budäus L, Spethmann J, Schlomm T, Salomon G, Rink M, Haese A, Steuber T, Heinzer H, Huland H, Graefen M, Michl U
UROLOGY. 2012;80(4):877-882.

Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy
Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, Shariat S, Chun F, Perrotte P, Graefen M, Karakiewicz P
UROLOGY. 2012;80(2):347-353.

[Secondary malignancies in urinary diversions].
Kälble T, Hofmann I, Thüroff J, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt F, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief C, Karl A, Müller S, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann K, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon W, Miller S, Weingärtner K, Schilling A, Piechota H, Becht J, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M
UROLOGE. 2012;51(4):500, 502-506.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A, Diedler T, Burkhardt L, Mayer P, Colin D, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T
AM J PATHOL. 2012;181(2):401-412.

Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression.
Lange T, Ullrich S, Müller I, Nentwich M, Stübke K, Feldhaus S, Knies C, Hellwinkel O, Vessella R, Abramjuk C, Anders M, Schröder-Schwarz J, Schlomm T, Huland H, Sauter G, Schumacher U
CLIN CANCER RES. 2012;18(5):1364-1373.

[Psychosocial predictors of utilization of medical rehabilitation services among prostate cancer patients].
Lehmann C, Beierlein V, Hagen-Aukamp C, Kerschgens C, Rhee M, Frühauf S, Otto J, Graefen M, Krüll A, Berger D, Koch U, Bergelt C
REHABILITATION. 2012;51(3):160-170.

Post-biopsy arteriovenous fistula in transplant kidney: treatment with superselective transcatheter embolisation.
Lorenzen J, Schneider A, Körner K, Regier M, Adam G, Nolte Ernsting C
EUR J RADIOL. 2012;81(5):721-726.

Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy.
Lughezzani G, Zorn K, Budäus L, Sun M, Lee D, Shalhav A, Zagaya G, Shikanov S, Gofrit O, Thong A, Albala D, Sun L, Cronin A, Vickers A, Karakiewicz P
EUR UROL. 2012;62(4):590-596.

A review of integrated staging systems for renal cell carcinoma.
Meskawi M, Sun M, Trinh Q, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, Shariat S, Montorsi F, Perrotte P, Karakiewicz P
EUR UROL. 2012;62(2):303-314.

Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer
Minner S, De Silva C, Rink M, Dahlem R, Chun F, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2012;44(5):448-452.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S, Lübke A, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W
HISTOPATHOLOGY. 2012;61(3):445-453.

Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma.
Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C
CANCER-AM CANCER SOC. 2012;118(5):1268-1275.

Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations
Mitropoulos D, Artibani W, Graefen M, Remzi M, Rouprêt M, Truss M, Panel E
EUR UROL. 2012;61(2):341-349.

Does low-risk prostate cancer detection change with repeat biopsies?
Najari B, Rink M, Graefen M, Shariat S, Chun F
EUR UROL. 2012;61(1):230-1.

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy.
Novara G, Ficarra V, Mocellin S, Ahlering T, Carroll P, Graefen M, Guazzoni G, Menon M, Patel V, Shariat S, Tewari A, Hendrik V, Zattoni F, Montorsi F, Mottrie A, Rosen R, Wilson T
EUR UROL. 2012;62(3):382-404.

Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy.
Novara G, Ficarra V, Rosen R, Artibani W, Costello A, Eastham J, Graefen M, Guazzoni G, Shariat S, Stolzenburg J, Hendrik V, Zattoni F, Montorsi F, Mottrie A, Wilson T
EUR UROL. 2012;62(3):431-452.

Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder
Otto W, May M, Fritsche H, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Höfner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Müller S, Kocot A, Riedmiller H, Wieland W, Stief C, Bastian P, Burger M
GENDER MED. 2012;9(6):481-9.

Urethral 'cripples': two-staged procedures.
Riechardt S, Dahlem R, Fisch M
CURR OPIN UROL. 2012;22(6):484-486.

Two-stage urethroplasty with buccal mucosa
Riechardt S, Fisch M
BJU INT. 2012;109(1):150-162.

Das Urothelkarzinom des oberen Harntraktes. Ein Update über klinische und pathologische prognostische Faktoren
Rink M, Adam M, Hansen J, Chun F, Ahyai S, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, Shariat S
UROLOGE. 2012;51(9):1228-39.

[Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].
Rink M, Adam M, Hansen J, Chun F, Ahyai S, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, Shariat S
UROLOGE. 2012;51(9):1228-1239.

Biomolecular predictors of urothelial cancer behavior and treatment outcomes.
Rink M, Cha E, Green D, Hansen J, Robinson B, Lotan Y, Sagalowsky A, Chun F, Karakiewicz P, Fisch M, Scherr D, Shariat S
CURR UROL REP. 2012;13(2):122-135.

Das fortgeschrittene Urothelkarzinom der Harnblase beim älteren Patienten. Ein Überblick über Inzidenz, Prognose und therapeutische Möglichkeiten
Rink M, Chun F, Chromecki T, Fajkovic H, Dahlem R, Fisch M, Shariat S
UROLOGE. 2012;51(6):820-828.

Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
Rink M, Chun F, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth L, Ahyai S, Friedrich M, Shariat S, Fisch M, Pantel K, Riethdorf S
EUR UROL. 2012;61(4):810-817.

Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.
Rink M, Ehdaie B, Cha E, Green D, Karakiewicz P, Babjuk M, Margulis V, Raman J, Svatek R, Fajkovic H, Lee R, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche H, Pycha A, Fisch M, Scherr D, Shariat S, Consortium B, Collaboration U
EUR UROL. 2012;62(4):677-684.

Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma.
Rink M, Fajkovic H, Cha E, Gupta A, Karakiewicz P, Chun F, Lotan Y, Shariat S
EUR UROL. 2012;61(4):854-855.

Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma
Rink M, Robinson B, Green D, Cha E, Hansen J, Comploj E, Margulis V, Raman J, Ng C, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo C, Chun F, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz P, Scherr D, Shariat S
J UROLOGY. 2012;188(2):398-404.

Can we apply nomograms derived in the United States to European patients? Yes, we can!
Rink M, Shariat S
EUR UROL. 2012;61(1):65-66.

Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?
Rink M, Shariat S, Xylinas E, Fitzgerald J, Hansen J, Green D, Kamat A, Novara G, Daneshmand S, Fradet Y, Tagawa S, Bastian P, Kassouf W, Trinh Q, Karakiewicz P, Fritsche H, Tilki D, Chun F, Volkmer B, Babjuk M, Merseburger A, Scherr D, Lotan Y, Svatek R
WORLD J UROL. 2012;30(6):807-814.

Risk of cancer-specific mortality following recurrence after radical nephroureterectomy
Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee R, Hansen J, Cha E, Raman J, Remzi M, Bensalah K, Novara G, Matin S, Chun F, Kikuchi E, Kassouf W, Martinez-Salamanca J, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz P, Scherr D, Vickers A, Shariat S
ANN SURG ONCOL. 2012;19(13):4337-4344.

Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer
Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz P, Abdennabi J, Fajkovic H, Loidl W, Chun F, Fisch M, Scherr D, Shariat S
J UROLOGY. 2012;188(6):2120-2127.

Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer
Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz P, Novara G, Dahlem R, Shariat S
EUR UROL. 2012;62(6):1204-1206.

Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature.
Rocco B, Cozzi G, Spinelli M, Coelho R, Patel V, Tewari A, Wiklund P, Graefen M, Mottrie A, Gaboardi F, Gill I, Montorsi F, Artibani W, Rocco F
EUR UROL. 2012;62(5):779-790.

International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.
Roscigno M, Cha E, Rink M, Seitz C, Novara G, Chromecki T, Fritsche H, Matsumoto K, Walton T, Carballido J, Luigi F, Bertini R, Ficarra V, Otto W, Karakiewicz P, Pycha A, Fajkovic H, Naspro R, Scherr D, Montorsi F, Shariat S
BJU INT. 2012;110(5):674-681.

Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery.
Salonia A, Burnett A, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall J, Stief C
EUR UROL. 2012;62(2):261-272.

Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function.
Salonia A, Burnett A, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall J, Stief C
EUR UROL. 2012;62(2):273-286.

Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients.
Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, Heinzer H, Hansen J, Budäus L, Steurer S, Wittmer C, Minner S, Haese A, Sauter G, Graefen M, Huland H
EUR UROL. 2012;62(2):333-340.

Predicting the risk of lymph node invasion during radical prostatectomy using the European Association of Urology guideline nomogram: a validation study.
Schmitges J, Karakiewicz P, Sun M, Abdollah F, Budäus L, Isbarn H, Bianchi M, Trinh Q, Schlomm T, Chun F, Graefen M, Steuber T
EJSO-EUR J SURG ONC. 2012;38(7):624-629.

Blood transfusions in radical prostatectomy: a contemporary population-based analysis.
Schmitges J, Sun M, Abdollah F, Trinh Q, Jeldres C, Budäus L, Bianchi M, Hansen J, Schlomm T, Perrotte P, Graefen M, Karakiewicz P
UROLOGY. 2012;79(2):332-338.

The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy.
Schmitges J, Trinh Q, Bianchi M, Sun M, Abdollah F, Ahyai S, Jeldres C, Steuber T, Perrotte P, Shariat S, Menon M, Montorsi F, Graefen M, Karakiewicz P
INT UROL NEPHROL. 2012.

Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy.
Schmitges J, Trinh Q, Jonas L, Budäus L, Larbig R, Schlomm T, Karakiewicz P, Heinzer H, Huland H, Graefen M, Steuber T
EJSO-EUR J SURG ONC. 2012;38(11):1082-1088.

Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy.
Schmitges J, Trinh Q, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, Shariat S, Menon M, Montorsi F, Graefen M, Karakiewicz P
UROLOGY. 2012;79(4):796-803.

Venous thromboembolism after radical prostatectomy: the effect of surgical caseload.
Schmitges J, Trinh Q, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, Shariat S, Montorsi F, Menon M, Graefen M, Karakiewicz P
BJU INT. 2012;110(6):828-833.

Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.
Schmitges J, Trinh Q, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, Shariat S, Chun F, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz P
BJU INT. 2012;110(6 Pt B):183-190.

Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P, Steurer S, Huland H, Graefen M
J CLIN ONCOL. 2012;30(32):341-344.

The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.
Schubert M, Joniau S, Gontero P, Kneitz S, Scholz C, Kneitz B, Briganti A, Karnes R, Tombal B, Walz J, Hsu C, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M
ADV UROL. 2012;2012:612707.

Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M
BJU INT. 2012;110(2):195-200.

Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners.
Seiler D, Randazzo M, Leupold U, Zeh N, Isbarn H, Chun F, Ahyai S, Baumgartner M, Huber A, Recker F, Kwiatkowski M
UROLOGY. 2012;80(3):564-569.

Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.
Shariat S, Chromecki T, Cha E, Karakiewicz P, Sun M, Fradet Y, Isbarn H, Scherr D, Bastian P, Pummer K, Fajkovic H, Sagalowsky A, Ashfaq R, Doblinger M, Cote R, Lotan Y
J UROLOGY. 2012;187(2):457-462.

Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.
Shariat S, Ehdaie B, Rink M, Cha E, Svatek R, Chromecki T, Fajkovic H, Novara G, David S, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky A, Clozel T, Bastian P, Kassouf W, Fritsche H, Burger M, Izawa J, Tilki D, Abdollah F, Chun F, Sonpavde G, Karakiewicz P, Scherr D, Gonen M
EUR UROL. 2012;61(2):237-242.

Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification.
Shariat S, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman J, Remzi M, Koppie T, Bensalah K, Guo C, Mikami S, Sircar K, Ng C, Haitel A, Kabbani W, Chun F, Wood C, Scherr D, Karakiewicz P, Langner C
EUR UROL. 2012;62(2):224-231.

Inkontinenzmanagement beim orthotopen Blasenersatz
Soave A, Dahlem R, Rink M, Ahyai S, Fisch M
UROLOGE. 2012;51(4):494-9.

[Management of urinary incontinence after orthotopic urinary diversion].
Soave A, Dahlem R, Rink M, Ahyai S, Fisch M
UROLOGE. 2012;51(4):494-499.

Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.
Sobottka I, Wegscheider K, Balzer O, Böger R, Hallier O, Giersdorf I, Streichert T, Haddad M, Platzer U, Cachovan G
ANTIMICROB AGENTS CH. 2012;56(5):2565-2569.

Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age.
Stahl P, Kilgué A, Tennstedt P, Minner S, Krohn A, Simon R, Krause G, Izbicki J, Graefen M, Sauter G, Schlomm T, Wilczak W
PROSTATE. 2012;72(8):898-903.

National trends and disparities in the use of minimally invasive adult pyeloplasty.
Sukumar S, Sun M, Karakiewicz P, Friedman A, Chun F, Sammon J, Ghani K, Ravi P, Bianchi M, Jeong W, Shariat S, Hansen J, Peabody J, Elder J, Menon M, Trinh Q
J UROLOGY. 2012;188(3):913-918.

Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy.
Sun M, Abdollah F, Bianchi M, Trinh Q, Shariat S, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
EUR J CANCER. 2012;48(10):1503-1511.

Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.
Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, Shariat S, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
BJU INT. 2012;109(12):1807-1812.

Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series.
Sun M, Abdollah F, Shariat S, Schmitges J, Trinh Q, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz P
EJSO-EUR J SURG ONC. 2012;38(1):80-87.

Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis.
Sun M, Bianchi M, Hansen J, Trinh Q, Abdollah F, Tian Z, Sammon J, Shariat S, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
EUR UROL. 2012;62(4):696-703.

Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy.
Sun M, Bianchi M, Trinh Q, Abdollah F, Schmitges J, Jeldres C, Shariat S, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
J UROLOGY. 2012;187(2):405-410.

The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers.
Tennstedt P, Köster P, Brüchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R
INT J ONCOL. 2012;40(1):261-268.

HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome.
Tribius S, Hoffmann A, Bastrop S, Görögh T, Haag J, Röcken C, Clauditz T, Grob T, Wilczak W, Tennstedt P, Borcherding A, Petersen C, Hoffmann M
ORAL ONCOL. 2012;48(11):1178-1184.

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.
Trinh Q, Sammon J, Sun M, Ravi P, Ghani K, Bianchi M, Jeong W, Shariat S, Hansen J, Schmitges J, Jeldres C, Rogers C, Peabody J, Montorsi F, Menon M, Karakiewicz P
EUR UROL. 2012;61(4):679-685.

Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.
Trinh Q, Schmitges J, Bianchi M, Sun M, Shariat S, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers C, Peabody J, Menon M, Karakiewicz P
BJU INT. 2012;110(2b):21-27.

Does partial nephrectomy at an academic institution result in better outcomes?
Trinh Q, Schmitges J, Sun M, Sammon J, Shariat S, Sukumar S, Zorn K, Bianchi M, Jeldres C, Perrotte P, Graefen M, Rogers C, Peabody J, Menon M, Karakiewicz P
WORLD J UROL. 2012;30(4):505-510.

Morbidity and mortality of radical prostatectomy differs by insurance status.
Trinh Q, Schmitges J, Sun M, Sammon J, Shariat S, Zorn K, Sukumar S, Bianchi M, Perrotte P, Graefen M, Rogers C, Peabody J, Menon M, Karakiewicz P
CANCER-AM CANCER SOC. 2012;118(7):1803-1810.

Open radical prostatectomy in the elderly: a case for concern?
Trinh Q, Schmitges J, Sun M, Shariat S, Sukumar S, Tian Z, Bianchi M, Sammon J, Perrotte P, Rogers C, Graefen M, Peabody J, Menon M, Karakiewicz P
BJU INT. 2012;109(9):1335-1340.

Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States.
Trinh Q, Schmitges J, Sun M, Sukumar S, Sammon J, Shariat S, Jeldres C, Bianchi M, Tian Z, Perrotte P, Rogers C, Graefen M, Peabody J, Menon M, Karakiewicz P
CANCER-AM CANCER SOC. 2012;118(7):1894-1900.

Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R, Barreto F, Venz S, Scharf C, Barett C, Mannsperger H, Brase J, Kuner R, Schlomm T, Sauter G, Sültmann H, Korf U, Bokemeyer C, Walther R, Brümmendorf T, Balabanov S
J PROTEOME RES. 2012;11(4):2452-2466.

The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance.
van Poppel H, Haese A, Graefen M, de La Taille A, Irani J, de Reijke T, Remzi M, Marberger M
BJU INT. 2012;109(3):360-366.

Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection.
Walz J, Bladou F, Rousseau B, Laroche J, Salem N, Gravis G, Briganti A, Chun F, Karakiewicz P, Fournier G
UROLOGY. 2012;79(3):546-551.

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling
Xylinas E, Cha E, Sun M, Rink M, Trinh Q, Novara G, Green D, Pycha A, Fradet Y, Daneshmand S, Svatek R, Fritsche H, Kassouf W, Scherr D, Faison T, Crivelli J, Tagawa S, Zerbib M, Karakiewicz P, Shariat S
BRIT J CANCER. 2012;107(11):1826-1832.

Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy.
Xylinas E, Rink M, Margulis V, Karakiewicz P, Bensalah K, Shariat S, Collaboration U
EUR UROL. 2012;62(1):25-26.

Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence.
Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat S, Collaboration U
EUR UROL. 2012;61(5):1069-1070.

Collaborative research networks as a platform for virtual multidisciplinary, international approach to managing difficult clinical cases: an example from the Upper Tract Urothelial Carcinoma Collaboration
Xylinas E, Rouprêt M, Kluth L, Scherr D, Shariat S
EUR UROL. 2012;62(5):943-5.

Impact of caseload on total hospital charges: a direct comparison between minimally invasive and open radical prostatectomy--a population based study.
Abdollah F, Budäus L, Sun M, Morgan M, Johal R, Thuret R, Zorn K, Isbarn H, Haese A, Jeldres C, Perrotte P, Montorsi F, Graefen M, Karakiewicz P
J UROLOGY. 2011;185(3):855-861.

Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study.
Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Jeldres C, Shariat S, Graefen M, Perrotte P, Montorsi F, Karakiewicz P
J UROLOGY. 2011;186(3):824-828.

Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy.
Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, Shariat S, Briganti A, Perrotte P, Montorsi F, Karakiewicz P
UROLOGY. 2011;78(6):1363-1367.

A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study.
Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
PROSTATE. 2011;71(14):1587-1594.

Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy.
Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, Shariat S, Perrotte P, Rigatti P, Montorsi F, Karakiewicz P
BJU INT. 2011;108(11):1769-1775.

Surgical caseload is an important determinant of continent urinary diversion rate at radical cystectomy: a population-based study.
Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
ANN SURG ONCOL. 2011;18(9):2680-2687.

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
EUR UROL. 2011;60(5):920-930.

The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment.
Abdollah F, Sun M, Shariat S, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz P
J UROLOGY. 2011;185(6):2078-2084.

Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.
Abdollah F, Sun M, Thuret R, Schmitges J, Shariat S, Perrotte P, Montorsi F, Karakiewicz P
ANN SURG ONCOL. 2011;18(10):2988-2996.

Decision curve analysis to compare 3 versions of Partin Tables to predict final pathologic stage.
Augustin H, Sun M, Isbarn H, Pummer K, Karakiewicz P
UROL ONCOL-SEMIN ORI. 2011.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M, Bjartell A, Chun F, de La Taille A, Freedland S, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H
EUR UROL. 2011;60(5):1045-1054.

Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.
Auprich M, Chun F, Ward J, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A
EUR UROL. 2011;59(1):96-105.

Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer
Beer A, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, Maurer T, Kübler H, Wester H, Gaa J, Krause B
MOL IMAGING BIOL. 2011;13(2):352-61.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase J, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk L, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H
BMC CANCER. 2011;11:507.

Circulating miRNAs are correlated with tumor progression in prostate cancer.
Brase J, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H
INT J CANCER. 2011;128(3):608-616.

The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a population-based study.
Budäus L, Abdollah F, Sun M, Johal R, Morgan M, Thuret R, Zorn K, Lughezzani G, Isbarn H, Haese A, Shariat S, Montorsi F, Perrotte P, Graefen M, Karakiewicz P
BJU INT. 2011;108(6):888-893.

Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: a population-based study.
Budäus L, Morgan M, Abdollah F, Zorn K, Sun M, Johal R, Thuret R, Abdo A, Schmitges J, Isbarn H, Jeldres C, Perrotte P, Graefen M, Karakiewicz P
EJSO-EUR J SURG ONC. 2011;37(5):429-434.

Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade.
Budäus L, Spethmann J, Isbarn H, Schmitges J, Beesch L, Haese A, Salomon G, Schlomm T, Fisch M, Heinzer H, Huland H, Graefen M, Steuber T
BJU INT. 2011;108(8):1256-1261.

Impact of surgical experience on in-hospital complication rates in patients undergoing minimally invasive prostatectomy: a population-based study.
Budäus L, Sun M, Abdollah F, Zorn K, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, Shariat S, Perrotte P, Graefen M, Karakiewicz P
ANN SURG ONCOL. 2011;18(3):839-847.

MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review.
Catto J, Alcaraz A, Bjartell A, Ralph D, Evans C, Fussel S, Hamdy F, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T
EUR UROL. 2011;59(5):671-681.

Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Choschzick M, Oosterwijk E, Müller V, Wölber L, Simon R, Moch H, Tennstedt P
VIRCHOWS ARCH. 2011;459(2):193-200.

Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.
Chromecki T, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee R, Cha E, Karakiewicz P, Ng C, Raman J, Chun F, Fritsche H, Matsumoto K, Kassouf W, Walton T, Bastian P, Martínez-Salamanca J, Scherr D, Shariat S
WORLD J UROL. 2011;29(4):473-480.

Benign prostatic hyperplasia and lower urinary tract symptoms: research priorities.
Cosimo D, Ahyai S, Autorino R, Bachmann A, Bialek W, Briganti A, Reich O, Sosnowski R, Thiruchelvam N, Novara G, Group E
EUR UROL. 2011;60(6):1205-1206.

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.
de La Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A
J UROLOGY. 2011;185(6):2119-2125.

Intracranial melanotic schwannoma: a case report of recurrence with extra- and intradural manifestation two decades after initial diagnosis and treatment
Ditz C, Brunswig K, Meyer C, Reusche E, Nowak G, Tronnier V
CENT EUR NEUROSURG. 2011;72(4):211-4.

Reconstructive surgery.
Fisch M
CURR OPIN UROL. 2011;21(6):447-448.

Salvage radical prostatectomy in 2011: an established therapeutic option?
Graefen M
EUR UROL. 2011;60(2):211-213.

[Prostate-specific antigen for treatment monitoring].
Graefen M, Fröhner M, Wirth M
UROLOGE. 2011;50(3):309-312.

Haemodynamics and cardiac function during robotic-assisted laparoscopic prostatectomy in steep Trendelenburg position.
Haas S, Haese A, Goetz A, Kubitz J
INT J MED ROBOT COMP. 2011;7(4):408-413.

Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.
Hellwinkel O, Asong L, Rogmann J, Sültmann H, Wagner C, Schlomm T, Eichelberg C
PROSTATE CANCER P D. 2011;14(1):38-45.

Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
Huang Y, Isharwal S, Haese A, Chun F, Makarov D, Feng Z, Han M, Humphreys E, Epstein J, Partin A, Veltri R
BJU INT. 2011;107(10):1562-1569.

Gleason 6 Prostate Cancer in One or Two Biopsy Cores Can Harbor More Aggressive Disease.
Katz M, Shikanov S, Sun M, Abdollah F, Budäus L, Gong E, Eggener S, Steinberg G, Zagaja G, Shalhav A, Karakiewicz P, Zorn K
J ENDOUROL. 2011;25(4):699-703.

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
Leeuwen v, Kölble K, Huland H, Huland H, Hambrock T, Barentsz J, Schröder F
EUR UROL. 2011;59(2):183-190.

Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study.
Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budäus L, Thuret R, Shariat S, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz P
BJU INT. 2011;107(6):905-911.

Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder.
Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budäus L, Widmer H, Graefen M, Montorsi F, Shariat S, Perrotte P, Karakiewicz P
UROLOGY. 2011;77(3):660-666.

A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer.
Lughezzani G, Sun M, Shariat S, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz P
CANCER-AM CANCER SOC. 2011;117(1):103-109.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Lübke A, Krohn A, Mayer P, Simon R, Tennstedt P, Müller J, Scholz L, Brase J, Liu A, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
CLIN CANCER RES. 2011;17(18):5878-5888.

Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W, Bokemeyer C, Huland H, Sauter G, Schlomm T
HUM PATHOL. 2011;42(12):1946-1952.

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T
PROSTATE. 2011;71(3):281-288.

Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery.
Nuhn P, Bastian P, Novara G, Svatek R, Karakiewicz P, Skinner E, Fradet Y, Izawa J, Kassouf W, Montorsi F, Müller S, Fritsche H, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney C, Shariat S
UROL INT. 2011;87(1):42-48.

Open retropubic reanastomosis for highly recurrent and complex bladder neck stenosis.
Pfalzgraf D, Beuke M, Isbarn H, Reiss C, Meyer-Moldenhauer W, Dahlem R, Fisch M
J UROLOGY. 2011;186(5):1944-1947.

Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.
Rink M, Chun F, Minner S, Friedrich M, Mauermann O, Heinzer H, Huland H, Fisch M, Pantel K, Riethdorf S
BJU INT. 2011;107(10):1668-1675.

Tissue-based molecular markers for renal cell carcinoma
Rink M, Chun F, Robinson B, Sun M, Karakiewicz P, Bensalah K, Fisch M, Scherr D, Lee R, Margulis V, Shariat S
MINERVA UROL NEFROL. 2011;63(4):293-308.

Older patients suffer from adverse histopathological features after radical cystectomy
Rink M, Dahlem R, Kluth L, Minner S, Ahyai S, Eichelberg C, Fisch M, Chun F
INT J UROL. 2011;18(8):576-84.

Full functional-length urethral sphincter preservation during radical prostatectomy.
Schlomm T, Heinzer H, Steuber T, Salomon G, Engel O, Michl U, Haese A, Graefen M, Huland H
EUR UROL. 2011;60(2):320-329.

A population-based analysis of temporal perioperative complication rates after minimally invasive radical prostatectomy.
Schmitges J, Trinh Q, Abdollah F, Sun M, Bianchi M, Budäus L, Zorn K, Perotte P, Schlomm T, Haese A, Montorsi F, Menon M, Graefen M, Karakiewicz P
EUR UROL. 2011;60(3):564-571.

Surgery for high-risk localized prostate cancer.
Schmitges J, Trinh Q, Walz J, Graefen M
Ther Adv Urol. 2011;3(4):173-182.

Rapid quantification of telomerase activity employing an improved real-time telomeric repeat amplification protocol in clinical tissue samples eliminates interference by PCR inhibitors
Schriefer P, Günes C, Wege H
J Cancer Sci Ther. 2011;3(8):176-180.

Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.
Schwarzenbach H, Chun F, Isbarn H, Huland H, Pantel K
J CANCER RES CLIN. 2011;137(5):811-819.

[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Siebels M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche G
UROLOGE. 2011;50(9):1110-1117.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T, Budäus L, Walz J, Zorn K, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A
BJU INT. 2011;107(11):1755-1761.

No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe.
Stieler K, Schindler S, Schlomm T, Hohn O, Bannert N, Simon R, Minner S, Schindler M, Fischer N
PLOS ONE. 2011;6(10):25592.

Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study.
Sun M, Abdollah F, Budäus L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, Shariat S, Montorsi F, Graefen M, Perrotte P, Karakiewicz P
ANN SURG ONCOL. 2011;18(10):2997-3004.

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.
Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat S, Montorsi F, Patard J, Perrotte P, Karakiewicz P
EUR UROL. 2011;59(1):135-141.

Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.
Svatek R, Shariat S, Novara G, Skinner E, Fradet Y, Bastian P, Kamat A, Kassouf W, Karakiewicz P, Fritsche H, Izawa J, Tilki D, Ficarra V, Volkmer B, Isbarn H, Dinney C
BJU INT. 2011;107(6):898-904.

Tumor grade improves the prognostic ability of American Joint Committee on Cancer stage in patients with penile carcinoma.
Thuret R, Sun M, Abdollah F, Budäus L, Lughezzani G, Liberman D, Morgan M, Johal R, Jeldres C, Latour M, Shariat S, Iborra F, Guiter J, Patard J, Perrotte P, Karakiewicz P
J UROLOGY. 2011;185(2):501-507.

Conditional survival predictions after surgery for patients with penile carcinoma.
Thuret R, Sun M, Abdollah F, Schmitges J, Shariat S, Iborra F, Guiter J, Patard J, Perrotte P, Karakiewicz P
CANCER-AM CANCER SOC. 2011;117(16):3723-3730.

A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma.
Thuret R, Sun M, Lughezzani G, Budäus L, Liberman D, Abdollah F, Morgan M, Johal R, Jeldres C, Latour M, Shariat S, Iborra F, Guiter J, Patard J, Perrotte P, Karakiewicz P
ANN SURG ONCOL. 2011;18(2):439-446.

Radical prostatectomy at academic versus nonacademic institutions: a population based analysis.
Trinh Q, Schmitges J, Sun M, Shariat S, Sukumar S, Bianchi M, Tian Z, Jeldres C, Sammon J, Perrotte P, Graefen M, Peabody J, Menon M, Karakiewicz P
J UROLOGY. 2011;186(5):1849-1854.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
Ummanni R, Jost E, Balabanov M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, Sültmann H, Meyer-Schwesinger C, Brümmendorf T, Balabanov S
MOL CANCER. 2011;10:129.

Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform.
Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf T, Balabanov S
PLOS ONE. 2011;6(2):16833.

Surgical anatomy of the prostate in the era of radical robotic prostatectomy.
Walz J, Graefen M, Huland H
CURR OPIN UROL. 2011;21(3):173-178.

Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
Walz J, Joniau S, Chun F, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein E, Scardino P, Reuther A, Poppel H, Graefen M, Huland H, Karakiewicz P
BJU INT. 2011;107(5):765-770.

Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy.
Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, Graefen M, Adam G, Wedegärtner U
J COMPUT ASSIST TOMO. 2011;35(2):223-228.

MR Imaging of Prostate Cancer: Diffusion Weighted Imaging and (3D) Hydrogen 1 (H) MR Spectroscopy in Comparison with Histology.
Yamamura J, Salomon G, Buchert R, Hohenstein A, Graessner J, Huland H, Graefen M, Adam G, Wedegärtner U
RADIOL RES PRACT. 2011;2011:616852.

Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer.
Abdollah F, Sun M, Thuret R, Budäus L, Jeldres C, Graefen M, Briganti A, Perrotte P, Rigatti P, Montorsi F, Karakiewicz P
EUR UROL. 2010;58(6):828-892.

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.
Ahyai S, Gilling P, Kaplan S, Kuntz R, Madersbacher S, Montorsi F, Speakman M, Stief C
EUR UROL. 2010;58(3):384-397.

The presence of prostate cancer on saturation biopsy can be accurately predicted.
Ahyai S, Isbarn H, Karakiewicz P, Chun F, Reichert M, Walz J, Steuber T, Jeldres C, Schlomm T, Heinzer H, Salomon G, Budäus L, Perrotte P, Huland H, Graefen M, Haese A
BJU INT. 2010;105(5):636-641.

Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer.
Ahyai S, Zacharias M, Isbarn H, Steuber T, Eichelberg C, Köllermann J, Fisch M, Karakiewicz P, Huland H, Graefen M, Chun F
BJU INT. 2010;106(4):478-483.

Head to head comparison of three generations of Partin tables to predict final pathological stage in clinically localised prostate cancer.
Augustin H, Isbarn H, Auprich M, Bonstingl D, Al-Ali B, Mannweiler S, Pummer K
EUR J CANCER. 2010;46(12):2235-2241.

External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome.
Auprich M, Haese A, Walz J, Pummer K, de La Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun F
EUR UROL. 2010;58(5):727-732.

A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma.
Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, Shariat S, Crépel M, Alasker A, Widmer H, Arjane P, Patard J, Perrotte P, Montorsi F, Graefen M, Karakiewicz P
BJU INT. 2010;105(3):359-364.

BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood
Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, Hannemann J, Fisch M, Pantel K, Weier H, Bielawski K, Brandt B
CLIN CANCER RES. 2010;16(13):3340-3348.

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
Bhojani N, Capitanio U, Nazareno S, Jeldres C, Isbarn H, Shariat S, Graefen M, Arjane P, Duclos A, Lattouf J, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz P
INT J RADIAT ONCOL. 2010;76(2):342-348.

Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.
Bob D, Schlegel P, Salomon G, Eckersberger E, Sadri H, Graefen M
CAN J UROL. 2010;17(4):5265-5271.

[Problems, objective, and substance of early detection of prostate cancer].
Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H
UROLOGE. 2010;49(2):181-189.

The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer.
Borgmann K, Raabe A, Reuther S, Szymczak S, Schlomm T, Isbarn H, Gomolka M, Busjahn A, Bonin M, Ziegler A, Dikomey E
RADIOTHER ONCOL. 2010;96(1):19-24.

Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification.
Brase J, Mannsperger H, Fröhlich H, Stephan G, Schmidt C, Wiemann S, Beissbarth T, Schlomm T, Sültmann H, Korf U
PROTEOME SCI. 2010;8:36.

Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends.
Budäus L, Abdollah F, Sun M, Morgan M, Johal R, Thuret R, Zorn K, Isbarn H, Shariat S, Montorsi F, Perrotte P, Graefen M, Karakiewicz P
J UROLOGY. 2010;184(6):2285-2290.

The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.
Budäus L, Graefen M, Salomon G, Isbarn H, Lughezzani G, Sun M, Chun F, Schlomm T, Steuber T, Haese A, Köllermann J, Sauter G, Fisch M, Heinzer H, Huland H, Karakiewicz P
INT J UROL. 2010;17(10):862-868.

Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage.
Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, Chun F, Salomon G, Steuber T, Köllermann J, Sauter G, Ahyai S, Zacharias M, Fisch M, Schlomm T, Haese A, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz P
J UROLOGY. 2010;184(4):1341-1346.

Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature.
Chun F, Epstein J, Ficarra V, Freedland S, Montironi R, Montorsi F, Shariat S, Schröder F, Scattoni V
EUR UROL. 2010;58(6):851-864.

A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
Crépel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, Capitanio U, Shariat S, Arjane P, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
UROLOGY. 2010;76(4):883-888.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal A, Brüchmann M, Zustin J, Isbarn H, Hellwinkel O, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf T, Izbicki J, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T
CLIN CANCER RES. 2010;16(1):56-64.

Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
Fritsche H, Burger M, Svatek R, Jeldres C, Karakiewicz P, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian P, Volkmer B, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa J, Ficarra V, Lerner S, Sagalowsky A, Schoenberg M, Kamat A, Dinney C, Lotan Y, Shariat S
EUR UROL. 2010;57(2):300-309.

Editorial comment on: Cost comparison of robotic, laparoscopic and open radical prostatectomy for prostate cancer.
Graefen M
EUR UROL. 2010;57(3):458.

Low quality of evidence for robot-assisted laparoscopic prostatectomy: a problem not only in the robotic literature.
Graefen M
EUR UROL. 2010;57(6):934-938.

The modified Clavien system: a plea for a standardized reporting system for surgical complications.
Graefen M
EUR UROL. 2010;57(3):387-389.

Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society.
Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Detlef R, Schmidberger H, Uder M, Zeeb H
UROL INT. 2010;85(1):1-10.

A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.
Heuer R, Gill I, Guazzoni G, Kirkali Z, Marberger M, Richie J, Rosette d, Jean J
EUR UROL. 2010;57(2):223-232.

[Type and extent of preoperative imaging before radical prostatectomy].
Isbarn H, Kellermann S, Salomon G, Steuber T, Huland H, Graefen M
UROLOGE. 2010;49(3):396-400.

Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter.
Jeldres C, Lughezzani G, Sun M, Isbarn H, Shariat S, Budäus L, Lattouf J, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
J UROLOGY. 2010;183(4):1324-1329.

Highly predictive survival nomogram after upper urinary tract urothelial carcinoma.
Jeldres C, Sun M, Lughezzani G, Isbarn H, Shariat S, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
CANCER-AM CANCER SOC. 2010;116(16):3774-3784.

A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma.
Lughezzani G, Jeldres C, Isbarn H, Shariat S, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
UROLOGY. 2010;75(1):118-124.

Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma.
Lughezzani G, Sun M, Budäus L, Thuret R, Perrotte P, Karakiewicz P
J CLIN ONCOL. 2010;28(18):299-301.

Effect of the number of biopsy cores on prostate cancer detection and staging.
Lughezzani G, Sun M, Budäus L, Thuret R, Shariat S, Perrotte P, Karakiewicz P
FUTURE ONCOL. 2010;6(3):381-390.

Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy.
Lughezzani G, Sun M, Perrotte P, Alasker A, Jeldres C, Isbarn H, Budäus L, Lattouf J, Valiquette L, Bénard F, Saad F, Graefen M, Montorsi F, Karakiewicz P
INT J RADIAT ONCOL. 2010;78(5):1307-1313.

Depression, anxiety, post-traumatic stress disorder and health-related quality of life and its association with social support in ambulatory prostate cancer patients.
Mehnert A, Lehmann C, Graefen M, Huland H, Koch-Gromus U
EUR J CANCER CARE. 2010;19(6):736-745.

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf T, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T
CLIN CANCER RES. 2010;16(5):1553-1560.

Y chromosome loss is a frequent early event in urothelial bladder cancer.
Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, Terracciano L, Simon R, Sauter G, Wilczak W
PATHOLOGY. 2010;42(4):356-359.

Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients.
Novara G, Svatek R, Karakiewicz P, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian P, Kassouf W, Fritsche H, Izawa J, Tilki D, Dinney C, Lerner S, Schoenberg M, Volkmer B, Sagalowsky A, Shariat S
J UROLOGY. 2010;183(6):2165-2170.

Two-staged urethroplasty: buccal mucosa and mesh graft techniques.
Pfalzgraf D, Olianas R, Schreiter F, Fisch M
AKTUEL UROL. 2010;41(1):5-9.

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Ploussard G, Haese A, Hendrik V, Marberger M, Stenzl A, Mulders P, Huland H, Bastien L, Abbou C, Remzi M, Tinzl M, Feyerabend S, Stillebroer A, Gils V, Martijn P, Schalken J, de La Taille A
BJU INT. 2010;106(8):1143-1147.

Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
Remzi M, Haese A, Hein V, Alexandre D, Stenzl A, Hennenlotter J, Marberger M
BJU INT. 2010;106(8):1138-1142.

Continent Catheterizable Pouches for Urinary Diversion
Rink M, Kluth L, Eichelberg E, Fisch M, Dahlem R
EUR UROL SUPPL. 2010;9(10):754-762.

Primäres diffuses Neurofibrom der Harnblase: Ein seltener Fallbericht und Literaturübersicht
Rink M, Minner S, Tsourlakis M, Wilczak W, Fisch M, Dahlem R
UROLOGE. 2010;49(11):1398-1400.

From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.
Schlomm T, Chun F, Erbersdobler A
Methods Mol Biol. 2010;664:177-189.

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
Shariat S, Chade Daher C, Karakiewicz P, Ashfaq R, Isbarn H, Fradet Y, Bastian P, Nielsen M, Capitanio U, Jeldres C, Montorsi F, Lerner S, Sagalowsky A, Cote R, Lotan Y
J UROLOGY. 2010;183(1):68-75.

Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.
Shariat S, Youssef R, Gupta A, Chade Daher C, Karakiewicz P, Isbarn H, Jeldres C, Sagalowsky A, Ashfaq R, Lotan Y
J UROLOGY. 2010;183(5):1744-1750.

Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection.
Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, Shariat S, Budäus L, Lattouf J, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
J UROLOGY. 2010;183(3):970-975.

Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients.
Tilki D, Svatek R, Karakiewicz P, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche H, Bastian P, Izawa J, Stief C, Ficarra V, Lerner S, Schoenberg M, Dinney C, Skinner E, Lotan Y, Sagalowsky A, Shariat S
J UROLOGY. 2010;183(1):87-93.

Laparoskopische "Fast-track"-Sigmaresektion bei Divertikulitis in Deutschland. Ergebnisse einer prospektiven Qualitätssicherungsmassnahme
Tsilimparis N, Haase O, Wendling P, Kipfmüller K, Schmid M, Engemann R, Schwenk W
DEUT MED WOCHENSCHR. 2010;135(36):1743-8.

A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy.
Walz J, Burnett A, Costello A, Eastham J, Graefen M, Guillonneau B, Menon M, Montorsi F, Myers R, Rocco B, Villers A
EUR UROL. 2010;57(2):179-192.

Nuclear grading versus Gleason grading in small samples containing prostate cancer: a tissue microarray study.
Wittschieber D, Köllermann J, Schlomm T, Sauter G, Erbersdobler A
PATHOL ONCOL RES. 2010;16(4):479-484.

Application of ice cold irrigation during vascular pedicle control of robot-assisted radical prostatectomy: EnSeal instrument cooling to reduce collateral thermal tissue damage.
Zorn K, Bhojani N, Gautam G, Shikanov S, Gofrit O, Jayram G, Katz M, Cagiannos I, Budäus L, Abdollah F, Sun M, Karakiewicz P, Shalhav A, Al-Ahmadie H
J ENDOUROL. 2010;24(12):1991-1996.

Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure.
Adam C, Salomon G, Walther S, Zaak D, Khoder W, Becker A, Reich O, Blana A, Ganzer R, Denzinger S, Popken G, Sroka R, Knüchel-Clarke R, Köllermann J, Sauter G, Hartmann A, Bertz S, Graefen M, Huland H, Wieland W, Stief C
EUR UROL. 2009.

Partin Tables cannot accurately predict the pathological stage at radical prostatectomy.
Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, Shariat S, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz P
EJSO-EUR J SURG ONC. 2009;35(2):123-128.

Prävention der erektilen Dysfunktion
Böck J, Sommer F
blickpunkt der Mann. 2009;7(1):10-14.

In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
Bolenz C, Weiss C, Wenzel M, Gabriel U, Steidler A, Becker A, Herrmann E, Trojan L, Michel M
J CANCER RES CLIN. 2009;135(5):679-686.

[PSA--Quo vadis?]
Börgermann C, Loertzer H, Luboldt H, Hammerer P, Fornara P, Graefen M, Rübben H
UROLOGE. 2009;48(9):1008, 1010, 1012-1014.

Pelvic lymph node dissection in prostate cancer.
Briganti A, Blute M, Eastham J, Graefen M, Heidenreich A, Karnes J, Montorsi F, Studer U
EUR UROL. 2009;55(6):1251-1265.

Prediction of sexual function after radical prostatectomy.
Briganti A, Capitanio U, Chun F, Karakiewicz P, Salonia A, Bianchi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F
CANCER-AM CANCER SOC. 2009;115(13):3150-3159.

Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Briganti A, Karakiewicz P, Chun F, Nazareno S, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F
INT J UROL. 2009;16(8):676-681.

Current Technique of Open Intrafascial Nerve-Sparing Retropubic Prostatectomy.
Budäus L, Isbarn H, Schlomm T, Heinzer H, Haese A, Steuber T, Salomon G, Huland H, Graefen M
EUR UROL. 2009.

A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.
Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat S, Perrotte P, Antebi E, Patard J, Montorsi F, Karakiewicz P
BJU INT. 2009;103(11):1496-1500.

Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist.
Capitanio U, Isbarn H, Shariat S, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
UROLOGY. 2009.

Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors.
Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, Shariat S, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz P
UROLOGY. 2009;74(2):373-377.

Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).
Capitanio U, Perrotte P, Zini L, Jeldres C, Shariat S, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz P
BJU INT. 2009.

Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases.
Capitanio U, Shariat S, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman J, Bolenz C, Bensalah K, Koppie T, Kassouf W, Fernández M, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo C, Ng C, Montorsi F, Wood C, Margulis V, Karakiewicz P
EUR UROL. 2009.

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
Chun F, de La Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Abbou C, Stillebroer A, Gils v, Martijn P, Schalken J, Fradet Y, Marks L, Ellis W, Partin A, Haese A
EUR UROL. 2009;56(4):659-667.

Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659-68.
Chun F, de La Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Abbou C, Stillebroer A, Gils v, Martijn P, Schalken J, Fradet Y, Marks L, Ellis W, Partin A, Haese A
EUR UROL. 2009.

Recursive Partitioning (CART)
Chun F, Haese A, Graefen M
2009. Encyclopedia of Medical Decision Making. Sage Publications: 1-7.

Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?
Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, Shariat S, Widmer H, Arjane P, Graefen M, Montorsi F, Patard J, Perrotte P, Karakiewicz P
UROLOGY. 2009.

Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment.
Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat S, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard J, Karakiewicz P
UROLOGY. 2009.

Longevity of spermatozoa in the post-ejaculatory urine of fertile men.
Engelbertz F, Korda J, Engelmann U, Rothschild M, Banaschak S
FORENSIC SCI INT. 2009.

Prognostic value of microvessel density in prostate cancer: a tissue microarray study.
Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A
WORLD J UROL. 2009.

Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.
Erbersdobler A, Isbarn H, Steiner I, Schlomm T, Chun F, Mirlacher M, Sauter G
UROLOGY. 2009.

Seminal vesicle amyloidosis does not provide any protection from invasion by prostate cancer.
Erbersdobler A, Köllermann J, Graefen M, Röcken C, Schlomm T
BJU INT. 2009;103(3):324-326.

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies.
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Hendrik V
EUR UROL. 2009;55(5):1037-1063.

Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A
PROSTATE. 2009;69(9):976-981.

Intraoperative photodynamic evaluation of surgical margins during endoscopic extraperitoneal radical prostatectomy with the use of 5-aminolevulinic acid.
Ganzer R, Blana A, Denzinger S, Wieland W, Adam C, Becker A, Khoder W, Walther S, Stief C, Zaak D, Salomon G, Hartmann A, Knuechel R, Bertz S, Popken G
J ENDOUROL. 2009;23(9):1387-1394.

Editorial comment on: Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Graefen M
EUR UROL. 2009;55(2):410-411.

Editorial comment on: Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging.
Graefen M
EUR UROL. 2009;55(3):638.

Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases.
Guevremont C, Mija F, Isbarn H, Jeldres C, Lughezzani G, Sun M, Audet P, Perrotte P, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2009;3(6):92-93.

Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
Haubold K, Rink M, Spath B, Friedrich M, Chun F, Marx G, Amirkhosravi A, Francis J, Bokemeyer C, Eifrig B, Langer F
THROMB HAEMOSTASIS. 2009;101(6):1147-1155.

Prostate cancer in the elderly.
Heinzer H, Steuber T
UROL ONCOL-SEMIN ORI. 2009;27(6):668-672.

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Helo P, Cronin A, Danila D, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen R, Pettersson K, Chun F, Steuber T, Huland H, Guillonneau B, Eastham J, Scardino P, Fleisher M, Scher H, Lilja H
CLIN CHEM. 2009;55(4):765-773.

Reply to A. Edward Friedman's Letter to the Editor re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and Prostate Cancer: Revisiting Old Paradigms. Eur Urol 2009;56:48-56.
Isbarn H
EUR UROL. 2009.

Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series.
Isbarn H, Ahyai S, Chun F, Budäus L, Schlomm T, Salomon G, Zacharias M, Erbersdobler A, Köllermann J, Sauter G, Huland H, Graefen M, Steuber T
EUR UROL. 2009;55(2):394-401.

Reply from Authors re: Evangelos Liatsikos, Panagiotis Kallidonis. Laparoscopic or Open Nephroureterectomy? Which is the More Efficient Way to go? Eur Urol. In press.
Isbarn H, Capitanio U, Shariat S, Karakiewicz P
EUR UROL. 2009.

Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series.
Isbarn H, Jeldres C, Budäus L, Salomon G, Schlomm T, Steuber T, Chun F, Ahyai S, Capitanio U, Haese A, Heinzer H, Huland H, Graefen M, Karakiewicz P
UROLOGY. 2009;73(3):615-619.

Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.
Isbarn H, Jeldres C, Capitanio U, Zini L, Shariat S, Lughezzani G, Sun M, Ahyai S, Duclos A, Jolivet-Tremblay M, Lattouf J, Valiquette L, Perrotte P, Montorsi F, Graefen M, Karakiewicz P
J ENDOUROL. 2009.

Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.
Isbarn H, Jeldres C, Shariat S, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
J UROLOGY. 2009;182(5):2177-2181.

A population based assessment of perioperative mortality after cystectomy for bladder cancer.
Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, Shariat S, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz P
J UROLOGY. 2009;182(1):70-77.

Predicting cancer-control outcomes in patients with renal cell carcinoma.
Isbarn H, Karakiewicz P
CURR OPIN UROL. 2009;19(3):247-257.

Risk factors: Improved risk stratification for prostate cancer.
Isbarn H, Karakiewicz P
NAT REV UROL. 2009;6(7):355-356.

Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.
Isbarn H, Karakiewicz P, Ahyai S, Chun F, Jeldres C, Haese A, Heinzer H, Zacharias M, Heuer R, Eichelberg C, Steuber T, Budäus L, Köllermann J, Salomon G, Schlomm T, Perrotte P, Fisch M, Huland H, Graefen M
BJU INT. 2009.

Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
Isbarn H, Karakiewicz P, Shariat S, Capitanio U, Palapattu G, Sagalowsky A, Lotan Y, Schoenberg M, Amiel G, Lerner S, Guru S
J UROLOGY. 2009;182(2):459-465.

Unilateral prostate cancer cannot be accurately predicted in low-risk patients.
Isbarn H, Karakiewicz P, Vogel S, Jeldres C, Lughezzani G, Briganti A, Montorsi F, Perrotte P, Ahyai S, Budäus L, Eichelberg C, Heuer R, Köllermann J, Sauter G, Schlomm T, Steuber T, Haese A, Zacharias M, Fisch M, Heinzer H, Huland H, Chun F, Graefen M
INT J RADIAT ONCOL. 2009.

External validation of a preoperative nomogram for prediction of the risk of recurrence after radical prostatectomy.
Isbarn H, Karakiewicz P, Walz J, Ahyai S, Steuber T, Haese A, Budäus L, Schlomm T, Eichelberg C, Heuer R, Heinzer H, Huland H, Graefen M, Chun F
INT J RADIAT ONCOL. 2009.

Limited Prognostic Value of Tumor Necrosis in Patients With Renal Cell Carcinoma.
Isbarn H, Patard J, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de La Taille A, Zini L, Villers A, Shariat S, Bertini R, Karakiewicz P
UROLOGY. 2009.

Testosterone and Prostate Cancer: Revisiting Old Paradigms.
Isbarn H, Pinthus J, Marks L, Montorsi F, Morales A, Morgentaler A, Schulman C
EUR UROL. 2009.

Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M
BJU INT. 2009.

A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States.
Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, Shariat S, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz P
UROLOGY. 2009.

Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia.
Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, Shariat S, Cloutier V, Lattouf J, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
J UROLOGY. 2009;182(2):626-632.

Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study.
Jeldres C, Suardi N, Perrotte P, Capitanio U, Walz J, Hutterer G, Saad F, Valiquette L, Graefen M, Widmer H, Karakiewicz P
CUAJ-CAN UROL ASSOC. 2009;3(1):13-21.

A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma.
Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, Shariat S, Lattouf J, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
UROLOGY. 2009.

Conditional survival predictions after nephrectomy for renal cell carcinoma.
Karakiewicz P, Nazareno S, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck A, Belldegrun A, Zini L, de La Taille A, Chautard D, Descotes J, Shariat S, Valeri A, Mulders P, Lang H, Lechevallier E, Patard J
J UROLOGY. 2009;182(6):2607-2612.

Persistent genital arousal disorder: a case report in a woman with lifelong PGAD where serendipitous administration of varenicline tartrate resulted in symptomatic improvement.
Korda J, Pfaus J, Goldstein I
J SEX MED. 2009;6(5):1479-1486.

Persistent genital arousal disorder (PGAD): case report of long-term symptomatic management with electroconvulsive therapy.
Korda J, Pfaus J, Kellner C, Goldstein I
J SEX MED. 2009;6(10):2901-2909.

Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy.
Lughezzani G, Budäus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun F, Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz P
EUR UROL. 2009.

Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.
Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat S, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz P
CANCER-AM CANCER SOC. 2009;115(24):5680-5687.

Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis.
Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat S, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard J, Graefen M, Montorsi F, Karakiewicz P
J UROLOGY. 2009;182(4):1287-1293.

Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients.
Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat S, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz P
EUR J CANCER. 2009.

Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma.
Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat S, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F, Karakiewicz P
BJU INT. 2009.

Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality.
Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, Shariat S, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz P
UROLOGY. 2009.

The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation.
Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat S, Guazzoni G, Montorsi F, Karakiewicz P
EUR J CANCER. 2009.

Should Bladder Cuff Excision Remain the Standard of Care at Nephroureterectomy in Patients with Urothelial Carcinoma of the Renal Pelvis? A Population-based Study.
Lughezzani G, Sun M, Perrotte P, Shariat S, Jeldres C, Budäus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz P
EUR UROL. 2009.

Gender-related Differences in Patients With Stage I to III Upper Tract Urothelial Carcinoma: Results From the Surveillance, Epidemiology, and End Results Database.
Lughezzani G, Sun M, Perrotte P, Shariat S, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz P
UROLOGY. 2009.

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non-Muscle-Invasive Bladder Cancer.
Malmström P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E, Solsona E, Stasi D, Savino M, Witjes J
EUR UROL. 2009.

[Metabolism of nitric oxide (NO) and arginine: significance for male health]
Mathers M, Brandt A, Rundstedt F, Roth S, Sommer F, Klotz T
AKTUEL UROL. 2009;40(4):235-241.

Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study.
Mathers M, Klotz T, Roth S, Lümmen G, Sommer F
ANDROLOGIA. 2009;41(3):169-175.

Psychische Belastung und Lebensqualität bei Prostatakrebspatienten im Behandlungsverlauf
Mehnert A, Lehmann C, Graefen M, Huland H, Koch-Gromus U
2009. Psychoonkologie: Eine Disziplin in der Entwicklung. Hogrefe-Verlag: 15-27.

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications.
Murphy D, Bjartell A, Ficarra V, Graefen M, Haese A, Montironi R, Montorsi F, Moul J, Novara G, Sauter G, Sulser T, van der Poel H
EUR UROL. 2009.

Interobserver variation in grading and staging of squamous cell carcinoma of the penis in relation to the clinical outcome.
Naumann C, Alkatout I, Hamann M, Al-Najar A, Hegele A, Korda J, Bolenz C, Klöppel G, Jünemann K, van der Horst C
BJU INT. 2009;103(12):1660-1665.

Lymphatic spread in squamous cell carcinoma of the penis is independent of elevated lymph vessel density.
Naumann C, Al-Najar A, Alkatout I, Hegele A, Korda J, Bolenz C, Kalthoff H, Sipos B, Juenemann K, van der Horst C
BJU INT. 2009;103(12):1655-1659.

Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer-specific survival in a matched case-control study.
Porter C, Capitanio U, Perrotte P, Walz J, Isbarn H, Kodama K, Gibbons R, Correa R, Karakiewicz P
BJU INT. 2009;103(5):597-602.

Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy.
Raman J, Ng C, Scherr D, Margulis V, Lotan Y, Bensalah K, Patard J, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie T, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood C, Roscigno M, Oya M, Langner C, Wolf J, Ströbel P, Fernández M, Karakiewcz P, Shariat S
EUR UROL. 2009.

Surgery illustrated--focus on details: dorsal buccal mucosal inlay for penile urethroplasty.
Riechardt S, Pfalzgraf D, Dahlem R, Fisch M
BJU INT. 2009;103(10):1444-1447.

Parathyroid Hormone-Related Protein and Granulocyte Colony-Stimulating Factor Overexpression in Poorly Differentiated Bladder Cancer Correlated with Decreasing Vigilance
Rink M, Budäus L, Schäfer H, Friedrich M, Schlomm T, Regier M, Graefen M, Salomon G
Curr Urol. 2009;3(1):56-56.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K, Hellwinkel O, Haukaas S, Halvorsen O, Øyan A, Haese A, Budäus L, Albrecht H, Akslen L, Schlomm T, Kalland K
APMIS. 2009;117(8):575-582.

[The value of real-time elastography in the diagnosis of prostate cancer]
Salomon G, Graefen M, Heinzer H, Huland H, Pallwein L, Aigner F, Frauscher F
UROLOGE. 2009;48(6):628-636.

The feasibility of prostate cancer detection by triple spectroscopy.
Salomon G, Hess T, Erbersdobler A, Eichelberg C, Greschner S, Sobchuk A, Korolik A, Nemkovich N, Schreiber J, Herms M, Graefen M, Huland H
EUR UROL. 2009;55(2):376-383.

Importance of baseline potency rate assessment of men diagnosed with clinically localized prostate cancer prior to radical prostatectomy.
Salomon G, Isbarn H, Budäus L, Schlomm T, Briganti A, Steuber T, Heinzer H, Haese A, Graefen M, Karakiewicz P, Huland H, Chun F
J SEX MED. 2009;6(2):498-504.

[Role of lymphnode dissection in prostate cancer]
Schlomm T, Börgermann C, Heinzer H, Rübben H, Huland H, Graefen M
UROLOGE. 2009;48(1):37-45.

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat S, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz P, Isbarn H, Jeldres C, Rigaud J, Sagalowsky A, Lotan Y
J UROLOGY. 2009;182(1):78-84.

Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy.
Shariat S, Godoy G, Lotan Y, Droller M, Karakiewicz P, Raman J, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie T, Kassouf W, Wheat J, Zigeuner R, Langner C, Wood C, Margulis V
BJU INT. 2009.

Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.
Shariat S, Karakiewicz P, Godoy G, Karam J, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian P, Nielsen M, Müller S, Sagalowsky A, Lotan Y
CLIN CANCER RES. 2009;15(22):7012-7019.

p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy.
Shariat S, Lotan Y, Karakiewicz P, Ashfaq R, Isbarn H, Fradet Y, Bastian P, Nielsen M, Capitanio U, Jeldres C, Montorsi F, Müller S, Karam J, Heukamp L, Netto G, Lerner S, Sagalowsky A, Cote R
J UROLOGY. 2009.

Impact of Immunotherapy in Metastatic Kidney Cancer in Germany after Introduction of New Target Therapy - Results of a Telephone Survey of the German Society of Immuno- and Targeted Therapy (DGFIT).
Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H
AKTUEL UROL. 2009.

[F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study.
Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun F, Haese A, Klutmann S, Köllermann J, Sauter G, Mester J, Mikecz P, Fisch M, Huland H, Graefen M, Salomon G
EUR J CANCER. 2009.

A Proposal for Reclassification of the Fuhrman Grading System in Patients with Clear Cell Renal Cell Carcinoma.
Sun M, Lughezzani G, Jeldres C, Isbarn H, Shariat S, Arjane P, Widmer H, Pharand D, Latour M, Perrotte P, Patard J, Karakiewicz P
EUR UROL. 2009.

A delay in radical nephroureterectomy can lead to upstaging.
Waldert M, Karakiewicz P, Raman J, Remzi M, Isbarn H, Lotan Y, Capitanio U, Bensalah K, Marberger M, Shariat S
BJU INT. 2009.

Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J, Chun F, Klein E, Reuther A, Graefen M, Huland H, Karakiewicz P
EUR UROL. 2009;55(2):412-419.

Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
Walz J, Chun F, Klein E, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz P
J UROLOGY. 2009;181(2):601-608.

External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.
Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat S, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz P
BJU INT. 2009.

A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma.
Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, Shariat S, Saad F, Arjane P, Duclos A, Lattouf J, Montorsi F, Karakiewicz P
CLIN CANCER RES. 2009;15(3):1013-1018.

Editorial comment on: Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
Ahyai S, Eichelberg C, Isbarn H, Zacharias M, Briganti A, Huland H, Chun F
EUR UROL. 2008.

Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level <or = 4.0 ng per milliliter.
Ahyai S, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich M, Karakiewicz P, Montorsi F, Huland H, Chun F
EUR UROL. 2008;53(4):750-757.

[Isolated manifestation of necrotizing vasculitis of the bladder: a case report]
Becker A, Astroza G, Quezada N, Riaño C, Urrutia J, Guzman S
UROLOGE. 2008;47(10):1347-1349.

Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma.
Bolenz C, Fernández M, Trojan L, Herrmann E, Becker A, Weiss C, Alken P, Ströbel P, Michel M
UROLOGY. 2008;72(2):364-369.

[Aggressive angiomyxoma in a male patient: a case report]
Böthig R, Ahyai S, Kühn K, Pramono S
AKTUEL UROL. 2008;39(1):64-67.

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
Briganti A, Capitanio U, Chun F, Gallina A, Suardi N, Salonia A, Pozzo D, Luigi F, Colombo R, Valerio D, Bertini R, Guazzoni G, Karakiewicz P, Montorsi F, Rigatti P
EUR UROL. 2008;54(4):794-802.

Is node-positive prostate cancer always a systemic disease?
Briganti A, Chun F, Karakiewicz P, Rigatti P, Montorsi F
EUR UROL. 2008;54(2):243-246.

A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer.
Briganti A, Gallina A, Suardi N, Chun F, Walz J, Heuer R, Salonia A, Haese A, Perrotte P, Valiquette L, Graefen M, Rigatti P, Montorsi F, Huland H, Karakiewicz P
BJU INT. 2008;101(5):556-560.

Acute abdomen caused by endometrial stromal sarcoma arising in extragonadal foci of endometriosis of the terminal ileum.
Budäus L, Menzel T, Hartmann V, Caselitz J, Doerner A
INT J COLORECTAL DIS. 2008;23(4):447-448.

Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer.
Capitanio U, Ahyai S, Graefen M, Jeldres C, Shariat S, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Péloquin F, Pharand D, Arjane P, Huland H, Karakiewicz P
UROLOGY. 2008;72(6):1203-1208.

Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Chun F, Briganti A
EUR UROL. 2008;54(3):702.

Editorial comment on: 11C-choline-positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
Chun F, Felix K
EUR UROL. 2008;54(2):400-401.

Editorial comment on: Prostate cancer characteristics in a multiracial community.
Chun F, Felix K
EUR UROL. 2008;53(3):538-539.

Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
Chun F, Haese A, Ahyai S, Walz J, Nazareno S, Capitanio U, Graefen M, Erbersdobler A, Huland H, Karakiewicz P
CANCER-AM CANCER SOC. 2008;113(4):701-709.

Prostate cancer diagnosis: importance of individualized risk stratification models over PSA alone.
Chun F, Karakiewicz P, Briganti A
EUR UROL. 2008;54(2):241-242.

Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
Chun F, Suardi N, Capitanio U, Jeldres C, Ahyai S, Graefen M, Haese A, Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz P
EUR UROL. 2008.

Editorial comment on: the periprostatic autonomic nerves--bundle or layer?
Eichelberg C
EUR UROL. 2008;54(5):1116.

Editorial comment on: topographical anatomy of periprostatic and capsular nerves: quantification and computerised planimetry.
Eichelberg C
EUR UROL. 2008;54(2):361.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C, Heuer R, Chun F, Hinrichs K, Zacharias M, Huland H, Heinzer H
EUR UROL. 2008;54(6):1373-1378.

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B
JNCI-J NATL CANCER I. 2008;100(20):1454-1463.

Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer.
Fischer N, Hellwinkel O, Schulz C, Chun F, Huland H, Aepfelbacher M, Schlomm T
J CLIN VIROL. 2008;43(3):277-283.

[Development of continent reservoirs]
Fisch M
UROLOGE. 2008;47(1):25-26, 28-32.

Continent cutaneous diversion.
Fisch M, Thüroff J
BJU INT. 2008;102(9):1314-1319.

Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, Salomon G, Chun F, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A
CLIN CANCER RES. 2008;14(23):7838-7842.

Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma.
Gabriel U, Bolenz C, Becker A, Schaaf A, Steidler A, Trojan L, Weiss C, Michel M
ONCOL REP. 2008;20(6):1419-1423.

Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
Gallina A, Chun F, Nazareno S, Eastham J, Perrotte P, Graefen M, Hutterer G, Huland H, Klein E, Reuther A, Montorsi F, Briganti A, Shariat S, Roehrborn C, de La Taille A, Salomon L, Karakiewicz P
BJU INT. 2008;101(12):1513-1518.

Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.
Gallina A, Nazareno S, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, Shariat S, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz P
INT J CANCER. 2008;123(3):647-652.

Epidemiological survey of 214 families with bladder exstrophy-epispadias complex.
Gambhir L, Höller T, Müller M, Schott G, Vogt H, Detlefsen B, Ebert A, Fisch M, Beaudoin S, Stein R, Boyadjiev S, Gearhart J, Rösch W, Utsch B, Boemers T, Reutter H, Ludwig M
J UROLOGY. 2008;179(4):1539-1543.

Words of wisdom. Re: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
Graefen M
EUR UROL. 2008;53(3):664-665.

[Active surveillance for prostate cancer]
Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H, Budäus L, Heinzer H, Huland H
UROLOGE. 2008;47(3):261-269.

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A, de La Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P, Huland H, Abbou C, Remzi M, Tinzl M, Feyerabend S, Stillebroer A, Gils v, Martijn P, Schalken J
EUR UROL. 2008;54(5):1081-1088.

Methylation of the TPEF- and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours.
Hellwinkel O, Kedia M, Isbarn H, Budäus L, Friedrich M
BJU INT. 2008;101(6):753-757.

A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer.
Hellwinkel O, Rogmann J, Asong L, Lübke A, Eichelberg C, Ahyai S, Isbarn H, Graefen M, Huland H, Schlomm T
BJU INT. 2008;101(11):1454-1460.

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer G, Karakiewicz P, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich M, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky A, Perrotte P, Lotan Y, Marberger M, Shariat S
BJU INT. 2008;101(5):561-565.

Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks.
Isbarn H, Boccon-Gibod L, Carroll P, Montorsi F, Schulman C, Smith M, Sternberg C, Studer U
EUR UROL. 2008.

[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]
Isbarn H, Budäus L, Pichlmeier U, Conrad S, Huland H, Friedrich M
UROLOGE. 2008;47(5):608-615.

High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer.
Jeldres C, Nazareno S, Capitanio U, Montorsi F, Shariat S, Perrotte P, Peloquin F, Pharand D, Graefen M, Karakiewicz P
BJU INT. 2008;102(4):463-467.

High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.
Jeldres C, Suardi N, Saad F, Montorsi F, Shariat S, Perrotte P, Bhojani N, Walz J, Hutterer G, Graefen M, Valiquette L, Karakiewicz P
EUR UROL. 2008;54(1):97-105.

Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
Jeldres C, Suardi N, Walz J, Hutterer G, Ahyai S, Lattouf J, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz P
EUR UROL. 2008;54(6):1306-1313.

Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.
Jeldres C, Suardi N, Walz J, Saad F, Hutterer G, Bhojani N, Shariat S, Perrotte P, Graefen M, Montorsi F, Karakiewicz P
EUR UROL. 2008;54(1):107-116.

The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer.
Karakiewicz P, Bhojani N, Neugut A, Shariat S, Jeldres C, Graefen M, Perrotte P, Peloquin F, Kattan M
J SEX MED. 2008;5(4):919-927.

Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum.
Karakiewicz P, Chun F, Gallina A, Nazareno S, Briganti A, Erbersdobler A, Schlomm T, Walz J, Currlin E, Michl U, Haese A, Arjane P, Heinzer H, Graefen M, Huland H
J ENDOUROL. 2008;22(3):533-538.

Expression and prognostic relevance of annexin A3 in prostate cancer.
Köllermann J, Schlomm T, Bang H, Schwall G, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A
EUR UROL. 2008;54(6):1314-1323.

Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial.
Kuntz R, Lehrich K, Ahyai S
EUR UROL. 2008;53(1):160-166.

Anatomische Varianten der Nasennebenhöhlen; multiplanare CT-Analyse an 641 Patienten
Leunig A, Betz C, Sommer B, Sommer F
LARYNGO RHINO OTOL. 2008;87(7):482-9.

Surgical anatomy of the frontal recess--is there a benefit in multiplanar CT-reconstruction?
Leunig A, Sommer B, Betz C, Sommer F
RHINOLOGY. 2008;46(3):188-94.

Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
Mathers M, Klotz T, Brandt A, Roth S, Sommer F
BJU INT. 2008;101(9):1129-1134.

[Is rehabilitation of erectile function following pelvic surgery reasonable? Review of the literature: from sports to PDE5 inhibitors]
Mathers M, Klotz T, Vahlensieck W, Zellner M, Lümmen G, Roth S, Huland H, Sommer F
UROLOGE. 2008;47(6):685-692.

Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.
Montorsi F, Brock G, Lee J, Shapiro J, Hendrik V, Graefen M, Stief C
EUR UROL. 2008;54(4):924-931.

Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany.
Natali A, Olianas R, Fisch M
J SEX MED. 2008;5(6):1503-1512.

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
Nazareno S, Capitanio U, Chun F, Graefen M, Perrotte P, Schlomm T, Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz P
CANCER-AM CANCER SOC. 2008;113(8):2068-2072.

A nomogram predicting long-term biochemical recurrence after radical prostatectomy.
Nazareno S, Porter C, Reuther A, Walz J, Kodama K, Gibbons R, Correa R, Montorsi F, Graefen M, Huland H, Klein E, Karakiewicz P
CANCER-AM CANCER SOC. 2008;112(6):1254-1263.

Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy.
Salomon G, Köllermann J, Thederan I, Chun F, Budäus L, Schlomm T, Isbarn H, Heinzer H, Huland H, Graefen M
EUR UROL. 2008;54(6):1354-1362.

Molecular cancer phenotype in normal prostate tissue.
Schlomm T, Hellwinkel O, Buness A, Ruschhaupt M, Lübke A, Chun F, Simon R, Budäus L, Erbersdobler A, Graefen M, Huland H, Poustka A, Sültmann H
EUR UROL. 2008.

Clinical significance of p53 alterations in surgically treated prostate cancers.
Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A
MODERN PATHOL. 2008;21(11):1371-1378.

Marked gene transcript level alterations occur early during radical prostatectomy.
Schlomm T, Näkel E, Lübke A, Buness A, Chun F, Steuber T, Graefen M, Simon R, Sauter G, Poustka A, Huland H, Erbersdobler A, Sültmann H, Hellwinkel O
EUR UROL. 2008;53(2):333-344.

[Identification and validation of clinically relevant molecular alterations in prostate cancer]
Schlomm T, Sültmann H, Köllermann J
UROLOGE. 2008;47(9):1193-1198.

Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H, Chun F, Müller I, Seidel C, Urban K, Erbersdobler A, Huland H, Pantel K, Friedrich M
BJU INT. 2008;102(2):253-258.

Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
Shariat S, Karam J, Walz J, Roehrborn C, Montorsi F, Margulis V, Saad F, Slawin K, Karakiewicz P
CLIN CANCER RES. 2008;14(12):3785-3791.

Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Shariat S, Walz J, Roehrborn C, Montorsi F, Jeldres C, Saad F, Karakiewicz P
J UROLOGY. 2008;179(4):1593-1597.

External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
Shariat S, Walz J, Roehrborn C, Zlotta A, Perrotte P, Suardi N, Saad F, Karakiewicz P
J CLIN ONCOL. 2008;26(9):1526-1531.

Serum markers for prostate cancer: a rational approach to the literature.
Steuber T, O'Brien M, Lilja H
EUR UROL. 2008;54(1):31-40.

Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J, Haese A, Scattoni V, Steuber T, Chun F, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz P
CANCER-AM CANCER SOC. 2008;113(10):2695-2703.

The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases.
Walz J, Montorsi F, Jeldres C, Nazareno S, Shariat S, Perrotte P, Arjane P, Graefen M, Pharand D, Karakiewicz P
BJU INT. 2008;101(7):826-832.

Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population.
Walz J, Nazareno S, Hutterer G, Perrotte P, Gallina A, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz P
J ENDOUROL. 2008;22(2):369-376.

Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.
Walz J, Nazareno S, Shariat S, Jeldres C, Perrotte P, Graefen M, Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz P
BJU INT. 2008;102(1):33-38.

Baseline prevalence of erectile dysfunction in a prostate cancer screening population.
Walz J, Perrotte P, Suardi N, Hutterer G, Jeldres C, Bénard F, Valiquette L, Graefen M, Montorsi F, Karakiewicz P
J SEX MED. 2008;5(2):428-435.

Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
Walz J, Shariat S, Suardi N, Perrotte P, Lotan Y, Palapattu G, Gupta A, Bastian P, Rogers C, Vazina A, Amiel G, Sagalowsky A, Schoenberg M, Lerner S, Karakiewicz P
BJU INT. 2008;101(11):1356-1361.

Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences.
Yossepowitch O, Bjartell A, Eastham J, Graefen M, Guillonneau B, Karakiewicz P, Montironi R, Montorsi F
EUR UROL. 2008.

Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E
EUR UROL. 2008;54(1):204-210.

Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.
Aalamian-Matheis M, Chatta G, Shurin M, Huland E, Huland H, Shurin G
ADV EXP MED BIOL. 2007;601:173-182.

Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial.
Ahyai S, Lehrich K, Kuntz R
EUR UROL. 2007;52(5):1456-1463.

[Salvage strategies after complications of hypospadias repair]
Beuke M, Fisch M
UROLOGE. 2007;46(12):1670-1675.

Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C, Alken P, Michel M
UROL ONCOL-SEMIN ORI. 2007;25(6):476-482.

Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
Briganti A, Chun F, Hutterer G, Gallina A, Shariat S, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz P
EUR UROL. 2007;52(3):733-743.

Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy.
Briganti A, Chun F, Salonia A, Gallina A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F, Karakiewicz P
UROLOGY. 2007;69(1):147-151.

A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer.
Briganti A, Chun F, Salonia A, Zanni G, Gallina A, Dehò F, Suardi N, Pozzo D, Filippo L, Valiquette L, Rigatti P, Montorsi F, Karakiewicz P
EUR UROL. 2007;51(1):112-120.

Prostate volume and adverse prostate cancer features: fact not artifact.
Briganti A, Chun F, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz P
EUR J CANCER. 2007;43(18):2669-2677.

Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy.
Briganti A, Fabbri F, Salonia A, Gallina A, Chun F, Dehò F, Zanni G, Suardi N, Karakiewicz P, Rigatti P, Montorsi F
EUR UROL. 2007;52(3):702-707.

Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
Briganti A, Karakiewicz P, Chun F, Gallina A, Salonia A, Zanni G, Valiquette L, Graefen M, Huland H, Rigatti P, Montorsi F
EUR UROL. 2007;51(6):1573-1581.

Management of erectile dysfunction after radical prostatectomy in 2007.
Briganti A, Salonia A, Gallina A, Chun F, Karakiewicz P, Graefen M, Huland H, Rigatti P, Montorsi F
WORLD J UROL. 2007;25(2):143-148.

Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
Briganti A, Shariat S, Chun F, Hutterer G, Roehrborn C, Gallina A, Rigatti P, Valiquette L, Montorsi F, Karakiewicz P
BJU INT. 2007;100(3):528-532.

Treatment of localized prostate cancer.
Burchardt M, Huland H
WORLD J UROL. 2007;25(1):1-2.

Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun F, Briganti A, Gallina A, Hutterer G, Shariat S, Antebie E, Walz J, Roehrborn C, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz P
EUR UROL. 2007;52(4):1067-1074.

Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy.
Chun F, Briganti A, Graefen M, Erbersdobler A, Walz J, Schlomm T, Meschke M, Haese A, Valiquette L, Huland H, Karakiewicz P
EUR J CANCER. 2007;43(2):375-382.

Development and external validation of an extended 10-core biopsy nomogram.
Chun F, Briganti A, Graefen M, Montorsi F, Porter C, Scattoni V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Schlomm T, Ahyai S, Eichelberg E, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz P
EUR UROL. 2007;52(2):436-444.

Development and external validation of an extended repeat biopsy nomogram.
Chun F, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A, Schlomm T, Latchemsetty K, Walz J, Kim J, Eichelberg C, Eichelberg E, Ahyai S, Erbersdobler A, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz P
J UROLOGY. 2007;177(2):510-515.

Zonal origin of localized prostate cancer does not affect the rate of biochemical recurrence after radical prostatectomy.
Chun F, Briganti A, Jeldres C, Erbersdobler A, Schlomm T, Steuber T, Gallina A, Walz J, Perrotte P, Huland H, Graefen M, Karakiewicz P
EUR UROL. 2007;51(4):949-955.

Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy.
Chun F, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Walz J, Eichelberg C, Salomon G, Haese A, Eichelberg E, Ahyai S, Bénard F, Huland H, Graefen M, Karakiewicz P
EUR J CANCER. 2007;43(3):536-543.

Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.
Chun F, Graefen M, Briganti A, Gallina A, Hopp J, Kattan M, Huland H, Karakiewicz P
EUR UROL. 2007;51(5):1233-1236.

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun F, Hutterer G, Perrotte P, Gallina A, Valiquette L, Benard F, McCormack M, Briganti A, Ionescu C, Jeldres C, Guay J, Saad F, Karakiewicz P
BJU INT. 2007;100(1):37-41.

A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer.
Chun F, Karakiewicz P, Briganti A, Walz J, Kattan M, Huland H, Graefen M
BJU INT. 2007;99(4):794-800.

Role of nomograms for prostate cancer in 2007.
Chun F, Karakiewicz P, Huland H, Graefen M
WORLD J UROL. 2007;25(2):131-142.

Screening men for prostate cancer and colorectal cancer: is practice evidence-based?
Chun F, Suardi N, Perrotte P, Lebeau T, Guay J, Benayoun S, Ramirez A, Bénard F, McCormack M, Valiquette L, Karakiewicz P
CAN J UROL. 2007;14(6):3727-3733.

Nerve distribution along the prostatic capsule.
Eichelberg C, Erbersdobler A, Michl U, Schlomm T, Salomon G, Graefen M, Huland H
EUR UROL. 2007;51(1):101-105.

Metastasized urachal carcinoma scanned with 11C-chlorine and 18F-fluorodeoxyglucose PET/CT
Essler M, Maurer T, Souvatzoglu M, Stollfuss J, Becker K, Treiber U, Hartung R, Krause B, Schwaiger M
NUKLEARMED-NUCL MED. 2007;46(3):N29-30.

Metastasized urachal carcinoma scanned with 11C-chlorine and 18F-fluorodeoxyglucose PET/CT: Nuklearmedizin
Essler M, Maurer T, Souvatzoglu M, Stollfuss J, Becker K, Treiber U, Hartung R, Krause B, Schwaiger M
NUKLEARMED-NUCL MED. 2007;46(3):N29-30.

Sigma-rectum pouch (Mainz pouch II).
Fisch M, Hohenfellner R
BJU INT. 2007;99(4):945-960.

Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich M, Pichlmeier U, Schwaibold H, Conrad S, Huland H
EUR UROL. 2007;52(4):1123-1129.

[DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder]
Friedrich M, Toma M, Chun J, Steuber T, Budäus L, Isbarn H, Huland H
UROLOGE. 2007;46(7):761-768.

Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy.
Gallina A, Briganti A, Chun F, Walz J, Hutterer G, Erbersdobler A, Eichelberg C, Schlomm T, Ahyai S, Perrotte P, Saad F, Montorsi F, Huland H, Graefen M, Karakiewicz P
BJU INT. 2007;100(6):1249-1253.

Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy.
Gallina A, Chun F, Briganti A, Shariat S, Montorsi F, Salonia A, Erbersdobler A, Rigatti P, Valiquette L, Huland H, Graefen M, Karakiewicz P
EUR UROL. 2007;52(1):98-105.

Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL.
Gallina A, Jeldres C, Chun F, Shariat S, Briganti A, Walz J, Roehrborn C, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz P
EUR UROL. 2007;52(5):1374-1380.

Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer.
Gallina A, Karakiewicz P, Chun F, Briganti A, Graefen M, Montorsi F, Walz J, Jeldres C, Erbersdobler A, Salonia A, Suardi N, Dehò F, Schlomm T, Scattoni V, Haese A, Heinzer H, Valiquette L, Rigatti P, Huland H
BJU INT. 2007;99(6):1404-1408.

Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.
Gallina A, Karakiewicz P, Hutterer G, Chun F, Briganti A, Walz J, Antebi E, Shariat S, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F
INT J CANCER. 2007;121(4):791-795.

Is the open retropubic radical prostatectomy dead?
Graefen M
EUR UROL. 2007;52(5):1281-1283.

Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz P
EUR J CANCER. 2007;43(7):1180-1187.

Prospective non-randomized evaluation of four mediators of the systemic response after extraperitoneal laparoscopic and open retropubic radical prostatectomy.
Jurczok A, Zacharias M, Wagner S, Hamza A, Fornara P
BJU INT. 2007;99(6):1461-1466.

Multi-institutional validation of a new renal cancer-specific survival nomogram.
Karakiewicz P, Briganti A, Chun F, Trinh Q, Perrotte P, Ficarra V, Cindolo L, Alexandre D, Tostain J, Mulders P, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes J, Lang H, Mejean A, Patard J
J CLIN ONCOL. 2007;25(11):1316-1322.

The equilibrium of XIAP and Smac/DIABLO expression is gradually deranged during the development and progression of testicular germ cell tumours.
Kempkensteffen C, Jäger T, Bub J, Weikert S, Hinz S, Christoph F, Krause H, Schostak M, Miller K, Schrader M
INT J ANDROL. 2007;30(5):476-483.

Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their sexual partners know?
Klotz T, Mathers M, Klotz R, Sommer F
J SEX MED. 2007;4(1):162-165.

[Pro and contra: 11C choline PET in diagnosis of prostate cancer]
Kotzerke J, Zöphel K, Salomon G, Graefen M, Heidenreich A
AKTUEL UROL. 2007;38(3):189-194.

Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
Langer F, Chun F, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, Bokemeyer C, Francis J
THROMB HAEMOSTASIS. 2007;97(3):464-470.

Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation.
Loppow D, Huland E, Heinzer H, Grönke L, Magnussen H, Holz O, Jörres R
EUR J MED RES. 2007;12(11):556-562.

[Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]
Mathers M, Lazica D, Klotz T, Sommer F, Roth S
UROLOGE. 2007;46(6):636-641.

Intraindividual comparison of 3D coronary MR angiography and coronary CT angiography.
Ozgun M, Rink M, Hoffmeier A, Botnar R, Heindel W, Fischbach R, Maintz D
ACAD RADIOL. 2007;14(8):910-916.

High accuracy of virtual simulation with the laser system Dorado CT4.
Rades D, Frenzel T, Schwarz R, Walz J, Cremers F, Albers D, Alberti W, Schmidt R
STRAHLENTHER ONKOL. 2007;183(2):89-93.

Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer
Rades D, Schwarz R, Todorovic M, Thurmann H, Graefen M, Walz J, Schild S, Dunst J, Alberti W
STRAHLENTHER ONKOL. 2007;183(7):398-402.

Do bladder cancer patients with metastatic spinal cord compression benefit from radiotherapy alone?
Rades D, Walz J, Schild S, Veninga T, Dunst J
UROLOGY. 2007;69(6):1081-1085.

[Solitary tumor of the spermatic cord]
Rödder K, Wintzer H, Fisch M
AKTUEL UROL. 2007;38(2):152-153.

Molecular staging of prostate cancer in the year 2007.
Schlomm T, Erbersdobler A, Mirlacher M, Sauter G
WORLD J UROL. 2007;25(1):19-30.

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun F, Haese A, Köllermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A
CLIN CANCER RES. 2007;13(22 Pt 1):6579-6584.

[Molecular high throughput research in prostate carcinoma]
Schlomm T, Sültmann H, Poustka A, Sauter G, Hellwinkel O, Huland H
UROLOGE. 2007;46(9):1097-1100.

Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H, Chun F, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich M, Huland H, Pantel K
INT J CANCER. 2007;120(7):1465-1471.

Therapy of recurrent disease after radical prostatectomy in 2007.
Schwarz R, Graefen M, Krüll A
WORLD J UROL. 2007;25(2):161-167.

Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial.
Sommer F, Klotz T, Engelmann U
ASIAN J ANDROL. 2007;9(1):134-141.

[Lifestyle, erectile dysfunction, hormones and metabolic syndrome. Opportunities for gender-specific prevention for men]
Sommer F, Mathers M
UROLOGE. 2007;46(6):628-635.

[Urological problems in patients with meningomyelocele. Diagnostic studies and management]
Stein R, Schröder A, Beetz R, Ermert A, Filipas D, Fisch M, Goepel M, Körner I, Schönberger B, Sparwasser C, Stöhrer M, Thüroff J
UROLOGE. 2007;46(12):1620-1642.

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.
Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis E, Remzi M, Djavan B, Wildhagen M, Blijenberg B, Finne P, Stenman U, Jung K, Meyer H
WORLD J UROL. 2007;25(1):95-103.

Circulating biomarkers for prostate cancer.
Steuber T, Helo P, Lilja H
WORLD J UROL. 2007;25(2):111-119.

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Steuber T, Vickers A, Haese A, Kattan M, Eastham J, Scardino P, Huland H, Lilja H
INT J CANCER. 2007;120(7):1499-1504.

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Steuber T, Vickers A, Serio A, Vaisanen V, Haese A, Pettersson K, Eastham J, Scardino P, Huland H, Lilja H
CLIN CHEM. 2007;53(2):233-240.

Colon pouch (Mainz III) for continent urinary diversion.
Stolzenburg J, Schwalenberg T, Liatsikos E, Sakelaropoulos G, Rödder K, Hohenfellner R, Fisch M
BJU INT. 2007;99(6):1473-1477.

[One molecule, two faces. Epithelial loss of cell adhesion molecule CEACAM1 activates angiogenesis in bladder and prostate cancer]
Tilki D, Oliveira-Ferrer L, Kilic N, Friedrich M, Stief C, Ergun S
UROLOGE. 2007;46(9):1128-1134.

Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer.
Walz J, Gallina A, Hutterer G, Perrotte P, Shariat S, Graefen M, McCormack M, Bénard F, Valiquette L, Saad F, Karakiewicz P
INT J RADIAT ONCOL. 2007;69(1):88-94.

Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.
Walz J, Gallina A, Perrotte P, Jeldres C, Trinh Q, Hutterer G, Traumann M, Ramirez A, Shariat S, McCormack M, Perreault J, Bénard F, Valiquette L, Saad F, Karakiewicz P
BJU INT. 2007;100(6):1254-1258.

A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat S, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz P
J CLIN ONCOL. 2007;25(24):3576-3581.

Basic principles of anatomy for optimal surgical treatment of prostate cancer.
Walz J, Graefen M, Huland H
WORLD J UROL. 2007;25(1):31-38.

[Technical aspects of nerve sparing during retropubic prostatectomy]
Walz J, Graefen M, Michl U, Heinzer H, Friedrich M, Eichelberg C, Haese A, Huland H
ANN UROL. 2007;41(1):23-30.

Ejaculatory disorders may affect screening for prostate cancer.
Walz J, Perrotte P, Gallina A, Bénard F, Valiquette L, McCormack M, Montorsi F, Karakiewicz P
J UROLOGY. 2007;178(1):232-238.

Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men.
Walz J, Perrotte P, Hutterer G, Suardi N, Jeldres C, Bénard F, Valiquette L, Karakiewicz P
BJU INT. 2007;100(6):1307-1311.

External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy.
Zorn K, Gallina A, Hutterer G, Walz J, Shalhav A, Zagaja G, Valiquette L, Gofrit O, Orvieto M, Taxy J, Karakiewicz P
J ENDOUROL. 2007;21(11):1345-1351.

[100 years prostate cancer: yesterday--today--tomorrow]
Budäus L, Wirth M, Wolff J, Bartsch G, Noldus J, Huland H
UROLOGE. 2006;45(4):122-126.

Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients.
Chun F, Briganti A, Antebi E, Graefen M, Currlin E, Steuber T, Schlomm T, Walz J, Haese A, Friedrich M, Ahyai S, Eichelberg C, Salomon G, Gallina A, Erbersdobler A, Perrotte P, Heinzer H, Huland H, Karakiewicz P
BJU INT. 2006;98(6):1204-1209.

The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
Chun F, Briganti A, Lebeau T, Fradet V, Steuber T, Walz J, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz P
EUR UROL. 2006;49(2):273-279.

Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.
Chun F, Briganti A, Shariat S, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currlin E, Scattoni V, Friedrich M, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn C, Huland H, Karakiewicz P
BJU INT. 2006;98(2):329-334.

Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer.
Chun F, Graefen M, Zacharias M, Haese A, Steuber T, Schlomm T, Walz J, Karakiewicz P, Huland H
WORLD J UROL. 2006;24(3):273-280.

Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer.
Chun F, Müller I, Lange I, Friedrich M, Erbersdobler A, Karakiewicz P, Graefen M, Pantel K, Huland H, Schwarzenbach H
BJU INT. 2006;98(3):544-548.

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.
Chun F, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, Haese A, Heinzer H, McCormack M, Huland H, Graefen M, Karakiewicz P
EUR UROL. 2006;49(5):820-826.

Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy.
Eichelberg C, Erbersdobler A, Haese A, Schlomm T, Chun F, Currlin E, Walz J, Steuber T, Graefen M, Huland H
EUR UROL. 2006;49(6):1011-1018.

[Superficial bladder carcinoma -- trend of less aggressive therapies]
Friedrich M
AKTUEL UROL. 2006;37(4):254-256.

[Success rates of two-layer, microsurgical vasovasostomy. Results from a patient questionnaire and comparison with one-layer technique]
Friedrich M, Friedrich E, Graefen M, Heinzer H, Michl U, Huland H, Noldus J
AKTUEL UROL. 2006;37(1):58-63.

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
Karakiewicz P, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich M, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky A, Marberger M, Shariat S
BJU INT. 2006;97(5):997-1001.

[Nutrition, lifestyle, physical activity, and supportive care during chemotherapeutic treatment]
Lümmen G, Jäger T, Sommer F, Ebert T, Schmitz-Draeger B
UROLOGE. 2006;45(5):555-558, 560-565.

64-slice multidetector coronary CT angiography: in vitro evaluation of 68 different stents
Maintz D, Seifarth H, Raupach R, Flohr T, Rink M, Sommer T, Ozgün M, Heindel W, Fischbach R
EUR RADIOL. 2006;16(4):818-26.

Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy.
Michl U, Friedrich M, Graefen M, Haese A, Heinzer H, Huland H
J UROLOGY. 2006;176(1):227-231.

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T, Haese A, Huland H, Steuber T, Christensen I, Brünner N, Danø K, Høyer-Hansen G, Lilja H
CLIN CHEM. 2006;52(5):838-844.

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat S, Marberger M, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich M, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky A, Roehrborn C, Karakiewicz P
J UROLOGY. 2006;176(3):919-926.

Evaluation of tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat erectile dysfunction.
Sommer F, Klotz T, Steinritz D, Bloch W
ASIAN J ANDROL. 2006;8(2):159-167.

Development and internal validation of preoperative transition zone prostate cancer nomogram.
Steuber T, Chun F, Erbersdobler A, Briganti A, Haese A, Graefen M, Schlomm T, Valiquette L, Huland H, Karakiewicz P
UROLOGY. 2006;68(6):1295-1300.

Adolescent smoking and depression: which comes first?
Steuber T, Danner F
ADDICT BEHAV. 2006;31(1):133-136.

Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
Steuber T, Erbersdobler A, Graefen M, Haese A, Huland H, Karakiewicz P
CANCER-AM CANCER SOC. 2006;106(4):775-782.

Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy.
Steuber T, Graefen M, Haese A, Erbersdobler A, Chun F, Schlom T, Perrotte P, Huland H, Karakiewicz P
J UROLOGY. 2006;175(3 Pt 1):939-944.

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T, Vickers A, Haese A, Becker C, Pettersson K, Chun F, Kattan M, Eastham J, Scardino P, Huland H, Lilja H
INT J CANCER. 2006;118(5):1234-1240.

CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer.
Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H, Hammerer P, Friedrich M, Schuch G, Galalae R, Stief C, Kilic E, Huland H, Ergun S
ONCOGENE. 2006;25(36):4965-4974.

High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
Walz J, Graefen M, Chun F, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz P
EUR UROL. 2006;50(3):498-505.

Transperitoneal laparoscopic adrenalectomy: outline of the preoperative management, surgical approach, and outcome.
Zacharias M, Haese A, Jurczok A, Stolzenburg J, Fornara P
EUR UROL. 2006;49(3):448-459.

Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
Friedrich M, Chandrasoma S, Siegmund K, Weisenberger D, Cheng J, Toma M, Huland H, Jones P, Liang G
EUR J CANCER. 2005;41(17):2769-2778.

[Selection criteria for the expected management of localised prostate cancer]
Graefen M, Salomon G, Currlin E, Eichelberg C, Schlomm T, Huland H
UROLOGE. 2005;44(11):1277-1278, 1280-1286.

Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
Graefen M, Walz J, Chun K, Schlomm T, Haese A, Huland H
EUR UROL. 2005;47(6):756-760.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A, Vaisanen V, Lilja H, Kattan M, Rittenhouse H, Pettersson K, Chan D, Huland H, Sokoll L, Partin A
J UROLOGY. 2005;173(3):752-756.

[Fast-track surgery in radical retropubic prostatectomy. First experiences with a comprehensive program to enhance postoperative convalescence]
Heinzer H, Heuer R, V Nordenflycht O, Eichelberg C, Friederich P, Goetz A, Huland H
UROLOGE. 2005;44(11):1287-1293.

Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer.
Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergün S
PROTEOMICS. 2005;5(16):4296-4304.

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening S, Jung K
J UROLOGY. 2005;174(6):2150-2153.

Detection of human telomerase RNA in the tumour-surrounding mucosa of bladder carcinomas as a marker for premalignant transformation.
Leuenroth S, Riethdorf S, Erbersdobler A, Riethdorf L, Löning T, Huland H, Friedrich M
BJU INT. 2005;96(4):553-557.

Surgical management of prostate cancer: advances based on a rational approach to the data.
Meraney A, Haese A, Palisaar J, Graefen M, Steuber T, Huland H, Klein E
EUR J CANCER. 2005;41(6):888-907.

Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure.
Palisaar R, Noldus J, Graefen M, Erbersdobler A, Haese A, Huland H
EUR UROL. 2005;47(2):176-184.

Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.
Schlomm T, Luebke A, Sültmann H, Hellwinkel O, Sauer U, Poustka A, David K, Chun F, Haese A, Graefen M, Erbersdobler A, Huland H
INT J ONCOL. 2005;27(3):713-720.

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich M, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky A, Wians F, Roehrborn C, Lotan Y, Perrotte P, Benayoun S, Marberger M, Karakiewicz P
J UROLOGY. 2005;173(5):1518-1525.

Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
Steuber T, Karakiewicz P, Augustin H, Erbersdobler A, Lange I, Haese A, Chun K, Walz J, Graefen M, Huland H
J UROLOGY. 2005;173(3):737-741.

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun K, Graefen M, Kattan M, Huland H, Lilja H
PROSTATE. 2005;63(1):13-18.

Low-latitude seasonality of Cretaceous temperatures in warm and cold episodes.
Steuber T, Rauch M, Masse J, Graaf J, Malkoc M
NATURE. 2005;437(7063):1341-1344.

DHPLC based fraction collection of TCR-gamma rearrangements in childhood ALL: direct sequencing of products amplified by a single or a multiplex PCR approach.
Zur Stadt U, Isbarn H, Schneppenheim R, Kabisch H
INT J ONCOL. 2005;27(2):547-552.

Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich M, Toma M, Petri S, Cheng J, Hammerer P, Erbersdobler A, Huland H
EUR UROL. 2004;45(6):737-743.

Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich M, Weisenberger D, Cheng J, Chandrasoma S, Siegmund K, Gonzalgo M, Toma M, Huland H, Yoo C, Tsai Y, Nichols P, Bochner B, Jones P, Liang G
CLIN CANCER RES. 2004;10(22):7457-7465.

Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Graefen M, Ohori M, Karakiewicz P, Cagiannos I, Hammerer P, Haese A, Erbersdobler A, Henke R, Huland H, Wheeler T, Slawin K, Scardino P, Kattan M
J UROLOGY. 2004;171(1):200-203.

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Haese A, Graefen M, Huland H, Lilja H
CURR UROL REP. 2004;5(3):231-240.

[Isoforms of free prostate-specific antigen]
Haese A, Noldus J, Steuber T, Huland H, Lilja H
UROLOGE. 2004;43(6):675-679.

[Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system]
Hammerer P, Augustin H, Blonski J, Graefen M, Haese A, Erbersdobler A, Daghofer F, Huland H
UROLOGE. 2004;43(3):307-312.

Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stones.
Hautmann S, Friedrich M, Fernandez S, Steuber T, Hammerer P, Braun P, Jünemann K, Huland H
UROL INT. 2004;73(3):238-243.

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S, Toma M, Gomez L, Friedrich M, Friedrich M, Jaekel T, Michl U, Schroeder G, Huland H, Juenemann K, Lokeshwar V
EUR UROL. 2004;46(4):466-471.

Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer.
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergün S
CANCER RES. 2004;64(24):8932-8938.

A side by side comparison of cytology and biomarkers for bladder cancer detection.
Schroeder G, Lorenzo-Gomez M, Hautmann S, Friedrich M, Ekici S, Huland H, Lokeshwar V
J UROLOGY. 2004;172(3):1123-1126.

Myeloid sarcoma of the prostate as first clinical manifestation of acute myeloid leukaemia.
Spethmann S, Heuer R, Hopfer H, Tuinmann G
LANCET ONCOL. 2004;5(1):62-63.

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
Toma M, Friedrich M, Hautmann S, Jäkel K, Erbersdobler A, Hellstern A, Huland H
WORLD J UROL. 2004;22(2):145-149.

Differences in biopsy features between prostate cancers located in the transition and peripheral zone.
Augustin H, Erbersdobler A, Graefen M, Jaekel T, Haese A, Huland H, Hammerer P
BJU INT. 2003;91(6):477-481.

Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?
Friedrich M, Hellstern A, Toma M, Hammerer P, Huland H
EUR UROL. 2003;43(2):141-146.

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer.
Friedrich M, Toma M, Hellstern A, Pantel K, Weisenberger D, Noldus J, Huland H
BJU INT. 2003;92(9):911-914.

Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence.
Friedrich M, Toma M, Petri S, Huland H
BJU INT. 2003;92(4):389-392.

Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables.
Graefen M, Augustin H, Karakiewicz P, Hammerer P, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H
EUR UROL. 2003;43(1):6-11.

[Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy]
Graefen M, Augustin H, Karakiewicz P, Hammerer P, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino P, Kattan M, Huland H
UROLOGE. 2003;42(5):685-692.

[Indications for and results of radical prostatectomy]
Graefen M, Hammerer P, Haese A, Huland H
UROLOGE. 2003;42(9):1203-1211.

Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Haese A, Chaudhari M, Miller M, Epstein J, Huland H, Palisaar J, Graefen M, Hammerer P, Poole E, O'Dowd G, Partin A, Veltri R
CANCER-AM CANCER SOC. 2003;97(4):969-978.

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino P, Huland E, Huland H, Lilja H
PROSTATE. 2003;54(3):181-186.

[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]
Haese A, Graefen M, Palisaar J, Huland E, Huland H
UROLOGE. 2003;42(9):1172-1187.

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland E, Huland H, Lilja H
J UROLOGY. 2003;170(6 Pt 1):2269-2273.

Total, free and complexed PSA and hK2 for early detection of prostate cancer.
Haese A, Khan M, Sokoll L
MLO Med Lab Obs. 2003;35(6):14-16, 20, 30-31.

Standardization of two immunoassays for human glandular kallikrein 2.
Haese A, Vaisanen V, Finlay J, Pettersson K, Rittenhouse H, Partin A, Bruzek D, Sokoll L, Lilja H, Chan D
CLIN CHEM. 2003;49(4):601-610.

Evaluation of renal growth by magnetic resonance imaging and computerized tomography volumes.
Heuer R, Sommer G, Shortliffe L
J UROLOGY. 2003;170(4 Pt 2):1659-1663.

[Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications]
Palisaar J, Eggert T, Graefen M, Haese A, Huland H
UROLOGE. 2003;42(9):1188-1195.

Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?
Cagiannos I, Graefen M, Karakiewicz P, Ohori M, Eastham J, Rabbani F, Fair W, Wheeler T, Hammerer P, Haese A, Erbersdobler A, Huland H, Scardino P, Kattan M
J CLIN ONCOL. 2002;20(8):2025-2030.

Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich M, Hellstern A, Hautmann S, Graefen M, Conrad S, Huland E, Huland H
J UROLOGY. 2002;168(2):470-474.

Characterization of cells prepared by dendritic cell-tumor cell fusion.
Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause S
Cancer Immun. 2002;2:15.

A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.
Graefen M, Karakiewicz P, Cagiannos I, Hammerer P, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino P, Kattan M
UROL ONCOL-SEMIN ORI. 2002;7(4):141-146.

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M, Karakiewicz P, Cagiannos I, Hammerer P, Haese A, Palisaar J, Huland E, Scardino P, Kattan M, Huland H
J UROLOGY. 2002;167(3):1306-1309.

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.
Graefen M, Karakiewicz P, Cagiannos I, Quinn D, Henshall S, Grygiel J, Sutherland R, Stricker P, Klein E, Kupelian P, Skinner D, Lieskovsky G, Bochner B, Huland H, Hammerer P, Haese A, Erbersdobler A, Eastham J, de Kernion J, Cangiano T, Schröder F, Wildhagen M, Kwast v, Theo H, Scardino P, Kattan M
J CLIN ONCOL. 2002;20(15):3206-3212.

Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A, Dworschack R, Partin A
J UROLOGY. 2002;168(2):504-508.

Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems.
Haese A, Dworschack R, Piccoli S, Sokoll L, Partin A, Chan D
CLIN CHEM. 2002;48(6 Pt 1):944-947.

Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma.
Haese A, Epstein J, Huland H, Partin A
CANCER-AM CANCER SOC. 2002;95(5):1016-1021.

Prediction of tumor heterogeneity in localized prostate cancer.
Huland H, Graefen M, Haese A, Hammerer P, Palisaar J, Pichlmeier U, Henke R, Erbersdobler A, Huland E, Lilja H
UROL CLIN N AM. 2002;29(1):213-222.

Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy.
Noldus J, Michl U, Graefen M, Haese A, Hammerer P, Huland H
EUR UROL. 2002;42(2):118-124.

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.
Palisaar R, Graefen M, Karakiewicz P, Hammerer P, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke R, Huland H
EUR UROL. 2002;41(2):155-161.

Urinary concentration and tissue messenger RNA expression of monocyte chemoattractant protein-1 as an indicator of the degree of hydronephrotic atrophy in partial ureteral obstruction.
Stephan M, Conrad S, Eggert T, Heuer R, Fernandez S, Huland H
J UROLOGY. 2002;167(3):1497-1502.

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H
J UROLOGY. 2002;168(5):1917-1922.

The beta 2 subunit of nitric oxide-sensitive guanylyl cyclase is developmentally regulated in rat kidney.
Behrends S, Budäus L, Kempfert J, Scholz H, Starbatty J, Vehse K
N-S ARCH PHARMACOL. 2001;364(6):573-576.

Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
Friedrich M, Blind C, Milde-Langosch K, Erbersdobler A, Conrad S, Löning T, Hammerer P, Huland H
EUR UROL. 2001;40(5):518-524.

Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.
Friedrich M, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Sölter J, Huland E, Riethdorf L, Conrad S, Hammerer P, Huland H
EUR UROL. 2001;39(2):159-166.

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
Graefen M, Haese A, Pichlmeier U, Hammerer P, Noldus J, Butz K, Erbersdobler A, Henke R, Michl U, Fernandez S, Huland H
J UROLOGY. 2001;165(3):857-863.

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H
PROSTATE. 2001;49(2):101-109.

New serum tests for the diagnosis of prostate cancer.
Haese A, Partin A
DRUG TODAY. 2001;37(9):607-616.

Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer.
Hautmann S, Lokeshwar V, Schroeder G, Civantos F, Duncan R, Gnann R, Friedrich M, Soloway M
J UROLOGY. 2001;165(6 Pt 1):2068-2074.

[Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers]
Hautmann S, Schroeder G, Civantos F, Duncan R, Gnann R, Friedrich M, Hellstern A, Huland H, Soloway M, Lokeshwar V
UROLOGE. 2001;40(2):121-126.

Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit.
Koglin M, Vehse K, Budäus L, Scholz H, Behrends S
J BIOL CHEM. 2001;276(33):30737-30743.

[Nerve-sparing radical retropubic prostatectomy. Results of a patient survey]
Noldus J, Michl U, Graefen M, Haese A, Hammerer P, Fernandez S, Huland H
UROLOGE. 2001;40(2):102-106.

Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich M, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H
J UROLOGY. 2000;163(3):1039-1042.

The correction of penile curvature with the Essed-Schröder technique: a long-term follow-up assessing functional aspects and quality of life.
Friedrich M, Evans D, Noldus J, Huland H
BJU INT. 2000;86(9):1034-1038.

[Therapeutic options in hormone refractory prostate carcinoma]
Graefen M, Hammerer P, Haese A, Huland H
UROLOGE. 2000;39(3):267-273.

[Prognostic markers for prostate cancer]
Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H
UROLOGE. 2000;39(1):14-21.

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, Lilja H
J UROLOGY. 2000;163(5):1491-1497.

Ratio free/total PSA (%f-PSA) in men with total PSA 0.5-3 ng/ml: improvement for prostate cancer detection?
Hammerer P, Graefen M, Henke R, Haese A, Huland E, Huland H
PROSTATE CANCER P D. 2000;3(1):19.

Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy.
Hammerer P, Graefen M, Henke R, Haese A, Palisaar J, Huland E, Huland H
ANTICANCER RES. 2000;20(6):5253-5255.

[Chemoprevention of prostatic carcinoma]
Hammerer P, Graefen M, Steuber T, Huland H
UROLOGE. 2000;39(4):304-308.

Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
Hautmann S, Huland E, Grupp C, Haese A, Huland H
ANTICANCER RES. 2000;20(3):2151-2154.

Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.
Hautmann S, Huland E, Wullbrand A, Friedrich M, Huland H
ANTICANCER RES. 2000;20(6):4495-4498.

Stage migration in clinically localized prostate cancer.
Noldus J, Graefen M, Haese A, Henke R, Hammerer P, Huland H
EUR UROL. 2000;38(1):74-78.

[Mucinous adenocarcinoma of the urachus. Case report and review of the literature]
Reek C, Graefen M, Erbersdobler A, Haese A
UROLOGE. 2000;39(6):572-575.

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H
EUR UROL. 1999;36(1):21-30.

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H
J UROLOGY. 1999;161(4):1206-1211.

Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
Haese A, Huland E, Graefen M, Huland H
ANTICANCER RES. 1999;19(4):2641-2644.

Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy
Heinzer H, Mir T, Huland E, Huland H
J CLIN ONCOL. 1999;17(11):3612-3620.

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Lilja H, Haese A, Björk T, Friedrich M, Piironen T, Pettersson K, Huland E, Huland H
J UROLOGY. 1999;162(6):2025-2029.

Microsatellite alterations at chromosomes 9p, 13q, and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder.
Erbersdobler A, Friedrich M, Schwaibold H, Henke R, Huland H
ONCOL RES. 1998;10(8):415-420.

Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy.
Graefen M, Hammerer P, Michl U, Noldus J, Haese A, Henke R, Huland E, Huland H
UROLOGY. 1998;51(3):437-442.

Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients
Rosenbaum C, Kluwe L, Mautner V, Friedrich R, Müller H, Hanemann C
NEUROBIOL DIS. 1998;5(1):55-64.

Improvement of ureteroileal anastomosis in continent urinary diversion with modified Le Duc procedure.
Schwaibold H, Friedrich M, Fernandez S, Conrad S, Huland H
J UROLOGY. 1998;160(3 Pt 1):718-720.

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H
J UROLOGY. 1997;158(6):2188-2192.

Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience
Huland E, Heinzer H, Mir T, Huland H
CANCER J SCI AM. 1997;3 Suppl 1:S98-105.

Letzte Aktualisierung aus dem FIS: 22.12.2024 - 23:33 Uhr